start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=裏表紙・英文目次
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=奥付
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=753
end-page=754
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=法学会雑誌第七五巻（通巻自第二六〇号　至第二六二号）総目次
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=751
end-page=751
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=岡山大学法学部・法学会令和７年度講演会全記録
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=743
end-page=749
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=佐藤　吾郎教授　略歴
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=737
end-page=741
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=吉野　夏己教授　略歴
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=729
end-page=735
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=河原　祐馬教授　略歴
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=727
end-page=727
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=本号執筆者紹介
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=438
end-page=410
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A Study on Water Pollution by Persistent Organic Pollutants（PFOS・PFOA）: Focused on Duty of Care in Transactions.
kn-title=PFOS・PFOA 等の残留性有機汚染物質による水質汚染に関する一考察 ― 取引上の義務の視点から―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TsujiH.
en-aut-sei=Tsuji
en-aut-mei=H.
kn-aut-name=辻博明
kn-aut-sei=辻
kn-aut-mei=博明
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学名誉教授
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=456
end-page=439
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Suizidteilnahme und Einwilligung zum Mord
kn-title=自殺関与と同意殺人
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ShiotaniT.
en-aut-sei=Shiotani
en-aut-mei=T.
kn-aut-name=塩谷毅
kn-aut-sei=塩谷
kn-aut-mei=毅
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=494
end-page=457
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=2024 Irish Dáil Éireann Election: An Analysis of NEDS 2024 Data
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NarihiroT.
en-aut-sei=Narihiro
en-aut-mei=T.
kn-aut-name=成廣孝
kn-aut-sei=成廣
kn-aut-mei=孝
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=586
end-page=496
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Possibility of a Japanese Approach to Standards of Judicial Review
kn-title=日本独自の違憲審査基準論の可能性
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ItoT.
en-aut-sei=Ito
en-aut-mei=T.
kn-aut-name=伊藤健
kn-aut-sei=伊藤
kn-aut-mei=健
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=656
end-page=588
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Le contrat social dans la Déclaration des droits de l’homme et du citoyen de 1789
kn-title=1789年フランス人権宣言と社会契約
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=HatanoS.
en-aut-sei=Hatano
en-aut-mei=S.
kn-aut-name=波多野敏
kn-aut-sei=波多野
kn-aut-mei=敏
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学名誉教授
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=706
end-page=657
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Development and Present State of Judicial Doctrine on the Speedy Trial Clause
kn-title=迅速裁判条項に関する判例法理の展開と現状
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=HaradaK. 
en-aut-sei=Harada
en-aut-mei=K. 
kn-aut-name=原田和往
kn-aut-sei=原田
kn-aut-mei=和往
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=726
end-page=707
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A Study on the Consequences of Invalid Election Results under Article 251 of the Public Offices Election Act
kn-title=公職選挙法251条（当選人本人の選挙犯罪）による当選無効の結果に関する一考察 ― 最三小判令和５年12月12日民集77巻９号2229頁を契機として―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=FukushigeS.
en-aut-sei=Fukushige
en-aut-mei=S.
kn-aut-name=福重さと子
kn-aut-sei=福重
kn-aut-mei=さと子
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=371
end-page=407
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=On F. Michelman’s Interpretation of Rawls’s Later Thought: An Examination of Its Republican Implications
kn-title=Ｆ・マイケルマンの後期ロールズ解釈について ―その共和主義的含意の検討
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=OmoriH.
en-aut-sei=Omori
en-aut-mei=H.
kn-aut-name=大森秀臣
kn-aut-sei=大森
kn-aut-mei=秀臣
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=349
end-page=370
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Liberalism and Moral Psychology: Jonathan Haidt and John Rawls
kn-title=リベラリズムと道徳心理学 ―ジョナサン・ハイトとジョン・ロールズ
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=OdagawaD.
en-aut-sei=Odagawa
en-aut-mei=D.
kn-aut-name=小田川大典
kn-aut-sei=小田川
kn-aut-mei=大典
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=表紙・目次
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=
article-no=
start-page=91
end-page=105
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260328
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Practical Research on Nurturing the Next Generation of Classical Japanese Instrument Music that Connects the Local and the Global Community (3) . The Potential for Developing Intercultural Competence through Questionnaire Surveys of Elementary and Junior High School Student.
kn-title=地域社会とグローバルをつなぐ和楽器音楽次世代育成の実践研究（３） 小中学生の質問紙調査に見る「異文化間能力」育成の可能性
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本研究は，「おかやま国際和楽器学生フェスティバル」の実践における，異文化間能力育成の可能性について，参加した小中学生の質問紙調査結果から検討した。<br>
　その結果，１）体験を通して形成された新たな認識により，和楽器音楽文化と自己との関係性を再認識・再構築し，和楽器音楽文化への積極的な関与を示す価値づけ・意味づけが行われ，内在化が促されたこと，２）越境文化としての和楽器音楽文化に対して，開放的・尊重的態度を示していたが，自己の文化的アイデンティティを意識する契機となったこと，３）和楽器音楽の共有を通して生じた共感の上に，相互理解や協働関係が構築されていたこと，４）「文化の共有の可能性についての認識」が形成されるなど，フェスティバルでの経験が，文化観の形成に影響を与える契機となっていたこと，が明らかになった。
en-copyright=
kn-copyright=

en-aut-name=HAYAKAWARinko
en-aut-sei=HAYAKAWA
en-aut-mei=Rinko
kn-aut-name=早川倫子
kn-aut-sei=早川
kn-aut-mei=倫子
aut-affil-num=1
ORCID=

en-aut-name=BEPPUYuko
en-aut-sei=BEPPU
en-aut-mei=Yuko
kn-aut-name=別府祐子
kn-aut-sei=別府
kn-aut-mei=祐子
aut-affil-num=2
ORCID=

en-aut-name=YAMAJIMiho
en-aut-sei=YAMAJI
en-aut-mei=Miho
kn-aut-name=山路みほ
kn-aut-sei=山路
kn-aut-mei=みほ
aut-affil-num=3
ORCID=

en-aut-name=HANAKUSAYoko
en-aut-sei=HANAKUSA
en-aut-mei=Yoko
kn-aut-name=花草容子
kn-aut-sei=花草
kn-aut-mei=容子
aut-affil-num=4
ORCID=

en-aut-name=TAKESHITANoriko
en-aut-sei=TAKESHITA
en-aut-mei=Noriko
kn-aut-name=竹下則子
kn-aut-sei=竹下
kn-aut-mei=則子
aut-affil-num=5
ORCID=

en-aut-name=TAKASUHiromi
en-aut-sei=TAKASU
en-aut-mei=Hiromi
kn-aut-name=髙須裕美
kn-aut-sei=髙須
kn-aut-mei=裕美
aut-affil-num=6
ORCID=

en-aut-name=MIYOSHIKeiko
en-aut-sei=MIYOSHI
en-aut-mei=Keiko
kn-aut-name=三好啓子
kn-aut-sei=三好
kn-aut-mei=啓子
aut-affil-num=7
ORCID=

en-aut-name=SHIMIZUNaoko
en-aut-sei=SHIMIZU
en-aut-mei=Naoko
kn-aut-name=清水尚子
kn-aut-sei=清水
kn-aut-mei=尚子
aut-affil-num=8
ORCID=

en-aut-name=TOSAChihiro
en-aut-sei=TOSA
en-aut-mei=Chihiro
kn-aut-name=土佐千紘
kn-aut-sei=土佐
kn-aut-mei=千紘
aut-affil-num=9
ORCID=

en-aut-name=NAKAMURA Ai
en-aut-sei=NAKAMURA 
en-aut-mei=Ai
kn-aut-name=中村愛
kn-aut-sei=中村
kn-aut-mei=愛
aut-affil-num=10
ORCID=

en-aut-name=HIGUCHIAki
en-aut-sei=HIGUCHI
en-aut-mei=Aki
kn-aut-name=樋口亜希
kn-aut-sei=樋口
kn-aut-mei=亜希
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=2
en-affil=Kurashiki City College
kn-affil=倉敷市立短期大学

affil-num=3
en-affil=Part-time Lecturer at Okayama University
kn-affil=岡山大学非常勤講師

affil-num=4
en-affil=Research Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科

affil-num=5
en-affil=Biwako-Gakuin University
kn-affil=びわこ学院大学短期大学部

affil-num=6
en-affil=Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=7
en-affil=Research Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科

affil-num=8
en-affil=Doctoral Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科

affil-num=9
en-affil=Yamaha Corporation
kn-affil=ヤマハ株式会社楽器事業本部

affil-num=10
en-affil=Doctoral Student at the Joint Graduate School in Science of School Education Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科

affil-num=11
en-affil=Okayama Prefectural School for the Deaf
kn-affil=岡山県立岡山聾学校
en-keyword=和楽器音楽 (Classical Japanese instrument)
kn-keyword=和楽器音楽 (Classical Japanese instrument)
en-keyword=異文化間能力 (‘Intercultural Competence’)
kn-keyword=異文化間能力 (‘Intercultural Competence’)
en-keyword=次世代育成 (the next generation)
kn-keyword=次世代育成 (the next generation)
en-keyword=質問紙調査 (questionnaire survey)
kn-keyword=質問紙調査 (questionnaire survey)
en-keyword=小学生・中学生 (elementary and junior high school students)
kn-keyword=小学生・中学生 (elementary and junior high school students)
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=
article-no=
start-page=75
end-page=89
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260328
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Summer Climate around Germany and the German Lied “Im Frühling” (In Spring) by F. Schubert: A Report of an Interdisciplinary Lesson Practice at the University Leading to the Understanding of Heterogeneous Others
kn-title=ドイツ付近の夏の気候とシューベルトの歌曲《春に》 異質な他者との出会いを促す大学での学際的授業の報告
en-subtitle=
kn-subtitle=
en-abstract=An interdisciplinary lesson practice for the university students leading to the understanding of heterogeneous others was made on a topic of summer climate and the seasonal feeling around Germany, as a continuing study of Kato et al. (2025). In the lesson practice, details of the climate and seasonal cycle around Germany were firstly explained and the German lied “Im Frühling” (In spring) composed by F. Schubert was appreciated, paying attention to how the scenes and emotions expressed by the lyrics “all summer long” in the 3rd verse of this song might differ whether we imagine the climate around Germany or that around Japan. It seems that the present activity provided an opportunity for the students to perceive the climate environments and seasonal feelings quite different from those familiar to them . However, how to explore the appreciation activities that focus also on the musical expression itself of that song is an interesting remaining problem, in order for the students to capture the summer scenery and emotions which Schubert himself imagined.
kn-abstract=　「異質な他者」への出会いを促す授業例の更なる蓄積のため，ドイツ付近の「夏」の気候と季節感に注目した教科横断的な授業を大学で実践した。授業では，ドイツ付近の気候と季節サイクルの中での「夏」の特徴を把握すると共に，シューベルトの歌曲《春に》を鑑賞した。《春に》の3 番の「夏の間じゅう，ずっと」という歌詞で歌われている情景や情感が，ドイツ付近と日本付近を想定した場合にどう違い得るか，に関する受講生の記述を分析した。その結果，日本の夏の高温多湿な環境からは原詩の情感そのものが成立し難いと感じた学生もいるなど，本実践は，自分たちの「当たり前」とは異なる気候や季節感にも目を向ける機会になり得たといえる。一方，日本とはかなり違う気候背景の中でシューベルトが思い描いたであろう情景・心情に授業で深く迫るための，音楽表現自体への踏み込み方についても，今後検討する必要性が示唆された。
en-copyright=
kn-copyright=

en-aut-name=KATOKuranoshin
en-aut-sei=KATO
en-aut-mei=Kuranoshin
kn-aut-name=加藤内藏進
kn-aut-sei=加藤
kn-aut-mei=内藏進
aut-affil-num=1
ORCID=

en-aut-name=NAGAOKAIsao
en-aut-sei=NAGAOKA
en-aut-mei=Isao
kn-aut-name=長岡功
kn-aut-sei=長岡
kn-aut-mei=功
aut-affil-num=2
ORCID=

en-aut-name=KATOHaruko
en-aut-sei=KATO
en-aut-mei=Haruko
kn-aut-name=加藤晴子
kn-aut-sei=加藤
kn-aut-mei=晴子
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=2
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=3
en-affil=Faculty of Education, Gufu Shotoku Gakuen University (Former affiliation)
kn-affil=元　岐阜聖徳学園大学教育学部
en-keyword=気候と音楽
kn-keyword=気候と音楽
en-keyword=ドイツ付近の夏の気候と季節感
kn-keyword=ドイツ付近の夏の気候と季節感
en-keyword=気候と文化理解の学際的ESD教師教育
kn-keyword=気候と文化理解の学際的ESD教師教育
en-keyword=異質な他者への理解
kn-keyword=異質な他者への理解
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=
article-no=
start-page=1
end-page=13
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260328
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Preschool Teachers’ Strategies and Practical Challenges in Supporting the School Enrollment of Foreign Children
kn-title=外国人幼児の就学支援における保育士の工夫と実践的課題
en-subtitle=
kn-subtitle=
en-abstract=This study aimed to clarify the specific practices and challenges faced by preschool teachers in supporting foreign children at the time of school enrollment. Semi-structured interviews were conducted with two preschool teachers who had experience in supporting foreign children, and qualitative analysis using SCAT was applied to organize the support provided to both children and their parents. The results revealed that, in terms of language support, teachers utilized visual aids and simplified Japanese, while in cultural support they sought to balance family culture with the culture of the preschool. Regarding developmental support, the importance of fostering non-cognitive skills and collaborating with medical institutions was highlighted. In parent support, participatory involvement and careful explanations were practiced; however, challenges remained in providing institutional information and establishing collaboration with local governments. Based on these findings, it is necessary to establish a regional collaborative system that can provide institutional support for families with multicultural backgrounds, standardize the provision of information, and build practical mechanisms to connect with Japanese language education resources, so that support does not rely solely on the individual efforts of preschool teachers.
kn-abstract=　本研究は，外国人幼児が就学期に直面する困難に対応するため，保育士が行っている具体的な保育実践における支援の工夫と課題を明らかにすることを目的とした。外国人幼児の支援経験を有する保育士2 名に半構造化インタビューを行い，SCAT を用いた質的分析により，幼児および保護者への支援内容を整理した。その結果，言語面では視覚的支援ややさしい日本語を活用し，文化面では家庭文化と日本の園文化の調整が行われていた。発達支援においては，非認知的スキルの育成や医療機関との連携の必要性が指摘された。保護者支援では，参加型の関わりや丁寧な説明が実践されていたが，制度情報の提供や行政との連携には課題が残された。これらの結果を踏まえ，今後は保育士の個別的努力に依存しないためにも，多文化背景をもつ家庭への支援を制度的に支える地域連携体制の整備や，情報提供の標準化，日本語教育資源との接続を図る実践的仕組みの構築が求められる。
en-copyright=
kn-copyright=

en-aut-name=CHENYiwen
en-aut-sei=CHEN
en-aut-mei=Yiwen
kn-aut-name=陳依文
kn-aut-sei=陳
kn-aut-mei=依文
aut-affil-num=1
ORCID=

en-aut-name=YANAGISAWAKazuki
en-aut-sei=YANAGISAWA
en-aut-mei=Kazuki
kn-aut-name=柳澤佳月
kn-aut-sei=柳澤
kn-aut-mei=佳月
aut-affil-num=2
ORCID=

en-aut-name=REN Xinyu
en-aut-sei=REN
en-aut-mei= Xinyu
kn-aut-name=任芯于
kn-aut-sei=任
kn-aut-mei=芯于
aut-affil-num=3
ORCID=

en-aut-name=YOSHITOSHIMunehisa
en-aut-sei=YOSHITOSHI
en-aut-mei=Munehisa
kn-aut-name=吉利宗久
kn-aut-sei=吉利
kn-aut-mei=宗久
aut-affil-num=4
ORCID=

affil-num=1
en-affil=The Joint Graduate School (Ph.D. Program) in Science of School Education, Hyogo University of Teacher, Hyogo University of Teacher Education
kn-affil=兵庫教育大学大学院連合学校教育学研究科博士課程

affil-num=2
en-affil=Graduate School of Education, Okayama University
kn-affil=岡山大学大学院教育学研究科

affil-num=3
en-affil=Graduate School of Education, Okayama University
kn-affil=岡山大学大学院教育学研究科

affil-num=4
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=外国人幼児 (foreign preschool children)
kn-keyword=外国人幼児 (foreign preschool children)
en-keyword=就学 (school enrollment)
kn-keyword=就学 (school enrollment)
en-keyword=保育士 (preschool teachers)
kn-keyword=保育士 (preschool teachers)
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3
article-no=
start-page=84
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260225
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose Immune checkpoint inhibitor (ICI)-based combination therapy is a standard first-line treatment for metastatic renal cell carcinoma (mRCC), with combinations such as nivolumab plus cabozantinib (Nivo + Cabo) and pembrolizumab plus lenvatinib (Pem + Len) demonstrating favorable oncologic outcomes. However, no direct comparisons between these two regimens have been conducted. This study aimed to compare the safety and oncologic outcomes of Nivo + Cabo and Pem + Len in patients with mRCC.<br>
Methods This retrospective study included 185 patients with mRCC treated with Nivo + Cabo (n = 81) or Pem + Len (n = 104) between January 2018 and June 2025 across multiple institutions. The primary outcome was a comparison of treatment-related adverse events (TrAEs). Oncologic outcomes, including objective response rate (ORR), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were compared using one-to-one propensity score matching.<br>
Results Any-grade TrAEs occurred in 90% of patients in the Nivo + Cabo group and 92% in the Pem + Len group (p = 0.6). Severe TrAEs (grade ≥ 3) were more frequent in the Pem + Len group (44%) than in the Nivo + Cabo group (30%, p = 0.048). Tyrosine kinase inhibitor dose reduction and treatment discontinuation rates were similar between groups. In the matched cohort (Nivo + Cabo: n = 74; Pem + Len: n = 74), ORRs were comparable (66% vs. 71%, p = 0.6). With a median follow-up of 17 months, no significant differences were observed in PFS (p = 0.4), CSS (p = 0.9), or OS (p = 0.5).<br>
Conclusions Nivo + Cabo and Pem + Len demonstrated similar oncologic efficacy as first-line treatments for mRCC. However, Pem + Len was associated with more severe TrAEs. Careful toxicity management and shared decision-making are essential when selecting ICI-based combinations.
en-copyright=
kn-copyright=

en-aut-name=YanagisawaTakafumi
en-aut-sei=Yanagisawa
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MoriKeiichiro
en-aut-sei=Mori
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KawadaTatsushi
en-aut-sei=Kawada
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsujinoTakuya
en-aut-sei=Tsujino
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MaenosonoRyoichi
en-aut-sei=Maenosono
en-aut-mei=Ryoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyodaShingo
en-aut-sei=Toyoda
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NukayaTakuhisa
en-aut-sei=Nukaya
en-aut-mei=Takuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MorinakaHirofumi
en-aut-sei=Morinaka
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TamuraKeita
en-aut-sei=Tamura
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FukuokayaWataru
en-aut-sei=Fukuokaya
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=UrabeFumihiko
en-aut-sei=Urabe
en-aut-mei=Fumihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MurakamiMasaya
en-aut-sei=Murakami
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakaharaKiyoshi
en-aut-sei=Takahara
en-aut-mei=Kiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FujitaKazutoshi
en-aut-sei=Fujita
en-aut-mei=Kazutoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=AzumaHaruhito
en-aut-sei=Azuma
en-aut-mei=Haruhito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=InamotoTeruo
en-aut-sei=Inamoto
en-aut-mei=Teruo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=KomuraKazumasa
en-aut-sei=Komura
en-aut-mei=Kazumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=KimuraTakahiro
en-aut-sei=Kimura
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
kn-affil=

affil-num=4
en-affil=Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
kn-affil=

affil-num=5
en-affil=Department of Urology, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=6
en-affil=Department of Urology, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=7
en-affil=Department of Urology, Faculty of Medicine, Kindai University
kn-affil=

affil-num=8
en-affil=Department of Urology, Fujita-Health University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Urology, Kawasaki Medical School
kn-affil=

affil-num=10
en-affil=Department of Urology, Hamamatsu Medical University
kn-affil=

affil-num=11
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Urology, Fujita-Health University School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Urology, Faculty of Medicine, Kindai University
kn-affil=

affil-num=17
en-affil=Department of Urology, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=18
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Department of Urology, Hamamatsu Medical University
kn-affil=

affil-num=20
en-affil=Department of Urology, Kawasaki Medical School
kn-affil=

affil-num=21
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=
en-keyword=Metastatic renal cell carcinoma
kn-keyword=Metastatic renal cell carcinoma
en-keyword=Immune checkpoint inhibitor
kn-keyword=Immune checkpoint inhibitor
en-keyword=Pembrolizumab
kn-keyword=Pembrolizumab
en-keyword=Lenvatinib
kn-keyword=Lenvatinib
en-keyword=Nivolumab
kn-keyword=Nivolumab
en-keyword=Cabozantinib
kn-keyword=Cabozantinib
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=3
article-no=
start-page=55
end-page=59
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260315
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Low Temperature Formation of Dense Yttria-Stabilized Zirconia Layer Using Hot Isostatic Pressing
kn-title=熱間静水圧加圧法を用いたイットリア安定化ジルコニア緻密層の低温形成
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The sintering conditions using hot isostatic press (HIP) of yttria-stabilized zirconia (YSZ) were investigated to obtain a dense YSZ layer at low sintering temperature such as 1000°C for an electrolyte of metal-supported solid oxide fuel cell. It was found that a dense YSZ pellet with relative density of 93% could be obtained under a sintering condition of 1000°C-10 hours with HIP in 195 MPa. On the other hand, in X-ray diffraction analysis of the dense YSZ pellet, peaks of the monoclinic phase were slightly detected in addition to peaks of the cubic phase. From energy dispersive X-ray spectroscopy analysis, a small amount of boron was detected in the dense YSZ pellet. It is considered that the YSZ crystalline phase transformation of cubic to monoclinic phase was occurred by the boron diffusion from the diffusion barrier coating of metal foil capsule used for the HIP.
en-copyright=
kn-copyright=

en-aut-name=MANABEKyohei
en-aut-sei=MANABE
en-aut-mei=Kyohei
kn-aut-name=真鍋享平
kn-aut-sei=真鍋
kn-aut-mei=享平
aut-affil-num=1
ORCID=

en-aut-name=ECHIGOMitsuaki
en-aut-sei=ECHIGO
en-aut-mei=Mitsuaki
kn-aut-name=越後満秋
kn-aut-sei=越後
kn-aut-mei=満秋
aut-affil-num=2
ORCID=

en-aut-name=KISHIMOTOAkira
en-aut-sei=KISHIMOTO
en-aut-mei=Akira
kn-aut-name=岸本昭
kn-aut-sei=岸本
kn-aut-mei=昭
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Osaka Gas Co. Ltd.
kn-affil=大阪ガス（株）

affil-num=2
en-affil=Osaka Gas Co. Ltd.
kn-affil=大阪ガス（株）

affil-num=3
en-affil=Institute of Academic and Research, Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=岡山大学学術研究院環境生命自然科学学域
en-keyword=dense yttria-stabilized zirconia
kn-keyword=dense yttria-stabilized zirconia
en-keyword=hot isostatic press
kn-keyword=hot isostatic press
en-keyword=low sintering temperature
kn-keyword=low sintering temperature
en-keyword=electrolyte
kn-keyword=electrolyte
en-keyword=metal-supported solid oxide fuel cell
kn-keyword=metal-supported solid oxide fuel cell
END

start-ver=1.4
cd-journal=joma
no-vol=46
cd-vols=
no-issue=
article-no=
start-page=ii
end-page=ii
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=目次
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=37
cd-vols=
no-issue=3
article-no=
start-page=580
end-page=589
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260304
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Cysteine-Specific Cationization Strategy for Versatile Antibody Production against Intrinsically Disordered Proteins
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Several autoantigens relevant to the immune system, especially those targeted by autoantibodies induced by antitumor responses, tend to be rich in disordered regions and are prone to aggregation. This inherent instability presents significant challenges for the production, purification, and analysis of autoantigens in laboratory settings. Cysteine-specific cationization can effectively solubilize and purify these challenging proteins, allowing the isolation of full-length water-soluble antigens in their denatured state. The purified antigens enable accurate multiplex autoantibody assays using a suspension Luminex bead array platform. However, well-validated positive control antibodies are essential to ensuring precise clinical diagnosis. In this study, we prepared and characterized a panel of control antibodies by immunizing rabbits with cysteine-specific S-cationized antigens. The resulting antibodies predominantly recognized linear epitopes and were highly effective as quality control reagents in autoantibody array assays. Additionally, these antibodies maintained their ability to bind to their native, unmodified intracellular counterparts, highlighting the usefulness of this approach for producing antibodies against intrinsically disordered proteins. Although a modest immune response against the S-cationized modification site was observed, it remained minimal and did not affect the usefulness of the antibodies for assay validation. We propose this versatile cysteine-specific cationization platform for managing unstable proteins rich in disordered regions, supporting antigen production for diagnostics, and antibody development for research and validation purposes.
en-copyright=
kn-copyright=

en-aut-name=SakaguchiRyui
en-aut-sei=Sakaguchi
en-aut-mei=Ryui
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MiyamotoAi
en-aut-sei=Miyamoto
en-aut-mei=Ai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KutsumaRikako
en-aut-sei=Kutsuma
en-aut-mei=Rikako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MoriTakeru
en-aut-sei=Mori
en-aut-mei=Takeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakashimaDaichi
en-aut-sei=Nakashima
en-aut-mei=Daichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MasuiMirei
en-aut-sei=Masui
en-aut-mei=Mirei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HonjoTomoko
en-aut-sei=Honjo
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FutamiMidori
en-aut-sei=Futami
en-aut-mei=Midori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MoriiMariko
en-aut-sei=Morii
en-aut-mei=Mariko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OshikiToshiyuki
en-aut-sei=Oshiki
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FutamiJunichiro
en-aut-sei=Futami
en-aut-mei=Junichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Bioscience, Faculty of Life Science, Okayama University of Science
kn-affil=

affil-num=9
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=10
en-affil=Division of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=11
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=3
article-no=
start-page=e202500639
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=PPy‐Coated Wire Actuators for the Micromechanostimulation of Cells: Fabrication and Characterization
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Cellular mechanotransduction signals play a crucial role in physiological and pathological conditions, including skeletal disorders. Although various systems exist to mechanically stimulate cultured cells, most are constrained by incubator incompatibility, limited physiological relevance, nonuniform stimulation, or complexity. The objective of this article is to develop and validate a compact, incubator-compatible tool capable of delivering localized and physiologically relevant mechanical stimulation to small cell populations. Here, we introduce a polypyrrole-based wire-shaped microactuator designed to induce localized mechanical stress to adjacent cells. These wire-shaped microactuators are biocompatible, easy-to-use, and compact for use within standard in vitro cell culture systems. Using a noncontact optical method, we characterize the actuation of polypyrrole-coated wires in an aqueous NaDBS electrolyte, showing radial expansion of 1.5–8 µm depending on the deposited polypyrrole film thickness, comparable to cellular dimensions. Next, the actuation is confirmed to be robust and stable to use in cell culture media at physiological temperature. To evaluate biological relevance, osteoblastic KUSA-A1 cells are mechanically stimulated inside the incubator and transcriptomic changes are assessed. Mechanical stimulation resulted in upregulation of genes previously associated with mechanotransduction, including Fos and Fosb. Additionally, several uncharacterized long noncoding RNAs are differentially expressed, suggesting potential novel players in the mechanotransduction pathway.
en-copyright=
kn-copyright=

en-aut-name=Ortega‐SantosAmaia B.
en-aut-sei=Ortega‐Santos
en-aut-mei=Amaia B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HayanoSatoru
en-aut-sei=Hayano
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HaraEmilio Satoshi
en-aut-sei=Hara
en-aut-mei=Emilio Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MartínezJose G.
en-aut-sei=Martínez
en-aut-mei=Jose G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KamiokaHiroshi
en-aut-sei=Kamioka
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=JagerEdwin W. H.
en-aut-sei=Jager
en-aut-mei=Edwin W. H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Sensor and Actuator Systems, Department of Physics Chemistry and Biology (IFM), Linköping University
kn-affil=

affil-num=2
en-affil=Department of Orthodontics, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Advanced Research Center for Oral and Craniofacial Sciences Dental School, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Sensor and Actuator Systems, Department of Physics Chemistry and Biology (IFM), Linköping University
kn-affil=

affil-num=5
en-affil=Department of Orthodontics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Sensor and Actuator Systems, Department of Physics Chemistry and Biology (IFM), Linköping University
kn-affil=
en-keyword=conducting polymers
kn-keyword=conducting polymers
en-keyword=mechanotransduction
kn-keyword=mechanotransduction
en-keyword=osteoblasts
kn-keyword=osteoblasts
en-keyword=polypyrrole
kn-keyword=polypyrrole
en-keyword=RNA sequencing
kn-keyword=RNA sequencing
en-keyword=soft-microactuators
kn-keyword=soft-microactuators
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=
article-no=
start-page=7
end-page=16
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260331
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A Preliminary Study on Nursing Care Technology: A Case Study of Elderly Care
kn-title=介護技術論試論―高齢者介護を事例として―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In the first part of this paper, it was confirmed that the term “kaigo” (nursing care) was coined and its meaning defined during discussions on enacting social welfare legislation accompanying societal aging, as the care aspect was being “differentiated” from the “family’s health and welfare functions.” The paper also examined how the term “kaigo gijutsu”(nursing care technique) has been defined and used. In the latter part, based on the author’s own definition of “kaigo gijutsu”(nursing care technology), an attempt was made to analyze examples of technology utilization in nursing care settings, focusing on papers published in specialized welfare and nursing care technology journals. Through this preliminary study, it was shown that the author’s definition of “nursing care technology” clearly distinguishes between the means for care activities—such as welfare equipment—and the care recipients and caregivers who make use of them, and that this definition is useful for grasping the essence of challenges in nursing care settings.
en-copyright=
kn-copyright=

en-aut-name=YOSHIBAYasuyuki
en-aut-sei=YOSHIBA
en-aut-mei=Yasuyuki
kn-aut-name=吉葉恭行
kn-aut-sei=吉葉
kn-aut-mei=恭行
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Faculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=岡山大学学術研究院ヘルスシステム統合科学学域
en-keyword=Nursing Care Technology
kn-keyword=Nursing Care Technology
en-keyword=Elderly Care
kn-keyword=Elderly Care
en-keyword=welfare equipment
kn-keyword=welfare equipment
END

start-ver=1.4
cd-journal=joma
no-vol=2025
cd-vols=
no-issue=
article-no=
start-page=9884345
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251120
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Comparing the Activity of Peripheral Blood Mononuclear Cells Frozen Under Electromagnetic Field Freezing and Standard Slow-Freezing
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Peripheral blood mononuclear cells (PBMCs) are cells obtained from the blood that are used not only in clinical tests but also in various research applications. The slow-freezing (SLF) method, currently the standard for PBMC cryopreservation, involves extended storage at −80°C before transfer to liquid nitrogen. Delays in this transfer, such as overnight or weekend holds, risk a gradual decline in cell viability. Additionally, variability in freezing duration can lead to inconsistent cell quality, emphasizing the need for an alternative freezing method that allows for more timely transfer to liquid nitrogen. This study is aimed at clarifying whether the method of using a freezer with an applied electromagnetic field (EMF) is superior to the currently used standard SLF method for PBMC cryopreservation. A comparison of the number of viable cells, cell viability, and cell activity showed that the EMF method was equivalent to the SLF method. However, the shortest time required for freezing was significantly shorter with the EMF method than the SLF method (0.25 vs. 3 h), allowing for earlier transfer of PBMC to liquid nitrogen. This demonstrates that the EMF method offers an advantage in operational efficiency, particularly for facilities that routinely process and store PBMCs, such as biobanks and other storage-focused departments.
en-copyright=
kn-copyright=

en-aut-name=MatsubaraTakehiro
en-aut-sei=Matsubara
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakagiMina
en-aut-sei=Takagi
en-aut-mei=Mina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UwaboTakahiro
en-aut-sei=Uwabo
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SohJunichi
en-aut-sei=Soh
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MoritaMizuki
en-aut-sei=Morita
en-aut-mei=Mizuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Okayama University Hospital Biobank
kn-affil=

affil-num=2
en-affil=Faculty of Health Sciences, Okayama University Medical School
kn-affil=

affil-num=3
en-affil=Department of Biorepository Research and Networking, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Thoracic Surgery, Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Okayama University Hospital Biobank
kn-affil=

affil-num=6
en-affil=Okayama University Hospital Biobank
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=1
article-no=
start-page=8840
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260317
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Tribolium castaneum with longer duration of tonic immobility have more variations corresponding to the human Parkinson’s disease genomic region
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Parkinson’s disease (PD) is a common neurodegenerative syndrome characterized by the loss of dopaminergic neurons and is also a progressive neurodegenerative disorder that is characterized by dopamine deficiency. We established strains artificially selected for longer and shorter durations of tonic immobility, an antipredator behavior that has received much attention recently, in the red flour beetle, Tribolium castaneum, a model insect species for molecular analyses different from Drosophila melanogaster. Previous studies have shown that the long strains (L-strain) have significantly lower levels of dopamine expression in the brain than the short strains (S-strain) and that they have an abnormal pattern of locomotor activity. Furthermore, previous studies have shown that administering dopamine to L-strain beetles reduces the duration of tonic immobility. Transcriptome analysis of brain and thorax of the L- and S-strains also showed differences in mRNA expression of genes involved in dopamine synthesis and tyrosine metabolism. These results indicate that the phenotype and molecular basis of the L-strain are similar to those of Parkinson’s syndrome symptoms. In order to establish a link between T. castaneum and PD, we compared the DNA sequences of the L- and S-strains to human genes affecting dopaminergic pathways. The DNA comparison revealed many mutated regions in these genes in the L-strain. We discuss the relationship between dopaminergic pathway genes and PD-like phenotypes across humans, Drosophila, and the red flour beetle.
en-copyright=
kn-copyright=

en-aut-name=TanakaKeisuke
en-aut-sei=Tanaka
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SasakiKen
en-aut-sei=Sasaki
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YajimaShunsuke
en-aut-sei=Yajima
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyatakeTakahisa
en-aut-sei=Miyatake
en-aut-mei=Takahisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=NODAI Genome Research Center, Tokyo University of Agriculture
kn-affil=

affil-num=2
en-affil=Graduate School of Agriculture, Tamagawa University
kn-affil=

affil-num=3
en-affil=NODAI Genome Research Center, Tokyo University of Agriculture
kn-affil=

affil-num=4
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=40
cd-vols=
no-issue=
article-no=
start-page=18
end-page=34
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260320
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=大津皇子と石川郎女の贈答歌 ―入門教材としての古典和歌―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=松田聡
kn-aut-sei=松田
kn-aut-mei=聡
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学
END

start-ver=1.4
cd-journal=joma
no-vol=68
cd-vols=
no-issue=3
article-no=
start-page=e70044
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260310
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Simple Method for RNA-Seq of Manually Isolated Chromatophores in Oryzias Fishes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=RNA sequencing (RNA-seq) has become an essential tool for analyzing gene expression and exploring cell type–specific transcriptomes. However, sample preparation and quality control remain challenging, as current approaches typically rely on dissecting tissues containing mixed cell populations or using flow cytometry to isolate fluorescently labeled cells. Here we present a simple and reliable method for RNA-seq of chromatophores (pigment cells) by manually isolating cells based on their natural pigmentation. We analyzed four chromatophore types—melanophores, xanthophores, iridophores, and leucophores—in medaka (Oryzias latipes). Remarkably, as few as 100 cells per type yielded reasonably high-quality transcriptomes sufficient to identify differentially expressed genes (DEGs). Furthermore, this method was successfully applied to a non-model medaka species, O. woworae, which shares the same four chromatophore types. Our approach enables efficient, low-cost, and cross-species transcriptome analysis of chromatophores without requiring transgenic markers or flow cytometry.
en-copyright=
kn-copyright=

en-aut-name=GodaMakoto
en-aut-sei=Goda
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MiyagiAsuka
en-aut-sei=Miyagi
en-aut-mei=Asuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SugiwakaKeisuke
en-aut-sei=Sugiwaka
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WatanabeMasakatsu
en-aut-sei=Watanabe
en-aut-mei=Masakatsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=Bessho‐UeharaManabu
en-aut-sei=Bessho‐Uehara
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HibiMasahiko
en-aut-sei=Hibi
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyodaAtsushi
en-aut-sei=Toyoda
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TanakaRieko
en-aut-sei=Tanaka
en-aut-mei=Rieko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MasengiKawilarang W. A.
en-aut-sei=Masengi
en-aut-mei=Kawilarang W. A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YamahiraKazunori
en-aut-sei=Yamahira
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=AnsaiSatoshi
en-aut-sei=Ansai
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HashimotoHisashi
en-aut-sei=Hashimoto
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Institute of Photonics Medicine, Hamamatsu University School of Medicine
kn-affil=

affil-num=2
en-affil=Institute of Photonics Medicine, Hamamatsu University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University
kn-affil=

affil-num=4
en-affil=Cellular and Structural Physiology Institute (CeSPI) and Graduate School of Pharmaceutical Sciences, Nagoya University
kn-affil=

affil-num=5
en-affil=Frontier Research Institute for Interdisciplinary Science, Tohoku University
kn-affil=

affil-num=6
en-affil=Department of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University
kn-affil=

affil-num=7
en-affil=Comparative Genomics Laboratory, National Institute of Genetics
kn-affil=

affil-num=8
en-affil=World Medaka Aquarium, Nagoya Higashiyama Zoo and Botanical Gardens
kn-affil=

affil-num=9
en-affil=Faculty of Fisheries and Marine Science, Sam Ratulangi University
kn-affil=

affil-num=10
en-affil=Tropical Biosphere Research Center, University of the Ryukyus
kn-affil=

affil-num=11
en-affil=Ushimado Marine Institute, Okayama University
kn-affil=

affil-num=12
en-affil=Department of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=1
article-no=
start-page=33
end-page=44
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260331
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Large-scale rainfall characteristics at the heavy rainfall event around the western Japan during 5–7 July 2018
kn-title=2018年7月5日〜7日の西日本豪雨における広域降水特性
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　Large-scale rainfall characteristics at the heavy rainfall event around the western Japan for 5–7 July 2018 were analyzed with use of the 10-mimute precipitation data at the surface meteorological observation stations of the Japan Meteorological Agency, and so on. In this case, the area with 3 days total precipitation of near or more than 300 mm was distributed widely from northern Kyushu to Shiga and Fukui Prefectures. As in the many heavy rainfall events around Kyushu District in the mature stage of the Baiu season, contribution of the intense rainfall with more than 4 mm/10-minute (24 mm/h) attained about one third of the areal mean total precipitation. However, it is noted that the "not so intense rain" with less than 2 mm/10-minute (12 mm/h) also contributed to about one third of the huge total precipitation in the wide area. In short, this case could be characterized by the mixture of the western Japan type heavy rainfall event and the eastern Japan type one.
en-copyright=
kn-copyright=

en-aut-name=KATOKuranoshin
en-aut-sei=KATO
en-aut-mei=Kuranoshin
kn-aut-name=加藤内藏進
kn-aut-sei=加藤
kn-aut-mei=内藏進
aut-affil-num=1
ORCID=

en-aut-name=MATSUMOTOKengo
en-aut-sei=MATSUMOTO
en-aut-mei=Kengo
kn-aut-name=松本健吾
kn-aut-sei=松本
kn-aut-mei=健吾
aut-affil-num=2
ORCID=

en-aut-name=OTANIKazuo
en-aut-sei=OTANI
en-aut-mei=Kazuo
kn-aut-name=大谷和男
kn-aut-sei=大谷
kn-aut-mei=和男
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域（理科）

affil-num=2
en-affil=Okayama Gakugeikan High School
kn-affil=岡山学芸館高等学校

affil-num=3
en-affil=TV Setouchi Broadcasting Co., LTD.
kn-affil=テレビせとうち(株)
en-keyword=western Japan heavy rainfall in July 2018
kn-keyword=western Japan heavy rainfall in July 2018
en-keyword=10-minute precipitation data
kn-keyword=10-minute precipitation data
en-keyword=east-west difference of the Baiu precipitation
kn-keyword=east-west difference of the Baiu precipitation
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=7
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260331
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Microtremor exploration in Kojima Bay area, Okayama Plain
kn-title=岡山平野児島湾岸部での微動アレイ探査
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　This report describes microtremor array observations conducted at two sites for deep exploration and three sites for shallow exploration around Kojima Bay area in the southern Okayama Plain. Based on these records, the ground velocity structures were estimated. The results yielded solutions indicating the depth of the top of the seismic base layer (equivalent to 3 km/s layer) ranges from 140 to 300 m, while the depth of the top of the engineering basement layer (equivalent to 0.6 km/s layer) is approximately about 13–14 m. The shallow exploration results also suggested the possible presence of an inversion layer. These estimated velocity structure models provided a reasonable explanation for the observed phase velocities.
en-copyright=
kn-copyright=

en-aut-name=YAMADANobuyuki
en-aut-sei=YAMADA
en-aut-mei=Nobuyuki
kn-aut-name=山田伸之
kn-aut-sei=山田
kn-aut-mei=伸之
aut-affil-num=1
ORCID=

en-aut-name=TAKENAKAHiroshi
en-aut-sei=TAKENAKA
en-aut-mei=Hiroshi
kn-aut-name=竹中博士
kn-aut-sei=竹中
kn-aut-mei=博士
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Faculty of Science and Technology, Kochi University
kn-affil=高知大学理工学部地球環境防災学科

affil-num=2
en-affil=Department of Earth Sciences, Okayama University
kn-affil=岡山大学学術研究院環境生命自然科学学域
en-keyword=Okayama Plain
kn-keyword=Okayama Plain
en-keyword=Kojima Bay
kn-keyword=Kojima Bay
en-keyword=Microtremor array exploration
kn-keyword=Microtremor array exploration
en-keyword=S-wave velocity structure model
kn-keyword=S-wave velocity structure model
END

start-ver=1.4
cd-journal=joma
no-vol=61
cd-vols=
no-issue=
article-no=
start-page=21
end-page=29
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260316
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Local Political Representation in Japan: An Attribute Analysis of Okayama Prefecture and Its Municipal Councilors
kn-title=日本の地方議員における代表性の検討：岡山県地方議員データの分析
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=IWABUCHIYasushi
en-aut-sei=IWABUCHI
en-aut-mei=Yasushi
kn-aut-name=岩淵泰
kn-aut-sei=岩淵
kn-aut-mei=泰
aut-affil-num=1
ORCID=

en-aut-name=KoebelMichel
en-aut-sei=Koebel
en-aut-mei=Michel
kn-aut-name=クベルミシェル
kn-aut-sei=クベル
kn-aut-mei=ミシェル
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院教育研究マネジメント領域

affil-num=2
en-affil=
kn-affil=ストラスブール大学
END

start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=3
article-no=
start-page=e72040
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of Overload on Imiquimod‐Induced Psoriasis Model Mice: A Basic Experimental Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Aim: Psoriasis is a skin disorder complicated by arthritis and enthesitis. The cytokines interleukin (IL)-17, IL-23, and tumor necrosis factor (TNF)-α are reportedly key effectors of psoriasis. Additionally, gamma delta (γδ) T cells exacerbate inflammation by producing inflammatory cytokines such as IL-17 and TNF-α. However, details regarding the mechanisms linking pathogenesis and mechanical stress remain unclear. This study aimed to investigate the effect of strenuous exercise on the pathology of psoriasis using mouse models of imiquimod (IMQ)-induced psoriasis.<br>
Methods: Twenty mice were randomly assigned to four groups: IMQ − TRED− (control), IMQ − TRED+ (treadmill running mice), IMQ + TRED− group (IMQ treated mice), and IMQ + TRED+ group (IMQ treated and treadmill running mice). The tissue sections from back skin and thymus were immunostained with antibodies against IL-17, IL-23, and γδ T cells. Shoulder sections were stained using hematoxylin and eosin, and Toluidine Blue and Picrosirius Red. Additionally, the shoulder tissue sections were immunostained with antibodies against TNF-α and matrix metalloproteinase (MMP)-13. Serum cytokine level was measured to evaluate systemic inflammation.<br>
Results: Strenuous exercise exacerbated pathological changes associated with psoriasis, including increased γδ T cell infiltration and upregulated IL-17 and IL-23 expression in the skin, as well as enhanced γδ T cell development and IL-17 expression in the thymus. Although strenuous exercise did not further worsen the modified PASI scores, histological and immunological markers of inflammation were significantly enhanced. Serum levels of TNF-α and IL-17 were significantly elevated in IMQ-induced psoriasis model mice. Moreover, pathological changes induced by strenuous exercise were observed in the enthesis, including angiogenesis and upregulated expression of TNF-α and MMP-13.<br>
Conclusion: This study revealed that strenuous exercise exacerbates pathological changes in IMQ-induced psoriasis model mice.
en-copyright=
kn-copyright=

en-aut-name=FurutaniTomoki
en-aut-sei=Furutani
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SaitoTaichi
en-aut-sei=Saito
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IkedaAsahi
en-aut-sei=Ikeda
en-aut-mei=Asahi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MashimaKenta
en-aut-sei=Mashima
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YukihiroNatsumi
en-aut-sei=Yukihiro
en-aut-mei=Natsumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KusakabeSatoki
en-aut-sei=Kusakabe
en-aut-mei=Satoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakamichiRyo
en-aut-sei=Nakamichi
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YoshidaAki
en-aut-sei=Yoshida
en-aut-mei=Aki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry, and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Okayama University Medical School Faculty of Medicine
kn-affil=

affil-num=4
en-affil=Okayama University Medical School Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Okayama University Medical School Faculty of Medicine
kn-affil=

affil-num=6
en-affil=Okayama University Medical School Faculty of Medicine Okayama Japan
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Locomotive Pain Center, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=enthesis
kn-keyword=enthesis
en-keyword=psoriasis
kn-keyword=psoriasis
en-keyword=strenuous exercise
kn-keyword=strenuous exercise
END

start-ver=1.4
cd-journal=joma
no-vol=57
cd-vols=
no-issue=3
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=裏表紙・英文目次
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=57
cd-vols=
no-issue=3
article-no=
start-page=111
end-page=126
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Die Agrarstruktur in Sachsen im 19. Jahrhundert（5）
kn-title=19世紀ザクセンの土地制度（５）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MatsuoNobushige
en-aut-sei=Matsuo
en-aut-mei=Nobushige
kn-aut-name=松尾展成
kn-aut-sei=松尾
kn-aut-mei=展成
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学名誉教授
END

start-ver=1.4
cd-journal=joma
no-vol=57
cd-vols=
no-issue=3
article-no=
start-page=93
end-page=109
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Environmental Conservation Costs and Operational Efficiency: Evidence from Japanese Manufacturing Firms
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　This study investigates whether environmental conservation costs (ECC) support the operational effectiveness and financial stability of Japanese manufacturing firms. Using a balanced panel of 128 non-financial companies listed on the Tokyo Stock Exchange from 2010 to 2022, we manually collected firm-level ECC data based on the Ministry of the Environment, Japan's guidelines from sustainability reports and matched them with financial data from Compustat Global/S&P Capital IQ. Applying pooled ordinary least squares regression with firm-level clustered standard errors and winsorized variables, we examine two aspects of performance as measures of operating efficiency and profitability: asset turnover and profit margin. The results show that ECC is positively associated with asset turnover and profit margin, and that the effect is stronger in more profitable companies, substantiating the Resource-Based View that green practices generate competitiveness. These findings contribute to sustainability finance research by going beyond perceptual measures of environmental, social, and governance ratings, and measuring actual firm-level spending on environmental activities, thereby providing more nuanced insights into how environmental practices translate into actual financial performance. This study offers clear managerial and policy implications by showing that transparent environmental conservation costs improve disclosure quality and serve as a measure of improved efficiency and profitability.
en-copyright=
kn-copyright=

en-aut-name=NazirYusra
en-aut-sei=Nazir
en-aut-mei=Yusra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TennojiyaTatsumasa
en-aut-sei=Tennojiya
en-aut-mei=Tatsumasa
kn-aut-name=天王寺谷達将
kn-aut-sei=天王寺谷
kn-aut-mei=達将
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Doctoral student at Graduate school of humanities and social sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Faculty of humanities and social sciences, Okayama University
kn-affil=
en-keyword=Environmental Accounting
kn-keyword=Environmental Accounting
en-keyword=Environmental Conservation Cost, Operating Efficiency
kn-keyword=Environmental Conservation Cost, Operating Efficiency
en-keyword=Profitability
kn-keyword=Profitability
en-keyword=Asset Turnover
kn-keyword=Asset Turnover
en-keyword=Sustainability
kn-keyword=Sustainability
en-keyword=Japanese Manufacturing Companies
kn-keyword=Japanese Manufacturing Companies
en-keyword=Resource-Based View
kn-keyword=Resource-Based View
END

start-ver=1.4
cd-journal=joma
no-vol=57
cd-vols=
no-issue=3
article-no=
start-page=41
end-page=91
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Re-theorizing Consumer Behavior in the Age of Human–AI Coexistence: The AIBCBM Framework
kn-title=AI 共生時代における消費者行動の再理論化―AIBCBM フレームワーク―
en-subtitle=
kn-subtitle=
en-abstract=　This study aims to construct and present the AI-Based Consumer Behavior Model（AIBCBM） as a theoretical framework that systematically explains the tripartite interaction among companies, consumers, and AI in environments where AI intervenes from the pre-decision stage. First, it identifies the critical theoretical limitations of existing consumer behavior models, which fail to adequately address contemporary phenomena such as algorithmic exposure, recursive learning loops, and AI-mediated social influence. Building upon this, the study presents the AIBCBM （AI-Based Consumer Behavior Model）, which conceptualizes consumer behavior in the era of AI symbiosis as a tripartite cyclical structure involving“ business–AI–consumer.”<br>
　In constructing the model, rather than oversimplifying complex reality, theoretical clarity and analytical tractability are ensured by separating it into a tripartite co-evolutionary structure model （Figure 2）, a behavioral process model illustrating the dynamics of behavior generation（Table 3）, a conceptual structure model（Figure 3）, and a behavioral typology model（Figure 4）. The theoretical contributions of this study are summarized in five points:<br>
（1） redefining System 1 as a behavioral generation mechanism;<br>
（2） redefining decision-making agents and power structures;<br>
（3） theoretically modeling nonlinear, high-speed feedback loops in consumer behavior;<br>
（4） Theoretical redefinition of non-consumption and JOMO as strategic behaviors grounded in well-being and human agency.<br>
（5） reconceptualizing consumer behavior from a "decision-making model" to a "behavior generation model."<br>
　Moreover, the duality highlighted in this study—where algorithm-driven utility enhancement and autonomy impairment can coexist—provides a new normative and theoretical evaluation framework for marketing strategies and policy design in the AI era. AIBCBM functions as a theoretical platform that integrates these perspectives, serving as a foundation for future theoretical development and empirical validation. In particular, AIBCBM is distinctive in positioning JOMO and non-consumption not as passive withdrawal from algorithmic environments, but as strategic behaviors through which consumers intentionally calibrate their distance from AI-constructed choice architectures to preserve human agency, well-being, and human-likeness.<br>
　Finally, the proposed model serves as a theoretical coordinate framework that systematically connects firm-side AI design, algorithmic dynamics, and consumer agency and well-being, thereby bridging empirical inquiry and normative design in the age of AI co-existence.
kn-abstract=　本研究は，AIが意思決定の前段階から介入する環境において，企業・消費者・AIの三者相互作用を体系的に説明する理論枠組みとして，Artificial Intelligence-Based Consumer Behavior Model（AIBCBM）を構築し，提示することを目的とする。まず，既存の消費者行動モデルが，アルゴリズム露出，再帰的学習ループ，AI媒介型社会的影響（Algorithmic Social Influence）といった現代的現象を十分に扱えないという決定的な理論的限界を明らかにする。そのうえで，AI共生時代における消費者行動を，「企業－AI－消費者」の三者循環構造として捉えるAIBCBMを提示する。<br>
　モデル構築に際しては，複雑な現実を過度に単純化するのではなく，三者共進化構造モデル（図２），行動生成の動態を示す行動プロセスモデル（表３），概念構造モデル（図３），行動類型モデル（図４）に分離することで，理論的明瞭性と分析可能性を確保した。本研究の理論的貢献は，①System １を行動生成メカニズムとして再定義した点，②意思決定主体と権力構造を再定義した点，③消費者行動における非線形・高速フィードバックループを理論化した点，④非消費やJOMOを，幸福と主体性に根ざした戦略的行動として理論的に再定義した点，⑤消費者行動を「意思決定モデル」から「行動生成モデル」へ理論的に転換した点に集約される。さらに，本研究が提示する，アルゴリズムによる効用の向上と自律性の毀損が併存しうるという二面性は，AI時代におけるマーケティング戦略および政策設計に対して，規範的かつ理論的な新たな評価軸を提供する。AIBCBMは，これらの視座を統合する理論的プラットフォームとして，今後の実証研究に向けた基盤として機能する。とりわけ， AIBCBMは，JOMOや非消費行動を，アルゴリズム環境からの受動的撤退ではなく，AIによって構築された選択環境との距離を意図的に調整し，人間らしさ（人間としての主体性やウェルビーイング）を保持するための戦略的行動として位置づける点に独自性を有する。さらに本モデルは，AI設計（企業側）・アルゴリズム動態（AI側）・主体性とウェルビーイング（Well-being）（消費者側）を同一枠組みで接続することで，AI共生時代の実証研究と規範設計を架橋する理論的座標軸を確立する。
en-copyright=
kn-copyright=

en-aut-name=ShazadigulSawut
en-aut-sei=Shazadigul
en-aut-mei=Sawut
kn-aut-name=夏扎提古丽沙吾提
kn-aut-sei=夏扎提古丽
kn-aut-mei=沙吾提
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Faculty of Humanities and Social Sciences, Okayama University
kn-affil=
en-keyword=行動生成モデル (Behavior Generation Model)
kn-keyword=行動生成モデル (Behavior Generation Model)
en-keyword=人間－AIの共同主体性 (Human-AI Co-agency/Shared Agency)
kn-keyword=人間－AIの共同主体性 (Human-AI Co-agency/Shared Agency)
en-keyword=アルゴリズム的選択環境 (Algorithmic Choice Architecture)
kn-keyword=アルゴリズム的選択環境 (Algorithmic Choice Architecture)
en-keyword=非消費／意図的な非使用 (Non-consumption/Intentional Non-use)
kn-keyword=非消費／意図的な非使用 (Non-consumption/Intentional Non-use)
en-keyword=再帰的学習ループ (Recursive Learning Loops)
kn-keyword=再帰的学習ループ (Recursive Learning Loops)
END

start-ver=1.4
cd-journal=joma
no-vol=57
cd-vols=
no-issue=3
article-no=
start-page=11
end-page=40
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Network Analysis of Interregional Information Exchange: A Study in the Takahashi River Basin Area
kn-title=地域間での情報交流に関するネットワーク分析：高梁川流域圏での調査による
en-subtitle=
kn-subtitle=
en-abstract=　This paper conducted network analysis focusing on information exchange among participating entities in the "Takahashi River Basin Economic Growth Strategy Council," operating within Okayama Prefecture's "Takahashi River Basin Core City Area." The Takahashi River Basin Collaborative Core City Area（ Takahashi River Basin Area）is a collaborative core city area encompassing ten municipalities located around the Takahashi River in Okayama Prefecture: Niimi City, Takahashi City, Soja City, Hayashima Town, Kurashiki City, Yakage Town, Ibara City, Asakuchi City, Satosho Town, and Kasaoka City. For the network analysis within the Takahashi River Basin Area, projects implemented within the area were classified into eight categories. A questionnaire survey was conducted regarding information exchange among participating entities for each project. Network metrics included calculating centrality indices（ degree centrality and betweenness centrality） for each project, along with density, transitivity, and reciprocity. By project type, tourism projects exhibited the densest network structure for information exchange. From a network perspective, tourism projects can be considered the most actively pursued initiative within the Takahashi River Basin area. Furthermore, across all projects, centrality indicators for specific administrative bodies and regional economic organizations, such as chambers of commerce and industry, generally showed high values. This clearly indicates their function as hubs for information exchange and as entities concentrating or dispersing information within the network. Based on the results of network analysis, two recommendations for future regional development in the Takahashi River Basin were proposed from a network perspective. The first is to aim for dense networks across all businesses by sharing the roles of information exchange hubs and information concentration/distribution entities among the entities involved, depending on the business. The second is to aim for a dense network overall by eliminating entities that are not participating at all in the Takahashi River Basin's information exchange network.
kn-abstract=　本稿では，岡山県の「高梁川流域連携中枢都市圏」で2014年から開催されている「高梁川流域経済成長戦略会議」における参加主体間の情報交流についてのネットワーク分析を行った。高梁川流域連携中枢都市圏（高梁川流域圏）とは，岡山県高梁川周辺に位置する現在の新見市，高梁市，総社市，早島町，倉敷市，矢掛町，井原市，浅口市，里庄町，笠岡市の10自治体が参加している連携中枢都市圏である。高梁川流域圏におけるネットワーク分析に際しては，同圏域内で展開されている事業を８つに分類し，それぞれの事業に関する参加主体間の情報交流についてアンケート調査を行った。ネットワーク指標については事業ごとに次数中心性と媒介中心性の中心性指標を，また事業別に密度，推移性，相互性を算出した。事業別にみると，観光事業についての情報交流が最も密なネットワーク構造をしており，ネットワークの視点では観光事業が高梁川流域圏内で最も勢力的に行われている事業といえる。また全事業において特定の行政主体や商工会議所をはじめとする地域経済団体等の中心性指標が全体的に大きな値をとっており，ネットワークにおいて情報交流のハブや情報の集中・分散主体として機能していることが明らかになった。分析結果を踏まえ，ネットワークの視点から高梁川流域圏の今度の地域振興について２点提言した。１つは事業によって情報交流のハブや情報の集中・分散主体を主体間で分担することによって，すべての事業で密なネットワークを築くことを目指すことである。もう１つは高梁川流域圏の情報交流ネットワークに全く参加していない主体をなくすことで，全体的に密なネットワークを目指すことである。
en-copyright=
kn-copyright=

en-aut-name=NakamuraRyohei
en-aut-sei=Nakamura
en-aut-mei=Ryohei
kn-aut-name=中村良平
kn-aut-sei=中村
kn-aut-mei=良平
aut-affil-num=1
ORCID=

en-aut-name=YokotaNatsumi
en-aut-sei=Yokota
en-aut-mei=Natsumi
kn-aut-name=横田夏実
kn-aut-sei=横田
kn-aut-mei=夏実
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学

affil-num=2
en-affil=
kn-affil=下関市役所
END

start-ver=1.4
cd-journal=joma
no-vol=57
cd-vols=
no-issue=3
article-no=
start-page=1
end-page=10
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 1998 Amendment to the Foreign Exchange and Foreign Trade Control Act and the Classification of Income from Gains and Losses on Foreign Currency Transactions: How Did the Amendment of 1998 Affect Income Classification?
kn-title=1998年の外国為替及び外国貿易管理法改正と 外国通貨の譲渡による損益の所得区分 ―1998年の法改正は所得区分にどのような影響を与えたのか―
en-subtitle=
kn-subtitle=
en-abstract=　The 1998 amendment to the Foreign Exchange and Foreign Trade Control Act（ subsequently renamed the Foreign Exchange and Foreign Trade Act） liberalized foreign exchange transactions, which had previously been restricted in principle to authorized foreign exchange banks. This amendment allowed all companies and individuals to freely conduct such transactions.<br>
　This paper first examines the basis for the tax authorities' view that "gains or losses from foreign currency transfers constitute miscellaneous income," drawing from government witness testimony in the Diet and the Tokyo District Court judgement of March 9, 2023. Then it concludes that the 1998 legal amendment, by enabling anyone to freely conduct foreign currency transactions both internationally and domestically, transformed foreign currency into a means of payment functioning as a measure of value. Consequently, it became impossible to conceptualize foreign currency as an asset subject to appreciation or depreciation, leading to the reclassification of income from its transfer from capital gains to miscellaneous income.
kn-abstract=　1998年の外国為替及び外国貿易管理法の改正（以降，外国為替及び外国貿易法に改名）により，それまで外国為替公認銀行に原則として限られていた外国為替取引が，あらゆる企業及び個人に解放され，自由に行うことができるようになった。<br>
　本稿は，まず課税当局の「外国通貨の譲渡による損益は雑所得に該当する」との見解の判断根拠を，国会における政府参考人答弁及び東京地裁令和５年３月９日判決から読み解き，そのうえで，1998年の法改正により外国通貨取引が対外及び国内において何人も自由に行うことができるようになったことから，外国通貨は支払手段として言わば価値の尺度として機能するようになり，資産の値上がり，値下がりを観念することができなくなった結果として，その譲渡による所得区分が譲渡所得から雑所得へと変化したとの結論を導くものである。
en-copyright=
kn-copyright=

en-aut-name=NakagawaYoshiyuki
en-aut-sei=Nakagawa
en-aut-mei=Yoshiyuki
kn-aut-name=中川吉之
kn-aut-sei=中川
kn-aut-mei=吉之
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=57
cd-vols=
no-issue=3
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=表紙・目次
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=22
cd-vols=
no-issue=9
article-no=
start-page=e772
end-page=e780
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202509
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Aging of the tricuspid valve annulus detected by photon-counting detector computed tomography: Importance of aortic root compression on occurrence of arrhythmias
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background The aortic root compresses the heart in elderly patients, potentially influencing the conduction system and causing atrial tachyarrhythmias. However, actual anatomic alterations in the right side of the heart because of aortic root compression have not yet been fully evaluated.<br>
Objective This study aimed to elucidate the alterations in the tricuspid valve annulus (TVA) caused by aortic root compression using a 3-dimensional endoscopic view of the heart constructed by photon-counting detector computed tomography, an emerging medical technology.<br>
Methods We analyzed 147 consecutive patients who underwent photon-counting detector computed tomography at our institute after excluding those with diseases that directly influenced the right side of the heart.<br>
Results Aortic root compression caused significant TVA deformation. We defined severe TVA compression as the length of the TVA compressed by the aortic root ≥80% of the major axis of the TVA. Severe compression was more prevalent in elderly patients (age ≥75 years [44%]; P < .01). The distance between the membranous septum and ostium of the coronary sinus was shortened, whereas the cavotricuspid isthmus was elongated in older patients. The regression analysis identified aging as a significant contributor to TVA compression. The short minor and long major axes of the TVA, incidence of atrial tachyarrhythmias (74% vs 45%; P < .01), and atrioventricular conduction disturbances (35% vs 15%; P < .01) were more frequently observed in patients with severe compression.<br>
Conclusion Aortic root compression deforms the TVA and alters the anatomic relationship between the atrioventricular conduction system and the cavotricuspid isthmus. Therefore, aortic root compression may contribute to the occurrence of atrial tachyarrhythmias and conduction disturbances in older patients.
en-copyright=
kn-copyright=

en-aut-name=MoritaHiroshi
en-aut-sei=Morita
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakagawaKoji
en-aut-sei=Nakagawa
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NagaseSatoshi
en-aut-sei=Nagase
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MorimotoYoshihisa
en-aut-sei=Morimoto
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MasudaTakuro
en-aut-sei=Masuda
en-aut-mei=Takuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UeokaAkira
en-aut-sei=Ueoka
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AsadaSaori
en-aut-sei=Asada
en-aut-mei=Saori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MiyamotoMasakazu
en-aut-sei=Miyamoto
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TohNorihisa
en-aut-sei=Toh
en-aut-mei=Norihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NishiiNobuhiro
en-aut-sei=Nishii
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Therapeutics, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=3
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Fukuyama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=6
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=8
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=10
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=11
en-affil=Department of Cardiovascular Therapeutics, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=
en-keyword=Tricuspid valve annulus
kn-keyword=Tricuspid valve annulus
en-keyword=Aortic root
kn-keyword=Aortic root
en-keyword=Photon-counting detector computed tomography
kn-keyword=Photon-counting detector computed tomography
en-keyword=Atrial tachyarrhythmia
kn-keyword=Atrial tachyarrhythmia
en-keyword=Conduction abnormality
kn-keyword=Conduction abnormality
END

start-ver=1.4
cd-journal=joma
no-vol=24
cd-vols=
no-issue=1
article-no=
start-page=146
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260115
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=MMP-3 cleavage of Lamin A induces pro-migratory nuclear deformity, nucleophagy, and their autophagic secretion with extracellular vesicles in metastatic cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that cleave a plethora of substrates, including components of the extracellular matrix and cell-surface-associated proteins, as well as intracellular targets. MMPs have also been found in extracellular vesicles (EVs), such as exosomes. MMP-3 promotes tumor growth, epithelial-to-mesenchymal transition, genome instability, migration, invasion, and metastasis of cancer cells, and nuclear MMP-3 controls gene transcription. Intranuclear proteolysis by MMPs may significantly alter cancer progression. However, the nuclear substrates of MMP-3 have not been well investigated. In this study, we performed proteomic analyses to identify the nuclear substrates and EV proteins regulated by MMP-3. While rabidly metastatic colon cancer (LuM1) three-dimensionally cultured tumoroids secreted EVs containing 30 protein types, including Lamin A (LMNA), MMP-3, fibronectin (FN1), HSPA8 (Hsc70), β-actin (ACTB), and vimentin (VIM), CRISPR/Cas9-based knockout of MMP-3 reduced the secretion of these proteins in EVs. Notably, EV-bound cleaved Lamin secretion was confirmed by immunoelectron microscopy. Also, MMP-3 formed proteolytic dimers via its hemopexin-like repeat domains in nuclei. Many nuclear MMP-3-binding proteins, including Lamin A/C, histones, topoisomerases, and hnRNPs, were screened by co-immunoprecipitation followed by proteomics. Proteolytic MMP-3 overexpression generated a C-terminal 30-kDa fragment of Lamin A, whose cleavage site was defined via structural analysis. MMP-3 digestion of Lamin A induced nuclear deformity (atypia) required for cell migration in confined space. The cleaved Lamin A and MMP-3 were transported with autophagosomes (LC3B+), nucleophagosomes, and amphisomes (CD63 + LC3B+) and co-secreted with EVs. Proteolytic MMP-3 also induced nuclear speckles of Lamin A, suggesting their roles in transcription and splicing. Clinical analysis revealed that high expressions of MMP3 and LMNA were significantly seen in head and neck squamous cell carcinoma (HNSC) than in the other 16 cancer types, and predicted poor prognosis of patients suffering from HNSC, pancreatic, rectum and lung adenocarcinomas at specific stages. Immunohistochemistry revealed that nuclear MMP-3 and cleaved Lamin were significantly higher expressed in stage IV metastatic HNSC cases than in stage I non-metastatic cases. Taken together, MMP3-cleavage of Lamin A induces nuclear deformity, nucleophagy, and their autophagic co-secretion with EVs in metastatic cancer. Also, high expression of MMP-3 and secretion of Lamin A can predict poor prognosis in multiple cancer types at specific stages.
en-copyright=
kn-copyright=

en-aut-name=EguchiTakanori
en-aut-sei=Eguchi
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TahaEman A.
en-aut-sei=Taha
en-aut-mei=Eman A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakanoKeisuke
en-aut-sei=Nakano
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TiwariVikas
en-aut-sei=Tiwari
en-aut-mei=Vikas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakebeKatsuki
en-aut-sei=Takebe
en-aut-mei=Katsuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InoueTomohiro
en-aut-sei=Inoue
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=XingLizi
en-aut-sei=Xing
en-aut-mei=Lizi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SogawaChiharu
en-aut-sei=Sogawa
en-aut-mei=Chiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkamotoKuniaki
en-aut-sei=Okamoto
en-aut-mei=Kuniaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=CalderwoodStuart K.
en-aut-sei=Calderwood
en-aut-mei=Stuart K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Biochemistry, Faculty of Science, Ain Shams University
kn-affil=

affil-num=3
en-affil=Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Council of Scientific & Industrial Research-Indian Institute of Toxicological Research
kn-affil=

affil-num=5
en-affil=Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology
kn-affil=

affil-num=9
en-affil=Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
kn-affil=
en-keyword=Lamin A (LMNA)
kn-keyword=Lamin A (LMNA)
en-keyword=Matrix metalloprotease (MMP)
kn-keyword=Matrix metalloprotease (MMP)
en-keyword=Proteolysis
kn-keyword=Proteolysis
en-keyword=Extracellular vesicle (EV)
kn-keyword=Extracellular vesicle (EV)
en-keyword=Exosome
kn-keyword=Exosome
en-keyword=Autophagy
kn-keyword=Autophagy
en-keyword=Amphisome
kn-keyword=Amphisome
en-keyword=Proteome
kn-keyword=Proteome
en-keyword=Nuclear deformity
kn-keyword=Nuclear deformity
en-keyword=Migration
kn-keyword=Migration
en-keyword=Metastatic cancer
kn-keyword=Metastatic cancer
en-keyword=Head and neck squamous cell carcinoma
kn-keyword=Head and neck squamous cell carcinoma
en-keyword=Colorectal cancer
kn-keyword=Colorectal cancer
END

start-ver=1.4
cd-journal=joma
no-vol=28
cd-vols=
no-issue=1
article-no=
start-page=32
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260102
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy remains limited.<br>
Methods: We conducted a multicenter retrospective cohort study of RA patients receiving SAR or JAKi as MTX-free monotherapy. To reduce confounding, 1:1 propensity score matching was performed in the overall cohort (n = 252, 126 per group) and separately within treatment-line strata: Phase 2 first-line biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs: 45 per group), Phase 3 second-line b/tsDMARDs (53 per group), and Phase 3 ≥ third-line b/tsDMARDs (47 per group). Outcomes over 12 months included drug retention, change in Clinical Disease Activity Index (CDAI), glucocorticoid (GC) tapering and discontinuation, low disease activity (LDA, CDAI ≤ 10), and safety profiles. Predictors of LDA were evaluated with logistic regression. This multicenter real-world.<br>
Results: Across matched strata by prior b/tsDMARDs, retention and CDAI change did not differ significantly between SAR and JAKi through 12 months. When classified by cause, adverse events (AEs)-related discontinuation was higher with JAKi, yielding lower AE-specific retention. Both groups demonstrated GC sparing overtime, with a greater increase in GC discontinuation for SAR than for JAKi in Phase 2. Baseline predictors of achieving LDA at 12 months included higher C-reactive protein (CRP) and platelet count (Plt) in both groups, with additional associations of younger age and lower hemoglobin (Hb) in the SAR. In safety analyses, overall AEs were less frequent with SAR than with JAKi, driven by lower risks of infection including herpes zoster, while other categories were similarly infrequent.<br>
Conclusion: SAR and JAKi showed no statistically significant differences in 12-month retention or disease control in MTX-free monotherapy settings. Higher CRP and Plt with lower Hb, particularly in younger patients, identified better response to SAR and support biomarker guided selection between IL-6Ri and JAKi. In Phase 2, GC discontinuation with SAR suggests a practical strategy to reduce AEs while maintaining efficacy. Prospective studies should validate these findings and define actionable thresholds.
en-copyright=
kn-copyright=

en-aut-name=NozakiYuji
en-aut-sei=Nozaki
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KishimotoKazuya
en-aut-sei=Kishimoto
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ItamiTetsu
en-aut-sei=Itami
en-aut-mei=Tetsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TomitaDaisuke
en-aut-sei=Tomita
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WadaYumiko
en-aut-sei=Wada
en-aut-mei=Yumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KotaniTakuya
en-aut-sei=Kotani
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakeuchiTohru
en-aut-sei=Takeuchi
en-aut-mei=Tohru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HidakaToshihiko
en-aut-sei=Hidaka
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HinoShoichi
en-aut-sei=Hino
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MiyamotoToshiaki
en-aut-sei=Miyamoto
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MiyakeHirofumi
en-aut-sei=Miyake
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HattaKazunari
en-aut-sei=Hatta
en-aut-mei=Kazunari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MamotoKenji
en-aut-sei=Mamoto
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=YamadaYutaro
en-aut-sei=Yamada
en-aut-mei=Yutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=OkanoTadashi
en-aut-sei=Okano
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=OkanoTakaichi
en-aut-sei=Okano
en-aut-mei=Takaichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SaegusaJun
en-aut-sei=Saegusa
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=HoritaMasahiro
en-aut-sei=Horita
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=KinoshitaKoji
en-aut-sei=Kinoshita
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=RaiShinya
en-aut-sei=Rai
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=2
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=3
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=4
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=7
en-affil=Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=8
en-affil=Rheumatology Center, Miyazaki Zenjinkai Hospital
kn-affil=

affil-num=9
en-affil=Department of Rheumatology and Clinical Immunology, Izumi City General Medical Center
kn-affil=

affil-num=10
en-affil=Miyamoto Internal Medicine and Rheumatology Clinic
kn-affil=

affil-num=11
en-affil=Department of General Internal Medicine, Tenri Hospital
kn-affil=

affil-num=12
en-affil=Department of General Internal Medicine, Tenri Hospital
kn-affil=

affil-num=13
en-affil=Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka Metropolitan University
kn-affil=

affil-num=14
en-affil=Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine
kn-affil=

affil-num=17
en-affil=Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=19
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=20
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=21
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=
en-keyword=Rheumatoid arthritis
kn-keyword=Rheumatoid arthritis
en-keyword=Methotrexate
kn-keyword=Methotrexate
en-keyword=Biological DMARDs
kn-keyword=Biological DMARDs
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=5
article-no=
start-page=2339
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Concentration-Dependent Synergistic Interfacial Interactions Between Multifunctional Acrylate and Silane Coupling Agents in an Organic–Inorganic Nanohybrid Material
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Synergistic effects of a multifunctional acrylate and a long-chain silane coupling agent were investigated in an organic–inorganic nanohybrid material. We tested the bond strength of nanohybrid composites treated with experimental primers containing silane coupling agents—3-methacryloxypropyl trimethoxysilane (γ-MPTS) or 8-methacryloxyoctyl trimethoxysilane (8-MOTS)—with or without multifunctional acrylates—trimethylolpropane triacrylate (A-TMPT) or dipentaerythritol hexaacrylate (A-DPH). Shear bond strength was evaluated after 24 h of water storage at 37 °C. Untreated control and silane-only groups exhibited low shear bond strengths (e.g., control: 2.4 ± 2.0 MPa) and failed exclusively at the adhesive interface. While addition of A-TMPT did not significantly improve bond strength, addition of A-DPH produced significantly higher shear bond strengths. Highest strength was achieved with 30% 8-MOTS and A-DPH (22.4 ± 6.1 MPa), followed by 20% γ-MPTS and A-DPH (19.0 ± 7.0 MPa), and A-DPH groups produced cohesive failures. Regardless of the silane used (γ-MPTS or 8-MOTS), incorporating A-DPH in the primer consistently yielded superior bond strengths, indicating a promising strategy for improved adhesion for such nanohybrid systems. These findings provide new insights into optimizing resin–filler interfacial interactions and may contribute to the development of restorative materials with improved long-term clinical durability.
en-copyright=
kn-copyright=

en-aut-name=MaruoYukinori
en-aut-sei=Maruo
en-aut-mei=Yukinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshiharaKumiko
en-aut-sei=Yoshihara
en-aut-mei=Kumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IrieMasao
en-aut-sei=Irie
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NagaokaNoriyuki
en-aut-sei=Nagaoka
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KodamaNaoki
en-aut-sei=Kodama
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshizaneMai
en-aut-sei=Yoshizane
en-aut-mei=Mai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AkiyamaKentaro
en-aut-sei=Akiyama
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Prosthodontics, Okayama University
kn-affil=

affil-num=2
en-affil=Health Research Institute, National Institute of Advanced Industrial Science and Technology
kn-affil=

affil-num=3
en-affil=Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Advanced Research Center for Oral and Craniofacial Sciences, Dental School, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Prosthodontics, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Occlusal and Oral Functional Rehabilitation, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Occlusal and Oral Functional Rehabilitation, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=silane coupling
kn-keyword=silane coupling
en-keyword=multifunctional acrylate
kn-keyword=multifunctional acrylate
en-keyword=bond strength
kn-keyword=bond strength
en-keyword=resin
kn-keyword=resin
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=
article-no=
start-page=e79545
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260302
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prescription Support Practice for Pharmacy Students: Pre-Post Educational Intervention Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: In the field of team-based care, pharmacists are vital for optimizing medication therapy. However, many medical professionals lack the opportunity to learn how to propose prescription changes with precision.<br>
Objective: This study aimed to address this knowledge gap by developing and assessing a new educational program for pharmacy students focused on prescription support and interprofessional collaboration.<br>
Methods: We recruited 191 fifth-year pharmaceutical students during the 2022‐2024 academic years. The program featured a 7-day intensive curriculum that included learning how to assist with prescriptions, analyzing clinical data, and engaging in role-playing exercises. A web-based questionnaire and a paper test were used to evaluate students’ awareness and knowledge both before and after the program. Statistical analyses were performed to verify the significance of changes; we utilized the Wilcoxon signed-rank test for the ordinal data derived from the specific behavioral objectives and 2-tailed paired t tests for the interval data from the knowledge tests. The magnitude of change was quantified using r for Wilcoxon tests and Cohen dz for 2-tailed t tests, with 95% CI calculated to ensure the stability and reliability of the observed results.<br>
Results: Analysis of the primary outcome specific behavioral objectives revealed statistically significant effects across all items (Wilcoxon signed-rank test; P<.001). Effect sizes (r=0.505‐0.835) ranged from moderate to large, with particularly large effects observed in identifying contents issue (r=0.835, 95% CI 0.126-0.330; P<.001). Knowledge test scores showed significant improvement in the following 3 subjects: pharmacology (r=−0.504, 95% CI –0.215 to 0.127; P<.001), organic chemistry (r=0.254, 95% CI –0.148 to –0.193; P=.004), and communication (r=0.221, 95% CI –0.151 to –0.190; P=.01). No significant changes were observed in pathology or pharmacokinetics.<br>
Conclusions: This program provides strong evidence that practical, hands-on learning with hospital pharmacists helps improve pharmacy students’ professional skills and optimize pharmaceutical therapies in interprofessional care. By teaching pharmacists to effectively propose prescription changes, the program equips them to become integral members of interprofessional care, ultimately leading to optimized pharmaceutical care for patients.
en-copyright=
kn-copyright=

en-aut-name=AizawaFuka
en-aut-sei=Aizawa
en-aut-mei=Fuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YagiKenta
en-aut-sei=Yagi
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HigashionnaTsukasa
en-aut-sei=Higashionna
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakahashiShimon
en-aut-sei=Takahashi
en-aut-mei=Shimon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ShinomiyaKazuaki
en-aut-sei=Shinomiya
en-aut-mei=Kazuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NiimuraTakahiro
en-aut-sei=Niimura
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=GodaMitsuhiro
en-aut-sei=Goda
en-aut-mei=Mitsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KawadaKei
en-aut-sei=Kawada
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IshizawaKeisuke
en-aut-sei=Ishizawa
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=

affil-num=2
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=6
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Pharmaceutical Care and Clinical Pharmacy, Tokushima Bunri University
kn-affil=

affil-num=8
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=

affil-num=9
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=10
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=11
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=
en-keyword=academic detailing
kn-keyword=academic detailing
en-keyword=pharmaceutical clinical practice
kn-keyword=pharmaceutical clinical practice
en-keyword=prescription support
kn-keyword=prescription support
en-keyword=professional education
kn-keyword=professional education
en-keyword=Interprofessional care
kn-keyword=Interprofessional care
END

start-ver=1.4
cd-journal=joma
no-vol=115
cd-vols=
no-issue=3
article-no=
start-page=117345
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202607
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Investigation of the cefazolin inoculum effect in blood culture-isolated methicillin-susceptible Staphylococcus aureus strains: A Japanese multicenter study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Cefazolin inoculum effect (CInE) is a microbiological phenomenon where the MIC of cefazolin against methicillin-susceptible Staphylococcus aureus (MSSA) strains increases with higher bacterial volumes.<br>
Method: We retrospectively investigated the prevalence and characteristics of the CInE among MSSA strains isolated from blood cultures at three Japanese hospitals. The collected isolates were screened for blaZ using PCR, and the cefazolin minimum inhibitory concentration (MIC) for the blaZ-positive MSSA isolates was measured at standard and high inoculum volumes. CInE-positive MSSA strains were defined as those with a cefazolin MIC ≥16 μg/mL at 107 CFU/mL and ≤8 μg/mL at 105 CFU/mL. In these blaZ-positive strains, we performed blaZ typing and tested a modified nitrocefin-based rapid examination to detect the CInE.<br>
Results: We collected 329 MSSA strains isolated from blood cultures. Of these, 96 (29.2%) were positive for the blaZ gene, with the following genotypes: type A (15, 15.6%), type B (3, 3.1%), type C (77, 80.2%), type D (0, 0.0%), and non-type (1, 1.0%). Among 96 blaZ-positive MSSA isolates, 11 exhibited the CInE, all of which harbored blaZ type A. The rapid nitrocefin test detected CInE positivity with high sensitivity (100%), specificity (94.1%), and diagnostic accuracy (94.8%).<br>
Conclusion: This study highlighted the low prevalence of CInE-presenting MSSA isolates in Japan. When the cefazolin MIC is ≥1 μg/mL or the penicillin G MIC is ≥0.25 μg/mL, the rapid nitrocefin test may be useful for considering the CInE in patients with high bacterial volume MSSA infections.
en-copyright=
kn-copyright=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TsujiShuma
en-aut-sei=Tsuji
en-aut-mei=Shuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GotohKazuyoshi
en-aut-sei=Gotoh
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IioKoji
en-aut-sei=Iio
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OgawaSakura
en-aut-sei=Ogawa
en-aut-mei=Sakura
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KoyanagiNorihito
en-aut-sei=Koyanagi
en-aut-mei=Norihito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ItoYuji
en-aut-sei=Ito
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KoganemaruHiroshi
en-aut-sei=Koganemaru
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YoshidaAtsushi
en-aut-sei=Yoshida
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=3
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=4
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Clinical Laboratory, Chutoen General Medical Center
kn-affil=

affil-num=7
en-affil=Department of General Internal Medicine, Chutoen General Medical Center
kn-affil=

affil-num=8
en-affil=Department of Infectious Diseases, Tokyo Metropolitan Institute for Geriatrics and Gerontology
kn-affil=

affil-num=9
en-affil=Department of Infectious Diseases, Tokyo Metropolitan Institute for Geriatrics and Gerontology
kn-affil=

affil-num=10
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=blaZ
kn-keyword=blaZ
en-keyword=Cefazolin inoculum effect
kn-keyword=Cefazolin inoculum effect
en-keyword=Methicillin-susceptible Staphylococcus aureus
kn-keyword=Methicillin-susceptible Staphylococcus aureus
en-keyword=Nitrocefin rapid test
kn-keyword=Nitrocefin rapid test
en-keyword=β-lactamase
kn-keyword=β-lactamase
END

start-ver=1.4
cd-journal=joma
no-vol=11
cd-vols=
no-issue=3
article-no=
start-page=e198959
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251223
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Collagen-binding C-type natriuretic peptide enhances chondrogenesis and osteogenesis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=C-type natriuretic peptide (CNP) is known to promote chondrocyte proliferation and bone formation; however, CNP’s extremely short half-life necessitates continuous intravascular administration to achieve bone-lengthening effects. Vosoritide, a CNP analog designed for resistance to neutral endopeptidase, allows for once-daily administration. Nonetheless, it distributes systemically rather than localizing to target tissues, which may result in adverse effects such as hypotension. To enhance local drug delivery and therapeutic efficacy, we developed a potentially novel synthetic protein by fusing a collagen-binding domain (CBD) to CNP, termed CBD-CNP. This fusion protein exhibited stability under heat conditions and retained the collagen-binding ability and bioactivity as CNP. CBD-CNP localized to articular cartilage in fetal murine tibiae and promoted bone elongation. Spatial transcriptomic analysis revealed that the upregulation of chondromodulin expression may contribute to its therapeutic effects. Treatment of CBD-CNP mixed with collagen powder to a fracture site of a mouse model increased bone mineral content and bone volume compared with CNP-22. Intraarticular injection of CBD-CNP to a mouse model of knee osteoarthritis suppressed subchondral bone thickening. By addressing the limitations of CNP’s rapid degeneration, CBD-CNP leverages its collagen-binding capacity to achieve targeted, sustained delivery in collagen-rich tissues, offering a promising strategy for enhancing chondrogenesis and osteogenesis.
en-copyright=
kn-copyright=

en-aut-name=HiraiKenta
en-aut-sei=Hirai
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SawamuraKenta
en-aut-sei=Sawamura
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=EsakiRyusaku
en-aut-sei=Esaki
en-aut-mei=Ryusaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SawadaRyusuke
en-aut-sei=Sawada
en-aut-mei=Ryusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkushaYuka
en-aut-sei=Okusha
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AoyamaEriko
en-aut-sei=Aoyama
en-aut-mei=Eriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SaitoHiroki
en-aut-sei=Saito
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UchidaKentaro
en-aut-sei=Uchida
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MimaTakehiko
en-aut-sei=Mima
en-aut-mei=Takehiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KubotaSatoshi
en-aut-sei=Kubota
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TsukaharaHirokazu
en-aut-sei=Tsukahara
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=ImagamaShiro
en-aut-sei=Imagama
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MatsushitaMasaki
en-aut-sei=Matsushita
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=MatsushitaOsamu
en-aut-sei=Matsushita
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=HosonoYasuyuki
en-aut-sei=Hosono
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Dental School
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Kitasato University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Kitasato University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Medical Technology, Faculty of Health Sciences, Ehime Prefectural University of Health Sciences
kn-affil=

affil-num=10
en-affil=Department of Biochemistry and Molecular DentistryBacteriology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=6
article-no=
start-page=oeaf162
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251031
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Sex differences in the progression of cardiovascular–kidney–metabolic syndrome
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aims Cardiovascular–kidney–metabolic (CKM) syndrome is a novel disease concept; however, sex differences in its progression remain uncertain. This study aimed to quantify the risk of cardiovascular disease (CVD) events across CKM stages and to explore sex differences in this association.<br>
Methods and results We included 1 332 436 individuals (581 423 males and 751 013 females) from the DeSC database between 2014 and 2023 who had no prior CVD (i.e. CKM Stage 4). CKM stages were categorized as follows: Stage 0 (no CKM risk factors); Stage 1 (excess or dysfunctional adiposity); Stage 2 [metabolic risk factors and chronic kidney diseases (CKD)], and Stage 3 (subclinical CVD). We used Cox models to examine the association of CKM stages with the risk of CVD events (newly developed CKM Stage 4), including myocardial infarction, stroke, heart failure, atrial fibrillation, and peripheral artery disease. The progression from CKM Stages 0 to 3 showed a dose-dependent increase in adjusted hazard ratios (HR) for developing CVD events, with the highest risk at Stage 3 [1.85 (95% CI: 1.80–1.90)]. A similar pattern was observed in both males and females. However, the magnitude of associations for CKM stages 1–3 differed between the sexes: HR by Stage 1, 1.12 (1.04–1.21) vs. 1.12 (1.07–1.16); by Stage 2, 1.78 (1.69–1.88) vs. 1.43 (1.39–1.48); by Stage 3, 1.99 (1.89–2.10) vs. 1.82 (1.76–1.88); and P-for-interaction values were 0.87, < 0.001, and 0.005, respectively.<br>
Conclusion In this large nationwide cohort, CKM stage progression was associated with higher CVD risk in both sexes, with modest sex-specific differences. These findings highlight the value of CKM staging for early risk assessment, regardless of sex.
en-copyright=
kn-copyright=

en-aut-name=TayaSatoshi
en-aut-sei=Taya
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=EjiriKentaro
en-aut-sei=Ejiri
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KanekoHidehiro
en-aut-sei=Kaneko
en-aut-mei=Hidehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SuzukiYuta
en-aut-sei=Suzuki
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MizunoAtsushi
en-aut-sei=Mizuno
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KoToshiyuki
en-aut-sei=Ko
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=JimbaTakahiro
en-aut-sei=Jimba
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AzegamiTatsuhiko
en-aut-sei=Azegami
en-aut-mei=Tatsuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OkadaAkira
en-aut-sei=Okada
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujiuKatsuhito
en-aut-sei=Fujiu
en-aut-mei=Katsuhito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakedaNorifumi
en-aut-sei=Takeda
en-aut-mei=Norifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MoritaHiroyuki
en-aut-sei=Morita
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HayashiKaori
en-aut-sei=Hayashi
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=NodeKoichi
en-aut-sei=Node
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=NangakuMasaomi
en-aut-sei=Nangaku
en-aut-mei=Masaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=YasunagaHideo
en-aut-sei=Yasunaga
en-aut-mei=Hideo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TakedaNorihiko
en-aut-sei=Takeda
en-aut-mei=Norihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Medicine, The University of Tokyo
kn-affil=

affil-num=4
en-affil=Department of Advanced Cardiology, The University of Tokyo
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Cardiology, Medical Quality Management Office, QI Center, St. Luke's International Hospital
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, The University of Tokyo
kn-affil=

affil-num=8
en-affil=Department of Cardiovascular Medicine, The University of Tokyo
kn-affil=

affil-num=9
en-affil=Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=11
en-affil=Department of Cardiovascular Medicine, The University of Tokyo
kn-affil=

affil-num=12
en-affil=Department of Cardiovascular Medicine, The University of Tokyo
kn-affil=

affil-num=13
en-affil=Department of Cardiovascular Medicine, The University of Tokyo
kn-affil=

affil-num=14
en-affil=Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Keio University School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Cardiovascular Medicine, Saga University
kn-affil=

affil-num=16
en-affil=Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine
kn-affil=

affil-num=17
en-affil=Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo
kn-affil=

affil-num=18
en-affil=Department of Cardiovascular Medicine, The University of Tokyo
kn-affil=

affil-num=19
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Cardiovascular–kidney–metabolic syndrome
kn-keyword=Cardiovascular–kidney–metabolic syndrome
en-keyword=Cardiovascular disease
kn-keyword=Cardiovascular disease
en-keyword=Sex difference
kn-keyword=Sex difference
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=1
article-no=
start-page=888
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251215
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=TRPV2 in muscle satellite cells is crucial for skeletal muscle remodelling
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Skeletal muscle remodelling relies on muscle stem cells (MuSCs) for regeneration after injury and hypertrophy in response to mechanical loading. However, the mechanisms that trigger MuSC activation and proliferation remain unclear. Transient receptor potential vanilloid 2 (TRPV2) ion channels respond to insulin-like growth factor-1 and mechanical stimuli to regulate the biological characteristics of various cells. Using a temporally inducible MuSC-specific conditional knockout (cKO) mouse, we show that TRPV2 regulates MuSC function and is essential for muscle remodelling. In cultured myofibre, MuSCs express TRPV2 and exhibit Ca2+ responses to the TRPV2 agonists 2-aminoethoxydiphenyl borate and probenecid, which are abolished upon TRPV2 deletion. TRPV2-deficient MuSCs exhibit reduced paired box 7 (Pax7) expression and impaired proliferation, suggesting TRPV2 is a factor that regulates the early stage of MuSC function. Myotube formation in MuSCs was enhanced by overexpression of TRPV2 and suppressed by TRPV2 deficiency, suggesting that TRPV2 is a factor that promotes myogenesis. Muscle-administered cardiotoxin promoted muscle regeneration and resulted in the appearance of numerous Pax7-positive MuSCs between myofibres. MuSC-specific TRPV2 cKO mice exhibit substantially impaired muscle regeneration after cardiotoxin-induced injury, drastically reducing Pax7-positive MuSCs between myofibres. In floxed mice, mechanical loading via synergist ablation induces hypertrophy and greatly increases the number of myonuclei per myofibre. In contrast, MuSC-specific TRPV2 cKO mice show no changes in myofibre thickness or nuclear number, either at baseline or after mechanical loading. Mechanical loading of floxed mice increased TRPV2+/Pax7+ double-positive MuSCs, but MuSC-specific TRPV2 cKO mice showed no change. Additionally, MuSCs exhibit Ca2+ responses to hypo-osmotic stimuli, which are suppressed by TRPV2 inhibitors and TRPV2 deletion, suggesting that MuSCs exhibit TRPV2-dependent mechanical responses. These results establish TRPV2 as a critical regulator of MuSC-mediated muscle remodelling, an important finding that may lead to therapeutic strategies for muscle repair and adaptation.
en-copyright=
kn-copyright=

en-aut-name=ChenYanzhu
en-aut-sei=Chen
en-aut-mei=Yanzhu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KatanosakaKimiaki
en-aut-sei=Katanosaka
en-aut-mei=Kimiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShibuyaMakoto
en-aut-sei=Shibuya
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=DongYubing
en-aut-sei=Dong
en-aut-mei=Yubing
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ZhangLidan
en-aut-sei=Zhang
en-aut-mei=Lidan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KanagawaMotoi
en-aut-sei=Kanagawa
en-aut-mei=Motoi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FukadaSo-ichiro
en-aut-sei=Fukada
en-aut-mei=So-ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NaruseKeiji
en-aut-sei=Naruse
en-aut-mei=Keiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KatanosakaYuki
en-aut-sei=Katanosaka
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Laboratory of Stem Cell Regeneration and Adaptation, Graduate School of Pharmaceutical Sciences, The University of Osaka
kn-affil=

affil-num=6
en-affil=Department of Cell Biology and Molecular Medicine, Ehime University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Laboratory of Stem Cell Regeneration and Adaptation, Graduate School of Pharmaceutical Sciences, The University of Osaka
kn-affil=

affil-num=8
en-affil=Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=70
cd-vols=
no-issue=3
article-no=
start-page=329
end-page=336
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251224
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prevalence and Modifiable Risk Factors of Dementia in People With Down Syndrome: Cross‐Sectional Study of Japan in Collaboration With the Intellectual Diversity for Goodness Research Consortium (INDIGO‐2019)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: People with Down syndrome (DS) have a strong genetic predisposition to Alzheimer's disease (AD). However, the clinical burden and associated risk factors in diverse, non-Western populations remain less understood. This study aimed to investigate the prevalence of dementia in Japanese adults with DS and to identify modifiable clinical factors associated with dementia.<br>
Methods: This cross-sectional multicentre study surveyed 133 adults with DS (mean age 50.1 years) residing in 45 welfare facilities across Japan in 2019. Dementia was diagnosed by a consensus panel of physicians using established criteria (DSM-5, ICD-10, DC-LD) after comprehensive assessments, including the Japanese version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID-J). Logistic regression analysis was performed to identify factors independently associated with dementia.<br>
Results: Forty-six participants (34.6%) were diagnosed with dementia. The prevalence rose sharply with age: 0% in their 30s, 30.8% in their 40s, 31.6% in their 50s and 65.5% in their 60s. After adjusting for covariates, older age, female sex, dyslipidaemia and visual impairment were independently associated with dementia.<br>
Conclusions: This study, the largest of its kind in Asia, confirms a high prevalence of dementia in institutionalized Japanese adults with DS. Crucially, this study is the first to identify dyslipidaemia and visual impairment as independent and potentially modifiable risk factors in this population. These findings highlight tangible targets for clinical interventions aimed at mitigating dementia risk in people with DS.
en-copyright=
kn-copyright=

en-aut-name=TakenoshitaShintaro
en-aut-sei=Takenoshita
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TeradaSeishi
en-aut-sei=Terada
en-aut-mei=Seishi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=InoueTomokazu
en-aut-sei=Inoue
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KurozumiTaku
en-aut-sei=Kurozumi
en-aut-mei=Taku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakakiManabu
en-aut-sei=Takaki
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KuwanoRyozo
en-aut-sei=Kuwano
en-aut-mei=Ryozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SuemitsuShigeru
en-aut-sei=Suemitsu
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Neuropsychiatry, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Neuropsychiatry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso
kn-affil=

affil-num=4
en-affil=Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso
kn-affil=

affil-num=5
en-affil=Department of Neuropsychiatry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso
kn-affil=

affil-num=7
en-affil=Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=8
cd-vols=
no-issue=11
article-no=
start-page=e2543107
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251112
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Importance  Brain metastases reduce overall survival rates of patients with non–small cell lung cancer (NSCLC); patients with epidermal growth factor receptor 2 (ERBB2 [formerly HER2])–mutant NSCLC are more likely to have baseline brain metastases. Trastuzumab deruxtecan (T-DXd) is an approved ERBB2-directed treatment for previously treated unresectable or metastatic ERBB2-mutant NSCLC.<br>
Objective  To assess the clinical effectiveness and safety of T-DXd 5.4 mg/kg and 6.4 mg/kg doses in patients with previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases.<br>
Design, Setting, and Participants  This post hoc secondary analysis pooled patients from the DESTINY-Lung01 (data cutoff date: December 3, 2021) and DESTINY-Lung02 (data cutoff date: December 23, 2022) clinical trials by T-DXd dose (5.4 mg/kg and 6.4 mg/kg). DESTINY-Lung01 was a multicenter, open-label, 2-cohort, nonrandomized phase 2 study, while DESTINY-Lung02 was a dose-blinded, multicenter, 2-cohort, randomized phase 2 study. Participants had a previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases at baseline. All statistical analyses were performed from April 2023 to October 2024.<br>
Intervention  Patients received a T-DXd dose of either 5.4 mg/kg or 6.4 mg/kg intravenously every 3 weeks.<br>
Main Outcome and Measure  Systemic and intracranial effectiveness by blinded independent central review using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1, sites of progression, and safety.<br>
Results  This analysis included 102 patients in the T-DXd 5.4-mg/kg dose group (65 females [64%]; median [range] age, 57.5 [37.0-83.0] years and 59.5 [30.0-79.0] years in patients with and without brain metastases, respectively) and 141 patients in the T-DXd 6.4-mg/kg dose group (94 females [67%]; median [range] age, 62.5 [29.0-88.0] years and 59.0 [27.0-83.0] years in patients with and without brain metastases, respectively). In each group, 31% (32 of 102) and 38% (54 of 141) of patients, respectively, had baseline brain metastases and 53% (17 of 32) and 44% (24 of 54), respectively, received prior brain metastasis treatment. In patients with and without brain metastases, systemic confirmed objective response rates (ORRs) were 47% (15 of 32; 95% CI, 29%-65%) and 50% (35 of 70; 95% CI, 38%-62%), respectively, with the T-DXd 5.4-mg/kg dose, and 50% (27 of 54; 95% CI, 36%-64%) and 59% (51 of 87; 95% CI, 48%-69%) with the T-DXd 6.4-mg/kg dose. Median progression-free survival was 7.1 (95% CI, 5.5-9.7) months in the T-DXd 5.4-mg/kg dose group and 7.1 (95% CI, 4.5-9.6) months in the T-DXd 6.4-mg/kg dose group of patients with baseline brain metastases. Among patients with measurable baseline brain metastases, intracranial confirmed ORRs were 50% (7 of 14; 95% CI, 23%-77%) with the T-DXd 5.4-mg/kg dose and 30% (9 of 30; 95% CI, 15%-49%) with the T-DXd 6.4-mg/kg dose. At both doses, the safety profile of T-DXd was generally manageable, regardless of baseline brain metastases, favoring the T-DXd 5.4 mg/kg dose.<br>
Conclusions and Relevance  In this secondary analysis, T-DXd at the approved dose of 5.4 mg/kg showed antitumor activity in patients with previously treated ERBB2-mutant metastatic NSCLC with or without brain metastases. This finding supports T-DXd 5.4 mg/kg use in this population.
en-copyright=
kn-copyright=

en-aut-name=JännePasi A.
en-aut-sei=Jänne
en-aut-mei=Pasi A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=PlanchardDavid
en-aut-sei=Planchard
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GotoKoichi
en-aut-sei=Goto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SmitEgbert F.
en-aut-sei=Smit
en-aut-mei=Egbert F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=de LangenAdrianus Johannes
en-aut-sei=de Langen
en-aut-mei=Adrianus Johannes
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=GotoYasushi
en-aut-sei=Goto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KuboToshio
en-aut-sei=Kubo
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=PérolMaurice
en-aut-sei=Pérol
en-aut-mei=Maurice
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FelipEnriqueta
en-aut-sei=Felip
en-aut-mei=Enriqueta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HayashiHidetoshi
en-aut-sei=Hayashi
en-aut-mei=Hidetoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NakagawaKazuhiko
en-aut-sei=Nakagawa
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ShimizuJunichi
en-aut-sei=Shimizu
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=NagasakaMisako
en-aut-sei=Nagasaka
en-aut-mei=Misako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=PereiraKaline
en-aut-sei=Pereira
en-aut-mei=Kaline
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TaguchiAyumi
en-aut-sei=Taguchi
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=AliAhmed
en-aut-sei=Ali
en-aut-mei=Ahmed
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KarnoubMaha
en-aut-sei=Karnoub
en-aut-mei=Maha
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=YonemochiRie
en-aut-sei=Yonemochi
en-aut-mei=Rie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=LeungDavid
en-aut-sei=Leung
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=LiBob T.
en-aut-sei=Li
en-aut-mei=Bob T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
kn-affil=

affil-num=2
en-affil=Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, Medical Oncology
kn-affil=

affil-num=3
en-affil=Department of Thoracic Oncology, Nation Cancer Center Hospital East
kn-affil=

affil-num=4
en-affil=Department of Pulmonary Diseases, Leiden University Medical Center
kn-affil=

affil-num=5
en-affil=Department of Thoracic Oncology, Netherlands Cancer Institute
kn-affil=

affil-num=6
en-affil=Department of Thoracic Oncology, National Cancer Center Hospital
kn-affil=

affil-num=7
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Medical Oncology, Centre Léon Bérard
kn-affil=

affil-num=10
en-affil=Department of Medical Oncology, Vall d’Hebron University and Vall d’Hebron Institute of Oncology
kn-affil=

affil-num=11
en-affil=Department of Medical Oncology, Kindai University Faculty of Medicine
kn-affil=

affil-num=12
en-affil=Department of Medical Oncology, Kindai University Faculty of Medicine
kn-affil=

affil-num=13
en-affil=Department of Thoracic Oncology, Aichi Cancer Center
kn-affil=

affil-num=14
en-affil=Division of Hematology-Oncology, Department of Medicine, University of California Irvine
kn-affil=

affil-num=15
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=16
en-affil=Daiichi Sankyo Co Ltd
kn-affil=

affil-num=17
en-affil=Daiichi Sankyo Europe GmbH
kn-affil=

affil-num=18
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=19
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=20
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=21
en-affil=Thoracic Oncology and Early Drug Development Service, Global Research Program, Memorial Sloan Kettering Cancer Center
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=
article-no=
start-page=39
end-page=50
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Inheritance and Changes of Accents in the Hiroshima City Dialect（1）: Generational Variation in One-, Two-, and Three-Mora Nouns
kn-title=広島市方言におけるアクセントの継承と変容（1）─ 1 拍・2 拍・3 拍名詞のアクセントの世代的動態 ─
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NAKATOYasue
en-aut-sei=NAKATO
en-aut-mei=Yasue
kn-aut-name=中東靖恵
kn-aut-sei=中東
kn-aut-mei=靖恵
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=
article-no=
start-page=13
end-page=28
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Events Commemorating VJ Day 80 and a Special Exhibition in Berlin, Germany
kn-title=戦後80周年の英国の対日戦勝記念日（VJ デイ）の催しおよびドイツ・ベルリンの企画展
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NAKAOTomoyo
en-aut-sei=NAKAO
en-aut-mei=Tomoyo
kn-aut-name=中尾知代
kn-aut-sei=中尾
kn-aut-mei=知代
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=12
article-no=
start-page=1814
end-page=1828
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Trastuzumab deruxtecan (T-DXd) demonstrated strong and durable responses in patients with previously treated HER2 (ERBB2) mutant (HER2m) metastatic NSCLC (mNSCLC) in the DESTINY-Lung02 primary analysis (December 23, 2022, data cutoff). This final analysis evaluated T-DXd efficacy and safety after 8 additional months of follow-up, including clinically relevant subgroups and patient-reported outcomes.<br>
Methods: DESTINY-Lung02 was a randomized, dose-blinded, multicenter, phase 2 trial. Patients with previously treated HER2m mNSCLC were randomized 2:1 to receive T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. Primary end point was confirmed objective response rate by blinded independent central review.<br>
Results: As of August 25, 2023, 102 and 50 patients had received T-DXd 5.4 or 6.4 mg/kg, respectively. Median follow-up (Q1–Q3) was 15.8 (8.2–20.7) months and 16.5 (9.4–20.8) months, respectively. Confirmed objective response rate (95% confidence interval) was 50.0% (51/102; 39.9%–60.1%) and 56.0% (28/50; 41.3%–70.0%), respectively. Safety profile was acceptable and generally manageable. Accordingly, median treatment duration (Q1–Q3) was 7.7 (3.7–14.4) months and 8.3 (2.8–13.1) months; drug-related grade 3 or higher treatment-emergent adverse events occurred in 39.6% (40/101) and 60.0% (30/50), with nausea most common (67.3% [68/101], 82.0% [41/50]). Adjudicated drug-related interstitial lung disease occurred in 14.9% (15/101) and 32.0% (16/50), mostly grade 1 or 2 with one grade 5 in each arm. Health-related quality of life was preserved for the duration of T-DXd treatment while sample size was sufficient for analysis, with no adverse effects on health-related quality of life observed at either dose.<br>
Conclusions: T-DXd demonstrated strong and durable responses at both doses, with no clinically significant changes in toxicity. The approved 5.4-mg/kg dose demonstrated a more favorable benefit-risk profile, including lower adjudicated drug-related interstitial lung disease incidence.<br>
ClinicalTrials.gov identifier: NCT04644237
en-copyright=
kn-copyright=

en-aut-name=JännePasi A.
en-aut-sei=Jänne
en-aut-mei=Pasi A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=GotoYasushi
en-aut-sei=Goto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KuboToshio
en-aut-sei=Kubo
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KimSang-We
en-aut-sei=Kim
en-aut-mei=Sang-We
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=PlanchardDavid
en-aut-sei=Planchard
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AhnMyung-Ju
en-aut-sei=Ahn
en-aut-mei=Myung-Ju
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SmitEgbert
en-aut-sei=Smit
en-aut-mei=Egbert
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=Johannes de LangenAdrianus
en-aut-sei=Johannes de Langen
en-aut-mei=Adrianus
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=PérolMaurice
en-aut-sei=Pérol
en-aut-mei=Maurice
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=Pons-TostivintElvire
en-aut-sei=Pons-Tostivint
en-aut-mei=Elvire
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NovelloSilvia
en-aut-sei=Novello
en-aut-mei=Silvia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HayashiHidetoshi
en-aut-sei=Hayashi
en-aut-mei=Hidetoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ShimizuJunichi
en-aut-sei=Shimizu
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KimDong-Wan
en-aut-sei=Kim
en-aut-mei=Dong-Wan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=PereiraKaline
en-aut-sei=Pereira
en-aut-mei=Kaline
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=ChengFu-Chih
en-aut-sei=Cheng
en-aut-mei=Fu-Chih
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TaguchiAyumi
en-aut-sei=Taguchi
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ChengYingkai
en-aut-sei=Cheng
en-aut-mei=Yingkai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=DuntonKyle
en-aut-sei=Dunton
en-aut-mei=Kyle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=AliAhmed
en-aut-sei=Ali
en-aut-mei=Ahmed
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=GotoKoichi
en-aut-sei=Goto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
kn-affil=

affil-num=2
en-affil=Department of Thoracic Oncology, National Cancer Central Hospital
kn-affil=

affil-num=3
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Oncology Department, Asan Medical Center, Seoul, and University of Ulsan College of Medicine, Ulsan
kn-affil=

affil-num=6
en-affil=Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, and Faculty of Medicine, Paris-Saclay University
kn-affil=

affil-num=7
en-affil=Department of Hematology and Oncology, Samsung Medical Center Sungkyunkwan, and University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Pulmonary Diseases, Leiden University Medical Center
kn-affil=

affil-num=9
en-affil=Department of Thoracic Oncology, Netherlands Cancer Institute
kn-affil=

affil-num=10
en-affil=Department of Medical Oncology, Léon Berard Centre
kn-affil=

affil-num=11
en-affil=Centre Hospitalier Universitaire Nantes, Nantes University
kn-affil=

affil-num=12
en-affil=Department of Oncology, University of Turin, Turin, and Azienda Ospedaliero-Universitaria San Luigi Gonzaga
kn-affil=

affil-num=13
en-affil=Department of Medical Oncology, Kindai University Hospital
kn-affil=

affil-num=14
en-affil=Department of Thoracic Oncology, Aichi Cancer Center Hospital
kn-affil=

affil-num=15
en-affil=Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital
kn-affil=

affil-num=16
en-affil=Daiichi Sankyo
kn-affil=

affil-num=17
en-affil=Daiichi Sankyo
kn-affil=

affil-num=18
en-affil=Daiichi Sankyo
kn-affil=

affil-num=19
en-affil=Daiichi Sankyo
kn-affil=

affil-num=20
en-affil=Daiichi Sankyo UK
kn-affil=

affil-num=21
en-affil=Daiichi Sankyo Europe GmbH
kn-affil=

affil-num=22
en-affil=Department of Thoracic Oncology, National Cancer Center Hospital East
kn-affil=
en-keyword=HER2-directed therapy
kn-keyword=HER2-directed therapy
en-keyword=HER2-mutant
kn-keyword=HER2-mutant
en-keyword=HER2-targeted
kn-keyword=HER2-targeted
en-keyword=Non–small cell lung cancer
kn-keyword=Non–small cell lung cancer
en-keyword=Trastuzumab deruxtecan
kn-keyword=Trastuzumab deruxtecan
END

start-ver=1.4
cd-journal=joma
no-vol=191
cd-vols=
no-issue=
article-no=
start-page=187
end-page=196
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A Practice Report on Strength-Based Intervention to Promote Positive Self-Understanding in Adolescents: Through the Approach of Developmentally Supportive Educational Counseling
kn-title=青年の肯定的自己理解を促す強み介入の実践報告 ― 発達支持的教育相談によるアプローチを通して ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本研究は，発達支持的教育相談として実施した強み認識授業が，青年の自己の強み選択の難易度に及ぼす影響を探索的に検討したものである。研究１では中国地方の公立中学校423名を対象にオンラインで，研究２では専門学校学生86名，大学生93名を対象に対面で，強み認識授業を実施し，授業後に，自己の強み選択の難易度を測定した。その結果，すべての群の強み選択の難易度の評価は，平野(2019)と比較して「容易である」との回答傾向を示した(Mdn = ７)。また，３群の強み選択の難易度の分布に統計的な有意差は認められなかった(p = .222)。この知見は，本授業が対象者の発達段階や実施形式(オンライン・対面)に関わらず，普遍的に強み特定を支援する機能を持つ可能性を示唆する。最後に，この知見をもとに，学校現場での教育相談の新たな展開を提言した。
en-copyright=
kn-copyright=

en-aut-name=IZUMITsuguyuki
en-aut-sei=IZUMI
en-aut-mei=Tsuguyuki
kn-aut-name=伊住継行
kn-aut-sei=伊住
kn-aut-mei=継行
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=青年
kn-keyword=青年
en-keyword=発達支持的教育相談
kn-keyword=発達支持的教育相談
en-keyword=開発的機能
kn-keyword=開発的機能
en-keyword=性格特性的強み介入
kn-keyword=性格特性的強み介入
en-keyword=ポジティブ心理学
kn-keyword=ポジティブ心理学
END

start-ver=1.4
cd-journal=joma
no-vol=191
cd-vols=
no-issue=
article-no=
start-page=119
end-page=130
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Treatment of Climate Change Content in Science Education at Primary and Middle Schools in India: Focusing on the NCERT Textbooks
kn-title=インドの小・中学校理科における気候変動に関する内容の取り扱い ― NCERT 発行の教科書に注目して ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本研究は，インドの国家教育政策2020および国家カリキュラム・フレームワーク2023に基づいて作成された NCERT 発行の学校教科書（第3～8 学年）を対象に，理科的内容を扱う教科の気候変動に関する内容の取り扱いの現状を分析した。分析では UNESCO による SDGs のための教育と Kagawa & Selby の「理解・緩和・適応」の考え方をもとに観点を設け，記述を抽出・分類した。その結果，初等教育段階の「The World Around Us」では生活世界に根ざした環境配慮の態度と行動の基礎形成が重視され，前期中等教育段階の「Science」では科学的な因果関係や気候変動対策の国際的枠組みが導入されており段階的深化が確認された。一方で，概念導入の遅れ，因果連鎖の不統一，行動変容に至る仕組みの弱さ，学際性の不足や語彙や概念の習得のスパイラルな学習の不足が明らかになった。現行教科書は，体系的かつ実効的な気候変動教育には未だ不十分であり，今後の改善が求められることを指摘した。
en-copyright=
kn-copyright=

en-aut-name=KAWAIKen
en-aut-sei=KAWAI
en-aut-mei=Ken
kn-aut-name=川井健
kn-aut-sei=川井
kn-aut-mei=健
aut-affil-num=1
ORCID=

en-aut-name=FUJIIHiroki
en-aut-sei=FUJII
en-aut-mei=Hiroki
kn-aut-name=藤井浩樹
kn-aut-sei=藤井
kn-aut-mei=浩樹
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Okayama University Graduate School of Humanities and Social Sciences Science Doctoral Course
kn-affil=岡山大学大学院社会文化科学研究科博士課程

affil-num=2
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=気候変動教育
kn-keyword=気候変動教育
en-keyword=持続可能な開発のための教育（ESD）
kn-keyword=持続可能な開発のための教育（ESD）
en-keyword=インド
kn-keyword=インド
en-keyword=小・中学校
kn-keyword=小・中学校
en-keyword=教科書
kn-keyword=教科書
END

start-ver=1.4
cd-journal=joma
no-vol=191
cd-vols=
no-issue=
article-no=
start-page=17
end-page=30
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Herbartian Seen by Early 20th Century Britain Teachers: An Analysis of Notes of Lessons on the Herbartian Method
kn-title=20 世紀初頭のイギリス教員から見たヘルバルト学派 ―『ヘルバルト教授法にかんする授業ノート』の分析 ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本論は，ジャーマン・インパクトを視座として，19-20 世紀にかけて教員養成改革がいかに展開されてきたのかを解明する研究の一部をなすものである。ここでは20 世紀初頭のイギリス教員がどのようにヘルバルト学派の教育思想を受容したのかを明らかにすることを目的とし，『ヘルバルト教授法にかんする授業ノート』の分析を行った。その結果，以下の共通点と相違点が明らかとなった。授業冒頭において目的を明らかにし，授業で学ばれる内容へと子どもの意識を集中させ，新しい知識を教授するという流れは，ヘルバルト学派の五段階教授法と共通していた。だが，第四および第五段階については大胆な変更が施されていた。20 世紀初頭のイギリス教員がヘルバルト学派の教育思想を正確に受容するよりも選択的に受容した可能性があることを解明した。
en-copyright=
kn-copyright=

en-aut-name=HIRATAYoshitsugu
en-aut-sei=HIRATA
en-aut-mei=Yoshitsugu
kn-aut-name=平田仁胤
kn-aut-sei=平田
kn-aut-mei=仁胤
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=ジャーマン・インパクト
kn-keyword=ジャーマン・インパクト
en-keyword=ヘルバルト学派
kn-keyword=ヘルバルト学派
en-keyword=イギリス
kn-keyword=イギリス
en-keyword=教員養成
kn-keyword=教員養成
en-keyword=教育史
kn-keyword=教育史
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=2
article-no=
start-page=284
end-page=293
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Some anaplastic lymphoma kinase (ALK) gene rearrangement–positive lung cancers show early resistance, within 3 months, to alectinib. This study investigated the clinical and molecular characteristics of these patients. We analyzed patients with unresectable stage III/IV disease without indications for radical radiotherapy and recurrent ALK-positive lung cancer who received alectinib as the primary ALK tyrosine kinase inhibitor between 2013 and 2021 at nine hospitals. In total, 103 patients were included. The median age was 65 years; 44 were male and 22 had brain metastases. The median progression-free survival and overall survival (OS) were 28.7 and 80.6 months. Nineteen patients treated for ≤3 months and 84 treated for >3 months were categorized into the early resistance and responder groups, respectively. The early resistance group had significantly shorter OS (8.4 months vs. not estimable, P < 0.001) and was significantly more likely to have brain metastases (42% vs. 17%, P = 0.027). They also showed elevated inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR). Univariate analysis identified brain metastases and high NLR as significant predictors of early resistance. Spatial transcriptome analysis and immunohistochemical staining revealed upregulation of annexin A1 (ANXA1), a calcium-dependent phospholipid-binding protein involved in inflammation and cancer progression, in the early resistance group. Interleukin 6 stimulation, prompted by elevated inflammatory markers, increased ANXA1 expression and reduced alectinib sensitivity. Knockdown of ANXA1 improved alectinib sensitivity in alectinib-resistant cells. In conclusion, brain metastases and high NLR are associated with early resistance. ANXA1 may play an important role in mediating early resistance. New treatment options for the early resistance group are required.
en-copyright=
kn-copyright=

en-aut-name=KuribayashiTadahiro
en-aut-sei=Kuribayashi
en-aut-mei=Tadahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MakimotoGo
en-aut-sei=Makimoto
en-aut-mei=Go
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OhashiKadoaki
en-aut-sei=Ohashi
en-aut-mei=Kadoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TomidaShuta
en-aut-sei=Tomida
en-aut-mei=Shuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=InoueHirofumi
en-aut-sei=Inoue
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YokoyamaToshihide
en-aut-sei=Yokoyama
en-aut-mei=Toshihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KuyamaShoichi
en-aut-sei=Kuyama
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KatoYuka
en-aut-sei=Kato
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KudoKenichiro
en-aut-sei=Kudo
en-aut-mei=Kenichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HoritaNaokatsu
en-aut-sei=Horita
en-aut-mei=Naokatsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KayataniHiroe
en-aut-sei=Kayatani
en-aut-mei=Hiroe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=InoueMasaaki
en-aut-sei=Inoue
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SugimotoKeisuke
en-aut-sei=Sugimoto
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TogashiYosuke
en-aut-sei=Togashi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

affil-num=1
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital
kn-affil=

affil-num=7
en-affil=Department of Respiratory Medicine, NHO Iwakuni Clinical Center
kn-affil=

affil-num=8
en-affil=Department of Thoracic Oncology and Medicine, National Hospital Organization, Shikoku Cancer Center
kn-affil=

affil-num=9
en-affil=Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
kn-affil=

affil-num=10
en-affil=Department of Respiratory Medicine, Kure Kyosai Hospital
kn-affil=

affil-num=11
en-affil=Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=12
en-affil=Department of Chest Surgery, Shimonoseki City Hospital
kn-affil=

affil-num=13
en-affil=Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital
kn-affil=

affil-num=14
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=15
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=17
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=4
cd-vols=
no-issue=3
article-no=
start-page=179
end-page=187
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250901
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Synthesis and applications of porous carbonaceous materials with inherited molecular structural features from the precursor molecules
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The carbonization of organic crystalline materials, such as metal organic frameworks and covalent organic frameworks, has emerged as a promising approach for producing functional porous carbonaceous materials. However, both the chemically defined long-term ordered structures and the local chemical structures derived from these precursor materials are generally lost, resulting in amorphous carbons. As a result, controlling the molecular-level structure of nanoporous carbons remains a significant challenge. We report a new bottom-up synthesis approach for porous carbons with a molecular-level design, involving the carbonization of well-designed precursor molecules by thermal polymerization. Among the resulting carbons, ordered carbonaceous frameworks, which contain a high-density of regularly aligned single-atomic metal species, have been identified as promising platforms for single-atom catalysts. This approach also enables the synthesis of various three-dimensional porous carbons that reflect the structural features of their precursor molecules. Recent progress in the synthesis and applications of porous carbons derived from molecular precursors is summarized, highlighting their potential for the development of functional materials.
en-copyright=
kn-copyright=

en-aut-name=ChidaKoki
en-aut-sei=Chida
en-aut-mei=Koki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshiTakeharu
en-aut-sei=Yoshi
en-aut-mei=Takeharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NishinaYuta
en-aut-sei=Nishina
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KamiyaKazuhide
en-aut-sei=Kamiya
en-aut-mei=Kazuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SakamotoRyota
en-aut-sei=Sakamoto
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TaniFumito
en-aut-sei=Tani
en-aut-mei=Fumito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OgoshiTomoki
en-aut-sei=Ogoshi
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NishiharaHirotomo
en-aut-sei=Nishihara
en-aut-mei=Hirotomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Institute of Multidisciplinary Research for Advanced Materials, Tohoku University
kn-affil=

affil-num=2
en-affil=Institute of Multidisciplinary Research for Advanced Materials, Tohoku University
kn-affil=

affil-num=3
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=4
en-affil=Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka
kn-affil=

affil-num=5
en-affil=Department of Chemistry, Graduate School of Science, Tohoku University
kn-affil=

affil-num=6
en-affil=Institute for Materials Chemistry and Engineering, Kyushu University
kn-affil=

affil-num=7
en-affil=Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University
kn-affil=

affil-num=8
en-affil=Institute of Multidisciplinary Research for Advanced Materials, Tohoku University
kn-affil=
en-keyword=Ordered carbonaceous frameworks (OCFs)
kn-keyword=Ordered carbonaceous frameworks (OCFs)
en-keyword=Porous carbon materials
kn-keyword=Porous carbon materials
en-keyword=Single-atom catalysts (SACs)
kn-keyword=Single-atom catalysts (SACs)
en-keyword=Catalyst supports
kn-keyword=Catalyst supports
END

start-ver=1.4
cd-journal=joma
no-vol=29
cd-vols=
no-issue=1
article-no=
start-page=146
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250719
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Safety and feasibility of D3 lymph node dissection in oldest-old patients undergoing colorectal cancer surgery: a multi-institutional, retrospective analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Colorectal cancer (CRC) is a significant health burden, with lymph node dissection (LND) playing a critical role in staging and guiding treatment. However, the optimal extent of LND for the oldest-old population (aged ≥ 90 years) remains undefined because of insufficient targeted clinical data. This study aimed to compare the short-term outcomes of D3 versus non-D3 LND in Stage II–III CRC in oldest-old patients.<br>
Methods This retrospective cohort study utilized data from the Setouchi Colorectal Neoplasm Registration database, including 282 oldest-old patients with CRC treated between 2011 and 2022. Patients were stratified into D3 and non-D3 LND groups, with inverse-probability-weighted regression adjustment implemented to address potential confounding factors. Postoperative complications and hospital stays were analyzed using regression models and descriptive statistics.<br>
Results D3 LND resulted in significantly higher lymph node harvests in both Stage II and Stage III patients (p < 0.01). There were no significant differences in overall or major postoperative complications between D3 and non-D3 groups. Hospital stays were comparable for Stage II patients but shorter for Stage III patients in the D3 group (p < 0.01). Complication rates ranged from 28% to 47.7%, with surgical site infections and pneumonia being the most common.<br>
Conclusions D3 LND can be safely performed in oldest-old patients with CRC without increasing postoperative complications or extending hospital stays. These findings support the feasibility of extensive LND in this age gr
en-copyright=
kn-copyright=

en-aut-name=InadaR.
en-aut-sei=Inada
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TeraishiF.
en-aut-sei=Teraishi
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MitsuhashiT.
en-aut-sei=Mitsuhashi
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakanagaS.
en-aut-sei=Takanaga
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ToshimaT.
en-aut-sei=Toshima
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OhtaniT.
en-aut-sei=Ohtani
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshidaR.
en-aut-sei=Yoshida
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HoriN.
en-aut-sei=Hori
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShigemitsuK.
en-aut-sei=Shigemitsu
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YamamotoS.
en-aut-sei=Yamamoto
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KubotaT.
en-aut-sei=Kubota
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OkanoY.
en-aut-sei=Okano
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NobuhisaT.
en-aut-sei=Nobuhisa
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TaniguchiF.
en-aut-sei=Taniguchi
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IshikawaW.
en-aut-sei=Ishikawa
en-aut-mei=W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShojiR.
en-aut-sei=Shoji
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MatsudaT.
en-aut-sei=Matsuda
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=UmeokaT.
en-aut-sei=Umeoka
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=FujiwaraT.
en-aut-sei=Fujiwara
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=Setouchi Colorectal Neoplasm Registration Study Group Collaborators
en-aut-sei=Setouchi Colorectal Neoplasm Registration Study Group Collaborators
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Surgery, Kagawa Rosai Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Saiseikai Okayama Hospital
kn-affil=

affil-num=7
en-affil=Department of Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=8
en-affil=Department of Surgery, Tottori Municipal Hospital
kn-affil=

affil-num=9
en-affil=Department of Surgery, Tsuyama Chuo Hospital
kn-affil=

affil-num=10
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=11
en-affil=Department of Surgery, Kobe Red Cross Hospital
kn-affil=

affil-num=12
en-affil=Department of Surgery, Onomichi City Hospital
kn-affil=

affil-num=13
en-affil=Department of Surgery, Himeji Red Cross Hospital
kn-affil=

affil-num=14
en-affil=Department of Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=15
en-affil=Department of Surgery, Fukuyama City Hospital
kn-affil=

affil-num=16
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=18
en-affil=Department of Surgery, Matsuyama City Hospital
kn-affil=

affil-num=19
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=20
en-affil=
kn-affil=
en-keyword=Lymph node dissection
kn-keyword=Lymph node dissection
en-keyword=Colorectal cancer
kn-keyword=Colorectal cancer
en-keyword=Oldest-old patients
kn-keyword=Oldest-old patients
en-keyword=Postoperative complication
kn-keyword=Postoperative complication
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=3
article-no=
start-page=e105012
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=2026310
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Rare Association of Congenital Glaucoma and Retinitis Pigmentosa: A 22-Year Follow-Up Case
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Primary congenital glaucoma is a rare congenital disease with a genetic background that shows high intraocular pressure due to ocular outflow anomalies. Retinitis pigmentosa is a predominant form of inherited retinal disorders. In this study, we present the case of a patient with primary congenital glaucoma in association with retinitis pigmentosa. A four-month-old female baby was brought to the emergency department due to corneal opacity in the left eye. The intraocular pressure measured by a hand-held applanation tonometer was 40 mmHg in the right eye and 36 mmHg in the left eye. She was otherwise healthy and diagnosed with primary congenital glaucoma. She immediately underwent trabeculotomy ab externo in both eyes under general anesthesia, and the intraocular pressure was lowered to 15 mmHg in the right eye and 12 mmHg in the left eye three weeks later. At the age of nine months, she was found to have retinal degeneration along the upper and lower vascular arcades of the fundus in both eyes and was diagnosed with retinitis pigmentosa. At the age of one year and 10 months, the visual acuity was measured at 0.2 in the right eye and 0.2 in the left eye for the first time by a preferential looking procedure. The intraocular pressure was 9 mmHg in both eyes under sedation, and she did not use any topical medication. At the age of three years and three months, the uncorrected visual acuity and best-corrected visual acuity with myopic astigmatism correction were 0.1 and 0.15, respectively, in the right eye and 0.6 and 0.7, respectively, in the left eye. Occlusion therapy with an eye patch over the left eye for one hour daily was started. At the age of four years and 10 months, the best-corrected visual acuity was 0.7 in both eyes. At the age of six years, occlusion therapy was discontinued, and full-correction glasses were prescribed, based on cycloplegic refraction. The visual acuity in the right eye decreased to 0.3 at the age of 11 years and further to 0.1 at the age of 12 years, while the visual acuity in the left eye remained 0.8. Afterwards, she maintained a visual acuity of 0.1 in the right eye and 0.8 in the left eye until the age of 22 years. An incidental presence of primary congenital glaucoma in this patient led to the detection of retinitis pigmentosa in earlier years and allowed long-term follow-up for 22 years. Even though genetic testing was not performed for this patient, the abnormal function of primary cilia, designated as ciliopathy, might explain the co-occurrence of primary congenital glaucoma and retinitis pigmentosa.
en-copyright=
kn-copyright=

en-aut-name=MatsuoToshihiko
en-aut-sei=Matsuo
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
en-keyword=ciliopathy
kn-keyword=ciliopathy
en-keyword=cycloplegic refraction
kn-keyword=cycloplegic refraction
en-keyword=full-correction glasses
kn-keyword=full-correction glasses
en-keyword=goldmann perimetry
kn-keyword=goldmann perimetry
en-keyword=occlusion therapy
kn-keyword=occlusion therapy
en-keyword=optical coherence tomography
kn-keyword=optical coherence tomography
en-keyword=photoreceptor ellipsoid zone
kn-keyword=photoreceptor ellipsoid zone
en-keyword=primary congenital glaucoma
kn-keyword=primary congenital glaucoma
en-keyword=retinitis pigmentosa
kn-keyword=retinitis pigmentosa
en-keyword=trabeculotomy
kn-keyword=trabeculotomy
END

start-ver=1.4
cd-journal=joma
no-vol=94
cd-vols=
no-issue=4
article-no=
start-page=522
end-page=529
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of Intermittent Low-temperature Storage Duration and Cycle on the Bolting and Flowering of Delphinium elatum in Summer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Early-bolting in summer is a major problem when growing delphinium seedlings in summer to produce cut flowers that will be shipped in autumn and winter. In this study, an intermittent low-temperature storage (ILTS) treatment that induces flower bud differentiation in strawberry and prevents rosette formation in Eustoma significantly increased the Delphinium elatum cut flower length. Moreover, ILTS was as effective as growing seedlings under cool conditions at preventing early-bolting. We analyzed the effects of six ILTS treatments that differed regarding the treatment temperature (5 and 10°C) and treatment cycle (3 days/3 days, 6 days/6 days, and 12 days/12 days; ambient conditions/cool and dark). Cut flowers were significantly longer with the 6 days/6 days treatment at 10°C than for the control treatment. Furthermore, repeating the ILTS treatment cycle (6 days ambient conditions/6 days at 10°C) a total of four times produced high-quality cut flowers regardless of the cultivar. Therefore, this ILTS treatment may be ideal for preventing early-bolting in D. elatum.
en-copyright=
kn-copyright=

en-aut-name=KawaiMika
en-aut-sei=Kawai
en-aut-mei=Mika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukuyasuMiwa
en-aut-sei=Fukuyasu
en-aut-mei=Miwa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TanakaYoshiyuki
en-aut-sei=Tanaka
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KitamuraYoshikuni
en-aut-sei=Kitamura
en-aut-mei=Yoshikuni
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YasubaKen-ichiro
en-aut-sei=Yasuba
en-aut-mei=Ken-ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshidaYuichi
en-aut-sei=Yoshida
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=GotoTanjuro
en-aut-sei=Goto
en-aut-mei=Tanjuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Agriculture, Kyoto University
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=cool storage
kn-keyword=cool storage
en-keyword=cut flower quality
kn-keyword=cut flower quality
en-keyword=high ambient temperature
kn-keyword=high ambient temperature
en-keyword=long day
kn-keyword=long day
en-keyword=Ranunculaceae
kn-keyword=Ranunculaceae
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=
article-no=
start-page=53
end-page=64
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Sixteen-Year Chronicle of Service as Mayor of Setouchi City
kn-title=瀬戸内市長としての16年間のあゆみ ― 市長の意思決定 ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TAKEHISAAkinari
en-aut-sei=TAKEHISA
en-aut-mei=Akinari
kn-aut-name=武久顕也
kn-aut-sei=武久
kn-aut-mei=顕也
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=前瀬戸内市長
END

start-ver=1.4
cd-journal=joma
no-vol=410
cd-vols=
no-issue=1
article-no=
start-page=171
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Robotic distal pancreatectomy using two-surgeon technique (TAKUMI-4): a technical note and initial outcomes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose With the increasing use of minimally invasive distal pancreatectomy, the use of robotic distal pancreatectomy (RDP) is also increasing worldwide. Standardized surgical protocols are essential for safe implementation of RDP. In this study, we present our surgical protocol and initial outcomes of RDP using “two-surgeon technique”.<br>
Methods Our standard RDP protocol included a two-surgeon technique for cooperation, rationality, and education. Short-term outcomes of RDP were also investigated. This retrospective study included 77 consecutive patients who underwent RDP at our institution between April 2021 and January 2025.<br>
Results The median operative time, estimated blood loss, and postoperative hospital stay were 214 min (interquartile range [IQR], 176–253), 10 mL (IQR, 0–50), and 9 days (IQR, 8–10), respectively. A textbook outcome was achieved in 84.4% of patients. Moreover, superior outcomes of RDP (n = 77) compared with those of laparoscopic distal pancreatectomy (n = 62) were confirmed in this study.<br>
Conclusion Using the two-surgeon technique, we successfully standardized and introduced the RDP program. The two-surgeon technique can contribute to the safe introduction of RDP and expansion of the program.
en-copyright=
kn-copyright=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Distal pancreatectomy
kn-keyword=Distal pancreatectomy
en-keyword=Robotic surgery: minimally invasive surgery
kn-keyword=Robotic surgery: minimally invasive surgery
en-keyword=Training
kn-keyword=Training
en-keyword=Outcomes
kn-keyword=Outcomes
END

start-ver=1.4
cd-journal=joma
no-vol=39
cd-vols=
no-issue=5
article-no=
start-page=3137
end-page=3145
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of visceral fat area on surgical difficulty during robotic distal pancreatectomy (TAKUMI-2)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Difficulty scoring systems (DSS) have been developed to quantify the surgical complexity of laparoscopic distal pancreatectomy (LDP). However, few studies have validated these systems in the context of robotic distal pancreatectomy (RDP). Moreover, the impact of body composition on RDP outcomes remains unexplored. This study aimed to investigate the risk factors of surgical difficulty in RDP, including body composition.<br>
Methods: This retrospective study included 72 consecutive patients who underwent RDP at our institution between April 2021 and October 2024. Using a modified DSS for LDP, patients were divided into three difficulty index groups. The association between the difficulty index and outcomes was investigated. Multivariate analyses were performed to identify risk factors associated with surgical difficulty (prolonged operative time) in RDP.<br>
Results: Patients were classified into three difficulty index groups: low (n = 28), intermediate (n = 25), and high (n = 19). Operative time was significantly associated with the surgical index (P = 0.01). Moreover, visceral fat area (VFA) was significantly correlated with operative time (r2 = 0.10, P = 0.008). The multivariate analyses found that VFA (≥ 100 cm2) (odds ratio [OR] 5.03, 95% confidence interval [CI] 1.32–22.4, P = 0.02), malignancy (OR 4.92, 95% CI 1.50–18.9, P = 0.01), and pancreatic resection on the portal vein (OR 4.14, 95% CI 1.24–15.9, P = 0.02) were significant risk factors associated with surgical difficulty.<br>
Conclusion: VFA could be a novel and useful factor for assessing the surgical difficulty associated with RDP.
en-copyright=
kn-copyright=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamadaMotohiko
en-aut-sei=Yamada
en-aut-mei=Motohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishiyamaTakeyoshi
en-aut-sei=Nishiyama
en-aut-mei=Takeyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NagaiYasuo
en-aut-sei=Nagai
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KanehiraNoriyuki
en-aut-sei=Kanehira
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Robotic distal pancreatectomy
kn-keyword=Robotic distal pancreatectomy
en-keyword=Difficulty score
kn-keyword=Difficulty score
en-keyword=Visceral fat area
kn-keyword=Visceral fat area
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=1
article-no=
start-page=e70069
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202501
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Metachronous Pancreatic Metastasis of Myxoid Liposarcoma Successfully Treated With Robotic Spleen‐Preserving Distal Pancreatectomy With Splenic Vessels Resections: A Case Report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Pancreatic metastasis of myxoid liposarcoma (MLS) after primary resection is extremely rare. Herein, we present a case of metachronous pancreatic metastasis of MLS that was successfully treated with robotic spleen-preserving distal pancreatectomy (SPDP) using the Warshaw technique. A 60-year-old woman underwent radical resection of a 25-cm MLS in the right thigh after receiving neoadjuvant radiotherapy. The patient developed a 6-cm solitary pancreatic metastasis of the MLS 2 years later. Because no other distant metastases were detected, robotic SPDP (Warshaw technique) was performed. The operative time was 140 min with minimal blood loss. Follow-up at 3 months showed no recurrence. To our knowledge, this is the first report of a case of metachronous pancreatic metastasis of MLS successfully treated with robotic SPDP. Curative resection using minimally invasive surgery should be performed for solitary pancreatic metastases from MLS.
en-copyright=
kn-copyright=

en-aut-name=SotaYumi
en-aut-sei=Sota
en-aut-mei=Yumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamadaMotohiko
en-aut-sei=Yamada
en-aut-mei=Motohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NishiyamaTakeyoshi
en-aut-sei=Nishiyama
en-aut-mei=Takeyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NagaiYasuo
en-aut-sei=Nagai
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KanehiraNoriyuki
en-aut-sei=Kanehira
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MasunagaAkari
en-aut-sei=Masunaga
en-aut-mei=Akari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=myxoid liposarcoma
kn-keyword=myxoid liposarcoma
en-keyword=pancreatic metastasis
kn-keyword=pancreatic metastasis
en-keyword=robotic surgery
kn-keyword=robotic surgery
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=
article-no=
start-page=103078
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma for which prognosis is typically poor without a timely diagnosis. To explore the safety and efficacy of standard chemotherapy combined with central nervous system (CNS)-directed therapy, we conducted a multicentre, single-arm, phase 2 trial in untreated IVLBCL patients without CNS involvement at diagnosis (PRIMEUR-IVL). In the primary analysis, the PRIMEUR-IVL study demonstrated 2-year progression-free survival (PFS) of 76% and 2-year overall survival (OS) of 92% with a low incidence (3%) of secondary CNS involvement (sCNSi).<br>
Methods We present a prespecified final analysis of the PRIMEUR-IVL study including 5-year PFS, OS and cumulative incidence of sCNSi. Participants were enrolled between June 2011 and July 2016, and the data cutoff date for the final analysis was 16 November 2021. The trial was registered in the UMIN Clinical Trial Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165).<br>
Findings With a median follow-up of 7.1 years (interquartile range 5.6–8.7), 5-year PFS in all 37 eligible patients was 68% (95% confidence interval [CI] 50%–80%) and OS was 78% (95% CI 61%–89%). No additional sCNSi was observed after the primary analysis. Severe adverse events after the primary analysis were grade 4 neutropenia (n = 1) and grade 4 myelodysplastic syndrome that did not require specific treatment (n = 1). Eight deaths occurred during the observation period after enrolment, due to primary disease (n = 6), sepsis (n = 1) and unknown sudden death (n = 1).<br>
Interpretation Long-term follow-up data demonstrated durable response for PFS and OS, and low cumulative incidence of sCNSi, indicating the efficacy of standard chemotherapy combined with CNS-directed therapy for untreated IVLBCL patients.<br>
Funding This study received financial support from the Japan Agency for Medical Research and Development, Center for Supporting Hematology-Oncology Studies, and National Cancer Center.
en-copyright=
kn-copyright=

en-aut-name=ShimadaKazuyuki
en-aut-sei=Shimada
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamaguchiMotoko
en-aut-sei=Yamaguchi
en-aut-mei=Motoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KuwatsukaYachiyo
en-aut-sei=Kuwatsuka
en-aut-mei=Yachiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsueKosei
en-aut-sei=Matsue
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SatoKeijiro
en-aut-sei=Sato
en-aut-mei=Keijiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KusumotoShigeru
en-aut-sei=Kusumoto
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NagaiHirokazu
en-aut-sei=Nagai
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakizawaJun
en-aut-sei=Takizawa
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FukuharaNoriko
en-aut-sei=Fukuhara
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NagafujiKoji
en-aut-sei=Nagafuji
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MiyazakiKana
en-aut-sei=Miyazaki
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OhtsukaEiichi
en-aut-sei=Ohtsuka
en-aut-mei=Eiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OkamotoAkinao
en-aut-sei=Okamoto
en-aut-mei=Akinao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SugitaYasumasa
en-aut-sei=Sugita
en-aut-mei=Yasumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=UchidaToshiki
en-aut-sei=Uchida
en-aut-mei=Toshiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KayukawaSatoshi
en-aut-sei=Kayukawa
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=WakeAtsushi
en-aut-sei=Wake
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=EnnishiDaisuke
en-aut-sei=Ennishi
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KondoYukio
en-aut-sei=Kondo
en-aut-mei=Yukio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=MeguroAkiko
en-aut-sei=Meguro
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=KinYoshihiro
en-aut-sei=Kin
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MinamiYosuke
en-aut-sei=Minami
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=HashimotoDaigo
en-aut-sei=Hashimoto
en-aut-mei=Daigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=NishiyamaTakahiro
en-aut-sei=Nishiyama
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=ShimadaSatoko
en-aut-sei=Shimada
en-aut-mei=Satoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=MasakiYasufumi
en-aut-sei=Masaki
en-aut-mei=Yasufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=OkamotoMasataka
en-aut-sei=Okamoto
en-aut-mei=Masataka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=AtsutaYoshiko
en-aut-sei=Atsuta
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=KiyoiHitoshi
en-aut-sei=Kiyoi
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=SuzukiRitsuro
en-aut-sei=Suzuki
en-aut-mei=Ritsuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=NakamuraShigeo
en-aut-sei=Nakamura
en-aut-mei=Shigeo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=KinoshitaTomohiro
en-aut-sei=Kinoshita
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

affil-num=1
en-affil=Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Hematological Malignancies, Mie University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Advanced Medicine, Nagoya University Hospital
kn-affil=

affil-num=4
en-affil=Division of Hematology/Oncology, Internal Medicine, Kameda Medical Center
kn-affil=

affil-num=5
en-affil=Department of Hematology, Nagano Red Cross Hospital
kn-affil=

affil-num=6
en-affil=Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=7
en-affil=Department of Hematology, National Hospital Organization Nagoya Medical Center
kn-affil=

affil-num=8
en-affil=Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine
kn-affil=

affil-num=9
en-affil=Department of Hematology and Rheumatology, Tohoku University Hospital
kn-affil=

affil-num=10
en-affil=Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Hematology and Oncology, Mie University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Hematology, Oita Prefectural Hospital
kn-affil=

affil-num=13
en-affil=Department of Hematology, Fujita Health University School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Hematology, Oami Municipal Hospital
kn-affil=

affil-num=15
en-affil=Department of Hematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
kn-affil=

affil-num=16
en-affil=Department of Clinical Oncology, Nagoya Memorial Hospital
kn-affil=

affil-num=17
en-affil=Department of Hematology, Toranomon Hospital Kajigaya
kn-affil=

affil-num=18
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=19
en-affil=Department of Internal Medicine, Toyama Prefectural Central Hospital
kn-affil=

affil-num=20
en-affil=Division of Hematology, Tochigi Cancer Center
kn-affil=

affil-num=21
en-affil=Department of Hematology, Daini Osaka Police Hospital
kn-affil=

affil-num=22
en-affil=Department of Hematology, National Cancer Center Hospital East
kn-affil=

affil-num=23
en-affil=Department of Hematology, Hokkaido University Faculty of Medicine, Graduate School of Medicine
kn-affil=

affil-num=24
en-affil=Division of Hematology, Ichinomiya Municipal Hospital
kn-affil=

affil-num=25
en-affil=Department of Pathology and Clinical Laboratories, Nagoya University Hospital
kn-affil=

affil-num=26
en-affil=Department of Hematology and Immunology, Kanazawa Medical University
kn-affil=

affil-num=27
en-affil=Department of Hematology, Fujita Health University School of Medicine
kn-affil=

affil-num=28
en-affil=Japanese Data Center for Hematopoietic Cell Transplantation
kn-affil=

affil-num=29
en-affil=Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=30
en-affil=Department of HSCT Data Management and Biostatistics, Nagoya University School of Medicine
kn-affil=

affil-num=31
en-affil=Department of Pathology and Clinical Laboratories, Nagoya University Hospital
kn-affil=

affil-num=32
en-affil=Department of Hematology and Cell Therapy, Aichi Cancer Center
kn-affil=
en-keyword=Central nervous system-directed therapy
kn-keyword=Central nervous system-directed therapy
en-keyword=Intravascular large B-Cell lymphoma
kn-keyword=Intravascular large B-Cell lymphoma
en-keyword=R-CHOP
kn-keyword=R-CHOP
en-keyword=Secondary central nervous system involvement
kn-keyword=Secondary central nervous system involvement
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=6
article-no=
start-page=e86575
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250623
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and objective: We had previously conducted a phase II study (LOGIK0902/OLCSG0905 study) involving the eight-week administration of gefitinib, followed by cisplatin-based chemoradiotherapy, to treat locally advanced, epidermal growth factor receptor (EGFR)-mutated, non-small cell lung cancer (NSCLC). Despite favorable overall survival outcomes, more than half of the patients relapsed after the protocol therapy, highlighting the need to clarify the clinical significance of retreatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated the efficacy and safety of EGFR-TKI retreatment after disease progression.<br>
Materials and methods: We included 14 patients who relapsed after the protocol treatment and received any type of EGFR-TKI as post-progression treatment in this sub-analysis. We evaluated the efficacy and safety of retreatment with EGFR-TKI in these patients.<br>
Results: Among the 14 patients, 11 (78.6%) responded to the induction of gefitinib in the treatment protocol. After relapse, 9/14 patients (64.3%) received gefitinib, 3/14 (21.4%) received afatinib, and 2/14 (14.3%) received erlotinib monotherapy, respectively. The median duration of post-progression EGFR-TKI treatment was 17.9 (0.7-45.5) months. The overall response rate (ORR) and disease control rate were 64.3% [9/14 patients; 95% confidence interval (CI): 35.1%-87.2%] and 85.7% (12/14 patients; 95% CI: 57.2%-98.2%), respectively. The median progression-free survival (PFS) and median survival durations after the initiation of EGFR-TKI retreatment were 11.8 months (95% CI: 5.7-20.7 months) and 47.4 months (95% CI: 31.8 months to not estimable), respectively. Adverse events were comparable to those previously reported.<br>
Conclusions: Patients with disease progression after protocol therapy demonstrated sensitivity to retreatment with an EGFR-TKI, with acceptable safety.
en-copyright=
kn-copyright=

en-aut-name=SaekiSho
en-aut-sei=Saeki
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SakataShinya
en-aut-sei=Sakata
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OdaNaohiro
en-aut-sei=Oda
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=InoueKoji
en-aut-sei=Inoue
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TamuraTomoki
en-aut-sei=Tamura
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyozawaRyo
en-aut-sei=Toyozawa
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HaradaDaijiro
en-aut-sei=Harada
en-aut-mei=Daijiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanakaKentaro
en-aut-sei=Tanaka
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=InoueKoji
en-aut-sei=Inoue
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ShioyamaYoshiyuki
en-aut-sei=Shioyama
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=GembaKenichi
en-aut-sei=Gemba
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SasakiTomonari
en-aut-sei=Sasaki
en-aut-mei=Tomonari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=BesshoAkihiro
en-aut-sei=Bessho
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KishimotoJunji
en-aut-sei=Kishimoto
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KatsuiKuniaki
en-aut-sei=Katsui
en-aut-mei=Kuniaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KiuraKatsuyuki
en-aut-sei=Kiura
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SugioKenji
en-aut-sei=Sugio
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

affil-num=1
en-affil=Department of Respiratory Medicine, Kumamoto University Hospital
kn-affil=

affil-num=2
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Respiratory Medicine, Kumamoto University Hospital
kn-affil=

affil-num=4
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Respiratory Medicine, Kitakyushu Municipal Medical Center
kn-affil=

affil-num=6
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center
kn-affil=

affil-num=8
en-affil=Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=9
en-affil=Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=10
en-affil=Department of Respiratory Medicine, Ehime Prefectural Central Hospital
kn-affil=

affil-num=11
en-affil=Radiation Oncology, Ion Beam Therapy Center, SAGA HIMAT Foundation
kn-affil=

affil-num=12
en-affil=Department of Respiratory Medicine, Chugoku Central Hospital
kn-affil=

affil-num=13
en-affil=Department of Radiation Oncology, Iizuka Hospital
kn-affil=

affil-num=14
en-affil=Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=15
en-affil=Center for Clinical and Translational Research, Kyushu University Hospital
kn-affil=

affil-num=16
en-affil=Department of Radiology, Division of Radiation Oncology, Kawasaki Medical School
kn-affil=

affil-num=17
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=18
en-affil=Thoracic and Breast Surgery, Oita University
kn-affil=
en-keyword=chemoradiotherapy
kn-keyword=chemoradiotherapy
en-keyword=egfr
kn-keyword=egfr
en-keyword=locally advanced setting
kn-keyword=locally advanced setting
en-keyword=non-small cell lung cancer
kn-keyword=non-small cell lung cancer
en-keyword=progression
kn-keyword=progression
en-keyword=retreatment
kn-keyword=retreatment
en-keyword=safety
kn-keyword=safety
en-keyword=targeted therapy
kn-keyword=targeted therapy
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=2
article-no=
start-page=100078
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Erythromelalgia presenting with posterior reversible encephalopathy syndrome: A pediatric case report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Erythromelalgia is a rare disorder characterized by erythema, warmth, and burning pain in the extremities. We report a pediatric case of erythromelalgia in a patient who developed posterior reversible encephalopathy syndrome (PRES), without any cutaneous signs.<br>
Case presentation: A previously healthy 12-year-old girl presented to our pediatric clinic with burning extremity pain that had persisted for 6 weeks. The patient was treated with analgesics; however, the pain was refractory to these agents. Seven days after the first visit, she developed afebrile seizures and was transferred to our hospital. Her initial blood pressure was 139/105 mmHg (+2.0 SD), and brain magnetic resonance imaging revealed high intensity areas in the bilateral parietal and occipital lobes, leading to a diagnosis of PRES. Her blood pressure was difficult to control with anti-hypertensive agents. Burning pain in her extremities was relieved by cooling and worsened by warming. Although erythema was not observed in her hands or legs, erythromelalgia was suspected based on the characteristic nature of her pain. Intravenous lidocaine was administered for diagnosis, which was dramatically effective. After initiating mexiletine, the burning pain in her extremities disappeared, and hypertension improved. A final diagnosis of erythromelalgia with PRES was made.<br>
Conclusion: A history of temperature-dependent pain relief and deterioration are important indicators of disease diagnosis, even if patients indicate a lack of erythema or warmth. Physicians should be aware that persistent pain due to erythromelalgia can lead to refractory hypertension and development of PRES.
en-copyright=
kn-copyright=

en-aut-name=SuzukiKengo
en-aut-sei=Suzuki
en-aut-mei=Kengo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UdaKazuhiro
en-aut-sei=Uda
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsugeMitsuru
en-aut-sei=Tsuge
en-aut-mei=Mitsuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ArakawaKyosuke
en-aut-sei=Arakawa
en-aut-mei=Kyosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShigeharaKenji
en-aut-sei=Shigehara
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ObaraTakafumi
en-aut-sei=Obara
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HasegawaKosei
en-aut-sei=Hasegawa
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TsukaharaHirokazu
en-aut-sei=Tsukahara
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Pediatric Acute Diseases, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Erythromelalgia
kn-keyword=Erythromelalgia
en-keyword=Posterior reversible encephalopathy syndrome
kn-keyword=Posterior reversible encephalopathy syndrome
en-keyword=Hypertension
kn-keyword=Hypertension
en-keyword=Child
kn-keyword=Child
END

start-ver=1.4
cd-journal=joma
no-vol=115
cd-vols=
no-issue=
article-no=
start-page=1
end-page=8
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260301
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of Branching Characteristics and Their Contribution to Yield in Everbearing Strawberry Cultivars under Forced Cultivation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　Enhancing continuous flowering in cultivated strawberries may result in insufficient photosynthetic products due to the lower limit of leaf number on each lateral shoot, leading to reduced yield and fruit quality. If strawberries could differentiate an appropriate number of tillers and allow each tiller to grow autonomously with sufficient leaf number on each lateral shoot, rather than flowering continuously on the main bud alone, plants could achieve high yields while preventing plant weakening and fruit quality deterioration. Therefore, this study evaluated branching characteristics of everbearing strawberry cultivars under forcing cultivation to identify cultivars with moderate tillering and moderately low continuous flowering. Pot experiments revealed that the number of tillers was high in ‘Summer Princess’ and ‘Miyazaki-natsuharuka’ but low in ‘Summer Berry’ and ‘Suzuakane’. This trend was independent of total number of lateral shoots, nodal position of first inflorescence, and the number of leaves on each lateral shoot, which serve as indicators of continuous flowering ability. Among seven tested cultivars, ‘DT17’ and ‘Miyazaki-natsuharuka’ showed intermediate values with 2.1 - 2.5 tillers per plant and 6.7 - 7.7 leaves on each lateral shoots. These cultivars showed yields of 747.0 - 1,028.5 g per plant under forcing cultivation, which were higher than other cultivars, along with consistent fruit quality. These results suggest that improving branching characteristics is a practical approach to enhancing fruit productivity in strawberries.
en-copyright=
kn-copyright=

en-aut-name=Hikawa-EndoMinori
en-aut-sei=Hikawa-Endo
en-aut-mei=Minori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SoneKazuyoshi
en-aut-sei=Sone
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MorishitaMasami
en-aut-sei=Morishita
en-aut-mei=Masami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Kyushu Okinawa Region Agricultural Research Center, NARO
kn-affil=

affil-num=2
en-affil=Kyushu Okinawa Region Agricultural Research Center, NARO
kn-affil=

affil-num=3
en-affil=Kyushu Okinawa Region Agricultural Research Center, NARO
kn-affil=
en-keyword=branching characteristics
kn-keyword=branching characteristics
en-keyword=continuous flowering ability
kn-keyword=continuous flowering ability
en-keyword=crown
kn-keyword=crown
en-keyword=strawberry
kn-keyword=strawberry
en-keyword=tiller
kn-keyword=tiller
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=裏表紙・英文目次
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=奥付
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=209
end-page=226
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Teaching and Learning：Japanese and International Student Collaboration in the Classroom
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This practical report introduces three intercultural collaborative trial classes designed to integrate Japanese and international students in first-year EFL classes. Using a CLIL-informed approach, the classes promoted intercultural understanding through culturally grounded activities and small-group communication tasks. Reflection surveys from both Japanese and international participants revealed overall positive experiences, with international students expressing strong enjoyment and Japanese students highlighting both linguistic gains and communication challenges. Analysis indicates that interaction across diverse cultural and linguistic backgrounds fostered intercultural awareness while motivating Japanese learners to further develop their speaking skills. The findings support the value of collaborative, content-based activities for enhancing intercultural understanding.
en-copyright=
kn-copyright=

en-aut-name=PUSINAAlexis
en-aut-sei=PUSINA
en-aut-mei=Alexis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OTOSHIJunko
en-aut-sei=OTOSHI
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=Institute for Promotion of Education and Campus Life, Okayama University

affil-num=2
en-affil=
kn-affil=Institute for Promotion of Education and Campus Life, Okayama University
en-keyword=collaborative learning
kn-keyword=collaborative learning
en-keyword=content and language integrated learning (CLIL)
kn-keyword=content and language integrated learning (CLIL)
en-keyword=intercultural understanding
kn-keyword=intercultural understanding
en-keyword=intercultural communication
kn-keyword=intercultural communication
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=195
end-page=208
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Examination of Accessible Outdoor Tourism Based on the Global Code of Ethics for Tourism：Practical Application of Outdoor Wheelchairs in World Natural Heritage Sites
kn-title=世界観光倫理憲章を踏まえたアクセシブルアウトドアツーリズムの検討 ―世界自然遺産地域でのアウトドア型車椅子を用いた実践を通じて―
en-subtitle=
kn-subtitle=
en-abstract=Promoting accessible outdoor tourism requires balancing conservation and protection with development. Therefore, this study aims to enable as many people as possible to participate in outdoor activities. This verification examines whether tours using outdoor wheelchairs can be conducted within World Natural Heritage sites. To achieve tourism that leaves no one behind, we believe the most reliable approach is to gradually expand the scope of accessible outdoor tourism through the accumulation of individual practices, even if progress is incremental.
kn-abstract=アクセシブルアウトドアツーリズムを進めていくためには，「保全・保護」と「開発」の両立が非常に重要な観点となる。そこで本実践では，一人でも多くの人がアウトドア活動に参加できることを目指し，世界自然遺産地域においてアウトドア型車椅子を用いたツアーが実現できるかどうかを検討することとした。「誰ひとり取り残さない観光」とは，世界観光倫理憲章でも標榜された目標であるが，このことを実現するためには，今回検討を行ったような一つ一つの実践を積み重ねることによって，少しずつであってもアクセシブルアウトドアツーリズムの可能範囲を広げていくことが，最も確実な取り組みなのではないかと考えている。
en-copyright=
kn-copyright=

en-aut-name=IKETANIKosuke
en-aut-sei=IKETANI
en-aut-mei=Kosuke
kn-aut-name=池谷航介
kn-aut-sei=池谷
kn-aut-mei=航介
aut-affil-num=1
ORCID=

en-aut-name=HARADAShin
en-aut-sei=HARADA
en-aut-mei=Shin
kn-aut-name=原田新
kn-aut-sei=原田
kn-aut-mei=新
aut-affil-num=2
ORCID=

en-aut-name=KUSUNOKIKeita
en-aut-sei=KUSUNOKI
en-aut-mei=Keita
kn-aut-name=楠敬太
kn-aut-sei=楠
kn-aut-mei=敬太
aut-affil-num=3
ORCID=

affil-num=1
en-affil=General Education and Global Studies Field, Okayama University
kn-affil=岡山大学学術研究院共通教育・グローバル領域

affil-num=2
en-affil=General Education and Global Studies Field, Okayama University
kn-affil=岡山大学学術研究院共通教育・グローバル領域

affil-num=3
en-affil=Institute of Student Support, Bukkyo University
kn-affil=佛教大学学生支援機構
en-keyword=観光
kn-keyword=観光
en-keyword=ユニバーサルツーリズム
kn-keyword=ユニバーサルツーリズム
en-keyword=アクセシビリティ
kn-keyword=アクセシビリティ
en-keyword=障害者支援
kn-keyword=障害者支援
en-keyword=アウトドア
kn-keyword=アウトドア
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=174
end-page=194
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Redesigning Writing Instruction through Peer–AI–Instructor Collaborative Triadic Feedback：Integrating AI in an Academic Writing Course
kn-title=ピア・AI・教員の三者協働フィードバックによるライティング授業の再設計 ―AI利用の実践報告－
en-subtitle=
kn-subtitle=
en-abstract=This paper presents the design of a triadic feedback model for an academic writing course that clarifies the role allocation and sequencing of feedback among peers, AI, and the instructor (student’s own draft → peer feedback → AI feedback（→ metacognitive reflection )→teacher feedback), and it describes its implementation and evaluation in 2024–2025. Post-course student surveys valued AI’s immediacy and capacity for elaboration, while also expressing concerns about dependence and limits to its effectiveness. Grade distributions showed a contraction of the lower-performing band after the introduction of the model, suggesting an overall uplift in learning outcomes. To counter misuse AI, explicit in-class instruction on constructive use, such as privileging diagnostic feedback over canned text and requiring metacognitive justification for accepting or rejecting AI suggestions, proved effective. We thus present the effectiveness and remaining challenges of a course design that leverages AI’s potential while keeping human judgment and ethics at its core.
kn-abstract=本稿は、アカデミック・ライティング授業におけるピア・AI・教員のそれぞれの役割と利用順序（自分→ピア→AI→（省察）→教員）を組み込んだ三者協働モデルを設計し、2024～2025年度に実践した内容を報告する。授業後の学生アンケートでは、AIの即時性・精緻化が評価される一方、依存や有効性の限界に関する懸念も表明された。成績分布においては、AI導入後に下位層が縮小し、学習成果の底上げが示唆された。また、AI誤用や濫用を防ぐには、教室内で建設的な利用法の具体的な指導（例：例文より診断的フィードバックを重視、AI提案の採否理由のメタ記述）が効果的であった。これらの結果から、AIの利点を活かしつつ、学生の判断を中心に据えるライティング授業設計の有効性と課題を提示する。
en-copyright=
kn-copyright=

en-aut-name=UzukaMariko
en-aut-sei=Uzuka
en-aut-mei=Mariko
kn-aut-name=宇塚万里子
kn-aut-sei=宇塚
kn-aut-mei=万里子
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Institute for Promotion of Education and Campus Life
kn-affil=教育推進機構
en-keyword=生成 AI
kn-keyword=生成 AI
en-keyword=アカデミック・ライティング
kn-keyword=アカデミック・ライティング
en-keyword=ピア評価
kn-keyword=ピア評価
en-keyword=メタ認知
kn-keyword=メタ認知
en-keyword=AI リテラシー
kn-keyword=AI リテラシー
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=155
end-page=173
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=An Attempt at Extensive Reading in Chinese at the Pre-Intermediate Level
kn-title=大学における中国語多読の試み
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　This study examines the implementation of the instruction for extensive reading in Chinese among 19 learners who completed one year of beginner-level Chinese studies comprising two 100-minute sessions per week. Regarding survey methods, a questionnaire using a five-point Likert scale and open-ended responses was utilized. The findings revealed that learners recognized extensive reading as an effective strategy for improving their reading comprehension and vocabulary. However, some challenges exist, including the lack of suitable books for extensive reading practices and difficulties in sustaining extensive reading habits.
en-copyright=
kn-copyright=

en-aut-name=ISHIITomomi
en-aut-sei=ISHII
en-aut-mei=Tomomi
kn-aut-name=石井友美
kn-aut-sei=石井
kn-aut-mei=友美
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Institute for Promotion of Education and Campus Life, Okayama University
kn-affil=岡山大学教育推進機構
en-keyword=中国語多読
kn-keyword=中国語多読
en-keyword=準中級レベル
kn-keyword=準中級レベル
en-keyword=多読ルール
kn-keyword=多読ルール
en-keyword=読解力
kn-keyword=読解力
en-keyword=語彙力
kn-keyword=語彙力
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=145
end-page=154
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Chi no Tanken (Inquiries of Knowledge) meets Multicultural Collaborative Learning：Transforming a Japanese Online Course for Global Learners
kn-title=「知の探研」× 多文化共修 ―オンライン授業再構築の試み―
en-subtitle=
kn-subtitle=
en-abstract=Okayama University launched a new undergraduate curriculum in April 2025. As part of this reform, Chi no Tanken, a general education course required for incoming students, was introduced. This paper reports on the first-year implementation of the course, offered in English as Inquiries of Knowledge, for students in the Discovery Program for Global Learners, many of whom are international students. Reconstructing the on-demand online course from a multicultural collaborative learning perspective required more than simply translating the materials into English. It also necessitated developing pedagogical strategies to foster collaborative learning in the online environment and to integrate linguistic and cultural considerations.
kn-abstract=岡山大学では2025年4月入学生から新カリキュラムがスタートした。学士課程改革の一環として導入されたのが全学共通・課題探究科目「知の探研」である。本稿では，新入生対象科目である「知の探研」を，海外生を含むグローバル・ディスカバリー・プログラム生向けに英語で “Inquiries of Knowledge” として開講した初年度の取り組みを報告する。とりわけオンデマンド型オンライン授業を, 本学が推進する多文化共修の視点で再構築するにあたり，教材を単に英訳するのではなく, オンライン環境においても協働学習を実現する工夫や，言語的・文化的配慮の統合が不可欠であることを明らかにする。
en-copyright=
kn-copyright=

en-aut-name=YAMAMOTOYumiko
en-aut-sei=YAMAMOTO
en-aut-mei=Yumiko
kn-aut-name=山本由美子
kn-aut-sei=山本
kn-aut-mei=由美子
aut-affil-num=1
ORCID=

en-aut-name=NGUYENKha Manh
en-aut-sei=NGUYEN
en-aut-mei=Kha Manh
kn-aut-name=グエン•カ•マン
kn-aut-sei=グエン•
kn-aut-mei=カ•マン
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Faculty of General and Global Studies (GDP), Okayama University
kn-affil=岡山大学学術研究院 共通教育・グローバル領域（GDP）

affil-num=2
en-affil=Discovery Program for Global Learners, Okayama University
kn-affil=岡山大学グローバル・ディスカバリー・プログラム
en-keyword=多文化共修
kn-keyword=多文化共修
en-keyword=協働学習
kn-keyword=協働学習
en-keyword=探究型学習
kn-keyword=探究型学習
en-keyword=オンデマンド型オンライン授業
kn-keyword=オンデマンド型オンライン授業
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=129
end-page=144
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Learner Narratives Based on Faculty-Specific Interviews and Orientation Practices：An Attempt to Enhance Foreign Language Learning Motivation at University Entrance
kn-title=学部別インタビューによる学習者ナラティブとオリエンテーション実践 ―大学入学時における外国語学習動機づけ促進の試み―
en-subtitle=
kn-subtitle=
en-abstract=Okayama University has implemented a comprehensive reform of its English curriculum as part of Target2025, a university-wide initiative launched in response to the new Course of Study issued by MEXT. The reform fosters close collaboration between the English section and other faculties to support undergraduate English learning across the university. We interviewed role models－successful English learners recommended by their faculties－about how they learned English. We also shared messages of encouragement for new students, which were recorded and shown during the orientation for English courses. This paper reviews the interview and orientation process, as well as first-year students’ responses to a subsequent survey.
kn-abstract=岡山大学では新学習指導要領実施に合わせ、「学習者中心の学び」の実現を目指すTarget2025と呼ばれる方針のもと英語カリキュラムの改革を進めてきた。この改革では、英語系教員と各部局とが密に連携しながら、学士課程全体を通した英語学習を全学的に展開していくことに焦点を当てている。その取り組みの一環として、各部局から推薦を受けたロールモデルとの学部別インタビューを実施し、英語学習についての詳細を聴き取った。また、新入生への激励のメッセージ動画を作成し、英語授業オリエンテーションで上映した。本稿では、インタビューで得られたナラティブやオリエンテーション実施の経緯、また、オリエンテーション後に実施したアンケート結果について報告する。
en-copyright=
kn-copyright=

en-aut-name=YOSHIDAAzumi
en-aut-sei=YOSHIDA
en-aut-mei=Azumi
kn-aut-name=吉田安曇
kn-aut-sei=吉田
kn-aut-mei=安曇
aut-affil-num=1
ORCID=

en-aut-name=TERANISHIMasako
en-aut-sei=TERANISHI
en-aut-mei=Masako
kn-aut-name=寺西雅子
kn-aut-sei=寺西
kn-aut-mei=雅子
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Institute for Promotion of Education and Campus Life, Okayama University
kn-affil=岡山大学教育推進機構

affil-num=2
en-affil=Institute for Promotion of Education and Campus Life, Okayama University
kn-affil=岡山大学教育推進機構
en-keyword=学部別インタビュー
kn-keyword=学部別インタビュー
en-keyword=学習者ナラティブ
kn-keyword=学習者ナラティブ
en-keyword=ロールモデル
kn-keyword=ロールモデル
en-keyword=オリエンテーション
kn-keyword=オリエンテーション
en-keyword=動機づけ
kn-keyword=動機づけ
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=120
end-page=128
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=From The Odyssey to The Zahir：The Evolution of Penelopeia Across Time and Tradition
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The story of a man who leaves home and strives to return has become one of the most enduring narrative patterns in world literature and folklore. Across centuries and cultures, it has been retold in myths, epics, folktales, and modern fiction—the story of the homecoming hero who, after long absence and peril, finds his way back to the place and the person he once called his own. This study explores the persistence and transformation of this universal motif through a comparative reading of Homer’s The Odyssey and Paulo Coelho’s The Zahir. It examines the evolving image of the waiting wife—from Homer’s Penelopeia, emblem of chastity and endurance, to Coelho’s Esther, a modern woman of independence and choice. Despite differences in setting, voice, and moral vision, both works embody the same human longing: to return, to be recognized, and to rediscover love that endures time and change. Beneath their differences lies the same truth—the heart to which every journey, whether physical or spiritual, must ultimately return.
en-copyright=
kn-copyright=

en-aut-name=KHALMIRZAEVASaida
en-aut-sei=KHALMIRZAEVA
en-aut-mei=Saida
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Faculty of General Education and Global Studies, Okayama University
kn-affil=
en-keyword=Homer
kn-keyword=Homer
en-keyword=The Odyssey
kn-keyword=The Odyssey
en-keyword=Paulo Coelho
kn-keyword=Paulo Coelho
en-keyword=The Zahir
kn-keyword=The Zahir
en-keyword=Penelopeia
kn-keyword=Penelopeia
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=100
end-page=119
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Developing a Short-form Scale to Assess Learner Beliefs Regarding English Learning Strategies
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Questionnaire surveys are a prevalent method in applied linguistics for investigating complex constructs, such as learner beliefs. However, their complex nature often creates overly lengthy instruments, making them impractical for classroom use or for obtaining timely educational insights. This study aimed to develop a simplified, yet robust version of an existing learner belief scale to address these challenges. The authors carefully selected 24 belief-specific items from an initial pool of 78 items from a previous study for use in an online survey, which was completed by 246 participants. The data were subject to exploratory factor analysis. This process resulted in a concise 12-item scale, could offer a more practical tool for language educators.
en-copyright=
kn-copyright=

en-aut-name=MORITANIHiroshi
en-aut-sei=MORITANI
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=PUSINAAlexis
en-aut-sei=PUSINA
en-aut-mei=Alexis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Institute for Promotion of Education and Campus Life, Okayama University
kn-affil=

affil-num=2
en-affil=Institute for Promotion of Education and Campus Life, Okayama University
kn-affil=
en-keyword=Questionnaire items
kn-keyword=Questionnaire items
en-keyword=Learner beliefs
kn-keyword=Learner beliefs
en-keyword=Language learning strategies
kn-keyword=Language learning strategies
en-keyword=Exploratory factor analysis
kn-keyword=Exploratory factor analysis
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=91
end-page=99
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=To What Extent are Parents of High School Students with Developmental Disabilities Aware of Support for Students with Disabilities at Universities?
kn-title=発達障害を有する高校生の保護者による障害学生支援の認知度
en-subtitle=
kn-subtitle=
en-abstract=　This study aimed to investigate how well parents of high school students with developmental disabilities are aware of support for students with disabilities and student counseling at universities, how they obtained information about these services, and what kind of information dissemination do you expect from universities when seeking information about these services. The results revealed that parents are not sufficiently informed about university student support services. Parents are requesting the holding of information sessions and consultation meetings regarding student support. Furthermore, It is necessary to actively disseminate information to high school teachers and further promote high school-university collaboration initiatives.
kn-abstract=　本研究では，発達障害を有する高校生の保護者が，「大学等における障害学生支援や学生相談をどの程度知っているか」，「大学等における障害学生支援や学生相談の情報をどのように入手したか」，「大学等における障害学生支援や学生相談の情報収集をする上で，大学等にどのような情報発信を期待するか」について調査を行った。その結果，まだ保護者に対し，十分に大学の学生支援の情報が行き届いていないこと，学生支援に関する情報発信を行う説明会や相談会を行うことが保護者から期待されていること，発達障害を有する高校生の高大移行を促進するために，高校の先生方に対する情報発信も精力的に行ったり，高大連携の取り組みをより行う必要があること等が見出された。
en-copyright=
kn-copyright=

en-aut-name=HARADAShin
en-aut-sei=HARADA
en-aut-mei=Shin
kn-aut-name=原田新
kn-aut-sei=原田
kn-aut-mei=新
aut-affil-num=1
ORCID=

en-aut-name=IketaniKosuke
en-aut-sei=Iketani
en-aut-mei=Kosuke
kn-aut-name=池谷航介
kn-aut-sei=池谷
kn-aut-mei=航介
aut-affil-num=2
ORCID=

en-aut-name=MATSUIMegumi
en-aut-sei=MATSUI
en-aut-mei=Megumi
kn-aut-name=松井めぐみ
kn-aut-sei=松井
kn-aut-mei=めぐみ
aut-affil-num=3
ORCID=

en-aut-name=MOCHIZUKINaoto
en-aut-sei=MOCHIZUKI
en-aut-mei=Naoto
kn-aut-name=望月直人
kn-aut-sei=望月
kn-aut-mei=直人
aut-affil-num=4
ORCID=

affil-num=1
en-affil=General Education and Global Studies Field, Okayama University
kn-affil=岡山大学学術研究院共通教育・グローバル領域

affil-num=2
en-affil=General Education and Global Studies Field, Okayama University
kn-affil=岡山大学学術研究院共通教育・グローバル領域

affil-num=3
en-affil=General Education and Global Studies Field, Okayama University
kn-affil=岡山大学学術研究院共通教育・グローバル領域

affil-num=4
en-affil=Health and Counseling Center, The University of Osaka
kn-affil=大阪大学キャンパスライフ健康支援・相談センター
en-keyword=障害学生支援
kn-keyword=障害学生支援
en-keyword=発達障害を有する高校生の保護者
kn-keyword=発達障害を有する高校生の保護者
en-keyword=早期支援
kn-keyword=早期支援
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=74
end-page=90
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Reconsidering the Sources of the Modern Korean Reader Textbook Chodeung-sohak
kn-title=近代韓国の読本教科書『初等小学』の底本に関する再考
en-subtitle=
kn-subtitle=
en-abstract=　This study examines the Japanese Meiji-period reader textbooks that appear to have been consulted in the compilation of the Korean modern reader textbook Chodeung-sohak(1906). While reviewing prior research, this paper newly identifies two previously unnoted source textbooks: one published by Kinkōdō in 1894 and another by Fukyūsya in 1893. The findings indicate that the Meiji-period reader most frequently referenced in Chodeung-sohak was Jinjō Kokugo Tokuhon published by Kinkōdō in 1900. Overall, it can be concluded that Chodeung-sohak relied primarily on the comparatively recent elementary-level readers issued by Kinkōdō and the Ministry of Education. 
kn-abstract=　本稿では、近代韓国の読本教科書『初等小学』（1906）の編纂において参照されたと思われる日本の明治期読本教科書について比較・考察を行った。まず、文部省編纂の検定『尋常小学読本』（1887）と第1期国定『尋常小学読本』（1903）、さらに金港堂出版の『尋常国語読本』（1900）及び『高等国語読本』（1900）との関連性について、先行研究の議論を再検討した。そのうえで、新たに金港堂の『新体読本 尋常小学用』（1894）と普及舎の『尋常小学新読本』（1893）の2種を底本として確認することができた。『初等小学』において最も多く参照された明治期読本教科書は金港堂の『尋常国語読本』（1900）であり、『初等小学』は、金港堂と文部省の比較的新しい尋常小学用読本教科書を優先的に参照したと思われる。
en-copyright=
kn-copyright=

en-aut-name=LEEAnkoo
en-aut-sei=LEE
en-aut-mei=Ankoo
kn-aut-name=李安九
kn-aut-sei=李
kn-aut-mei=安九
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Institute for Promotion of Education and Campus Life, Okayama University
kn-affil=岡山大学教育推進機構
en-keyword=『初等小学』
kn-keyword=『初等小学』
en-keyword=近代韓国の読本教科書
kn-keyword=近代韓国の読本教科書
en-keyword=明治期読本教科書
kn-keyword=明治期読本教科書
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=57
end-page=73
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Criteria for Faculty Decision-Making Regarding the Acceptance of International Students：From the perspective of faculty who accept many international students
kn-title=留学生受け入れにおける教員の判断基準 ―多くの留学生を受け入れている教員の視点から―
en-subtitle=
kn-subtitle=
en-abstract=　The declining birth rate significantly impacts domestic universities' enrolment, creating high expectations for increased international student intake. Within postgraduate education, however, a divide exists between faculty members who are and aren't proactive in accepting them. This study used semi-structured interviews to clarify the criteria faculty members use when accepting international students. The findings showed that while terminology varied, faculty commonly considered both “character” and “ability”. Furthermore, faculty who viewed international admissions positively had either studied or conducted research abroad and/or gained positive experiences from supervising their first international students. These factors fostered positive impressions and led to more proactive acceptance.
kn-abstract=　少子化は国内大学の定員充足率に深刻な影響を与えることから、留学生の受入増に期待が寄せられている。しかし、大学院教育において留学生受入に前向きな教員と、消極的な教員が見受けられる。本研究では、より多くの留学生を受け入れている教員が、どのような判断基準で受け入れを決定しているのかを、半構造化インタビューを通じて明らかにすることを試みた。その結果、判断基準に関しては、教員により表現は異なるが「人物」と「能力」を確認していることが分かった。また、受け入れを前向きに考える教員は、留学・在外研究員経験や、初めて受け入れた留学生指導を通じて良い経験をしたこと等が、留学生に対するプラスの印象をつくり、積極的な受け入れにつながっていることが明らかになった。
en-copyright=
kn-copyright=

en-aut-name=INAMORITakao
en-aut-sei=INAMORI
en-aut-mei=Takao
kn-aut-name=稲森岳央
kn-aut-sei=稲森
kn-aut-mei=岳央
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Faculty of General and Global Studies, Okayama University
kn-affil=学術研究院共通教育・グローバル領域
en-keyword=日本留学
kn-keyword=日本留学
en-keyword=大学院
kn-keyword=大学院
en-keyword=留学生
kn-keyword=留学生
en-keyword=受入教員
kn-keyword=受入教員
en-keyword=判断基準
kn-keyword=判断基準
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=41
end-page=56
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Mediating Role of Self-Understanding in the Association Between Autistic Traits and Mental Health
kn-title=自閉スペクトラム症特性と精神的健康の関連：自己理解による媒介効果の検討
en-subtitle=
kn-subtitle=
en-abstract=　This study examined whether positive and negative dimensions of self-understanding mediate the association between autistic traits and mental health in the general population. Analyzing cross-sectional data from 604 non-clinical Japanese adults, we found that higher autistic traits were significantly associated with poorer mental health. This association was partially mediated by the positive dimension of self-understanding, whereas the negative dimension did not mediate. Exploratory analyses suggested that this protective effect may be more pronounced in women than in men. These findings identify positive self-understanding as an actionable target for support and underscore the value of gender-informed approaches.
kn-abstract= 本研究は、自閉スペクトラム症特性と精神的健康の関連において、自己理解がどのような役割を果たすかを明らかにすることを目的とした。日本の成人604名のデータを利用した二次分析の結果、自閉スペクトラム症特性の高さと精神的健康の悪化との間には関連が認められた。この関連は、自己理解の肯定的側面によって部分的に媒介されることが示された。特にこの自己理解の保護的な効果は、男性よりも女性においてより強い可能性が示唆された。一方で、自己理解の否定的側面は媒介効果を示さなかった。これらの結果から、自閉スペクトラム症特性を持つ人々への支援において、肯定的な自己理解を促進することが重要であり、性差を考慮したアプローチの必要性が示唆された。
en-copyright=
kn-copyright=

en-aut-name=NISHIMURAHiroki
en-aut-sei=NISHIMURA
en-aut-mei=Hiroki
kn-aut-name=西村大樹
kn-aut-sei=西村
kn-aut-mei=大樹
aut-affil-num=1
ORCID=

en-aut-name=UCHIDAAkihiro
en-aut-sei=UCHIDA
en-aut-mei=Akihiro
kn-aut-name=内田晃裕
kn-aut-sei=内田
kn-aut-mei=晃裕
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Institute for Promotion of Education and Campus Life, Okayama University
kn-affil=岡山大学教育推進機構

affil-num=2
en-affil=Okayama Psychiatric Medical Center
kn-affil=地方独立行政法人岡山県精神科医療センター
en-keyword=自閉スペクトラム症
kn-keyword=自閉スペクトラム症
en-keyword=メンタルヘルス
kn-keyword=メンタルヘルス
en-keyword=精神的健康
kn-keyword=精神的健康
en-keyword=自己理解
kn-keyword=自己理解
en-keyword=性差
kn-keyword=性差
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=31
end-page=40
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A Study of Participant Interaction in Online Volunteer Japanese Language Classes：Toward the Advancement of Community-Based Japanese Language Education
kn-title=オンラインによるボランティア日本語教室における参加者間のインターアクションの分析 ―地域型日本語教育の実現に向けて―
en-subtitle=
kn-subtitle=
en-abstract=This study investigates interactional dynamics within an online volunteer-based Japanese language classroom, with the aim of contributing to the development of a community-based instructional model. Employing the FLint system, the research analyzes the speech patterns and instructional behaviors of both supporters and learners in classroom settings characterized by community-oriented features. The analysis yielded the following findings: (1) the mean number of utterances produced by supporters was greater than that of learners; and (2) the average amount of indirect behavior in supporters’ utterances by slightly exceeded that of direct behavior. In the interactive style, supporters were observed to actively employ subcategories of indirect behaviors—such as questioning, using ideas of learners, and repeating learner responses—in order to scaffold the learners’ process of verbalizing their intended messages. 
kn-abstract= 本研究では，地域型日本語教育のモデル構築に向け，地域型の特徴を有する教室内での支援者および参加者の発話や教授行動の傾向を明らかにすべく，外国語相互作用分析システムを用い，オンラインによるボランティア教室におけるインターアクションの分析を行った。分析の結果，（1）支援者の平均発話数が学習者より多いこと，（2）支援者の発話における間接的行動の割合が直接的行動よりもやや高いことが示された。「おしゃべり型の教育」では，学習者が伝えたいことを言語化していくプロセスの中で，間接的行動の下位分類の「質問」「学習者の意図の利用」「学習者の回答の繰り返し」等を支援者が積極的に使用し支援していることが分かった。
en-copyright=
kn-copyright=

en-aut-name=SUESHIGEMiwa
en-aut-sei=SUESHIGE
en-aut-mei=Miwa
kn-aut-name=末繁美和
kn-aut-sei=末繁
kn-aut-mei=美和
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Institute for Promotion of Education and Campus Life, Okayama University
kn-affil=岡山大学教育推進機構
en-keyword=地域型日本語教育
kn-keyword=地域型日本語教育
en-keyword=おしゃべり型
kn-keyword=おしゃべり型
en-keyword=オンラインボランティア教室
kn-keyword=オンラインボランティア教室
en-keyword=F-システム
kn-keyword=F-システム
en-keyword=インターアクション
kn-keyword=インターアクション
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=12
end-page=30
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Clinical Psychologists’ Reflective Practice in Group Experiences
kn-title=心理臨床家同士のグループ体験における反省的実践
en-subtitle=
kn-subtitle=
en-abstract=　Reflective practice is crucial for psychological clinicians, who participate in it in diverse group formats. This study analyzed discussions among psychological clinicians using the KJ method to explore their experiences in both general colleague (Study 1) and continuous groups (Study 2). Four aspects were found to be crucial for psychological clinicians’ reflective practice in group experiences, including whether the experience leads to introspection. Furthermore, gaining such insights as awareness of one’s fundamental human sensations and desires or of the factors restricting one’s freedom was found to constitute meaningful reflective practice in continuous groups.
kn-abstract=　心理臨床家にとって反省的実践は重要であり，多様な形態のグループに参加をすることによって反省的実践を行っている。本研究では，全般的な心理臨床家同士のグループにおける体験（研究1）および継続的なグループにおける体験（研究2）を探索することを目的として，数名の心理臨床家による話し合いをKJ法を援用して分析した。その結果，心理臨床家同士のグループ体験における反省的実践には，【グループ体験が内省につながるかどうか】などの4つ側面が重要であることが示された。また，継続的なグループにおける体験では，《本来の人としての感覚や欲求》や《自分を不自由にしている要因》などの【会における気づき】が得られることが反省的実践として有意義であることが明らかになった。
en-copyright=
kn-copyright=

en-aut-name=KOBASHIRyosuke
en-aut-sei=KOBASHI
en-aut-mei=Ryosuke
kn-aut-name=小橋亮介
kn-aut-sei=小橋
kn-aut-mei=亮介
aut-affil-num=1
ORCID=

en-aut-name=TANAKAMasashi
en-aut-sei=TANAKA
en-aut-mei=Masashi
kn-aut-name=田中将司
kn-aut-sei=田中
kn-aut-mei=将司
aut-affil-num=2
ORCID=

en-aut-name=MURASERin
en-aut-sei=MURASE
en-aut-mei=Rin
kn-aut-name=村瀬凜
kn-aut-sei=村瀬
kn-aut-mei=凜
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Institute for Promotion of Education and Campus Life, Okayama University
kn-affil=岡山大学教育推進機構

affil-num=2
en-affil=Tokai University
kn-affil=東海大学

affil-num=3
en-affil=Graduate School of Education and Human Development, Nagoya University
kn-affil=名古屋大学大学院教育発達科学研究科
en-keyword=心理臨床家
kn-keyword=心理臨床家
en-keyword=グループ体験
kn-keyword=グループ体験
en-keyword=反省的実践
kn-keyword=反省的実践
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=1
end-page=11
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Exploring the Connection Between Sexual/Gender Fluidity and ADHD
kn-title=セクシュアリティのゆらぎと発達障害のADHDとの関連
en-subtitle=
kn-subtitle=
en-abstract=To explore the relationship between sexual/gender fluidity and ADHD, a longitudinal web-based survey was conducted with adults aged 18 and over. The first survey collected responses from 11,018 participants, and the second, one year later, from 5,474. Participants were divided into four groups based on changes in identification with various aspects of sexuality. A one-way ANOVA showed that, except for “demiromantic” and “demisexual,” most sexualities (excluding “heterosexual” and “gay”) were associated with significantly higher ADHD scores in those who shifted from identifying to not identifying. These findings suggest a potential association between sexual/gender fluidity and ADHD.
kn-abstract=　セクシュアリティのゆらぎと発達障害のADHDとの関連を明らかにするため，WEBによる縦断調査を行った。18歳以上の成人を対象とし，第1回目の調査は11,018人，1年後の第2回目の調査では5,474人から回答を得た。性自認，性的指向，性表現の様々なセクシュアリティについて，2回の調査での該当・非該当で4群に分け，ADHD得点について1要因の被験者間分散分析を行った。「デミロマンティック」「デミセクシュアル」以外で群の主効果が有意であり，「異性愛」「ゲイ」を除くセクシュアリティで，2回とも「非該当」群よりも「該当→非該当」群のADHD得点が有意に高かった。これによりセクシュアリティのゆらぎとADHDとの関連が示唆された。
en-copyright=
kn-copyright=

en-aut-name=MATSUIMegumi
en-aut-sei=MATSUI
en-aut-mei=Megumi
kn-aut-name=松井めぐみ
kn-aut-sei=松井
kn-aut-mei=めぐみ
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Institute for Promotion of Education and Campus Life, Okayama University
kn-affil=岡山大学教育推進機構
en-keyword=セクシュアリティのゆらぎ
kn-keyword=セクシュアリティのゆらぎ
en-keyword=発達障害
kn-keyword=発達障害
en-keyword=ADHD
kn-keyword=ADHD
en-keyword=縦断調査
kn-keyword=縦断調査
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=
article-no=
start-page=106742
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202509
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Inscribed-type spherical speed reducer with uniform reduction ratio in all directions
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A spherical motor is an actuator that can generate rotational motion about all three orthogonal axes. However, it is difficult to obtain high output torque from most electromagnetic spherical motors, primarily due to limitations inherent in electromagnetic actuators, such as restricted magnetic force and thermal constraints. Since its torque cannot be increased using planar gears, spherical speed reducers that transmit rotational torque along three orthogonal axes through sphere-to-sphere contact are required. One major limitation of conventional spherical speed reducers is that their size increases significantly as the reduction ratio becomes higher. To address this issue, we propose a novel inscribed-type spherical speed reducer, in which the deceleration mechanism is integrated within the output sphere. This configuration enables a more compact design, reducing the overall size to approximately half that of conventional designs. To predict the angular velocity and transmitted torque, theoretical models for the rotation and torque transmission of the speed reducer were developed. According to the proposed model, the reduction ratio of the spherical speed reducer is 1/3. To verify the validity of these models, experiments were conducted to measure angular velocity and torque. The theoretical results agreed well with the experimental results. In addition, the theoretical torque exhibited an average relative error of 1.63 % compared to the experimental result. Therefore, it was confirmed that the rotation and torque transmission models were valid. These results demonstrate that a reduction ratio can be obtained in all directions of the 3-DOF of the spherical speed reducer, unlike conventional 1-DOF reducers.
en-copyright=
kn-copyright=

en-aut-name=NaramuraSeiya
en-aut-sei=Naramura
en-aut-mei=Seiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TonegawaKoichi
en-aut-sei=Tonegawa
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShimookaSo
en-aut-sei=Shimooka
en-aut-mei=So
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YanoTomoaki
en-aut-sei=Yano
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=GofukuAkio
en-aut-sei=Gofuku
en-aut-mei=Akio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KasashimaNagayoshi
en-aut-sei=Kasashima
en-aut-mei=Nagayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KamegawaTetsushi
en-aut-sei=Kamegawa
en-aut-mei=Tetsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=3
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Okayama Prefectural University
kn-affil=

affil-num=6
en-affil=National Institute of Advanced Industrial Science and Technology
kn-affil=

affil-num=7
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=Inscribed-type spherical speed reducer
kn-keyword=Inscribed-type spherical speed reducer
en-keyword=Rotation and torque transmission
kn-keyword=Rotation and torque transmission
en-keyword=Friction
kn-keyword=Friction
en-keyword=Spherical motor
kn-keyword=Spherical motor
en-keyword=Three-axis rotation
kn-keyword=Three-axis rotation
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=表紙・目次
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=5
article-no=
start-page=1877
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of Surgical Procedures for Rheumatoid Forefoot Deformities on Radiographic Foot Length and Width Variations
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: The number of patients with rheumatoid arthritis (RA) undergoing forefoot arthroplasty has increased to better control the disease. Despite patients frequently expressing concerns regarding postoperative foot appearance and footwear-related expectations, no study has investigated postoperative changes in foot length and width in patients with RA. The aim of this study was to evaluate the effect of surgical procedures for rheumatoid forefoot deformities on variations in radiologically determined foot length and width. Methods: In total, 72 feet of 50 women and 3 men (average age: 66.7 years) underwent joint-preserving arthroplasty (n = 33) and arthrodesis of the first metatarsophalangeal joint with shortening osteotomy of the lesser metatarsals or resection arthroplasty of the lesser metatarsal heads (n = 39); procedures were carried out in our institute from August 2013 to February 2020. The mean disease duration was 23.5 years, and the average follow-up period was 17.5 months. Pre- and postoperative hallux valgus angle (HVA), intermetatarsal angle (IMA) of the first and second metatarsals (M1M2A), and IMA of the first and fifth metatarsals (M1M5A) were measured on weightbearing radiographs as well as foot length and width. We also evaluated the correlation between changes in radiographic parameters and variations in radiologically determined foot length and width. Results: Radiologically determined foot width changed significantly from 10.1 cm to 9.7 cm (p < 0.01), while no significant difference was found between pre- and postoperative radiologically determined foot length. HVA, M1M2A, and M1M5A were significantly improved after the surgery (p < 0.01, p < 0.01, and p < 0.01, respectively). A significant negative correlation was found between the variation in radiologically determined foot length and changes in HVA (r = −0.29, p = 0.02) and M1M5A (r = −0.23, p < 0.05), while a significant positive correlation was found between the variation in the foot width and changes in HVA (r = 0.34, p < 0.01), M1M2A (r = 0.55, p < 0.01), and M1M5A (r = 0.45, p < 0.01). There were no significant differences between operative procedures regarding variation in radiologically determined foot length and width. Conclusions: Surgical procedure for rheumatoid forefoot deformity improved radiographic parameters and reduced radiographic foot width while maintaining foot length.
en-copyright=
kn-copyright=

en-aut-name=HoritaMasahiro
en-aut-sei=Horita
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KisoYohei
en-aut-sei=Kiso
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NasuYoshihisa
en-aut-sei=Nasu
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaharaRyuichi
en-aut-sei=Nakahara
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SaigaKenta
en-aut-sei=Saiga
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Kurashiki Sweet Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Okayama City Hospital
kn-affil=

affil-num=4
en-affil=Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=
en-keyword=forefoot surgery
kn-keyword=forefoot surgery
en-keyword=foot length
kn-keyword=foot length
en-keyword=foot width
kn-keyword=foot width
en-keyword=rheumatoid arthritis
kn-keyword=rheumatoid arthritis
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=1
article-no=
start-page=96
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260109
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of an oral exercise intervention on pre-frailty or frailty in older people: a randomized clinical trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Frailty is often experienced by older adults, which can lead to long-term health problems. We aimed to examine associations with improvements in nutritional status, sarcopenia (age-related loss of skeletal muscle mass and strength), and frailty in four groups with different oral exercise frequencies.<br>
Methods: We conducted a prospective, parallel multi-arm randomized controlled trial (Japan Registry of Clinical Trials (jRCT) 1062210063) to test the effects of oral exercise on frailty in older adults. Each intervention consisted of a standardized oral exercise protocol including neck exercises, lip exercises, and tongue movements, designed to improve oral function and reduce frailty. The primary outcome was the change in the number of frailty criteria from baseline to follow-up. Individuals aged ≥60 years were screened for frailty status using standardized criteria at the Department of Preventive Dentistry at Okayama University Hospital between October 2022 and December 2023. Those identified as pre-frailty or frailty were eligible and enrolled in the study. After screening 60 individuals, 58 eligible participants were randomly assigned using block randomization to one of four oral exercise frequency groups: 3 times/day & everyday, 3 times/day & 3 days/week, once/day & everyday, and once/day & 3 days/week. A two-way repeated measures analysis of variance was used to evaluate the impact of the four frequencies of oral exercise methods on frailty in older adults. Outcome assessors were blinded; participants were not.<br>
Results: Here we show the results of the 58 participants. Group sizes are: 3 times/day & everyday (n = 14), 3 times/day & 3 days/week (n = 15), once/day & everyday (n = 14), once/day & 3 days/week (n = 15). The trial is completed as planned, and all randomized participants are analyzed. The main effect of time is significant for the number of frailty criteria (F = 14.803, p < 0.001, partial eta squared = 0.215). The mean changes from baseline to follow-up are −0.357 (95% Confidence Interval −0.787 to 0.073) in the 3 times/day & everyday group, −0.600 (95% Confidence Interval −1.255 to 0.055) in the 3 times/day & 3 days/week group, −0.571 (95% Confidence Interval −1.379 to 0.236) in the once/day & everyday group, and −0.600 (95% Confidence Interval −1.008 to −0.192) in the once/day & 3 days/week group. The main effect of time is also significant for the number of oral hypofunction criteria (F = 16.456, p < 0.001, partial eta squared = 0.234). No important adverse events or side effects related to the intervention were observed.<br>
Conclusions: After conducting oral exercises for 3 months on older adults with pre-frailty or frailty, improvements in frailty are observed. Overall, these exercises could be a simple, low-cost way to support healthy aging in the community.
en-copyright=
kn-copyright=

en-aut-name=TakeuchiNoriko
en-aut-sei=Takeuchi
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SawadaNanami
en-aut-sei=Sawada
en-aut-mei=Nanami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=InadaSakura
en-aut-sei=Inada
en-aut-mei=Sakura
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MoritaManabu
en-aut-sei=Morita
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=EkuniDaisuke
en-aut-sei=Ekuni
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Preventive Dentistry, Division of Dentistry, Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Section of Preventive and Public Health Dentistry, Division of Oral Health, Growth and Development, Faculty of Dental Science, Kyushu University
kn-affil=

affil-num=3
en-affil=Division of Health Promotion, Okayama-City Health Center
kn-affil=

affil-num=4
en-affil=Department of Oral Health Sciences, Faculty of Health Care Sciences, Takarazuka University of Medical and Health Care
kn-affil=

affil-num=5
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=3
article-no=
start-page=102931
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Tick-borne pathogens in ticks collected from Humans: A prospective clinical pilot study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Tick-borne diseases (TBDs), particularly Japanese spotted fever, are an increasing public health concern in Japan. Data on pathogens carried by ticks removed directly from patients and their associated clinical outcomes remain limited. This prospective study investigated pathogen carriage in patient-derived ticks and evaluated the clinical risk of TBDs. Between April and October 2025, ticks were collected from patients presenting with tick bites at two medical institutions in Western Japan. Ticks were morphologically identified and spotted fever group rickettsiae (SFGR) was detected by nested PCR targeting the 17-kDa antigen gene, followed by sequence analysis. Clinical data, including patient background, antibiotic prescriptions, and outcomes, were reviewed. Clinical information was available for 70 patients (median age; 75 years), of whom 88.6% were prescribed prophylactic antibiotics. Ticks were collected from 60 patients (85.7%), and seven adults without antibiotic prophylaxis were followed for disease onset. Sixty-two ticks, predominantly Amblyomma testudinarium (88.7%), were analyzed. SFGR was detected in eight ticks (12.9%), including seven A. testudinarium and one Ixodes nipponensis, collected from seven patients. Two patients bitten by Rickettsia tamurae–carrying ticks were observed for one month without antibiotics and remained asymptomatic. In this prospective analysis, no clinically apparent rickettsiosis was observed following bites from R. tamurae–positive ticks without antibiotic prophylaxis; however, subclinical infection could not be excluded. Despite the small sample size, our findings suggest that the clinical risk associated with R. tamurae infection may be low. Direct analysis of removed ticks from patients may help characterize pathogen reservoirs and inform targeted approaches to TBDs.
en-copyright=
kn-copyright=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SumidaTakaomi
en-aut-sei=Sumida
en-aut-mei=Takaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KawamataOsamu
en-aut-sei=Kawamata
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HidaniYoshimi
en-aut-sei=Hidani
en-aut-mei=Yoshimi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Numakuma Hospital
kn-affil=

affil-num=3
en-affil=Numakuma Hospital
kn-affil=

affil-num=4
en-affil=Numakuma Hospital
kn-affil=

affil-num=5
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=Epidemiology
kn-keyword=Epidemiology
en-keyword=Japanese spotted fever
kn-keyword=Japanese spotted fever
en-keyword=Spotted fever group rickettsiae
kn-keyword=Spotted fever group rickettsiae
en-keyword=Tick bite
kn-keyword=Tick bite
en-keyword=Tick-borne disease
kn-keyword=Tick-borne disease
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=3
article-no=
start-page=102933
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Comments on “In vitro activity of cefiderocol against carbapenem-resistant Gram-negative pathogens in Japan”
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=OgawaSakura
en-aut-sei=Ogawa
en-aut-mei=Sakura
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamamotoMari
en-aut-sei=Yamamoto
en-aut-mei=Mari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TsujiShuma
en-aut-sei=Tsuji
en-aut-mei=Shuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=GotohKazuyoshi
en-aut-sei=Gotoh
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=5
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=6
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=1
article-no=
start-page=2
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251226
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Threshold Selection Method in Code Plagiarism Checking Function for Code Writing Problem in Java Programming Learning Assistant System Considering AI-Generated Codes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To support novice learners, the Java programming learning assistant system (JPLAS) has been developed with various features. Among them, code writing problem (CWP) assigns writing an answer code that passes a given test code. The correctness of an answer code is validated by running it on JUnit. In previous works, we implemented a code plagiarism checking function that calculates the similarity score for each pair of answer codes based on the Levenshtein distance. When the score is higher than a given threshold, this pair is regarded as plagiarism. However, a method for finding the proper threshold has not been studied. In addition, AI-generated codes have become threats in plagiarism, as AI has grown in popularity, which should be investigated. In this paper, we propose a threshold selection method based on Tukey’s IQR fences. It uses a custom upper threshold derived from the statistical distribution of similarity scores for each assignment. To better accommodate skewed similarity distributions, the method introduces a simple percentile-based adjustment for determining the upper threshold. We also design prompts to generate answer codes using generative AI and apply them to four AI models. For evaluation, we used a total of 745 source codes of two datasets. The first dataset consists of 420 answer codes across 12 CWP instances from 35 first-year undergraduate students in the State Polytechnic of Malang, Indonesia (POLINEMA). The second dataset includes 325 answer codes across five CWP assignments from 65 third-year undergraduate students at Okayama University, Japan. The applications of our proposals found the following: (1) any pair of student codes whose score is higher than the selected threshold has some evidence of plagiarism, (2) some student codes have a higher similarity than the threshold with AI-generated codes, indicating the use of generative AI, and (3) multiple AI models can generate code that resembles student-written code, despite adopting different implementations. The validity of our proposal is confirmed.
en-copyright=
kn-copyright=

en-aut-name=PermatasariPerwira Annissa Dyah
en-aut-sei=Permatasari
en-aut-mei=Perwira Annissa Dyah
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MentariMustika
en-aut-sei=Mentari
en-aut-mei=Mustika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KinariSafira Adine
en-aut-sei=Kinari
en-aut-mei=Safira Adine
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AungSoe Thandar
en-aut-sei=Aung
en-aut-mei=Soe Thandar
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FunabikiNobuo
en-aut-sei=Funabiki
en-aut-mei=Nobuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KyawHtoo Htoo Sandi
en-aut-sei=Kyaw
en-aut-mei=Htoo Htoo Sandi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=WaiKhaing Hsu
en-aut-sei=Wai
en-aut-mei=Khaing Hsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Engineering Science, Akita University
kn-affil=
en-keyword=Java programming learning
kn-keyword=Java programming learning
en-keyword=JPLAS
kn-keyword=JPLAS
en-keyword=JUnit
kn-keyword=JUnit
en-keyword=code writing problem
kn-keyword=code writing problem
en-keyword=plagiarism
kn-keyword=plagiarism
en-keyword=Levenshtein distance
kn-keyword=Levenshtein distance
en-keyword=threshold
kn-keyword=threshold
en-keyword=IQR
kn-keyword=IQR
en-keyword=AI-generated
kn-keyword=AI-generated
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=69
end-page=74
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effective Treatment of Advanced Hepatocellular Carcinoma with Extensive Peritoneal Dissemination Using Lenvatinib
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Patients with hepatocellular carcinoma (HCC) and extensive peritoneal dissemination generally have a poor prognosis and are often resistant to systemic therapy. We report the case of a 47-year-old woman with HCC and massive peritoneal dissemination who presented with malignant ascites requiring repeated cell-free and concentrated ascites reinfusion therapy and peritoneovenous shunt placement, as well as malignant pleural effusion requiring pleurodesis. Combined immunotherapy with durvalumab/tremelimumab was initiated;however, disease progression was observed after three treatment courses, prompting a switch to lenvatinib therapy. Two months after initiation of lenvatinib, CT imaging demonstrated complete disappearance of arterial enhancement in the primary hepatic lesion, along with reduction in the size of peritoneal dissemination nodules. Thirteen months after switching to lenvatinib (16 months after the initial diagnosis), the alpha-fetoprotein level continued to decrease, and the disease remained stable under treatment. Despite the extremely high tumor burden, lenvatinib achieved disease stabilization and symptomatic improvement.
en-copyright=
kn-copyright=

en-aut-name=WakatsukiShinya
en-aut-sei=Wakatsuki
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakamotoShinya
en-aut-sei=Sakamoto
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UenoAkiko
en-aut-sei=Ueno
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NambaTakaomi
en-aut-sei=Namba
en-aut-mei=Takaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamamotoYorito
en-aut-sei=Yamamoto
en-aut-mei=Yorito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsumotoManabu
en-aut-sei=Matsumoto
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IwataJun
en-aut-sei=Iwata
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkabayashiTakehiro
en-aut-sei=Okabayashi
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=7
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=
en-keyword=diagnostic laparoscopy
kn-keyword=diagnostic laparoscopy
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=peritoneal dissemination
kn-keyword=peritoneal dissemination
en-keyword=lenvatinib
kn-keyword=lenvatinib
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=47
end-page=54
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Time Course of the Development and Loss of Delta-9-tetrahydrocannabinol Tolerance: Effects on Hypothermia and Spontaneous Locomotor Activity in Mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Deregulation of cannabis use is gradually expanding in Europe and the United States. However, the biological processes driving tolerance to delta-9-tetrahydrocannabinol (Δ9-THC), the main psychoactive component of cannabis, remain unclear. Thus, this study aimed to investigate the mechanisms and time course of tolerance development and loss to Δ9-THC in mice. Male ICR mice (7 weeks old) were administered Δ9-THC once daily for 3 days and then divided into three groups according to the washout period (3-, 10-, and 17-day washout groups). After each washout, changes in body temperature and locomotor activity were measured following re-exposure to Δ9-THC. Furthermore, the mRNA expression levels of CB1 and CB2 receptors in the brain were evaluated using real-time PCR. On day 1, significant hypothermia and reduced spontaneous locomotor activity were observed in the Δ9-THC-treated mice compared with the vehicle-treated mice. Tolerance to the hypothermic and locomotor-suppressing effects of Δ9-THC developed on days 2 and 3, respectively, and dissipated after 3 and 11 days of washout, respectively. These differences in the rates of tolerance development and recovery may reflect distinct underlying mechanisms. No significant changes in receptor mRNA expression were observed. These findings highlight the complexity of Δ9-THC tolerance and its potential implications for long-term cannabis use.
en-copyright=
kn-copyright=

en-aut-name=EguchiYukiomi
en-aut-sei=Eguchi
en-aut-mei=Yukiomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IrieKeiichi
en-aut-sei=Irie
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamashitaYuta
en-aut-sei=Yamashita
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=EguchiMiyu
en-aut-sei=Eguchi
en-aut-mei=Miyu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakanoTakafumi
en-aut-sei=Nakano
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MishimaKenichi
en-aut-sei=Mishima
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=2
en-affil=Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=3
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=4
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=5
en-affil=Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=6
en-affil=Department of Oncology and Infectious Disease Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=7
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=
en-keyword=delta-9-tetrahydrocannabinol
kn-keyword=delta-9-tetrahydrocannabinol
en-keyword=cannabis
kn-keyword=cannabis
en-keyword=tolerance
kn-keyword=tolerance
en-keyword=locomotor
kn-keyword=locomotor
en-keyword=hypothermic
kn-keyword=hypothermic
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=39
end-page=46
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Kinesiophobia Is Associated with Disability, Poor Quality of Life, Psychological Morbidity, and Surgery Dissatisfaction in Patients with Lumbar Microdiscetomy: A Cross-Sectional Controlled Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The study aimed to determine the prevalence of kinesiophobia in patients who had undergone lumbar microdiscectomy and to examine its associations with pain intensity, disability, quality of life, depression, anxiety, and satisfaction with surgery. Forty-eight patients with microdiscectomy and 48 healthy controls were enrolled. The Tampa Scale for Kinesiophobia (TSK), Roland-Morris Disability Index (RMDI), Hospital Anxiety and Depression Scale (HADS-A and HADS-D, respectively), and Short Form-36 Health Survey (SF-36) were administered to both groups. The scores of TSK, RMDI, HADS-A, and HADS-D were significantly higher and SF-36 scores were significantly lower in the microdiscectomy than the control group (p<0.001 for all). In the microdiscectomy group, median (min-max) RMDI, HADS-A, and HADS-D scores were 19 (4-34), 10 (0-18), and 9 (0-18), respectively, in kinesiophobic patients, and were significantly higher than 6 (2-20), 3 (0-11), 2.5 (0-11) in non-kinesiophobic patients (all p<0.001). The median (min-max) SF-36 PCS, SF-36 MCS, and VAS scores for surgery satisfaction were 36.5 (8.7-75), 52.1 (11-95), 5, 5 (0-10), respectively, in kinesiophobic patients and were significantly lower than 71 (28-95), 85.5 (9-93), 8.5 (3-10) in non-kinesiophobic patients (all p<0.05). TSK scores were significantly correlated with RMDI, HADS-A, HADS-D, SF-36, and surgery satisfaction scores (all p<0.05). Kinesiophobic patients with lumbar microdiscectomy therefore showed greater disability and psychological morbidity, poorer quality of life, and lower satisfaction with surgery.
en-copyright=
kn-copyright=

en-aut-name=TezelNihal
en-aut-sei=Tezel
en-aut-mei=Nihal
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=CanAslı Gençay
en-aut-sei=Can
en-aut-mei=Aslı Gençay
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Physical and Rehabilitation Medicine, Health Sciences University
kn-affil=

affil-num=2
en-affil=Department of Physical and Rehabilitation Medicine, Faculty of Medicine, Ankara Yıldırım Beyazıt University
kn-affil=
en-keyword=kinesiophobia
kn-keyword=kinesiophobia
en-keyword=microdiscectomy
kn-keyword=microdiscectomy
en-keyword=disability
kn-keyword=disability
en-keyword=quality of life
kn-keyword=quality of life
en-keyword=depression
kn-keyword=depression
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=17
end-page=30
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Development of a Stroke Discharge Support Evaluation Scale for Ward Nurses in Acute Care Hospitals
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study aimed to develop a scale enabling nurses to objectively evaluate their own stroke discharge support, as a basis for enhancing its overall effectiveness. A draft scale was created based on a literature review, and consisted of a 51-item, 5-point Likert-type questionnaire administered to ward nurses engaged in stroke discharge support at acute care hospitals. Factor analysis was performed to refine the scale. Construct validity was assessed using the known-groups method, and reliability was evaluated through internal consistency analysis. The resulting Stroke Discharge Support Evaluation Scale comprises 29 items across 5 factors, each rated on a 5-point Likert scale. Analysis of the data collected from 237 valid responses demonstrated good internal consistency and supported the scale’s construct validity. The Stroke Discharge Support Evaluation Scale is a reliable and valid tool enabling ward nurses in acute care hospitals to evaluate their own stroke discharge support.
en-copyright=
kn-copyright=

en-aut-name=YanoHideki
en-aut-sei=Yano
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakahataYoko
en-aut-sei=Takahata
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamaguchiTakeshi
en-aut-sei=Yamaguchi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SaitoShinya
en-aut-sei=Saito
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Nursing, Faculty of Human Health Sciences, Niimi University
kn-affil=

affil-num=2
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Faculty of Nursing, Shikoku University
kn-affil=

affil-num=4
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=
en-keyword=stroke
kn-keyword=stroke
en-keyword=discharge support
kn-keyword=discharge support
en-keyword=scale development
kn-keyword=scale development
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=7
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Usefulness of D-dimer Assay to Confirm the Course of Overt Venous Thromboembolism (VTE) in Cancer Patients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Venous thromboembolism (VTE) is a serious complication in patients with cancer. In this population, the presence of thrombi is often assessed at cancer diagnosis by measuring D-dimer levels, which have high sensitivity but low specificity for identifying VTE at this clinical time point. However, the usefulness of D-dimer measurement during anticoagulation therapy has not been fully established, despite its widespread use. In this retrospective observational study, we investigated whether D-dimer measurement during anticoagulation therapy in cancer patients could predict overt VTE at follow-up. The study included patients who underwent D-dimer testing and contrast-enhanced computed tomography between 30 and 100 days after initiation of anticoagulation therapy. Eighty-two patients were included: 60 with cancer and 22 without. The diagnostic performance of D-dimer for overt VTE was as follows: sensitivity, 85.7%; specificity, 87.2%; positive predictive value, 78.3%; and negative predictive value, 89.2%. These findings suggest that D-dimer measurement at follow-up has high sensitivity and specificity for overt VTE in cancer patients and may aid in assessing thrombotic status. Clinically, if anticoagulation therapy is continued until D-dimer levels become negative, the absence of overt VTE could be inferred without additional invasive testing.
en-copyright=
kn-copyright=

en-aut-name=YamaokaHidenaru
en-aut-sei=Yamaoka
en-aut-mei=Hidenaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshidaMasashi
en-aut-sei=Yoshida
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SarashinaToshihiro
en-aut-sei=Sarashina
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AkagiSatoshi
en-aut-sei=Akagi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MunemasaMitsuru
en-aut-sei=Munemasa
en-aut-mei=Mitsuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakamuraKazufumi
en-aut-sei=Nakamura
en-aut-mei=Kazufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ItoHiroshi
en-aut-sei=Ito
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Medicine, IMS Tokyo Katsushika General Hospital
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Seisukai Kuroda Clinic
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Cardiovascular Medicine, Okayama Rosai Hospital
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=D-dimer
kn-keyword=D-dimer
en-keyword=venous
kn-keyword=venous
en-keyword=thromboembolism
kn-keyword=thromboembolism
en-keyword=cancer
kn-keyword=cancer
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=
article-no=
start-page=40
end-page=53
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Proposed locations of villages recorded in the Silla Village Register
kn-title=「新羅村落文書」に記された村の比定地 ―西原京所属の村（いわゆるＤ村）の検討―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The Silla Village Register is a fragmentary record from the Unified Silla period that details the economic conditions of villages under the jurisdiction of small capitals (小京) and local counties (郡 / 県). In analyzing this register, it is essential to consider the geographical conditions of the locations; however, the exact locations of the villages have long remained unidentified in previous studies. Therefore, this study builds on the readings proposed by Choi Kyŏng-sŏn ( 최 경 선 ) and examines official histories and geographical texts from the Chosŏn dynasty, as well as topographic maps from the early 20th century. As a result, this paper proposes a concrete candidate for the location of one of the four villages under the jurisdiction of Sŏwŏn-gyŏng (西原京), commonly referred to as Village D. It has been clarified that Village D can be read as " 西原京□椒子村" and it is highly likely to correspond to present-day Chojŏng-ri, Naesu-ŭp, Heungdeok-gu, Cheongju City (清州市清原区内秀邑椒井里). It was also found that Village D’s characteristic of having few rice paddies and a high proportion of upland field cultivation closely matches the actual local geographical conditions, which are characterized by limited water resources.
en-copyright=
kn-copyright=

en-aut-name=MURAKAMINana
en-aut-sei=MURAKAMI
en-aut-mei=Nana
kn-aut-name=村上菜菜
kn-aut-sei=村上
kn-aut-mei=菜菜
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Research Institute for the Dynamics of Civilizations, Okayama University
kn-affil=
en-keyword=Silla Village Register
kn-keyword=Silla Village Register
en-keyword=Unified Silla
kn-keyword=Unified Silla
en-keyword=village history
kn-keyword=village history
en-keyword=Sŏwŏn-gyŏng
kn-keyword=Sŏwŏn-gyŏng
END

start-ver=1.4
cd-journal=joma
no-vol=153
cd-vols=
no-issue=3
article-no=
start-page=191
end-page=199
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260114
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of Schizophrenia Spectrum Disorders on the Receipt of Invasive and Systemic Therapy for Colorectal Cancer: A Nationwide Multicenter Retrospective Cohort Study in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: This study examined treatment disparities for colorectal cancer among patients diagnosed with schizophrenia spectrum disorders (SSD), focusing on invasive treatments and stage-appropriate systemic therapy within a universal healthcare system.<br>
Method: In this nationwide retrospective cohort study (2018–2021), we identified 248,966 colorectal cancer patients, including 2337 diagnosed with SSD, using linked cancer registry and insurance claims data in Japan. The presence of SSD was classified according to ICD-10 codes F20–29. We used multivariable logistic regression to compare the odds of receiving stage-appropriate adjuvant chemotherapy and systemic therapy, as well as the odds of receiving surgical or endoscopic treatments, between the two groups. The analysis adjusted for age, sex, clinical stage, and scores on the Charlson Comorbidity Index and Barthel Index.<br>
Results: The clinical stage distribution at diagnosis for colorectal cancer differed significantly between patients with SSD and those without psychiatric disorders (p < 0.001). After adjusting for clinical stage and other covariates, patients with SSD demonstrated significantly lower odds of receiving surgical or endoscopic treatment (adjusted odds ratio [aOR], 0.83; 95% CI, 0.73–0.94). The disparities were more pronounced for systemic therapy; patients with SSD had substantially lower odds of receiving adjuvant chemotherapy for stage III disease (aOR, 0.33; 95% CI, 0.26–0.41) and systemic therapy for stage IV disease (aOR, 0.23; 95% CI, 0.17–0.31).<br>
Conclusion: Patients with SSD encounter substantial disparities in accessing standard colorectal cancer care, particularly systemic therapies. These findings highlight the urgent need for interventions to ensure equitable cancer treatment for this vulnerable population.
en-copyright=
kn-copyright=

en-aut-name=FujiwaraMasaki
en-aut-sei=Fujiwara
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamadaYuto
en-aut-sei=Yamada
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IshiiTaisuke
en-aut-sei=Ishii
en-aut-mei=Taisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WatanabeTomone
en-aut-sei=Watanabe
en-aut-mei=Tomone
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujimoriMaiko
en-aut-sei=Fujimori
en-aut-mei=Maiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakayaNaoki
en-aut-sei=Nakaya
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawamuraToshihiko
en-aut-sei=Kawamura
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OtsukiKoji
en-aut-sei=Otsuki
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShigeyasuKunitoshi
en-aut-sei=Shigeyasu
en-aut-mei=Kunitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ShimazuTaichi
en-aut-sei=Shimazu
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HinotsuShiro
en-aut-sei=Hinotsu
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=UchitomiYosuke
en-aut-sei=Uchitomi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=InagakiMasatoshi
en-aut-sei=Inagaki
en-aut-mei=Masatoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Neuropsychiatry, Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center
kn-affil=

affil-num=4
en-affil=Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center
kn-affil=

affil-num=5
en-affil=Division of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center
kn-affil=

affil-num=6
en-affil=Tohoku Medical Megabank Organization, Tohoku University
kn-affil=

affil-num=7
en-affil=Department of Medical Informatics, Shimane University Hospital
kn-affil=

affil-num=8
en-affil=Department of Psychiatry, Faculty of Medicine, Shimane University
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Medical Development Field, Okayama University
kn-affil=

affil-num=10
en-affil=Division of Behavioral Sciences, National Cancer Center Institute for Cancer Control, National Cancer Center
kn-affil=

affil-num=11
en-affil=Department of Biostatistics and Data Management, Sapporo Medical University
kn-affil=

affil-num=12
en-affil=Department of Cancer Survivorship and Digital Medicine, The Jikei University School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Psychiatry, Faculty of Medicine, Shimane University
kn-affil=
en-keyword=colorectal cancer
kn-keyword=colorectal cancer
en-keyword=healthcare disparities
kn-keyword=healthcare disparities
en-keyword=psycho-oncology
kn-keyword=psycho-oncology
en-keyword=schizophrenia spectrum disorders
kn-keyword=schizophrenia spectrum disorders
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=1
article-no=
start-page=e70285
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260108
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Cardiogenic cerebral infarction after Takotsubo cardiomyopathy in a patient with catatonia: A case report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Takotsubo cardiomyopathy (TTC) is a transient cardiac condition often triggered by an emotional or physical stress. TTC usually has a benign clinical course with full recovery. However, in rare cases, TTC is complicated by cardiogenic shock, left ventricular rupture, or ventricular thrombus. We report a case of a patient with catatonia who developed TTC and subsequently experienced extensive cerebral infarction.<br>
Case Presentation: A 71-year-old woman with no prior psychiatric history was admitted for catatonia following a suicide attempt. During hospitalization, she exhibited electrocardiography (ECG) abnormalities and elevated D-dimer levels. Transthoracic echocardiography revealed apical hypokinesis and basal hyperkinesis, consistent with TTC, along with an intraventricular thrombus. Cardiovascular CT angiography confirmed normal coronary arteries. She was diagnosed with TTC complicated by left ventricular thrombus and deep vein thrombosis. Anticoagulant therapy was initiated. Despite improvement in catatonia with lorazepam, she developed right hemiplegia and aphasia on Day 5 due to cardiogenic cerebral infarction from thromboembolism. Thrombolytic therapy was not indicated, and conservative treatment was provided. Although cardiac function normalized by Day 16, she was left with severe neurological deficits.<br>
Conclusion: The case highlights the diagnostic challenges of TTC in non-communicative psychiatric patients and the potential for severe complications. Psychiatrists need to be aware of the development of TTC as a serious physical complication in patients with catatonia.
en-copyright=
kn-copyright=

en-aut-name=FujiwaraMasaki
en-aut-sei=Fujiwara
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamadaYuto
en-aut-sei=Yamada
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OsawaKazuhiro
en-aut-sei=Osawa
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakamotoShinji
en-aut-sei=Sakamoto
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KodamaMasafumi
en-aut-sei=Kodama
en-aut-mei=Masafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Neuropsychiatry, Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=4
en-affil=Department of Neuropsychiatry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Okayama Psychiatric Medical Center
kn-affil=
en-keyword=catatonia
kn-keyword=catatonia
en-keyword=cerebral infarction
kn-keyword=cerebral infarction
en-keyword=depression
kn-keyword=depression
en-keyword=Takotsubo cardiomyopathy
kn-keyword=Takotsubo cardiomyopathy
en-keyword=ventricular thrombus
kn-keyword=ventricular thrombus
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=02
article-no=
start-page=113
end-page=125
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=2026
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Clinical genetics in comitant strabismus and idiopathic superior oblique muscle palsy
kn-title=斜視の遺伝子研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=共同性斜視は遺伝要因と環境要因からなる多因子疾患で、内斜視と外斜視に大別される。遺伝要因は家族歴、一卵性双生児の表現型一致率から推定され、環境要因には妊娠・分娩時の低酸素状態がある。一方、遺伝要因がある非共同性（麻痺性）斜視として上斜筋腱低形成を呈する特発性上斜筋麻痺がある。遺伝統計学の連鎖解析を使って、内斜視と外斜視の小家系群で4番染色体MGST2を疾患感受性遺伝子候補と同定し、MGST2ノックアウトマウスを作成した。小動物用MRIで解析すると、そのホモ接合体では野生型と比べて眼球形状が有意に横長で体積が大きいことを見出した。次いで遺伝統計学別法の全ゲノム関連解析を内斜視、外斜視、特発性上斜筋麻痺を対象として行った。Infinium Asian Screening Array-24 v1.0でSNPを決めた内斜視253検体、外斜視356検体、上斜筋麻痺102検体を疾患群とした。対照集団としては、バイオバンクジャパン (BBJ) の疾患群とは違うアレイ(OmniExpress)でSNPを決めた182,476検体「BBJ (180K)」、疾患群と同じアレイでSNPを決めたBBJの53409検体「BBJ (ASA)」および長浜コホート3570検体を使った。３対照集団との比較で共通して検出された遺伝子は、上斜筋麻痺群で神経細胞移動に関与するDAB1であった。最も大きい対照集団「BBJ (180K)」との比較では内斜視、外斜視、上斜筋麻痺を含む疾患群全体で眼発生に関与するRARB (retinoic acid receptor β) が検出された。斜視関連遺伝子は眼球形態に関与する可能性がある。特発性上斜筋麻痺は共同性斜視とは独立した疾患と理解されるが、共通の遺伝基盤もあるかもしれない。
en-copyright=
kn-copyright=

en-aut-name=MatsuoToshihiko
en-aut-sei=Matsuo
en-aut-mei=Toshihiko
kn-aut-name=松尾俊彦
kn-aut-sei=松尾
kn-aut-mei=俊彦
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=岡山大学学術研究院ヘルスシステム統合科学学域
en-keyword=双生児調査
kn-keyword=双生児調査
en-keyword=斜視頻度
kn-keyword=斜視頻度
en-keyword=家族歴
kn-keyword=家族歴
en-keyword=全ゲノム関連解析
kn-keyword=全ゲノム関連解析
en-keyword=連鎖解析
kn-keyword=連鎖解析
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=4
article-no=
start-page=1422
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260211
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Perioperative Ozoralizumab Management for Patients with Rheumatoid Arthritis Who Underwent Orthopaedic Surgery: A Retrospective Case Series
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: Launched in Japan in 2022, ozoralizumab (OZR) is a novel, anti-tumour necrosis factor (TNF)-α inhibitor for treating rheumatoid arthritis (RA) that is refractory to conventional therapies. However, there is a lack of evidence regarding its perioperative management. Methods: This retrospective case series included nine patients with RA who underwent a total of 12 either RA-related (n = 9) or unrelated (n = 3) orthopaedic procedures. We reviewed patient demographics, surgical procedures, perioperative OZR discontinuation periods, and postoperative complications. Results: The mean preoperative OZR discontinuation period was 15.8 days (range, 2–25 days). Sutures were removed at a mean of 12.8 days postoperatively (range, 11–14 days) after adequate wound healing had been confirmed. The mean total discontinuation period was 34.9 days (range, 27–43 days). No cases of surgical site infection (SSI) or delayed wound healing (DWH) were observed during a minimum follow-up period of three months. One patient experienced a disease flare before OZR was restarted. Conclusions: Preoperative OZR discontinuation for up to four weeks appeared to be safe in this cohort. These findings may assist orthopaedic surgeons in determining an appropriate perioperative discontinuation strategy for OZR that minimises SSI and DWH risk while reducing the likelihood of RA flare.
en-copyright=
kn-copyright=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NasuYoshihisa
en-aut-sei=Nasu
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HaradaRyozo
en-aut-sei=Harada
en-aut-mei=Ryozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaharaRyuichi
en-aut-sei=Nakahara
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HoritaMasahiro
en-aut-sei=Horita
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NatsumedaMasamitsu
en-aut-sei=Natsumeda
en-aut-mei=Masamitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NaniwaShuichi
en-aut-sei=Naniwa
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama City Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Kurashiki Sweet Hospital
kn-affil=

affil-num=4
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=5
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=6
en-affil=Rheumatic Disease Center, Mabi Memorial Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=delayed wound healing
kn-keyword=delayed wound healing
en-keyword=discontinuation
kn-keyword=discontinuation
en-keyword=ozoralizumab
kn-keyword=ozoralizumab
en-keyword=orthopaedic surgery
kn-keyword=orthopaedic surgery
en-keyword=perioperative management
kn-keyword=perioperative management
en-keyword=rheumatoid arthritis
kn-keyword=rheumatoid arthritis
en-keyword=surgical site infection
kn-keyword=surgical site infection
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260210
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Starch Synthase 3 isoforms are essential for normal starch granule initiation in wheat endosperm
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=DingJinjin
en-aut-sei=Ding
en-aut-mei=Jinjin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FahyBrendan
en-aut-sei=Fahy
en-aut-mei=Brendan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsushimaRyo
en-aut-sei=Matsushima
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=JiangQiantao
en-aut-sei=Jiang
en-aut-mei=Qiantao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SeungDavid
en-aut-sei=Seung
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=John Innes Centre, Norwich Research Park
kn-affil=

affil-num=2
en-affil=John Innes Centre, Norwich Research Park
kn-affil=

affil-num=3
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=4
en-affil=State Key Laboratory of Crop Gene Exploration and Utilization in Southwest China, Triticeae Research Institute, Sichuan Agricultural University
kn-affil=

affil-num=5
en-affil=John Innes Centre, Norwich Research Park
kn-affil=
en-keyword=resistant starch
kn-keyword=resistant starch
en-keyword=starch
kn-keyword=starch
en-keyword=starch granule
kn-keyword=starch granule
en-keyword=starch synthase
kn-keyword=starch synthase
en-keyword=wheat
kn-keyword=wheat
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=3
article-no=
start-page=563
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260131
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of Surface Morphology Formed by Additive Manufacturing on the Adhesion of Dental Cements to Zirconia
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Durable bonding to zirconia remains difficult because its chemically inert surface resists acid etching. Additive manufacturing (AM) enables controlled surface morphology, which may enhance micromechanical retention without additional treatments. Methods: Zirconia specimens with three AM-derived surface designs—(1) concave–convex hemispherical patterns, (2) concave hemispherical patterns, and (3) as-printed surfaces—were fabricated using a slurry-based 3D printing system and sintered at 1500 °C. Zirconia specimens fabricated by subtractive manufacturing using CAD/CAM systems, polished with 15 µm diamond lapping film and with or without subsequent alumina sandblasting, served as controls. Surface morphology was analyzed by FE-SEM, and shear bond strength (SBS) was tested after cementation with a resin-based luting agent. Results: SEM revealed regular layered textures and designed hemispherical structures (~300 µm) in AM specimens, along with step-like irregularities (~40 µm) at layer boundaries. The concave–convex AM group showed significantly higher SBS than both sandblasted and polished subtractive-manufactured zirconia (p < 0.05). Vertically printed specimens demonstrated greater bonding strength than those printed parallel to the bonding surface, indicating that build orientation affects resin infiltration and interlocking. Conclusion: AM-derived zirconia surfaces can provide superior and reproducible micromechanical retention compared with conventional treatments. Further optimization of printing parameters and evaluation of long-term durability are needed for clinical application.
en-copyright=
kn-copyright=

en-aut-name=YoshiharaKumiko
en-aut-sei=Yoshihara
en-aut-mei=Kumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NagaokaNoriyuki
en-aut-sei=Nagaoka
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LeeSungho
en-aut-sei=Lee
en-aut-mei=Sungho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MaruoYukinori
en-aut-sei=Maruo
en-aut-mei=Yukinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SpirrettFiona
en-aut-sei=Spirrett
en-aut-mei=Fiona
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KiriharaSoshu
en-aut-sei=Kirihara
en-aut-mei=Soshu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshidaYasuhiro
en-aut-sei=Yoshida
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=Van MeerbeekBart
en-aut-sei=Van Meerbeek
en-aut-mei=Bart
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=National Institute of Advanced Industrial Science and Technology (AIST), Health and Medical Research Institute
kn-affil=

affil-num=2
en-affil=Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Dental School
kn-affil=

affil-num=3
en-affil=National Institute of Advanced Industrial Science and Technology (AIST)
kn-affil=

affil-num=4
en-affil=Department of Prosthodontics, Okayama University
kn-affil=

affil-num=5
en-affil=Joining and Welding Research Institute, Osaka University
kn-affil=

affil-num=6
en-affil=Joining and Welding Research Institute, Osaka University
kn-affil=

affil-num=7
en-affil=Department of Biomaterials and Bioengineering, Faculty of Dental Medicine, Hokkaido University
kn-affil=

affil-num=8
en-affil=Department of Oral Health Sciences, BIOMAT, KU Leuven
kn-affil=
en-keyword=additive manufacturing
kn-keyword=additive manufacturing
en-keyword=bond strength
kn-keyword=bond strength
en-keyword=dental crown
kn-keyword=dental crown
en-keyword=dental resin cement
kn-keyword=dental resin cement
en-keyword=dental zirconia
kn-keyword=dental zirconia
END

start-ver=1.4
cd-journal=joma
no-vol=60
cd-vols=
no-issue=
article-no=
start-page=19
end-page=29
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251210
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Literary Afterimage of Himiko（3）――A Study of Japanese Women and Images of Japan in Ming and Qing Popular Literature――
kn-title=卑弥呼の残像（下）――明清通俗文学作品に描かれた日本人女性と日本イメージ――
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=YUSAToru
en-aut-sei=YUSA
en-aut-mei=Toru
kn-aut-name=遊佐徹
kn-aut-sei=遊佐
kn-aut-mei=徹
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=60
cd-vols=
no-issue=
article-no=
start-page=1
end-page=18
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251210
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Descriptions and Materials on the Local Government Histories of Okayama and Hiroshima prefectures
kn-title=大田植の分布と種類に関する検討（3）―岡山県・広島県の自治体史等における記述・資料―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TAKANOHiroshi
en-aut-sei=TAKANO
en-aut-mei=Hiroshi
kn-aut-name=髙野宏
kn-aut-sei=髙野
kn-aut-mei=宏
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=65
cd-vols=
no-issue=4
article-no=
start-page=300
end-page=309
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20130222
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Synthesis of biopterin and related pterin glycosides
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Certain pterins having a hydroxyalkyl side chain at C-6 have been found as glycosidic forms in certain prokaryotes, such as 2′-O-(α-D-glucopyranosyl)biopterin from various kinds of cyanobacteria, and limipterin from a green sulfur photosynthetic bacterium. Synthetic studies on glycosides of biopterin and related pterins have been made in view of the structural proof as well as for closer examination of their biological activities and functions. The syntheses of these natural pterin glycosides have effectively been achieved, mostly through appropriately protected N2-(N,N-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]pterin derivatives as glycosyl acceptors, and are reviewed here. © 2013 IUBMB Life 65(4):300–309, 2013.
en-copyright=
kn-copyright=

en-aut-name=HanayaTadashi
en-aut-sei=Hanaya
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamamotoHiroshi
en-aut-sei=Yamamoto
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=2
en-affil=School of Pharmacy, Shujitsu University
kn-affil=
en-keyword=pteridine
kn-keyword=pteridine
en-keyword=pterin glycoside
kn-keyword=pterin glycoside
en-keyword=biopterin
kn-keyword=biopterin
en-keyword=ciliapterin
kn-keyword=ciliapterin
en-keyword=neopterin
kn-keyword=neopterin
en-keyword=limipterin
kn-keyword=limipterin
en-keyword=tepidopterin
kn-keyword=tepidopterin
en-keyword=asperopterin-A
kn-keyword=asperopterin-A
en-keyword=protecting group
kn-keyword=protecting group
en-keyword=glycosylation
kn-keyword=glycosylation
END

start-ver=1.4
cd-journal=joma
no-vol=70
cd-vols=
no-issue=1
article-no=
start-page=355
end-page=365
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2006
dt-pub=2006
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Synthesis of 6- and 7-(1,2,3-Trihydroxy-1,2-O-isopropylidenepropyl)pteridines and Deoxygenation of Their 3’-Hydroxy Groups
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Treatment of 3,4-O-isopropylidene-L-threo-pentos-2-ulose (7) with 5,6-diamino-1,3-dimethyluracil (8) afforded 1,3-dimethyl-6-[(1R,2S)-1,2,3-trihydroxy-1,2-O-isopropylidenepropyl]lumazine (9a) and its 7-substituted isomer (9b). Deoxygenation of 3’-hydroxy groups of 9a,b was investigated in connection with a practical transformation of neopterin into biopterin.
en-copyright=
kn-copyright=

en-aut-name=HanayaTadashi
en-aut-sei=Hanaya
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakayamaDaisuke
en-aut-sei=Takayama
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamamotoHiroshi
en-aut-sei=Yamamoto
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical efficacy and safety of endoscopic ultrasound-guided ablation therapies for pancreatic neuroendocrine tumors: a systematic review and meta-analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Pancreatic neuroendocrine tumors (pNETs) are rare; however, they are increasingly being detected. Although surgical resection remains the standard treatment, its invasiveness has prompted interest in less invasive alternatives, particularly for small non-functional pNETs (NF-pNETs) and insulinomas.<br>
Objectives: To evaluate the clinical efficacy and safety of endoscopic ultrasound-guided ethanol injection (EUS-EI) and radiofrequency ablation (EUS-RFA) for pNETs.<br>
Design: A systematic review and meta-analysis.<br>
Data sources and methods: A literature search of PubMed, MEDLINE, and Google Scholar was conducted (April 2005–April 2025). Studies were eligible if they reported clinical outcomes of EUS-EI or EUS-RFA in adult patients with insulinomas or NF-pNETs. The primary endpoints were clinical success (short-term symptom resolution or radiological response) and adverse event (AE) rates. Data were pooled using a random-effects model.<br>
Results: Twenty-six studies were included in the meta-analysis. For insulinomas, the pooled clinical success rate was 77% (95% confidence interval (CI), 59–88) for EUS-EI and 95% (95% CI, 89–97) for EUS-RFA. The pooled incidence of total AEs was 32% (95% CI, 17–51) for EUS-EI and 25% (95% CI, 15–39) for EUS-RFA. For NF-pNETs, the pooled clinical success rates were 76% (95% CI, 54–90) for EUS-EI and 85% (95% CI, 74–92) for EUS-RFA, and the pooled incidence of total AEs was 27% (95% CI, 20–35) and 26% (95% CI, 17–38), respectively. The most common moderate or severe AEs were pancreatitis in 12 patients (7.6%) after EUS-EI, and pancreatic fluid collection in 4 patients (1.9%) and pancreatic duct stricture in 3 patients (1.4%) after EUS-RFA. One fatal case occurred in a 97-year-old patient following EUS-RFA.<br>
Conclusion: Both EUS-EI and EUS-RFA are effective, relatively safe, and minimally invasive treatment options for pNETs. However, severe AE can occur, and careful patient selection and treatment indication are essential.<br>
Trial registration: Not registered.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujiiYuki
en-aut-sei=Fujii
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UchidaDaisuke
en-aut-sei=Uchida
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakeuchiYasuto
en-aut-sei=Takeuchi
en-aut-mei=Yasuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=
en-keyword=ablation techniques
kn-keyword=ablation techniques
en-keyword=endoscopic ultrasonography
kn-keyword=endoscopic ultrasonography
en-keyword=ethanol
kn-keyword=ethanol
en-keyword=pancreatic neuroendocrine tumors
kn-keyword=pancreatic neuroendocrine tumors
en-keyword=radiofrequency ablation
kn-keyword=radiofrequency ablation
END

start-ver=1.4
cd-journal=joma
no-vol=85
cd-vols=
no-issue=10
article-no=
start-page=2375
end-page=2390
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2012
dt-pub=2012
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Synthetic Studies on Natural Pterin Glycosides
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Some pterins having various kind of sugars attached to the hydroxyalkyl side-chain at C-6 are known to occur in certain prokaryotes as exemplified by 2'-O-(α-D-glucopyranosyl)biopterin isolated from various kinds of cyanobacteria. A synthetic exploration of various types of glycosides of biopterin and related pterins has been undertaken owing to a marked interest in their physiological functions and biological activities as well as the structural proof of those natural products. This review summarizes our synthetic studies on natural pterin glycosides by employing the appropriately protected N2-(N,N-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]pterin derivatives as glycosyl accepters.
en-copyright=
kn-copyright=

en-aut-name=HanayaTadashi
en-aut-sei=Hanaya
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamamotoHiroshi
en-aut-sei=Yamamoto
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=2
en-affil=School of Pharmacy, Shujitsu University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=62
cd-vols=
no-issue=12
article-no=
start-page=2021
end-page=2029
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=An Improved Synthesis of a Key Intermediate for Glycosylation of Biopterin and Its Application for the First Synthesis of Microcystbiopterin B
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A key intermediate for the selective 2′-O-glycosylation of biopterin, N2-(N,N-dimethylaminomethylene)-1′-O-(4-methoxybenzyl)-3-[2-(4-nitrophenyl)ethyl]biopterin (12), was efficiently synthesized via a novel route starting from d-glucose, leading to an improved overall yield. This new pathway involves the preparation of a 5-deoxy-l-arabinose phenylhydrazone derivative (9) as a crucial intermediate in the construction of the pteridine ring. Utilizing compound 12, the first synthesis of microcystbiopterin B (4) was accomplished by glycosylation of 12 with 4,6-di-O-acetyl-2-O-(4-methoxybenzyl)-3-O-methyl-α-d-glucopyranosyl bromide (19) in the presence of silver triflate and tetramethylurea, followed by stepwise deprotection.
en-copyright=
kn-copyright=

en-aut-name=HanayaTadashi
en-aut-sei=Hanaya
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MaedaYuta
en-aut-sei=Maeda
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IwasakiKatsuya
en-aut-sei=Iwasaki
en-aut-mei=Katsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=
en-keyword=microcystbiopterin B 
kn-keyword=microcystbiopterin B 
en-keyword=pteridine
kn-keyword=pteridine
en-keyword=pterin glycoside
kn-keyword=pterin glycoside
en-keyword=structural identification
kn-keyword=structural identification
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=3
article-no=
start-page=e80971
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250321
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prospective Evaluation of the Safety and Compression Performance of Novel Compression Denim Jeans in Healthy Volunteers and Patients With Lymphedema
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives: The treatment of lower-extremity lymphedema, whether congenital or acquired, remains challenging. Long-term management aimed at reducing complications and maximizing quality of life is essential. Compression stockings are crucial in this management; however, their application is limited by patient experience (ease of wear, texture, breathability, and appearance). This highlights the need to evaluate alternative compression garments that maintain therapeutic efficacy while improving patient adherence.<br>
Methods: We developed a novel compression denim product (Flow plus Jeans®) using advanced sewing technology. Its baseline performance (compression ability) was evaluated by measuring pressure gradients at three points (ankle, calf, and thigh) using a mannequin-based compression testing system and compared with those of existing stockings. Thereafter, a safety assessment was conducted on healthy volunteers to evaluate potential adverse effects, including changes in lower limb circumference, signs of deep vein thrombosis (DVT) via ultrasound, and skin complications. A clinical trial in patients with lymphedema was then performed to compare its efficacy with that of conventional compression stockings.<br>
Results: Baseline performance testing with a mannequin revealed that Flow plus Jeans demonstrated compression levels and pressure gradients at three calf points comparable to those of standard compression stockings. A safety study involving nine healthy volunteers confirmed that Flow plus Jeans caused no significant changes in lower-limb circumferences after three days of wear, with no cases of DVT or skin complications. In a subsequent clinical trial involving nine female patients with lymphedema, the jeans showed non-inferiority to existing stockings concerning lower-limb circumference measurements at six points (pre-use vs. six months post-use), with patient-reported experiences assessed via questionnaires. Notably, patients reported enhanced satisfaction regarding the jeans' fashionability, which could serve as an incentive for long-term adherence.<br>
Conclusion: Our findings suggest that Flow plus Jeans represent a promising novel option for the long-term management of lymphedema, offering an alternative that balances medical efficiency with improved patient satisfaction and demonstrates safety in healthy individuals.
en-copyright=
kn-copyright=

en-aut-name=OusakaDaiki
en-aut-sei=Ousaka
en-aut-mei=Daiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamadaKiyoshi
en-aut-sei=Yamada
en-aut-mei=Kiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SakanoNoriko
en-aut-sei=Sakano
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KirinoSatoe
en-aut-sei=Kirino
en-aut-mei=Satoe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyakeKazumasa
en-aut-sei=Miyake
en-aut-mei=Kazumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakahashiTakumi
en-aut-sei=Takahashi
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsuokaAkihiro
en-aut-sei=Matsuoka
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamadaShintaro
en-aut-sei=Yamada
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShinaokaAkira
en-aut-sei=Shinaoka
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OozawaSusumu
en-aut-sei=Oozawa
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Departments of Plastic and Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Rehabilitation, Lymphedema Treatment Center, Kousei Hospital
kn-affil=

affil-num=6
en-affil=Division of Business Management, Matsuoka Corporation
kn-affil=

affil-num=7
en-affil=Division of Production Engineering, Matsuoka Corporation
kn-affil=

affil-num=8
en-affil=Division of Sales, Kaihara Corporation
kn-affil=

affil-num=9
en-affil=Department of Lymphatics and Edematology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Clinical Safety, Okayama University Hospital
kn-affil=
en-keyword=compression garments
kn-keyword=compression garments
en-keyword=denim jeans
kn-keyword=denim jeans
en-keyword=long-term management
kn-keyword=long-term management
en-keyword=lower-extremity lymphedema
kn-keyword=lower-extremity lymphedema
en-keyword=quality of life
kn-keyword=quality of life
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=3
article-no=
start-page=369
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260123
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of the July 2018 Heavy Rain Disaster on the Endangered Nagoya Daruma Pond Frog (Pelophylax porosus brevipodus) in Rice Fields of Mabi Town, Kurashiki City, Western Japan: Changes in Population Structure over Five Years
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Rice paddy fields (referred to below as rice fields) are important not only for food production, but also as habitats for various species. The Nagoya Daruma Pond Frog (Pelophylax porosus brevipodus) is an endangered frog species endemic to Japan, mainly living in and around rice field areas. In July 2018, heavy rainfall caused severe flooding in Mabi Town of Okayama Prefecture, western Japan, submerging numerous rice fields and affecting local frog populations, including P. porosus brevipodus. To clarify whether the population structure of P. porosus brevipodus changed following the flood disaster in the rice fields of Mabi Town, we conducted quantitative field surveys in a rice fallow field in mid-October before (2017) and after (2018, 2020–2022, excluding 2019) the flood. The number of frogs declined sharply after the 2018 flood, reaching only a few individuals by 2020, but showed a substantial recovery in 2021 following the resumption of rice cultivation, although numbers decreased again in 2022. This recovery, despite fluctuations, indicates that habitat restoration through rice farming played a key role in enabling the population to rebound. Our findings underscore the importance of maintaining and restoring rice field environments after natural disasters for the survival and long-term recovery of P. porosus brevipodus.
en-copyright=
kn-copyright=

en-aut-name=NakajimaRyo
en-aut-sei=Nakajima
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AzumiDaisuke
en-aut-sei=Azumi
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TadaMasakazu
en-aut-sei=Tada
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaichiJunya
en-aut-sei=Nakaichi
en-aut-mei=Junya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatsuharaKoki R.
en-aut-sei=Katsuhara
en-aut-mei=Koki R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakataKazuyoshi
en-aut-sei=Nakata
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Okayama Prefectural Public Interest Incorporated Foundation for Environmental Conservation
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=agroecosystem
kn-keyword=agroecosystem
en-keyword=conservation ecology
kn-keyword=conservation ecology
en-keyword=endangered amphibian
kn-keyword=endangered amphibian
en-keyword=paddy field
kn-keyword=paddy field
en-keyword=post-disaster habitat recovery
kn-keyword=post-disaster habitat recovery
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=12
article-no=
start-page=e095428
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effectiveness of education programme to increase competency of health cadres in Indonesia: a cluster non-randomised controlled trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives Health cadres, who assist midwives in supporting pregnant women in community settings, need to enhance their competencies in identifying risk factors and referring high-risk pregnant women to midwives for further care. Since the capabilities of these health cadres are influenced by maternal complications, an educational programme was implemented to strengthen their skills. Therefore, this study aimed to evaluate the competency of health cadres by providing a researcher-developed educational programme.<br>
Design An open-label, cluster non-randomised controlled trial.<br>
Setting and participants Health cadres with at least 1 year of work experience were recruited at six public health centres (PHCs) in Banjarnegara Regency, Indonesia.<br>
Interventions Six PHCs were selected and allocated into intervention group (IG=3 PHCs) and control group (CG=3 PHCs) groups. A total of 133 female health cadres were enrolled across the selected PHCs. At each PHC, a systematic random sampling method was used to select the participants. The researchers and health professionals provided a 3-week period of theoretical and scenario-based simulations to the IG, while the CG received no education.<br>
Outcome measures Researcher-developed questionnaires and checklists were used to assess the knowledge, skills (health assessment, communication, attitude) and confidence. The primary endpoint was competency, a total score of knowledge and skills. The outcome domains were compared between the two groups, and a linear mixed-effect model was used to account for cluster-level variation.<br>
Results A total of 130 (97.7%) completed the study (IG:64, CG:66). The competency score showed significant improvement at endline (CG=49.5 and IG=52.5; p=0.002). The median scores for health assessment skills (CG=12 vs IG=14; p<0.001) and communication skills (CG=7 vs IG=8; p<0.001) were increased in the IG compared with the CG. Mixed-effect model indicated that groups (β (95% CI) 2.49 (0.57 to 4.41), p=0.012), baseline knowledge (β(95% CI) 0.73 (0.54 to 0.92), p<0.001) and midline health assessment skills (β (95% CI) 0.54 (0.25 to 0.82), p<0.001) were significant positive predictors, while age was negatively associated with competency (β (95% CI) −0.20 (−0.30 to −0.10), p<0.001)).<br>
Conclusion Education effectively increased the competency of health cadres. A well-structured education programme is necessary for health cadres to improve and maintain their competencies in monitoring high-risk pregnant women.<br>
Trial registration number NCT06134518.
en-copyright=
kn-copyright=

en-aut-name=SulistyoriniDewie
en-aut-sei=Sulistyorini
en-aut-mei=Dewie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HuqK A T M Ehsanul
en-aut-sei=Huq
en-aut-mei=K A T M Ehsanul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BabaitaAbdulfatai Olamilekan
en-aut-sei=Babaita
en-aut-mei=Abdulfatai Olamilekan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AiveySadia A
en-aut-sei=Aivey
en-aut-mei=Sadia A
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HuiyingGao
en-aut-sei=Huiying
en-aut-mei=Gao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KazawaKana
en-aut-sei=Kazawa
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FukushimaYasuko
en-aut-sei=Fukushima
en-aut-mei=Yasuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KakoMayumi
en-aut-sei=Kako
en-aut-mei=Mayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MoriyamaMichiko
en-aut-sei=Moriyama
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=2
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=3
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=4
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=5
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=6
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=8
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=9
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=131
cd-vols=
no-issue=1
article-no=
start-page=e2025JB033390
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Electrical Conductivity of Carbonatite Melts to 20 GPa: Constraints on Partial Melting Atop the 410‐km Discontinuity and in the Lower Mantle Transition Zone
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Deep-origin carbonatite melts are considered to be the products of partial-melting of the oceanic crust in the subduction zones. In this study, we conducted electrical conductivity (EC) measurements on two samples, the composition of which resemble the partial-melting products atop the 410-km discontinuity and in the lower part of the transition zone. The EC of carbonatite melts was investigated using impedance spectroscopy combined with a multi-anvil press up to 20 GPa. Pressure has a great effect on the EC of the carbonatite melts. While the EC dropped overall by 0.6 log unit from 3 to 20 GPa for varying compositions, the pressure effect becomes weaker above 10 GPa. The Hashin-Shtrikman mixing model indicates that melt fraction of 0–0.3 vol% is necessary to account for the EC atop the 410-km discontinuity beneath NE China, north Philippine Sea, north Pacific, and Australian craton. However, this value soars to 1–4.5 vol% for the lower part of the transition zone in the same regions, and further increases to 3.7–7.3 vol% for cold subduction regions if the slab surface temperature is 300 K lower. The difference in the needed melt fraction at different depths implies that the magnitude of partial melting is much larger in the lower part of the mantle transition zone, and it is thus likely to be the main barrier to the recycled carbonates towards the deep interior.
en-copyright=
kn-copyright=

en-aut-name=ZhaoBin
en-aut-sei=Zhao
en-aut-mei=Bin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ZhuJintao
en-aut-sei=Zhu
en-aut-mei=Jintao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ChenQi
en-aut-sei=Chen
en-aut-mei=Qi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YoshinoTakashi
en-aut-sei=Yoshino
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=2
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=3
en-affil=Center for Advanced Radiation Sources, University of Chicago
kn-affil=

affil-num=4
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=
en-keyword=carbon
kn-keyword=carbon
en-keyword=carbonatite melts
kn-keyword=carbonatite melts
en-keyword=electrical conductivity
kn-keyword=electrical conductivity
en-keyword=impedance spectroscopy
kn-keyword=impedance spectroscopy
en-keyword=multi-anvil press
kn-keyword=multi-anvil press
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=1
article-no=
start-page=ofaf790
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251223
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of Candida Care Bundle Compliance on the Prognosis of Patients With Candidemia: A Multicenter Retrospective Cohort Study With Propensity Score Matching Analysis (2016–2023)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background. Candidemia is a life-threatening infection with high mortality, and appropriate management is essential to improve patient outcomes. The Candida Care Bundle aims to standardize hospital management for patients with candidemia and reduce mortality.<br>
Methods. This retrospective multicenter cohort study included candidemia cases from 9 hospitals in Japan between 2016 and 2023. Compliance to the Candida Care Bundle was evaluated based on 5 elements: central venous catheter removal within 24 hours, appropriate antifungal therapy, ophthalmologic examination, follow-up blood cultures, and antifungal treatment for ≥2 weeks after clearance. Patients were categorized into high (4–5 items) and low (0–3 items) compliance groups. The primary and secondary outcomes were defined as 30-day survival and the development of endophthalmitis, with propensity score matching used to adjust for potential confounders.<br>
Results. Among 230 patients, 160 (69.5%) were classified into the high compliance group, which exhibited significantly lower 30-day mortality than the low compliance group (8.8% vs 57.1%, P < .01). Even after matching, the high compliance group remained independently associated with improved survival (hazard ratio [HR]: 0.15; 95% confidence interval [CI]: .08–.30). C. albicans (HR: 1.95; 95% CI: 1.01–3.52) and central line-associated bloodstream infection (HR: 2.63; 95% CI: 1.35–5.12) were associated with the fatal outcome. Endophthalmitis involved 23.6% of the patients, being associated with C. albicans (odds ratio [OR]: 8.18; 4.46–19.30) and central line-associated bloodstream infection (OR: 2.69; 1.08–6.70).<br>
Conclusions. Strict compliance to the Candida Care Bundle significantly improves survival, underscoring its importance in candidemia management.
en-copyright=
kn-copyright=

en-aut-name=AkazawaHidemasa
en-aut-sei=Akazawa
en-aut-mei=Hidemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiguchiToshie
en-aut-sei=Higuchi
en-aut-mei=Toshie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyoshiTomoko
en-aut-sei=Miyoshi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakanoYasuhiro
en-aut-sei=Nakano
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IioKoji
en-aut-sei=Iio
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AkamatsuYukinobu
en-aut-sei=Akamatsu
en-aut-mei=Yukinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HarukiYuto
en-aut-sei=Haruki
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IwamotoYoshitaka
en-aut-sei=Iwamoto
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TanakaShuichi
en-aut-sei=Tanaka
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujisatoShun
en-aut-sei=Fujisato
en-aut-mei=Shun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AkoSoichiro
en-aut-sei=Ako
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of General Internal Medicine, Okayama Red Cross Hospital
kn-affil=

affil-num=4
en-affil=Center for Medical Education and Internationalization, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of General Medicine, Tottori Municipal Hospital
kn-affil=

affil-num=8
en-affil=Department of Pharmacy, Tsuyama Chuo Hospital
kn-affil=

affil-num=9
en-affil=Department of General Medicine, NHO Okayama Medical Center
kn-affil=

affil-num=10
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Pharmacy, Okayama Rousai Hospital
kn-affil=

affil-num=12
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=candida bundle
kn-keyword=candida bundle
en-keyword=candidemia
kn-keyword=candidemia
en-keyword=endophthalmitis
kn-keyword=endophthalmitis
en-keyword=prognosis
kn-keyword=prognosis
en-keyword=propensity score matching
kn-keyword=propensity score matching
END

start-ver=1.4
cd-journal=joma
no-vol=49
cd-vols=
no-issue=1
article-no=
start-page=66
end-page=73
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260110
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Exploratory Analysis for Development Predictive Models of Immune Checkpoint Inhibitor-Induced Myocarditis Using a Nationwide Claims Database
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Immune checkpoint inhibitors (ICIs), essential in cancer therapy, can cause severe immune-related adverse events (irAEs), including myocarditis with a high fatality rate. Currently, the pathogenesis, biomarkers, and risk factors of ICI-induced myocarditis (ICIM) are not fully understood. This exploratory study aimed to develop machine learning-based models to predict the onset of ICIM within 3 months of starting ICI therapy, using a large health insurance database. The models were constructed using the Light Gradient Boosting Machine (LightGBM) and Random Forest algorithms, incorporating clinical variables such as comorbidities and prior medication classifications. In this study, a strategy combining undersampling and bagging was used to minimize the impact of highly imbalanced datasets. The Random Forest model demonstrated superior performance compared with the LightGBM model, and the SHapley Additive exPlanations (SHAP) analysis for the Random Forest model revealed that the concurrent use of ICIs was the most important variable for predictions. Although predictive performance remains limited (AUROC ≈ 0.63), this exploratory framework demonstrates the feasibility of developing data-driven risk prediction models for ICIM. Future studies with expanded datasets and integration of laboratory parameters are warranted to improve predictive accuracy and potential clinical applicability.
en-copyright=
kn-copyright=

en-aut-name=YamamotoReina
en-aut-sei=Yamamoto
en-aut-mei=Reina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakagomiKoki
en-aut-sei=Nakagomi
en-aut-mei=Koki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UchiyamaMiyu
en-aut-sei=Uchiyama
en-aut-mei=Miyu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MichiharaAyana
en-aut-sei=Michihara
en-aut-mei=Ayana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OzakiAya F.
en-aut-sei=Ozaki
en-aut-mei=Aya F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=PatelPranav M.
en-aut-sei=Patel
en-aut-mei=Pranav M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TaniokaMaki
en-aut-sei=Tanioka
en-aut-mei=Maki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=UeharaTakashi
en-aut-sei=Uehara
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Clinical Pharmacy, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Clinical Pharmacy, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Clinical Pharmacy Practice, School of Pharmacy &amp; Pharmaceutical Sciences, University of California
kn-affil=

affil-num=7
en-affil=Division of Cardiology, School of Medicine, University of California
kn-affil=

affil-num=8
en-affil=Medical AI Project, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=machine learning
kn-keyword=machine learning
en-keyword=immune checkpoint inhibitor
kn-keyword=immune checkpoint inhibitor
en-keyword=myocarditis
kn-keyword=myocarditis
en-keyword=adverse event
kn-keyword=adverse event
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=11
article-no=
start-page=1023
end-page=1032
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Bioconversion and Metabolic Fate of the n-1 Polyunsaturated Fatty Acids, 6,9,12,15- Hexadecatetraenoic (C16:4 n-1) and 8,11,14,17- Octadecatetraenoic (C18:4 n-1) Acids, in HepG2 Cells
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Fish oil contains not only major fatty acids with double bonds at the n-3, n-6, n-7, and n-9 positions but also those with a double bond at the n-1 position, such as 6,9,12,15-hexadecatetraenoic acid (C16:4 n-1; HDTA). However, intracellular bioconversion and metabolic fate of n-1 polyunsaturated fatty acids (PUFA) remain unclear. Therefore, in this study, we aimed to assess the intracellular bioconversion and metabolic fate of HDTA and its metabolite, 8,11,14,17- octadecatetraenoic acid (C18:4 n-1; ODTA), using HepG2 cells. Based on the results of cell viability and cytotoxicity assays for HDTA and ODTA, the concentration of each fatty acid supplemented in the experiments was set at 10 μM. HepG2 cell culture with HDTA revealed C20:4 n-1 as a new HDTA metabolite, along with previously reported ODTA. Our findings suggest that the HDTA taken up by HepG2 cells undergoes elongation to form ODTA and C20:4 n-1. Following supplementation with HDTA, ODTA, and 5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; EPA), fatty acids disappeared from the culture medium within 24 h. Notably, the total relative level of HDTA and its metabolites, including ODTA and C20:4 n-1 in HDTA- and ODTA-supplemented cells were significantly lower than the total relative level of EPA and its metabolites, including 7,10,13,16,19-docosapentaenoic acid (C22:5 n-3), C24:6 n-3, and 4,7,10,13,16,19-docosahexaenoic acid (C22:6 n-3) in the EPA-supplemented cells. Except for a portion that was intracellularly elongated, most HDTA was taken up by HepG2 cells and may undergo rapid fatty acid β-oxidation. However, RNA-sequencing and real-time polymerase chain reaction analysis revealed no significant changes in fatty acid β-oxidation–related gene expression levels in HDTA-supplemented cells. Collectively, these results provide novel insights into the intracellular bioconversion mechanisms and metabolic fate of HDTA and ODTA in HepG2 cells, suggesting that the metabolic fate of n-1 PUFA is distinct from that of common PUFA.
en-copyright=
kn-copyright=

en-aut-name=SugimotoKoki
en-aut-sei=Sugimoto
en-aut-mei=Koki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishiguchiHideto
en-aut-sei=Nishiguchi
en-aut-mei=Hideto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HosomiRyota
en-aut-sei=Hosomi
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TanizakiToshifumi
en-aut-sei=Tanizaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsushimaTadahiro
en-aut-sei=Tsushima
en-aut-mei=Tadahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=BabaNaomichi
en-aut-sei=Baba
en-aut-mei=Naomichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MisawaYoshihisa
en-aut-sei=Misawa
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WangZiyi
en-aut-sei=Wang
en-aut-mei=Ziyi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OnoMitsuaki
en-aut-sei=Ono
en-aut-mei=Mitsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MurakamiYuki
en-aut-sei=Murakami
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KandaSeiji
en-aut-sei=Kanda
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=FukunagaKenji
en-aut-sei=Fukunaga
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Faculty of Food and Nutritional Sciences, Toyo University
kn-affil=

affil-num=2
en-affil=Faculty of Chemistry, Materials, and Bioengineering, Kansai University
kn-affil=

affil-num=3
en-affil=Faculty of Chemistry, Materials, and Bioengineering, Kansai University
kn-affil=

affil-num=4
en-affil=Bizen Chemical Co., Ltd.
kn-affil=

affil-num=5
en-affil=Bizen Chemical Co., Ltd.
kn-affil=

affil-num=6
en-affil=Bizen Chemical Co., Ltd.
kn-affil=

affil-num=7
en-affil=Bizen Chemical Co., Ltd.
kn-affil=

affil-num=8
en-affil=Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Hygiene and Public Health, Kansai Medical University
kn-affil=

affil-num=11
en-affil=Department of Hygiene and Public Health, Kansai Medical University
kn-affil=

affil-num=12
en-affil=Faculty of Chemistry, Materials, and Bioengineering, Kansai University
kn-affil=
en-keyword=n-1 polyunsaturated fatty acids
kn-keyword=n-1 polyunsaturated fatty acids
en-keyword=hexadecatetraenoic acid
kn-keyword=hexadecatetraenoic acid
en-keyword=octadecatetraenoic acid
kn-keyword=octadecatetraenoic acid
en-keyword=HepG2
kn-keyword=HepG2
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=6
article-no=
start-page=660
end-page=671
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250914
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Electronic Structure of the S1 State Manganese Cluster in Photosystem II Investigated Using Q-Band Selective Hole-Burning
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The electronic structure of the S1 state of photosystem II (PSII) was investigated using selective hole burning of Q-band pulsed electron paramagnetic resonance. The free induction decay and spin–echo signals of the tyrosine radical YD• in the plant PSII oscillated because of the magnetic dipole–dipole interaction with the S1 state Mn cluster. The initial period was 410 ns (2.44 MHz) and was assigned to the S = 1 spin state. Based on the oscillation analysis, both Mn1 and Mn4 and both Mn2 and Mn3 were assigned as Mn(III) and Mn(IV), respectively, which is consistent with the quantum chemical calculations. The 410 ns period was accounted for in the simplified model using the isotropic spin density distribution ratio [1.6:–1.1:–1.1:1.6] for Mn1–4 ions. This oscillation was identical with that observed in the presence of methanol. The oscillation decreased in PsbP/Q- and PsbO/P/Q-depleted PSII. In Thermosynechococcus vulcanus, two periods, 390 ns (2.56 MHz) and 630 ns (1.59 MHz), were detected, indicating that the cyanobacterial S1 state includes two isomers, S = 1 and S ≥ 2 spins. The S ≥ 2 spin was not detected in PsbO/U/V-depleted PSII without polyethylene glycol. The S ≥ 2 state was consistent with the reported quantum chemical calculation using S = 3. A simplified model accounted for the S = 1 state as the spin density distribution [1.8:–1.3:–1.3:1.8] and for the S ≥ 2 state as the isotropic spin density distribution [−0.5:0.5:0.5:0.5] for Mn1–4 ions. In combination with quantum chemical calculations, the most probable protonated structure is W1 = H2O, W2 = H2O, O4 = O2–, and O5 = O2– for the S1 state. These results demonstrate that the selective hole burning method is a powerful tool to complement X-ray studies to determine the valence and protonation structure of manganese clusters, not only in the S1 state but also in higher S-states and general metal clusters, which would provide important insights into the water oxidation mechanism.
en-copyright=
kn-copyright=

en-aut-name=KosakiShinya
en-aut-sei=Kosaki
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakamuraNaohiko
en-aut-sei=Nakamura
en-aut-mei=Naohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakajimaYoshiki
en-aut-sei=Nakajima
en-aut-mei=Yoshiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShenJian-Ren
en-aut-sei=Shen
en-aut-mei=Jian-Ren
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MinoHiroyuki
en-aut-sei=Mino
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Physics, Graduate School of Science, Nagoya University
kn-affil=

affil-num=2
en-affil=Department of Physics, Graduate School of Science, Nagoya University
kn-affil=

affil-num=3
en-affil=Research Institute for Interdisciplinary Science, Advanced Research Field, and Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Research Institute for Interdisciplinary Science, Advanced Research Field, and Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Physics, Graduate School of Science, Nagoya University
kn-affil=
en-keyword=Photosystem II
kn-keyword=Photosystem II
en-keyword=Oxygen evolution
kn-keyword=Oxygen evolution
en-keyword=S1 state
kn-keyword=S1 state
en-keyword=Mn cluster
kn-keyword=Mn cluster
en-keyword=EPR
kn-keyword=EPR
en-keyword=Selective hole-burning
kn-keyword=Selective hole-burning
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251211
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=First-line atezolizumab combination therapies were approved for the treatment of metastatic non-small cell lung cancer (NSCLC) based on results from the global phase 3 trials IMpower130, IMpower132, and IMpower150. These trials reported 12-month overall survival (OS) rates of 60%–67% with atezolizumab combination therapy. J-TAIL-2 (NCT04501497), a prospective, multicenter, observational study, evaluated atezolizumab combination therapy in routine clinical practice in Japan. Patients ≥ 20 years old with NSCLC received atezolizumab plus carboplatin and nab-paclitaxel (atezo + CnP), atezolizumab plus carboplatin or cisplatin plus pemetrexed (atezo + PP), or atezolizumab plus bevacizumab plus carboplatin and paclitaxel (atezo + bev + CP) in clinical practice. The primary endpoint was the 12-month OS rate. Secondary endpoints included OS, progression-free survival, and subgroup analyses, including IMpower-unlike (did not meet the main eligibility criteria of each IMpower trial) and IMpower-like patients. In total, 814 patients were enrolled (atezo + CnP, n = 217; atezo + PP, n = 211; atezo + bev + CP, n = 386). The IMpower-unlike group included patients with Eastern Cooperative Oncology Group performance status ≥ 2, autoimmune disease, or interstitial lung disease. Twelve-month OS rates (95% confidence interval [CI]) were 62.9% (55.8–69.2), 72.1% (65.2–77.9), and 68.3% (63.2–72.9) with atezo + CnP, atezo + PP, and atezo + bev + CP, respectively. OS hazard ratios (95% CI) in the IMpower-unlike vs. -like subgroups were 1.36 (0.91–2.05), 1.08 (0.70–1.68), and 1.49 (1.09–2.06), respectively. No new safety signals were observed. Real-world efficacy and safety for each atezolizumab combination were comparable to those in the relevant IMpower trials.
en-copyright=
kn-copyright=

en-aut-name=YoshiokaHiroshige
en-aut-sei=Yoshioka
en-aut-mei=Hiroshige
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishioMakoto
en-aut-sei=Nishio
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OhashiKadoaki
en-aut-sei=Ohashi
en-aut-mei=Kadoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OsoegawaAtsushi
en-aut-sei=Osoegawa
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KikuchiEiki
en-aut-sei=Kikuchi
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KimuraHideharu
en-aut-sei=Kimura
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=GotoYasushi
en-aut-sei=Goto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShimizuJunichi
en-aut-sei=Shimizu
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MiyauchiEisaku
en-aut-sei=Miyauchi
en-aut-mei=Eisaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YoshinoIchiro
en-aut-sei=Yoshino
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MisumiToshihiro
en-aut-sei=Misumi
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=WatanabeYasutaka
en-aut-sei=Watanabe
en-aut-mei=Yasutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HataAkito
en-aut-sei=Hata
en-aut-mei=Akito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KisoharaAkira
en-aut-sei=Kisohara
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KuyamaShoichi
en-aut-sei=Kuyama
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=YamaguchiMasafumi
en-aut-sei=Yamaguchi
en-aut-mei=Masafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MiwaAsako
en-aut-sei=Miwa
en-aut-mei=Asako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=IwasawaShunichiro
en-aut-sei=Iwasawa
en-aut-mei=Shunichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=TanakaMisa
en-aut-sei=Tanaka
en-aut-mei=Misa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=GemmaAkihiko
en-aut-sei=Gemma
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Thoracic Oncology, Kansai Medical University
kn-affil=

affil-num=2
en-affil=Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research
kn-affil=

affil-num=3
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University
kn-affil=

affil-num=6
en-affil=Department of Respiratory Medicine, Kanazawa University Hospital
kn-affil=

affil-num=7
en-affil=Department of Thoracic Oncology, National Cancer Center Hospital
kn-affil=

affil-num=8
en-affil=Department of Thoracic Oncology, Aichi Cancer Center Hospital
kn-affil=

affil-num=9
en-affil=Department of Respiratory Medicine, Tohoku University Hospital
kn-affil=

affil-num=10
en-affil=International University of Health and Welfare, Narita Hospital
kn-affil=

affil-num=11
en-affil=Department of Data Science, National Cancer Center Hospital East
kn-affil=

affil-num=12
en-affil=Department of Thoracic Oncology, Saitama Cancer Center
kn-affil=

affil-num=13
en-affil=Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center
kn-affil=

affil-num=14
en-affil=Department of Respiratory Medicine, Kasukabe Medical Center
kn-affil=

affil-num=15
en-affil=Department of Respiratory Medicine, NHO Iwakuni Clinical Center
kn-affil=

affil-num=16
en-affil=Department of Thoracic Oncology, NHO Kyushu Cancer Center
kn-affil=

affil-num=17
en-affil=Chugai Pharmaceutical Co., Ltd.
kn-affil=

affil-num=18
en-affil=Chugai Pharmaceutical Co., Ltd.
kn-affil=

affil-num=19
en-affil=Chugai Pharmaceutical Co., Ltd.
kn-affil=

affil-num=20
en-affil=Nippon Medical School
kn-affil=
en-keyword=atezolizumab
kn-keyword=atezolizumab
en-keyword=chemotherapy
kn-keyword=chemotherapy
en-keyword=lung cancer
kn-keyword=lung cancer
en-keyword=non-small cell
kn-keyword=non-small cell
en-keyword=observational
kn-keyword=observational
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=4
article-no=
start-page=1041
end-page=1054
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250904
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Tarlatamab is a bispecific T-cell engager (BiTE®) immunotherapy that binds delta-like ligand 3 on the surface of small cell lung cancer (SCLC) cells and CD3 on T cells, facilitating T cell-mediated cancer cell lysis. In the primary analysis of the phase 2 DeLLphi-301 study (NCT05060016), tarlatamab showed a favourable benefit-to-risk profile with durable objective responses and promising survival outcomes in patients with previously treated SCLC. Here, phase 2 data for the Asia region subgroup are presented.<br>
Methods: Patients with previously treated, advanced SCLC received 10 mg tarlatamab every 2 weeks. The primary endpoint was objective response rate (ORR) by blinded independent central review (RECIST version 1.1). Key secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS) and safety. The present analysis includes patients enrolled at sites in Asia.<br>
Results: A total of 43 patients were enrolled at sites in Asia. ORR was 46.3% (95% confidence interval [CI], 30.7–62.6) and median DOR was 7.2 months (95% CI 3.9 to not estimable). The median follow-up was 16.6 months for PFS and 21.2 months for OS. Median PFS was 5.4 months (95% CI 3.0–8.1) and median OS was 19.0 months (95% CI 11.4 to not estimable). The most common treatment-emergent adverse event (AE) was cytokine release syndrome (48.8%), and all such events were grade 1 or 2. There were no discontinuations due to treatment-related AEs.<br>
Conclusions: Tarlatamab demonstrated durable responses and promising survival outcomes with a manageable safety profile in this post hoc analysis of patients from Asia with previously treated SCLC.<br>
Trial Registration: ClinicalTrials.gov, NCT05060016.
en-copyright=
kn-copyright=

en-aut-name=AhnMyung-Ju
en-aut-sei=Ahn
en-aut-mei=Myung-Ju
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ChoByoung Chul
en-aut-sei=Cho
en-aut-mei=Byoung Chul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OhashiKadoaki
en-aut-sei=Ohashi
en-aut-mei=Kadoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IzumiHiroki
en-aut-sei=Izumi
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=LeeJong-Seok
en-aut-sei=Lee
en-aut-mei=Jong-Seok
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HanJi-Youn
en-aut-sei=Han
en-aut-mei=Ji-Youn
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ChiangChi-Lu
en-aut-sei=Chiang
en-aut-mei=Chi-Lu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HuangShuang
en-aut-sei=Huang
en-aut-mei=Shuang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HamidiAli
en-aut-sei=Hamidi
en-aut-mei=Ali
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MukherjeeSujoy
en-aut-sei=Mukherjee
en-aut-mei=Sujoy
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=XuKrista Lin
en-aut-sei=Xu
en-aut-mei=Krista Lin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AkamatsuHiraoki
en-aut-sei=Akamatsu
en-aut-mei=Hiraoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Hematology-Oncology Department, Samsung Medical Center (SMC), Sungkyunkwan University School of Medicine
kn-affil=

affil-num=2
en-affil=Medical Oncology Department-501, ABMRC, Yonsei University
kn-affil=

affil-num=3
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Thoracic Oncology, National Cancer Center Hospital East
kn-affil=

affil-num=5
en-affil=Hematology/Oncology, Seoul National University Bundang Hospital
kn-affil=

affil-num=6
en-affil=Center for Lung Cancer, National Cancer Center-Graduate School of Cancer Science and Policy
kn-affil=

affil-num=7
en-affil=Department of Chest Medicine, Taipei Veterans General Hospital
kn-affil=

affil-num=8
en-affil=Amgen Inc.
kn-affil=

affil-num=9
en-affil=Amgen Inc.
kn-affil=

affil-num=10
en-affil=Amgen Inc.
kn-affil=

affil-num=11
en-affil=Amgen Asia Pacific Pte. Ltd.
kn-affil=

affil-num=12
en-affil=Internal Medicine III, Wakayama Medical University
kn-affil=
en-keyword=Small cell lung cancer (SCLC)
kn-keyword=Small cell lung cancer (SCLC)
en-keyword=Tarlatamab
kn-keyword=Tarlatamab
en-keyword=DLL3
kn-keyword=DLL3
en-keyword=Bispecific T-cell engager
kn-keyword=Bispecific T-cell engager
en-keyword=Asian patients
kn-keyword=Asian patients
END

start-ver=1.4
cd-journal=joma
no-vol=113
cd-vols=
no-issue=4
article-no=
start-page=117030
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Time to positivity for differentiating blood culture contamination: A 20-hour cutoff for major contaminants
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Blood culture remains the gold standard for diagnosing bacteremia; however, contamination inevitably occurs in 2-3% of cases, requiring differentiation between true bacteremia and contamination. Although time to positivity (TTP) aids in this clinical decision, with detection after 24 hours generally indicating contamination, technological advances in blood culture systems may have shortened this threshold interval.<br>
Methods: This study retrospectively analyzed blood culture data in our hospital from April 2023 to January 2025 to determine the optimal TTP cutoff. Patients with positive blood cultures for major contaminating bacteria were included. Cases were classified as true bacteremia or contamination based on a comprehensive chart review conducted by the antimicrobial stewardship audit, and TTP was compared between the groups. Sensitivity, specificity, and Youden index at various TTP cutoffs were utilized to determine the optimal threshold using the receiver operating characteristic curve analysis.<br>
Results: Seventy-one patients were enrolled, with 34 cases classified as true bacteremia and 37 as contamination. Identified bacteria included coagulase-negative staphylococci (70.4%), viridans group streptococci (18.3%), and others (11.3%). The median TTP was significantly shorter in the true bacteremia group compared with the contamination group (18.6 vs.25.8 hours, p < 0.001). In the contamination group, 43.2% of the cases demonstrated positive growth within 24 hours. Based on sensitivity, specificity, and Youden index, the optimal threshold was estimated to be 20 hours. A subgroup analysis of the CNS-only cohort yielded concordant results.<br>
Conclusion: This study suggests that a 20-hour TTP threshold could help effectively differentiate true bacteremia from contamination in current clinical settings.
en-copyright=
kn-copyright=

en-aut-name=ManabeYohei
en-aut-sei=Manabe
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakamotoKenta
en-aut-sei=Nakamoto
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OguniKohei
en-aut-sei=Oguni
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AkazawaHidemasa
en-aut-sei=Akazawa
en-aut-mei=Hidemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FujitaYasushi
en-aut-sei=Fujita
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KiguchiTakashi
en-aut-sei=Kiguchi
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IioKoji
en-aut-sei=Iio
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Nursing, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Nursing, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=
en-keyword=Bacteremia
kn-keyword=Bacteremia
en-keyword=Blood stream infection
kn-keyword=Blood stream infection
en-keyword=Contamination
kn-keyword=Contamination
en-keyword=Incubation time
kn-keyword=Incubation time
en-keyword=Time to positivity
kn-keyword=Time to positivity
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250923
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Hospital-acquired pneumonia caused by multidrug-resistant Streptococcus pneumoniae serotype 15A
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Streptococcus pneumoniae remains a common cause of community-acquired pneumonia but is an infrequent pathogen in hospital-acquired pneumonia (HAP). Non-vaccine serotypes of multidrug-resistant (MDR) S. pneumoniae strains have been emerging globally, posing an increased risk of nosocomial infection.<br>
Case A 71 year-old man developed pneumonia on postoperative day 4 following spinal fusion surgery. Despite initial treatment with ampicillin/sulbactam, his condition deteriorated, requiring ICU admission and mechanical ventilation. Microbiological testing confirmed S. pneumoniae as a causative pathogen, and ceftriaxone was empirically administered based on the local antibiogram. However, antimicrobial susceptibility testing revealed resistant profiles to penicillin (minimum inhibitory concentration [MIC], 8 µg/mL), ceftriaxone (MIC, 16 µg/mL), meropenem (MIC, 1 µg/mL), macrolides, and clindamycin, while demonstrating susceptibility to levofloxacin and vancomycin. The therapeutic regimen was subsequently adjusted to levofloxacin, resulting in clinical improvement. The isolate was later identified as serotype 15A, sequence type 63 (ST63).<br>
Conclusion This case highlights that MDR S. pneumoniae can cause early-onset HAP and may not be covered by standard empiric therapies, emphasizing the need for careful evaluation of treatment response. Continued surveillance of infections caused by vaccine-escape clones like MDR serotype 15A is essential, given their increasing clinical relevance.
en-copyright=
kn-copyright=

en-aut-name=AkazawaHidemasa
en-aut-sei=Akazawa
en-aut-mei=Hidemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakamotoKenta
en-aut-sei=Nakamoto
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OguniKohei
en-aut-sei=Oguni
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShimbeMadoka
en-aut-sei=Shimbe
en-aut-mei=Madoka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ChangBin
en-aut-sei=Chang
en-aut-mei=Bin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AkedaYukihiro
en-aut-sei=Akeda
en-aut-mei=Yukihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Bacteriology I, National Institute of Infectious Diseases, Japan Institute for Health Security
kn-affil=

affil-num=7
en-affil=Department of Bacteriology I, National Institute of Infectious Diseases, Japan Institute for Health Security
kn-affil=

affil-num=8
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=Antimicrobial resistance
kn-keyword=Antimicrobial resistance
en-keyword=Multidrug-resistant
kn-keyword=Multidrug-resistant
en-keyword=Nosocomial infection
kn-keyword=Nosocomial infection
en-keyword=Sequence type 63
kn-keyword=Sequence type 63
en-keyword=Serotype 15A
kn-keyword=Serotype 15A
en-keyword=Streptococcus pneumoniae
kn-keyword=Streptococcus pneumoniae
END

start-ver=1.4
cd-journal=joma
no-vol=190
cd-vols=
no-issue=6
article-no=
start-page=90
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250922
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prognostic Value of Serum (1→3)-β-D-Glucan Levels in Patients with Candidemia Stratified by Compliance with Candida Bundle: A Multicenter Retrospective Cohort Study (2016–2023)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Candidemia is a severe systemic infection with a high mortality risk. While β-D-glucan (BDG) serves as a diagnostic biomarker, its prognostic value in candidemia, particularly in association with Candida bundle compliance, remains unclear.<br>
Methods In this retrospective multicenter cohort study, we evaluated 96 patients with candidemia across nine Japanese hospitals between 2016 and 2023. Candida bundle compliance was assessed using five key components: central venous catheter removal within 24 h of diagnosis, appropriate initial antifungal therapy, ophthalmologic examination, follow-up blood cultures until clearance, and antifungal therapy for at least two weeks post-clearance. Analyses stratified patients by serum BDG status (positive/negative) and compliance with the Candida bundle (high: 4–5 points; low: 0–3 points). The primary outcome was 30-day mortality, and the secondary outcome was defined as endophthalmitis incidence.<br>
Results Of 96 eligible patients with candidemia, 70 (72.9%) were BDG-positive and 26 (27.1%) were BDG-negative. The overall 30-day mortality was 17.7%. Among BDG-positive patients, 15 (21.4%) died, while 2 (7.7%) died in BDG-negative cohorts (p = 0.09). Serum BDG positivity demonstrated a statistically significant association with decreased survival rates in the low bundle adherence group (p = 0.02), whereas this correlation was not observed among patients in the high-compliance cohort (p = 0.66). Endophthalmitis occurred in 25.0% of patients, without significant correlation to serum BDG status. C. albicans was associated with a significantly higher incidence of endophthalmitis compared with non-albicans species (45.7% vs. 8.9%).<br>
Conclusions Serum BDG positivity potentially correlates with worse survival in candidemia, particularly in patients with low bundle compliance. This emphasizes the importance of adherence to standardized Candida management protocols for optimizing patient outcomes.
en-copyright=
kn-copyright=

en-aut-name=AkazawaHidemasa
en-aut-sei=Akazawa
en-aut-mei=Hidemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiguchiToshie
en-aut-sei=Higuchi
en-aut-mei=Toshie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyoshiTomoko
en-aut-sei=Miyoshi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakanoYasuhiro
en-aut-sei=Nakano
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IioKoji
en-aut-sei=Iio
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AkamatsuYukinobu
en-aut-sei=Akamatsu
en-aut-mei=Yukinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HarukiYuto
en-aut-sei=Haruki
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IwamotoYoshitaka
en-aut-sei=Iwamoto
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TanakaShuichi
en-aut-sei=Tanaka
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujisatoShun
en-aut-sei=Fujisato
en-aut-mei=Shun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AkoSoichiro
en-aut-sei=Ako
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of General Internal Medicine, Okayama Red Cross Hospital
kn-affil=

affil-num=4
en-affil=Center for Medical Education and Internationalization, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of General Medicine, Tottori Municipal Hospital
kn-affil=

affil-num=8
en-affil=Department of Pharmacy, Tsuyama Chuo Hospital
kn-affil=

affil-num=9
en-affil=Department of General Medicine, NHO Okayama Medical Center
kn-affil=

affil-num=10
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Pharmacy, Okayama Rousai Hospital
kn-affil=

affil-num=12
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=Candidemia
kn-keyword=Candidemia
en-keyword=Prognosis
kn-keyword=Prognosis
en-keyword=β-D-glucan
kn-keyword=β-D-glucan
en-keyword=Candida bundle
kn-keyword=Candida bundle
en-keyword=Endophthalmitis
kn-keyword=Endophthalmitis
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=149
end-page=149
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 19th Annual Meeting of Japanese Association of Medical Technology Education
kn-title=第19回日本臨床検査学教育学会学術大会
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=HirohataSatoshi
en-aut-sei=Hirohata
en-aut-mei=Satoshi
kn-aut-name=廣畑聡
kn-aut-sei=廣畑
kn-aut-mei=聡
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Medical Technology, Faculty of Health Sciences, Okayama University
kn-affil=岡山大学学術研究院保健学域　検査技術科学
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=147
end-page=148
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Don't give up because of pregnancy loss: Treatment and care for recurrent pregnancy loss. The 7th Annual Meeting of the Japan Society for Recurrent Pregnancy Loss, held in Okayama
kn-title=流死産をあきらめない：不育症の治療とケア―第７回日本不育症学会学術集会を岡山で開催―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NakatsukaMikiya
en-aut-sei=Nakatsuka
en-aut-mei=Mikiya
kn-aut-name=中塚幹也
kn-aut-sei=中塚
kn-aut-mei=幹也
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Faculty of Health Sciences, Okayama University, The Reproduction Center, Okayama University Hospital, OKAYAMA Infertility Consultation Center
kn-affil=岡山大学学術研究院保健学域，岡山大学病院　リプロダクションセンター，岡山県不妊専門相談センター
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=144
end-page=146
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 77th Annual Congress of the Japan Society of Obstetrics and Gynecology
kn-title=第77回日本産科婦人科学会学術講演会開催報告
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MasuyamaHisashi
en-aut-sei=Masuyama
en-aut-mei=Hisashi
kn-aut-name=増山寿
kn-aut-sei=増山
kn-aut-mei=寿
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　産科・婦人科学
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=140
end-page=143
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Infectious diseases in the post-COVID-19 era
kn-title=ポストコロナの感染症
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=UdaKazuhiro
en-aut-sei=Uda
en-aut-mei=Kazuhiro
kn-aut-name=宇田和宏
kn-aut-sei=宇田
kn-aut-mei=和宏
aut-affil-num=1
ORCID=

en-aut-name=TsukaharaHirokazu
en-aut-sei=Tsukahara
en-aut-mei=Hirokazu
kn-aut-name=塚原宏一
kn-aut-sei=塚原
kn-aut-mei=宏一
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Pediatric Regional Healthcare, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　小児地域医療学講座

affil-num=2
en-affil=Department of Pediatrics, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　小児医科学
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=137
end-page=139
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Drug interaction (64. Drug interactions of anti-cytomegalovirus agents)
kn-title=薬物相互作用（64―抗サイトメガロウイルス薬の薬物相互作用）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TeramotoYoshikazu
en-aut-sei=Teramoto
en-aut-mei=Yoshikazu
kn-aut-name=寺本賀一
kn-aut-sei=寺本
kn-aut-mei=賀一
aut-affil-num=1
ORCID=

en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=濱野裕章
kn-aut-sei=濱野
kn-aut-mei=裕章
aut-affil-num=2
ORCID=

en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院　薬剤部

affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院　薬剤部

affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院　薬剤部
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=132
end-page=136
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Advances in and future perspectives on robot-assisted surgery in the field of thoracic surgery
kn-title=呼吸器外科領域におけるロボット支援手術の進化と展望
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=OkazakiMikio
en-aut-sei=Okazaki
en-aut-mei=Mikio
kn-aut-name=岡﨑幹生
kn-aut-sei=岡﨑
kn-aut-mei=幹生
aut-affil-num=1
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=豊岡伸一
kn-aut-sei=豊岡
kn-aut-mei=伸一
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　呼吸器・乳腺内分泌学

affil-num=2
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　呼吸器・乳腺内分泌学
en-keyword=ロボット支援下手術
kn-keyword=ロボット支援下手術
en-keyword=RATS
kn-keyword=RATS
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=126
end-page=131
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A survey of college students' knowledge and awareness of hereditary cancer
kn-title=遺伝性腫瘍に関する大学生の知識と意識調査
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　Genomic information plays a critical role in the diagnosis and treatment of various diseases, as well as in the management of asymptomatic individuals. This study assessed the knowledge and understanding of genetics and hereditary cancer among college students who received cancer education in Japan. The study subjects were students from fields such as education, medicine, law, and economics who participated during the period from February to December 2023. The students attended in-person lectures on genomic medicine, and they were then asked to complete an anonymous survey via Google Forms. Over 90％ of the participants reported understanding the content of the lectures, and >80％ indicated that they found the lecture's content understandable at a junior high school level. Over 60％ felt that the appropriate time to begin such education would be in late elementary or junior high school. These results indicate a high level of acceptance of hereditary cancer education among young people. However, challenges remain in their understanding of the roles of genetic factors in cancer development and the mechanisms by which inheritance and phenotype are manifested. The relevant educational programs need to be further refined and strengthened.
en-copyright=
kn-copyright=

en-aut-name=SogawaReimi
en-aut-sei=Sogawa
en-aut-mei=Reimi
kn-aut-name=十川麗美
kn-aut-sei=十川
kn-aut-mei=麗美
aut-affil-num=1
ORCID=

en-aut-name=WadaTakahito
en-aut-sei=Wada
en-aut-mei=Takahito
kn-aut-name=和田敬仁
kn-aut-sei=和田
kn-aut-mei=敬仁
aut-affil-num=2
ORCID=

en-aut-name=HirasawaAkira
en-aut-sei=Hirasawa
en-aut-mei=Akira
kn-aut-name=平沢晃
kn-aut-sei=平沢
kn-aut-mei=晃
aut-affil-num=3
ORCID=

en-aut-name=KumamotoKensuke
en-aut-sei=Kumamoto
en-aut-mei=Kensuke
kn-aut-name=隈元謙介
kn-aut-sei=隈元
kn-aut-mei=謙介
aut-affil-num=4
ORCID=

en-aut-name=OhmoriIori
en-aut-sei=Ohmori
en-aut-mei=Iori
kn-aut-name=大守伊織
kn-aut-sei=大守
kn-aut-mei=伊織
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Clinical Genetics and Genomic Medicine, Kagawa University Hospital
kn-affil=香川大学医学部附属病院　臨床遺伝ゲノム診療科

affil-num=2
en-affil=Department of Genomic Medicine, Kyoto University Graduate School of Medicine
kn-affil=京都大学大学院医学研究科　ゲノム医療学

affil-num=3
en-affil=Department of Clinical Genomic Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　臨床遺伝医療学

affil-num=4
en-affil=Department of Clinical Genetics and Genomic Medicine, Kagawa University Hospital
kn-affil=香川大学医学部附属病院　臨床遺伝ゲノム診療科

affil-num=5
en-affil=Special Needs Education, Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域　特別支援教育
en-keyword=遺伝性腫瘍 (hereditary cancer)
kn-keyword=遺伝性腫瘍 (hereditary cancer)
en-keyword=ゲノム教育 (genome education)
kn-keyword=ゲノム教育 (genome education)
en-keyword=市民教育 (public education)
kn-keyword=市民教育 (public education)
en-keyword=学校教育 (school education)
kn-keyword=学校教育 (school education)
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=118
end-page=125
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The results of COVID-19 antibody testing studies in Bizen, Japan
kn-title=備前市における新型コロナウイルス感染症の抗体検査に関する研究の成果報告
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　We conducted two prospective cohort studies (June 2022–March 2023 and Nov 2023–Jan 2024) of 1,899 and 445 residents and other individuals who are affiliated with institutions in the city of Bizen in Japan's Okayama prefecture (population 32,320 as of 2020). We measured the subjects' titers of antibodies against SARS-CoV-2, evaluated changes in their antibody titers, and assessed the associations of the titers with the subjects' vaccination status, infection, and COVID-19 status/severity. This report summarizes the two studies' findings. These prospective studies based on a wide age range in a general population provide information that can be used to determine the appropriate timing of vaccination during a pandemic.
en-copyright=
kn-copyright=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=頼藤貴志
kn-aut-sei=頼藤
kn-aut-mei=貴志
aut-affil-num=1
ORCID=

en-aut-name=SasakiAyako
en-aut-sei=Sasaki
en-aut-mei=Ayako
kn-aut-name=佐々木綾子
kn-aut-sei=佐々木
kn-aut-mei=綾子
aut-affil-num=2
ORCID=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=松本尚美
kn-aut-sei=松本
kn-aut-mei=尚美
aut-affil-num=3
ORCID=

en-aut-name=KadowakiTomoka
en-aut-sei=Kadowaki
en-aut-mei=Tomoka
kn-aut-name=門脇知花
kn-aut-sei=門脇
kn-aut-mei=知花
aut-affil-num=4
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=三橋利晴
kn-aut-sei=三橋
kn-aut-mei=利晴
aut-affil-num=5
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=高尾総司
kn-aut-sei=高尾
kn-aut-mei=総司
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Science, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　疫学・衛生学

affil-num=2
en-affil=Kurashiki City Public Health Center
kn-affil=倉敷市保健所

affil-num=3
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Science, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　疫学・衛生学

affil-num=4
en-affil=Center for Public Health Action in Applied Epidemiology, National Institute of Infectious Diseases
kn-affil=国立感染症研究所　応用疫学研究センター

affil-num=5
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=岡山大学病院　新医療研究開発センター

affil-num=6
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Science, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　疫学・衛生学
en-keyword=COVID-19
kn-keyword=COVID-19
en-keyword=ワクチン (vaccination)
kn-keyword=ワクチン (vaccination)
en-keyword=抗体価 (antibody titer)
kn-keyword=抗体価 (antibody titer)
en-keyword=感染 (infection)
kn-keyword=感染 (infection)
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=108
end-page=117
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Recent research developments in the Department of Pediatrics, Okayama University
kn-title=岡山大学小児医科学教室における最近の研究成果
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TsukaharaHirokazu
en-aut-sei=Tsukahara
en-aut-mei=Hirokazu
kn-aut-name=塚原宏一
kn-aut-sei=塚原
kn-aut-mei=宏一
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Pediatrics, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　小児医科学
en-keyword=岡山大学
kn-keyword=岡山大学
en-keyword=小児医科学
kn-keyword=小児医科学
en-keyword=臨床・基礎医学
kn-keyword=臨床・基礎医学
en-keyword=biopsychosocial
kn-keyword=biopsychosocial
en-keyword=physician-scientist
kn-keyword=physician-scientist
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=98
end-page=107
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Clinical development of oncolytic virotherapy for cancer: From gene therapy to virotherapy
kn-title=がん治療用ウイルス製剤の創薬研究―遺伝子治療からウイルス療法への展開―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=藤原俊義
kn-aut-sei=藤原
kn-aut-mei=俊義
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学学術研究院医歯薬学域　消化器外科学
en-keyword=消化器がん
kn-keyword=消化器がん
en-keyword=テロメラーゼ
kn-keyword=テロメラーゼ
en-keyword=アデノウイルス
kn-keyword=アデノウイルス
en-keyword=食道癌
kn-keyword=食道癌
en-keyword=p53がん抑制遺伝子
kn-keyword=p53がん抑制遺伝子
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=95
end-page=97
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2024 Incentive Award of the Okayama Medical Association in Cardiovascular and Pulmonary Research (2024 Sunada Prize)
kn-title=令和６年度岡山医学会賞　胸部・循環研究奨励賞（砂田賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KawanaShinichi
en-aut-sei=Kawana
en-aut-mei=Shinichi
kn-aut-name=川名伸一
kn-aut-sei=川名
kn-aut-mei=伸一
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=岡山大学大学院医歯薬学総合研究科 呼吸器・乳腺内分泌外科学
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=92
end-page=94
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2024 Incentive Award of the Okayama Medical Association in General Medical Science (2024 Yuuki Prize)
kn-title=令和６年度岡山医学会賞　総合研究奨励賞（結城賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=YumotoTetsuya
en-aut-sei=Yumoto
en-aut-mei=Tetsuya
kn-aut-name=湯本哲也
kn-aut-sei=湯本
kn-aut-mei=哲也
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=岡山大学大学院医歯薬学総合研究科　救命救急・災害医学
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=89
end-page=91
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2024 Incentive Award of the Okayama Medical Association in Cancer Research (2024 Hayashibara Prize and Yamada Prize)
kn-title=令和６年度岡山医学会賞　がん研究奨励賞（林原賞・山田賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TakihiraShota
en-aut-sei=Takihira
en-aut-mei=Shota
kn-aut-name=棏平将太
kn-aut-sei=棏平
kn-aut-mei=将太
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=岡山大学大学院医歯薬学総合研究科　整形外科学
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3
article-no=
start-page=168
end-page=178
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Polyphyletic domestication and inter-lineage hybridization magnified genetic diversity of cultivated melon, Cucumis melo L.
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Melon accessions with diverse geographical origins were classified into large and small seed-types by length of seed at the boundary of 9 mm, and into five populations based on polymorphisms in the nuclear genome. They were further divided into three maternal lineages, Ia, Ib, and Ic, by polymorphisms in the chloroplast genome. By combining these three classifications, the Europe/US subsp. melo and the East Asian subsp. agrestis were characterized as [large seed, Ib, PopA1 or A2] and [small seed, Ia, PopB1 or B2], respectively, indicating nearly perfect divergence. In South Asia, in addition to the Europe/US and East Asian types, recombinant types between the two types were detected and accounted for 34.8% of South Asian melon. The finding of such an intermixed structure of genetic variation supported the Indian origin of Ia and Ib types. As to Momordica popular in South Asia, seed length was intermediate between the large and small seed-types, and chloroplast type was a mixture of Ia and Ib, suggesting its origin from the recombinant type. In Africa, three lineages of melon were distributed allopatrically and showed distinct divergence. Subsp. agrestis of the Ic type proved to be endemic to Africa, indicating its African origin.
en-copyright=
kn-copyright=

en-aut-name=TanakaKatsunori
en-aut-sei=Tanaka
en-aut-mei=Katsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShigitaGentaro
en-aut-sei=Shigita
en-aut-mei=Gentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=DungTran Phuong
en-aut-sei=Dung
en-aut-mei=Tran Phuong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NhiPhan Thi Phuong
en-aut-sei=Nhi
en-aut-mei=Phan Thi Phuong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakahashiMami
en-aut-sei=Takahashi
en-aut-mei=Mami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MondenYuki
en-aut-sei=Monden
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishidaHidetaka
en-aut-sei=Nishida
en-aut-mei=Hidetaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IshikawaRyuji
en-aut-sei=Ishikawa
en-aut-mei=Ryuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KatoKenji
en-aut-sei=Kato
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Faculty of Agriculture and Life Science, Hirosaki University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=4
en-affil=University of Agriculture and Forestry, Hue University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=8
en-affil=Faculty of Agriculture and Life Science, Hirosaki University
kn-affil=

affil-num=9
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=chloroplast genome
kn-keyword=chloroplast genome
en-keyword=Cucumis melo
kn-keyword=Cucumis melo
en-keyword=domestication
kn-keyword=domestication
en-keyword=genetic diversity
kn-keyword=genetic diversity
en-keyword=melon
kn-keyword=melon
en-keyword=molecular polymorphism
kn-keyword=molecular polymorphism
en-keyword=seed size
kn-keyword=seed size
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=8
article-no=
start-page=938
end-page=943
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: The final manufactured tisagenlecleucel product should meet the commercial product release specifications to ensure the quality in terms of safety, purity, identity, and potency. However, it may occasionally fail to meet these specifications due to the nature of patient-derived cells with variable properties as starting material and the complex manufacturing process. The final product that does not meet at least one of the commercial release specifications is referred to as “out-of-specification” (OOS). However, the benefit-risk profile of OOS tisagenlecleucel has not yet been fully elucidated.<br>
Aims: To evaluate the safety and efficacy of OOS tisagenlecleucel in Japanese patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL).<br>
Methods: This is a single-arm, open-label, multicenter phase 3b study (NCT04094311). Patients consistent with label indication were enrolled and followed-up for 3 months.<br>
Results: Of the 29 patients enrolled between December 2019 and May 2022 across 13 qualified sites in Japan, 28 received tisagenlecleucel, and of these, 23 had r/r DLBCL and 5 had r/r B-ALL. The primary reasons for OOS were low cell viability (15 of 24 batches) and low dose (8 of 23 batches) tisagenlecleucel in the r/r DLBCL group, and high dose (4 of 5 batches) in the r/r B-ALL group. In patients with r/r DLBCL, the grade 3 or 4 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in 3 and 1 patients, respectively. Response assessments were performed for 15 of 23 patients with r/r DLBCL: 6 achieved a complete response, and 1 achieved a partial response as the best response within 3 months.<br>
Conclusions: Despite the limited patient sample size, our findings affirm that the infusion of OOS tisagenlecleucel is a viable option, with no observed increase in toxicity and outcomes comparable to those of in-specification products in clinical and real-world studies.
en-copyright=
kn-copyright=

en-aut-name=KatoKoji
en-aut-sei=Kato
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KatoJun
en-aut-sei=Kato
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GotoHideki
en-aut-sei=Goto
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KobayashiTakeshi
en-aut-sei=Kobayashi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakahashiYoshiyuki
en-aut-sei=Takahashi
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SakaidaEmiko
en-aut-sei=Sakaida
en-aut-mei=Emiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HiramatsuHidefumi
en-aut-sei=Hiramatsu
en-aut-mei=Hidefumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamamotoMasahide
en-aut-sei=Yamamoto
en-aut-mei=Masahide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YoshiharaSatoshi
en-aut-sei=Yoshihara
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=AndoJun
en-aut-sei=Ando
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KohKatsuyoshi
en-aut-sei=Koh
en-aut-mei=Katsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=FukushimaKentaro
en-aut-sei=Fukushima
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IwamotoFumiko
en-aut-sei=Iwamoto
en-aut-mei=Fumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TiwariRanjan
en-aut-sei=Tiwari
en-aut-mei=Ranjan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital
kn-affil=

affil-num=2
en-affil=Division of Hematology, Department of Medicine, Keio University School of Medicine
kn-affil=

affil-num=3
en-affil=Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital
kn-affil=

affil-num=4
en-affil=Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Hematology, Chiba University Hospital
kn-affil=

affil-num=7
en-affil=Department of Pediatrics, Graduate School of Medicine, Kyoto University
kn-affil=

affil-num=8
en-affil=Department of Hematology, Institute of Science Tokyo Hospital
kn-affil=

affil-num=9
en-affil=Department of Hematology, Hyogo Medical University Hospital
kn-affil=

affil-num=10
en-affil=Department of Cell Therapy and Transfusion Medicine, Juntendo University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Hematology/Oncology, Saitama Children’s Medical Center
kn-affil=

affil-num=12
en-affil=Department of Hematology and Oncology, Osaka University Graduate School of Medicine
kn-affil=

affil-num=13
en-affil=Medical Affairs, Novartis Pharma K.K.
kn-affil=

affil-num=14
en-affil=Development Advance Quantitative Sciences, Novartis Healthcare Private Limited
kn-affil=

affil-num=15
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=
en-keyword=CAR-T
kn-keyword=CAR-T
en-keyword=DLBCL
kn-keyword=DLBCL
en-keyword=Out-of-specification
kn-keyword=Out-of-specification
en-keyword=Safety
kn-keyword=Safety
en-keyword=Tisagenlecleucel
kn-keyword=Tisagenlecleucel
END

start-ver=1.4
cd-journal=joma
no-vol=134
cd-vols=
no-issue=1
article-no=
start-page=24
end-page=30
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260101
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Preparation of brookite-type titanium dioxide particle layer on titanium surfaces via hydrothermal treatment and evaluation of in vitro apatite-forming ability
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In this study, we prepared a brookite-type titanium dioxide particle layer on the surface of titanium substrates via hydrothermal treatment in aqueous urea solutions containing sodium chloride (NaCl) and examined its in vitro apatite-forming ability. Increasing the urea concentration suppressed the formation of anatase-type titanium dioxide on the titanium substrate, forming a particle layer composed of pure brookite-type titanium dioxide. The size and packing density of brookite-type titanium dioxide particles formed on the titanium substrate increased with the NaCl concentration in a 7.0 mol·dm−3 urea solution. When titanium substrates hydrothermally treated in aqueous solutions of 7.0 mol·dm−3 urea and 2.0 mol·dm−3 NaCl were soaked in a simulated body fluid for various periods up to 7 d, the substrate surface was densely covered with hemispherical apatite particles (5.3 µm in diameter) within 3 d, indicating that the brookite-type titanium dioxide particle layer had an excellent apatite-forming ability comparable to that of the anatase-type titanium dioxide particle layer.
en-copyright=
kn-copyright=

en-aut-name=HayakawaSatoshi
en-aut-sei=Hayakawa
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakamotoYushi
en-aut-sei=Nakamoto
en-aut-mei=Yushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KojimaSeiya
en-aut-sei=Kojima
en-aut-mei=Seiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NagaokaNoriyuki
en-aut-sei=Nagaoka
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KataokaTakuya
en-aut-sei=Kataoka
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshiokaTomohiko
en-aut-sei=Yoshioka
en-aut-mei=Tomohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Faculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=4
en-affil=Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Dental School
kn-affil=

affil-num=5
en-affil=Faculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=6
en-affil=Faculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
en-keyword=Brookite-type titanium dioxide
kn-keyword=Brookite-type titanium dioxide
en-keyword=Hydrothermal treatment
kn-keyword=Hydrothermal treatment
en-keyword=Urea
kn-keyword=Urea
en-keyword=Sodium chloride
kn-keyword=Sodium chloride
en-keyword=Apatite-forming ability
kn-keyword=Apatite-forming ability
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251222
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Suppression of Na+ Uptake Via Apoplastic Flow by Chitosan in Rice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose: Chitosan enhances tolerance to salinity in rice. Apoplastic flow plays a crucial role in the accumulation of sodium (Na+) in rice under salinity. This study investigated the effects of exogenous chitosan on apoplastic flow and Na+ uptake in NaCl-treated rice seedlings. Methods: We employed an apoplastic tracer, trisodium salt of 8-hydroxy-1,3,6-pyrenetrisulphonic acid (PTS), in order to evaluate apoplastic flow in rice (Oryza sativa L., cv. Nipponbare) seedlings that were hydroponically grown in the solution containing NaCl (0 and 25 mM), and chitosan (0 mg L− 1, 10 mg L− 1, and 50 mg L− 1). Results: Application of 25 mM NaCl significantly increased PTS uptake and Na+ content in shoots but did not affect K+ content, resulting in a lower K+/Na+ ratio although 25 mM NaCl did not affect the seedling growth. The application of chitosan suppressed Na+-enhanced PTS uptake and Na+ accumulation in shoots without affecting the K+ content, which led to a higher K+/Na+ ratio. Moreover, chitosan did not affect the reducing sugar content or electrical conductivity in the solution containing NaCl. Conclusions: These results suggest that application of chitosan suppressed Na+-enhanced apoplastic flow to reduce Na+ uptake in rice seedlings.
en-copyright=
kn-copyright=

en-aut-name=ZhaoMaoxiang
en-aut-sei=Zhao
en-aut-mei=Maoxiang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=GalibMd. Asadulla Al
en-aut-sei=Galib
en-aut-mei=Md. Asadulla Al
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakamuraToshiyuki
en-aut-sei=Nakamura
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakamuraYoshimasa
en-aut-sei=Nakamura
en-aut-mei=Yoshimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HiraiYoshihiko
en-aut-sei=Hirai
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakashimaYoshitaka
en-aut-sei=Nakashima
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MunemasaShintaro
en-aut-sei=Munemasa
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MoriIzumi C.
en-aut-sei=Mori
en-aut-mei=Izumi C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MurataYoshiyuki
en-aut-sei=Murata
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=6
en-affil=
kn-affil=

affil-num=7
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=8
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=9
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=
en-keyword=Rice · Salinity
kn-keyword=Rice · Salinity
en-keyword=Apoplastic flow
kn-keyword=Apoplastic flow
en-keyword=Trisodium-8-hydroxy-1,3,6-pyrenetrisulphonic acid
kn-keyword=Trisodium-8-hydroxy-1,3,6-pyrenetrisulphonic acid
en-keyword=Chitosan
kn-keyword=Chitosan
END

start-ver=1.4
cd-journal=joma
no-vol=25
cd-vols=
no-issue=1
article-no=
start-page=1908
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251125
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of Streptococcus mutans strains possessing genes encoding collagen-binding proteins in the Japanese population
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Streptococcus mutans harbors collagen-binding protein genes, namely cnm and cbm, which are implicated in its virulence and pathogenicity in both oral and extraoral infections. Although both genes were initially identified in S. mutans isolated from Japanese populations, their geographical prevalence, distribution, and genetic relatedness within Japan remain largely unexplored. This study investigates the prevalence of S. mutans strains carrying cnm and cbm genes across Japan, correlates these findings with clinical data, and analyzes the genetic relatedness of cnm-positive and cnm-negative strains using multilocus sequence typing (MLST).<br>
Methods Dental plaque specimens were collected from 1248 individuals from eight Japanese cities (Hiroshima, Fukuoka, Nagasaki, Niigata, Okayama, Osaka, Tokushima, and Tokyo) and plated on selective medium for S. mutans isolation. S. mutans was confirmed in 523 subjects by colony morphology and PCR using species-specific primers, and the presence of the cnm and cbm genes was determined by PCR with gene-specific primers. Demographic (age, sex) and oral examination (caries prevalence, caries experience, number of teeth) data were recorded. MLST was employed to genotype selected cnm-positive and cnm-negative S. mutans strains to assess their clonal relationships.<br>
Results Among 523 subjects possessing S. mutans (aged 3–90 years), we detected cnm-positive strains in all cities; specifically, the prevalence ranged from 5.5% in Okayama to 25.0% in Tokushima. In contrast, cbm-positive strains were less common and undetectable in some regions. Furthermore, subjects harboring cnm-positive S. mutans were significantly older (p = 0.002) and had higher caries prevalence and experience (p < 0.001). MLST revealed evolutionary relationships among cnm-positive strains across the cities but no discernible region-specific clustering. Clonal relationships partially reflected cnm gene distribution, particularly for exclusively cnm-positive or cnm-negative clonal complexes, but inconsistencies involving serotypes and cnm presence within some clonal complexes and sequence types were also noted.<br>
Conclusions The cnm-positive S. mutans strains are widely distributed throughout Japan and are associated with increased age and caries burden. Although core genome analysis revealed some clonal patterns, the non-uniform distribution of the non-core cnm gene is likely influenced by horizontal gene transfer, providing S. mutans with adaptive advantages irrespective of its core genetic background or serotype.
en-copyright=
kn-copyright=

en-aut-name=OkudaMakoto
en-aut-sei=Okuda
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SuehiroYuto
en-aut-sei=Suehiro
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LapirattanakulJinthana
en-aut-sei=Lapirattanakul
en-aut-mei=Jinthana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaShuhei
en-aut-sei=Naka
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=Matsumoto-NakanoMichiyo
en-aut-sei=Matsumoto-Nakano
en-aut-mei=Michiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NomuraRyota
en-aut-sei=Nomura
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OkawaRena
en-aut-sei=Okawa
en-aut-mei=Rena
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakanoKazuhiko
en-aut-sei=Nakano
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka
kn-affil=

affil-num=2
en-affil=Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka
kn-affil=

affil-num=3
en-affil=Department of Oral Microbiology, Faculty of Dentistry, Mahidol University
kn-affil=

affil-num=4
en-affil=Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=7
en-affil=Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka
kn-affil=

affil-num=8
en-affil=Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka
kn-affil=
en-keyword=Collagen-binding protein gene
kn-keyword=Collagen-binding protein gene
en-keyword=cnm gene
kn-keyword=cnm gene
en-keyword=cbm gene
kn-keyword=cbm gene
en-keyword=Japan
kn-keyword=Japan
en-keyword=Multilocus sequence typing
kn-keyword=Multilocus sequence typing
en-keyword=Serotype
kn-keyword=Serotype
en-keyword=Streptococcus mutans
kn-keyword=Streptococcus mutans
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=103457
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Efficient variant phasing utilizing a replication cycle reaction system
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose: When 2 heterozygous variants are detected in autosomal recessive disease genes, determining whether they are in cis or in trans is essential. Subcloning polymerase chain reaction products or complementary DNA is limited by variant distance (up to 10 kb) and complementary DNA availability. Droplet digital polymerase chain reaction, effective up to 100 kb, faces probe design challenges. We used replication cycle reaction (RCR), which replicates large DNA fragments based on E. coli chromosome replication, to phase widely spaced heterozygous variants.<br>
Methods: Circular DNA molecules were formed by ligating CRISPR/Cas9-cleaved genomic fragments with an oriC-AmpR cassette, then amplified by RCR. Using a genomic DNA (gDNA) sample that is previously analyzed by long-read sequencing, we optimized reaction conditions (including gDNA to oriC-AmpR cassette ratios) and validated phasing accuracy via electrophoresis and Sanger sequencing. Finally, we applied this method to 7 patients harboring 2 heterozygous pathogenic variants (4.3-152 kb apart).<br>
Results: RCR amplified genomic regions up to 104 kb. Lower gDNA-to-cassette ratios favored monoallelic amplification, enabling straightforward phasing, whereas higher ratios yielded biallelic products requiring transformation-based allele separation. For variants 152 kb apart, an intervening single-nucleotide variant enabled phased reconstruction. Ultimately, RCR confirmed compound heterozygosity in all 7 patients.<br>
Conclusion: This method effectively phases multiple heterozygous variants across large genomic distances.
en-copyright=
kn-copyright=

en-aut-name=MitsutakeAkihiko
en-aut-sei=Mitsutake
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IshiuraHiroyuki
en-aut-sei=Ishiura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsukawaTakashi
en-aut-sei=Matsukawa
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MitsuiJun
en-aut-sei=Mitsui
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsujiShoji
en-aut-sei=Tsuji
en-aut-mei=Shoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TodaTatsushi
en-aut-sei=Toda
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=2
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=4
en-affil=Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=5
en-affil=Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=6
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=
en-keyword=Autosomal recessive inheritance
kn-keyword=Autosomal recessive inheritance
en-keyword=Compound heterozygosity
kn-keyword=Compound heterozygosity
en-keyword=Replication cycle reaction
kn-keyword=Replication cycle reaction
en-keyword=Variant phasing
kn-keyword=Variant phasing
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=1
article-no=
start-page=100217
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260428
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=In memoriam, Nobuhiko Matsuo, 1931-2025
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MatsuoToshihiko
en-aut-sei=Matsuo
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Healthcare Science, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Department of Ophthalmology, Okayama University Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=94
cd-vols=
no-issue=3
article-no=
start-page=401
end-page=407
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of Storage Temperature and a Sugar-ester Edible Coating on Postharvest Quality and Storage Life of ‘Fuyu’ Persimmon (Diospyros kaki Thunb.)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In ‘Fuyu’ persimmons (Diospyros kaki Thunb.), crunchiness is a preferred postharvest attribute among both distributors and consumers. The present study first examined softening characteristics during storage at 0, 5, 10, 15, 20, and 25°C. Fruit stored at 0°C remained firm for 84 d, while that stored at 5°C had a 100% softening rate within 35 d. At 10 and 15°C, over 70% of fruit softened within 49 d and 63 d, respectively. The softening rate was relatively slower at 20 and 25°C, with only 27% softened fruit after 56 d at 25°C. The potential of a newly developed sugar-ester (SE) edible coating to delay fruit softening and maintain postharvest quality was then assessed during storage at 0 and 25°C. Uncoated fruit stored at 0°C for 56 d developed chilling injury (CI) symptoms (rapid fruit softening and peel browning) within 2 d of rewarming at 20°C. These CI symptoms were notably mitigated in SE-coated fruit. At 25°C, SE coating also delayed fruit softening and peel color change in addition to reducing fruit shrinkage. In conclusion, in ‘Fuyu’ persimmons ambient temperature (20–25°C) storage in combination with an edible SE coating is recommended for the high demand Christmas and new year seasons and 0°C storage with an edible SE coating is suitable for longer storage and distribution.
en-copyright=
kn-copyright=

en-aut-name=MuqadasMaqsood
en-aut-sei=Muqadas
en-aut-mei=Maqsood
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MitaloOscar W.
en-aut-sei=Mitalo
en-aut-mei=Oscar W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OhashiKyohei
en-aut-sei=Ohashi
en-aut-mei=Kyohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OtsukiTakumi
en-aut-sei=Otsuki
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YanoChikara
en-aut-sei=Yano
en-aut-mei=Chikara
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HejaziZiaurrahman
en-aut-sei=Hejazi
en-aut-mei=Ziaurrahman
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HiraNatsuki
en-aut-sei=Hira
en-aut-mei=Natsuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UshijimaKoichiro
en-aut-sei=Ushijima
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KuboYasutaka
en-aut-sei=Kubo
en-aut-mei=Yasutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Graduate School of Environmental, Life Science, Natural Science and Technology Okayama University
kn-affil=

affil-num=2
en-affil=Faculty of Life and Environmental Sciences, University of Tsukuba
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental, Life Science, Natural Science and Technology Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental, Life Science, Natural Science and Technology Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental, Life Science, Natural Science and Technology Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Agriculture, University of Miyazaki
kn-affil=

affil-num=7
en-affil=Shiga R&amp;D Center, Mitsubishi Chemical Corporation
kn-affil=

affil-num=8
en-affil=Graduate School of Environmental, Life Science, Natural Science and Technology Okayama University
kn-affil=

affil-num=9
en-affil=Graduate School of Environmental, Life Science, Natural Science and Technology Okayama University
kn-affil=
en-keyword=chilling injury
kn-keyword=chilling injury
en-keyword=long-term storage
kn-keyword=long-term storage
en-keyword=postharvest life
kn-keyword=postharvest life
en-keyword=shrinkage
kn-keyword=shrinkage
en-keyword=softening
kn-keyword=softening
END

start-ver=1.4
cd-journal=joma
no-vol=198
cd-vols=
no-issue=1
article-no=
start-page=kiaf196
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250430
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Role of polar localization of the silicon transporter OsLsi1 in metalloid uptake by rice roots
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Low silicon (Si) rice 1 (OsLsi1) is a key transporter mediating Si uptake in rice (Oryza sativa). It is polarly localized at the distal side of the root exodermis and endodermis. Although OsLsi1 is also permeable to other metalloids, such as boron (B), germanium (Ge), arsenic (As), antimony (Sb), and selenium (Se), the role of its polar localization in the uptake of these metalloids remains unclear. In this study, we investigated the role of OsLsi1 polar localization in metalloid uptake by examining transgenic rice plants expressing polarly or nonpolarly localized OsLsi1 variants. Loss of OsLsi1 polar localization resulted in decreased accumulation of Ge, B, and As in shoots but increased Sb accumulation, while Se accumulation remained unaffected under normal conditions. Experiments with varying B concentrations revealed that B uptake is significantly lower at low B concentrations (0.3 to 3 μm) but higher at high B concentrations (300 μm) in plants expressing nonpolarly localized OsLsi1, despite the similar B permeability of both OsLsi1 variants in Xenopus oocytes and their comparable protein abundance in roots. Additionally, the loss of OsLsi1 polarity did not affect the abundance, localization, or high B-induced degradation of the borate transporter 1 (OsBOR1), an efflux transporter that cooperates with OsLsi1 for B uptake. Taken together, our findings demonstrate that the polar localization of OsLsi1 plays a critical role in regulating metalloid uptake, depending on the presence or absence of efflux transporters cooperating with OsLsi1.
en-copyright=
kn-copyright=

en-aut-name=KonishiNoriyuki
en-aut-sei=Konishi
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=Mitani-UenoNamiki
en-aut-sei=Mitani-Ueno
en-aut-mei=Namiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MaJian Feng
en-aut-sei=Ma
en-aut-mei=Jian Feng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=2
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=3
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=2
article-no=
start-page=140
end-page=115
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251223
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Paul Oertmanns “Vorteilsausgleichung” und die öffentlichrechtliche Entschädigung
kn-title=Paul Oertmann のVorteilsausgleichung と損失補償
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=HamaguchiK. 
en-aut-sei=Hamaguchi
en-aut-mei=K. 
kn-aut-name=濱口弘太郎
kn-aut-sei=濱口
kn-aut-mei=弘太郎
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院法務学域
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=457
end-page=461
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Exacerbation of Proteinuria in a Patient with Behçet’s Disease and IgA Nephropathy Following Colchicine Discontinuation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This case involves a 23-year-old male who was diagnosed with Behçet’s disease 5 years ago and managed with colchicine. Two months ago, he underwent renal biopsy due to abnormal urinalysis and kidney dysfunction, leading to a diagnosis of IgA nephropathy. He subsequently underwent tonsillectomy followed by glucocorticoid pulse therapy. However, after the tonsillectomy, discontinuing colchicine led to increased proteinuria, despite the glucocorticoid pulse therapy. Upon reintroducing colchicine, urinary protein excretion decreased, achieving incomplete remission. These findings suggest that colchicine may be effective in decreasing proteinuria in patients with Behçet’s disease complicated by IgA nephropathy.
en-copyright=
kn-copyright=

en-aut-name=AsakawaTomohiko
en-aut-sei=Asakawa
en-aut-mei=Tomohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UchidaHaruhito A.
en-aut-sei=Uchida
en-aut-mei=Haruhito A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatayamaYu
en-aut-sei=Katayama
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakurabuYoshimasa
en-aut-sei=Sakurabu
en-aut-mei=Yoshimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatayamaKatsuyoshi
en-aut-sei=Katayama
en-aut-mei=Katsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OnishiYasuhiro
en-aut-sei=Onishi
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=Matsuoka-UchiyamaNatsumi
en-aut-sei=Matsuoka-Uchiyama
en-aut-mei=Natsumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakeuchiHidemi
en-aut-sei=Takeuchi
en-aut-mei=Hidemi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanakaKeiko
en-aut-sei=Tanaka
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TsujiKenji
en-aut-sei=Tsuji
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=UmebayashiRyoko
en-aut-sei=Umebayashi
en-aut-mei=Ryoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakemotoRika
en-aut-sei=Takemoto
en-aut-mei=Rika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Behçet’s disease
kn-keyword=Behçet’s disease
en-keyword=IgA nephropathy
kn-keyword=IgA nephropathy
en-keyword=colchicine
kn-keyword=colchicine
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=451
end-page=455
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Recurrence of FVIII Inhibitor during Surgery in a Patient with Severe Hemophilia A Receiving Emicizumab Prophylaxis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Emicizumab, a bispecific monoclonal antibody, benefits patients with severe hemophilia A. It alters laboratory assessments of coagulation activity, requiring anti-idiotype monoclonal antibodies for accurate monitoring. A 64-year-old man, receiving emicizumab regularly, was admitted for laminoplasty. We planned to use FVIII replacement during the perioperative period after confirming the disappearance of inhibitors, monitoring coagulation activity with anti-idiotype monoclonal antibodies. Activated partial thromboplastin time was prolonged on postoperative day 2, prompting an immediate switch to eptacog alfa. The patient recovered without bleeding. This case underscores the necessity of anti-idiotype monoclonal antibodies for accurate monitoring.
en-copyright=
kn-copyright=

en-aut-name=HagiharaMoe
en-aut-sei=Hagihara
en-aut-mei=Moe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SeikeKeisuke
en-aut-sei=Seike
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HayashinoKenta
en-aut-sei=Hayashino
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YasuharaTakao
en-aut-sei=Yasuhara
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KinKyohei
en-aut-sei=Kin
en-aut-mei=Kyohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HirataYuichi
en-aut-sei=Hirata
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KobayashiHiroki
en-aut-sei=Kobayashi
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KitamuraWataru
en-aut-sei=Kitamura
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujiwaraHideaki
en-aut-sei=Fujiwara
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=AsadaNoboru
en-aut-sei=Asada
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Neurological Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Neurological Surgery, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Neurological Surgery, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Division of Transfusion and Cell Therapy, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=
en-keyword=emicizumab
kn-keyword=emicizumab
en-keyword=eptacog alfa
kn-keyword=eptacog alfa
en-keyword=hemophilia A
kn-keyword=hemophilia A
en-keyword=inhibitor
kn-keyword=inhibitor
en-keyword=anti-idiotype monoclonal antibodies to emicizumab
kn-keyword=anti-idiotype monoclonal antibodies to emicizumab
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=421
end-page=429
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of Thoron Inhalation and Cyclosporin A Treatment on Dextran Sulfate Sodium-Induced Oxidative Damage in Mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Radon (222Rn; Rn) and thoron (220Rn; Tn) inhalation have been reported to enhance antioxidant activity in various organs. However, the effects of Tn on the colon have not been investigated. This study aimed to clarify the effects of Tn inhalation, alone and in combination with cyclosporin A (CsA), on dextran sulfate sodium (DSS)-induced colitis, and the accompanying oxidative stress, in mice. Male BALB/c mice were subjected to continuous 8-day Tn inhalation (c-Tn, 533±128 Bq/m3) or alternate-day Tn inhalation over the same period (f-Tn, 577±63Bq/m3), followed by treatment with 3% DSS and either CsA or vehicle for 7 days. Although the disease activity index (DAI) decreased significantly by day 2 in the c-Tn group, scores remained significantly higher than those in the f-Tn group. In the c-Tn group, superoxide dismutase and catalase activity in the colon were significantly elevated compared with those in sham controls. Thus, DSS-induced damage was effectively inhibited in the earlier stages by the c-Tn mode of inhalation than by the f-Tn mode. These findings suggest that continuous Tn inhalation more effectively attenuated early colitis symptoms than alternate-day inhalation, potentially through upregulation of antioxidant defenses. Tn and CsA showed no combined effects.
en-copyright=
kn-copyright=

en-aut-name=TanakaAyumi
en-aut-sei=Tanaka
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NaoeShota
en-aut-sei=Naoe
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakenakaReiju
en-aut-sei=Takenaka
en-aut-mei=Reiju
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KanzakiNorie
en-aut-sei=Kanzaki
en-aut-mei=Norie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SakodaAkihiro
en-aut-sei=Sakoda
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamaokaKiyonori
en-aut-sei=Yamaoka
en-aut-mei=Kiyonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KataokaTakahiro
en-aut-sei=Kataoka
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Ningyo-toge Environmental Engineering Center, Japan Atomic Energy Agency
kn-affil=

affil-num=5
en-affil=Ningyo-toge Environmental Engineering Center, Japan Atomic Energy Agency
kn-affil=

affil-num=6
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=
en-keyword=thoron
kn-keyword=thoron
en-keyword=DSS
kn-keyword=DSS
en-keyword=antioxidant activity
kn-keyword=antioxidant activity
en-keyword=CsA
kn-keyword=CsA
en-keyword=colon
kn-keyword=colon
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=405
end-page=412
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration in Patients Aged 85 or Older
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated the treatment outcomes of patients aged ≥85 years with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) therapy using either treat-and-extend (TAE) or pro re nata (PRN) regimens for 1 year in real-world clinical practice. Eighty-five eyes from 85 patients were included. Among them, types 1, 2, and 3 macular neovascularization and polypoidal choroidal vasculopathy were present in 27.1%, 17.6%, 18.8%, and 36.5%, respectively. TAE and PRN regimens were used in 43.5% and 56.5% of patients, respectively. At baseline, the PRN group was older and had worse best-corrected visual acuity (BCVA), greater central retinal thickness, and more intraretinal fluid than the TAE group. In the TAE group, the mean number of injections was 7.6, BCVA improved significantly, and all retinal fluid rates decreased. In the PRN group, the mean number of injections was 3.9, BCVA remained unchanged, and the rates of macular fibrosis and atrophy increased. No serious adverse events were observed in either group. Anti-VEGF therapy was safe for patients aged ≥ 85 years with nAMD, and the TAE regimen effectively improved BCVA in this population. BCVA remained unchanged in the PRN-treated patients, with baseline disease severity and/or undertreatment potentially influencing the outcomes.
en-copyright=
kn-copyright=

en-aut-name=OuchiChihiro
en-aut-sei=Ouchi
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=Morizane HosokawaMio
en-aut-sei=Morizane Hosokawa
en-aut-mei=Mio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraShuhei
en-aut-sei=Kimura
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShiodeYusuke
en-aut-sei=Shiode
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MatobaRyo
en-aut-sei=Matoba
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MoritaTetsuro
en-aut-sei=Morita
en-aut-mei=Tetsuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MorizaneYuki
en-aut-sei=Morizane
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=anti-vascular endothelial growth factor therapy
kn-keyword=anti-vascular endothelial growth factor therapy
en-keyword=neovascular age-related macular degeneration
kn-keyword=neovascular age-related macular degeneration
en-keyword=age
kn-keyword=age
en-keyword=treat-and-extend
kn-keyword=treat-and-extend
en-keyword=pro re nata
kn-keyword=pro re nata
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=11
article-no=
start-page=1178
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251030
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Sensory Modality-Dependent Interplay Between Updating and Inhibition Under Increased Working Memory Load: An ERP Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: Working memory (WM) performance relies on the coordination of updating and inhibition functions within the central executive system. However, their interaction under varying cognitive loads, particularly across sensory modalities, remains unclear. Methods: This study examined how sensory modality modulates flanker interference under increasing WM loads. Twenty-two participants performed a visual n-back task at three load levels (1-, 2-, and 3-back) while ignoring visual (within-modality) or auditory (cross-modality) flankers. Results: Behaviorally, increased WM load (2- and 3-back) led to reduced accuracy (AC) and prolonged reaction times (RTs) in both conditions. In addition, flanker interference was observed under the 2-back condition in both the visual within-modality (VM) and audiovisual cross-modality (AVM) tasks. However, performance impairment emerged at a lower load (2-back) in the VM condition, whereas in the AVM condition, it only emerged at the highest load (3-back). Significant performance impairment in the AVM condition occurred at higher WM loads, suggesting that greater WM load is required to trigger interference. Event-related potential (ERP) results showed that N200 amplitudes increased significantly for incongruent flankers under the highest WM load (3-back) in the visual within-modality condition, reflecting greater inhibitory demands. In the cross-modality condition, enhanced N200 was not observed across all loads and even reversed at low load (1-back). Moreover, the results also showed that P300 amplitude increased with load in the within-modality condition but decreased in the cross-modality condition. Conclusions: These results demonstrated that the interaction between updating and inhibition is shaped by both WM load and sensory modality, further supporting a sensory modality-specific resource allocation mechanism. The cross-modality configurations may enable more efficient distribution of cognitive resources under high load, reducing interference between concurrent executive demands.
en-copyright=
kn-copyright=

en-aut-name=LuoYuxi
en-aut-sei=Luo
en-aut-mei=Yuxi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=GuoAo
en-aut-sei=Guo
en-aut-mei=Ao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WuJinglong
en-aut-sei=Wu
en-aut-mei=Jinglong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YangJiajia
en-aut-sei=Yang
en-aut-mei=Jiajia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Psychology, Institute of Education, China West Normal University
kn-affil=

affil-num=3
en-affil=Faculty of Biomedical Engineering, Shenzhen University of Advanced Technology
kn-affil=

affil-num=4
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
en-keyword=workingmemory load
kn-keyword=workingmemory load
en-keyword=attentional resource allocation
kn-keyword=attentional resource allocation
en-keyword=modality-specific interference
kn-keyword=modality-specific interference
en-keyword=inhibitory control
kn-keyword=inhibitory control
en-keyword=executive function
kn-keyword=executive function
en-keyword=sensory modality
kn-keyword=sensory modality
END

start-ver=1.4
cd-journal=joma
no-vol=22
cd-vols=
no-issue=12
article-no=
start-page=3199
end-page=3207
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Virtual endoscopic imaging of the heart using photon-counting detector computed tomography for electrophysiologists
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MoritaHiroshi
en-aut-sei=Morita
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AsadaSaori
en-aut-sei=Asada
en-aut-mei=Saori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyamotoMasakazu
en-aut-sei=Miyamoto
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakagawaKoji
en-aut-sei=Nakagawa
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NagaseSatoshi
en-aut-sei=Nagase
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MorimotoYoshimasa
en-aut-sei=Morimoto
en-aut-mei=Yoshimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawadaSatoshi
en-aut-sei=Kawada
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WadaTadashi
en-aut-sei=Wada
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MasudaTakuro
en-aut-sei=Masuda
en-aut-mei=Takuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=UeokaAkira
en-aut-sei=Ueoka
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TohNorihisa
en-aut-sei=Toh
en-aut-mei=Norihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NishiiNobuhiro
en-aut-sei=Nishii
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Therapeutics, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=5
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=6
en-affil=Department of Cardiovascular Medicine, Fukuyama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, Kochi Health Science Center
kn-affil=

affil-num=8
en-affil=Department of Cardiology, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=10
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=11
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=12
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=

affil-num=13
en-affil=Department of Cardiovascular Therapeutics, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry
kn-affil=
en-keyword=Photon-counting detector computed tomography
kn-keyword=Photon-counting detector computed tomography
en-keyword=Endoscopic view
kn-keyword=Endoscopic view
en-keyword=False tendon
kn-keyword=False tendon
en-keyword=Ablation
kn-keyword=Ablation
en-keyword=Anatomy
kn-keyword=Anatomy
END

start-ver=1.4
cd-journal=joma
no-vol=114
cd-vols=
no-issue=3
article-no=
start-page=117209
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Molecular epidemiological investigation of the carbapenemase-producing Enterobacterales isolates in Okayama prefecture, Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated the genetic characteristics of non-IMP type carbapenemase-producing Enterobacterales isolates detected in Japan. The isolates were found to carry diverse plasmids with high sequence similarity to those previously reported in other countries, underscoring the critical imperative for comprehensive nationwide epidemiological surveillance for the silent pandemic of the nightmare pathogen.
en-copyright=
kn-copyright=

en-aut-name=TsujiShuma
en-aut-sei=Tsuji
en-aut-mei=Shuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GotohKazuyoshi
en-aut-sei=Gotoh
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IioKoji
en-aut-sei=Iio
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SatoMayu
en-aut-sei=Sato
en-aut-mei=Mayu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InoueYasurou
en-aut-sei=Inoue
en-aut-mei=Yasurou
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SakitaSayaka
en-aut-sei=Sakita
en-aut-mei=Sayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FudeyasuTomoko
en-aut-sei=Fudeyasu
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OtsukaFumio
en-aut-sei=Otsuka
en-aut-mei=Fumio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=2
en-affil=Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=4
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Clinical Laboratory, Okayama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Clinical Laboratory, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Clinical Laboratory, Okayama Rosai Hospital
kn-affil=

affil-num=8
en-affil=Department of Clinical Laboratory, Microbiology Division, Tsuyama Chuo Hospital
kn-affil=

affil-num=9
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=Antimicrobial resistance
kn-keyword=Antimicrobial resistance
en-keyword=Carbapenemase-producing Enterobacterales
kn-keyword=Carbapenemase-producing Enterobacterales
en-keyword=New Delhi metallo-β-lactamase
kn-keyword=New Delhi metallo-β-lactamase
en-keyword=Klebsiella pneumoniae carbapenemase
kn-keyword=Klebsiella pneumoniae carbapenemase
en-keyword=Genomic surveillance
kn-keyword=Genomic surveillance
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=14
article-no=
start-page=4918
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250711
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Symptomatic Trends and Time to Recovery for Long COVID Patients Infected During the Omicron Phase
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Since the pathophysiology of long COVID is not yet fully understood, there are no specific methods for its treatment; however, its individual symptoms can currently be treated. Long COVID is characterized by symptoms that persist at least 2 to 3 months after contracting COVID-19, although it is difficult to predict how long such symptoms may persist. Methods: In the present study, 774 patients who first visited our outpatient clinic during the Omicron period from February 2022 to October 2024 were divided into two groups: the early recovery (ER) group (370 cases; 47.8%), who recovered in less than 180 days (median 33 days), and the persistent-symptom (PS) group (404 cases; 52.2%), who had symptoms that persisted for more than 180 days (median 437 days). The differences in clinical characteristics between these two groups were evaluated. Results: Although the median age of the two groups did not significantly differ (40 and 42 in ER and PS groups, respectively), the ratio of female patients was significantly higher in the PS group than the ER group (59.4% vs. 47.3%). There were no significant differences between the two groups in terms of the period after infection, habits, BMI, severity of COVID-19, and vaccination history. Notably, at the first visit, female patients in the PS group had a significantly higher rate of complaints of fatigue, insomnia, memory disturbance, and paresthesia, while male patients in the PS group showed significantly higher rates of fatigue and headache complaints. Patients with more than three symptoms at the first visit were predominant in the PS groups in both genders. Notably, one to two symptoms were predominant in the male ER group, while two to three symptoms were mostly reported in the female PS group. Moreover, the patients in the PS group had significantly higher scores for physical and mental fatigue and for depressive symptoms. Conclusions: Collectively, these results suggest that long-lasting long COVID is related to the number of symptoms and presents gender-dependent differences.
en-copyright=
kn-copyright=

en-aut-name=AkiyamaHiroshi
en-aut-sei=Akiyama
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakuradaYasue
en-aut-sei=Sakurada
en-aut-mei=Yasue
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HondaHiroyuki
en-aut-sei=Honda
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsudaYui
en-aut-sei=Matsuda
en-aut-mei=Yui
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OtsukaYuki
en-aut-sei=Otsuka
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TokumasuKazuki
en-aut-sei=Tokumasu
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakanoYasuhiro
en-aut-sei=Nakano
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakaseRyosuke
en-aut-sei=Takase
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OmuraDaisuke
en-aut-sei=Omura
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=UedaKeigo
en-aut-sei=Ueda
en-aut-mei=Keigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OtsukaFumio
en-aut-sei=Otsuka
en-aut-mei=Fumio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=11
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=fatigue
kn-keyword=fatigue
en-keyword=headache
kn-keyword=headache
en-keyword=insomnia
kn-keyword=insomnia
en-keyword=long COVID
kn-keyword=long COVID
en-keyword=Omicron variants
kn-keyword=Omicron variants
en-keyword=recovery
kn-keyword=recovery
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=35
article-no=
start-page=9749
end-page=9752
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250826
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Synthesis of a Pseudocytidine Nucleoside to Form a Stable and Selective Base Pair with Iso-guanosine in RNA
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Non-natural base pair formation provides insight into new functions of nucleic acids. Therefore, various artificial base pairs have been developed in both DNA and RNA. In this work, we successfully synthesized pseudocytidine from commercially available pseudouridine to form base pairs with isoguanine, also known as 2-OH-adenine, in RNA. Measurement of the melting temperature with the base pair incorporated at the center of a 13-mer RNA showed the highest value for the ψ-rC and iso-rG (2-OH-rA) base pair. This base pair formation exhibited a high melting temperature regardless of whether it was incorporated into the pyrimidine or purine strand, indicating that it can form a stable and selective duplex RNA.
en-copyright=
kn-copyright=

en-aut-name=MiyaharaRyo
en-aut-sei=Miyahara
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TaniguchiYosuke
en-aut-sei=Taniguchi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Graduate School of Pharmaceutical Sciences, Kyushu University
kn-affil=

affil-num=2
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=3
article-no=
start-page=e70101
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202503
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Synthesis of Oligodeoxynucleotide Containing Pseudo‐Deoxycytidine and Its Triphosphate Derivative
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This article describes a detailed synthetic protocol for the preparation of oligodeoxynucleotide (ODN) containing pseudo-deoxycytidine (ψdC) and its triphosphate derivative (ψdCTP). These molecules were synthesized as novel compounds that recognize iso-2'-deoxyguanosine (iso-dG) in DNA. Iso-dG is one of the tautomers of 2-hydroxy-2'-deoxyadenosine (2-OH-dA), which is known as an oxidatively damaged nucleobase, and its selective recognition in DNA is expected to play a very important role in the diagnosis and pathogenesis of diseases. The hydroxyl groups of the known glycal compound were protected with silyl groups, and then coupled with 5-iodouracil under Mizorogi-Heck reaction conditions, yielding ψdU after desilylation and diastereoselective reduction. The endocyclic amino group of ψdU was protected by the benzyl group. Subsequently, the carbonyl group at the 6-position of the nucleobase was activated and converted to an amino group through treatment with aqueous ammonia. The benzyl group was removed, and the exocyclic amino group was protected with a benzoyl group. On one hand, the silyl groups at the 3’ and 5’ positions were deprotected, converted into a phosphoramidite unit, and incorporated into an ODN. On the other hand, the hydroxyl group at the 5’ position was selectively deprotected and then directly converted into the triphosphate using Van Boom's reagent under acidic conditions. © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC.
en-copyright=
kn-copyright=

en-aut-name=MiyaharaRyo
en-aut-sei=Miyahara
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TaniguchiYosuke
en-aut-sei=Taniguchi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Graduate School of Pharmaceutical Sciences, Kyushu University
kn-affil=

affil-num=2
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=artificial nucleic acid
kn-keyword=artificial nucleic acid
en-keyword=2-hydroxy-2’-deoxyadenosine
kn-keyword=2-hydroxy-2’-deoxyadenosine
en-keyword=2-OH-dA
kn-keyword=2-OH-dA
en-keyword=pseudo-dC
kn-keyword=pseudo-dC
en-keyword=pseudo-deoxycytidine
kn-keyword=pseudo-deoxycytidine
en-keyword=tautomeric structure
kn-keyword=tautomeric structure
en-keyword=unnatural base pair
kn-keyword=unnatural base pair
END

start-ver=1.4
cd-journal=joma
no-vol=177
cd-vols=
no-issue=4
article-no=
start-page=e70398
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202507
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Comparative Transcriptome Reveals ART1-Dependent Regulatory Pathways for Fe Toxicity Response in Rice Roots
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Iron (Fe) is an essential element for plants, but an excess supply can have detrimental effects. Fe toxicity induces complex physiological and genetic responses, and due to this complexity, the knowledge of transcriptional regulatory mechanisms under Fe toxicity is very limited. Previous studies suggested that plant responses to excess Fe involve oxidative stress caused by reactive oxygen species (ROS), which itself causes transcriptional changes. We hypothesized that dissecting these complex responses could lead to the identification of a novel factor and conducted a comparative transcriptome analysis using roots of rice plants exposed to nutrient solutions containing 1 or 5 mM of hydrogen peroxide (a major form of ROS) or 300 mg L−1 of Fe (as FeSO4). Genes induced by hydrogen peroxide overlapped with 62%, 49%, and 30% of Fe toxicity-upregulated genes at 3 h, 1 day, and 3 days following treatment initiation. Subsequent gene co-expression analyses classified genes into 21 groups with varying responsiveness to ROS and Fe toxicity. Genes in group 15 were specifically upregulated by Fe toxicity and overlapped significantly with aluminum (Al)-inducible genes and target genes of the Zn-finger transcription factor, ART1, which regulates Al response in rice roots. Additional experiments using the art1 knock-out mutant demonstrated that ART1 is crucial for upregulating genes such as STAR2 and FRDL4 in response to Fe toxicity. This study reveals the contribution of ART1-dependent regulatory pathways in rice roots under Fe toxicity.
en-copyright=
kn-copyright=

en-aut-name=UedaYoshiaki
en-aut-sei=Ueda
en-aut-mei=Yoshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamajiNaoki
en-aut-sei=Yamaji
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WissuwaMatthias
en-aut-sei=Wissuwa
en-aut-mei=Matthias
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Crop, Livestock and Environment Division, Japan International Research Center for Agricultural Sciences
kn-affil=

affil-num=2
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=3
en-affil=Crop, Livestock and Environment Division, Japan International Research Center for Agricultural Sciences
kn-affil=
en-keyword=ART1
kn-keyword=ART1
en-keyword=gene co-expression analysis
kn-keyword=gene co-expression analysis
en-keyword=iron toxicity
kn-keyword=iron toxicity
en-keyword=reactive oxygen species
kn-keyword=reactive oxygen species
en-keyword=rice
kn-keyword=rice
END

start-ver=1.4
cd-journal=joma
no-vol=30
cd-vols=
no-issue=8
article-no=
start-page=1537
end-page=1544
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250528
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Our previous findings showed that the addition of metformin to nivolumab resulted in remarkable tumor regression and increased the number of tumor-infiltrating T cells in mouse models. Therefore, we conducted a phase Ib study using combination therapy with nivolumab and metformin in patients with refractory/recurrent solid tumors.<br>
Methods This study consisted of two parts: 1, evaluating the maximum tolerated dose (MTD), safety, pharmacokinetics in solid tumors, and 2, principally investigating the safety at the recommended dose limited to thoracic and pancreatic cancers. Metformin and nivolumab were administered orally at doses of 750–2,250 mg/day and biweekly at a fixed intravenous dose of 3 mg/kg, respectively. Dose-limiting toxicity was evaluated within the first 4 weeks. Both metformin and nivolumab were continued until disease progression or discontinued because of toxicity.<br>
Results In total, 17 and 24 patients were enrolled in parts 1 and 2, respectively. One patient experienced increased pancreatic enzyme levels (grade 4) and lactic acidosis (grade 3). No Grade 5 adverse events were observed. MTD was not reached up to 2,250 mg/day of metformin, 2,250 mg/day was selected for part 2. An objective response was observed in 4 of 41 patients. One-year progression-free and overall survival rates were 9.8% and 56.8%, respectively. Two patients remained alive without disease progression for more than three years.<br>
Conclusions Nivolumab and metformin combination therapy was well-tolerated and showed preliminary signals of efficacy in a subset of patients. Further verification of the underlying mechanism in cases where treatment is effective is required.<br>
Trial registration numbers UMIN registration number 000028405 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031915.
en-copyright=
kn-copyright=

en-aut-name=KuboToshio
en-aut-sei=Kubo
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KatoHironari
en-aut-sei=Kato
en-aut-mei=Hironari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HoriguchiShigeru
en-aut-sei=Horiguchi
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KozukiToshiyuki
en-aut-sei=Kozuki
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AsagiAkinori
en-aut-sei=Asagi
en-aut-mei=Akinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshidaMichihiro
en-aut-sei=Yoshida
en-aut-mei=Michihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=UdonoHeiichiro
en-aut-sei=Udono
en-aut-mei=Heiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KiuraKatsuyuki
en-aut-sei=Kiura
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center
kn-affil=

affil-num=5
en-affil=Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=6
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
en-keyword=Pancreatic cancer
kn-keyword=Pancreatic cancer
en-keyword=Thoracic tumors
kn-keyword=Thoracic tumors
en-keyword=Phase Ib
kn-keyword=Phase Ib
en-keyword=Anti-PD-1 antibody
kn-keyword=Anti-PD-1 antibody
en-keyword=Nivolumab
kn-keyword=Nivolumab
en-keyword=Metformin
kn-keyword=Metformin
END

start-ver=1.4
cd-journal=joma
no-vol=45
cd-vols=
no-issue=
article-no=
start-page=101049
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Neoadjuvant FOLFOXIRI for locally advanced rectal cancer: A retrospective analysis focusing on long-term anal preservation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To investigate the safety and efficacy of FOLFOXIRI as neoadjuvant chemotherapy (NAC) for locally advanced rectal cancer (LARC). The outcomes of preoperative and perioperative treatments, as well as long-term outcomes, were retrospectively compared between 26 patients who underwent FOLFOXIRI as NAC for LARC with cT3–4 and/or N+ at our institute between 2015 and 2022, and 31 patients with LARC who underwent neoadjuvant chemoradiotherapy (CAPOX-RT) at our institute between 2011 and 2022. Grade 3 or higher adverse events due to neoadjuvant treatment were significantly more common in the FOLFOXIRI group (11 cases, 42.3 %) than in the CAPOX-RT group (3 cases, 9.7 %), and most of these were neutropenia. Based on the postoperative pathological findings, the complete response rate was significantly lower in the FOLFOXIRI group (1 case, 3.8 %) than in the CAPOX-RT group (7 cases, 22.6 %), but there were no significant differences in the R0 resection rate, survival rate, or relapse-free survival rate. In the CAPOX-RT group, 17 patients (54.8 %) had anal preservation, and during the observation period, 4 patients required stoma construction due to loss of anal function in the late stage. In contrast, in the FOLFOXIRI group, there were no cases of loss of anal function among the 20 patients (76.9 %) who had anal preservation. FOLFOXIRI as NAC requires caution regarding hematological toxicity, but it can be an effective treatment option for patients with LARC who wish to preserve their anus.
en-copyright=
kn-copyright=

en-aut-name=ShojiRyohei
en-aut-sei=Shoji
en-aut-mei=Ryohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TeraishiFuminori
en-aut-sei=Teraishi
en-aut-mei=Fuminori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsumiYuki
en-aut-sei=Matsumi
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YoshidaYusuke
en-aut-sei=Yoshida
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KanayaNobuhiko
en-aut-sei=Kanaya
en-aut-mei=Nobuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShigeyasuKunitoshi
en-aut-sei=Shigeyasu
en-aut-mei=Kunitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KondoYoshitaka
en-aut-sei=Kondo
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MoriYoshiko
en-aut-sei=Mori
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KagawaShunsuke
en-aut-sei=Kagawa
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Locally advanced rectal cancer
kn-keyword=Locally advanced rectal cancer
en-keyword=Neoadjuvant chemotherapy
kn-keyword=Neoadjuvant chemotherapy
en-keyword=FOLFOXIRI
kn-keyword=FOLFOXIRI
en-keyword=Late pelvic toxicity
kn-keyword=Late pelvic toxicity
END

start-ver=1.4
cd-journal=joma
no-vol=89
cd-vols=
no-issue=3
article-no=
start-page=e70091
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202505
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Autoclaved lightweight aerated concrete suppressed N2O and CO2 emissions from paddy soil
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Autoclaved lightweight aerated concrete (AAC), a construction waste that is utilized as a soil amendment, can influence terrestrial carbon dioxide (CO2) emissions. Still, no evidence exists regarding its impact on the emission of nitrous oxide (N2O), which has a higher global warming potential. This study examined effects of AAC on CO2 and N2O emissions from paddy soil under compacted and non-compacted conditions, under 60% and 100% water-holding capacity (WHC). Samples were incubated in glass vials (25°C) for 21 days. Emissions of CO2 and N2O were measured on days 0, 1, 3, 7, 14, and 21 using gas chromatography. The results revealed that AAC significantly (p < 0.05) lowered N2O emission rate during the whole period of incubation, while it suppressed CO2 emission rate only at the early stages (∼7 days) of incubation. In compacted soil, the emissions of CO2 were significantly lower, while N2O was significantly higher than that in non-compacted soil, showing the influence of soil physical conditions. The emissions of CO2 and N2O were significantly lower at 100% WHC than those at 60% WHC. AAC suppressed both CO2 and N2O emissions under both compaction and WHC levels. The results confirm that AAC supports suppressing terrestrial emission of both CO2 and N2O, indicating that AAC has a potential as a sustainable soil amendment that enhances the climate change resilience.
en-copyright=
kn-copyright=

en-aut-name=RathnayakeNagoda R. R. W. S.
en-aut-sei=Rathnayake
en-aut-mei=Nagoda R. R. W. S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MaedaMorihiro
en-aut-sei=Maeda
en-aut-mei=Morihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LeelamanieDewpura A. L.
en-aut-sei=Leelamanie
en-aut-mei=Dewpura A. L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YatagaiAtsushi
en-aut-sei=Yatagai
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Soil Science, Faculty of Agriculture, University of Ruhuna
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Soil Science, Faculty of Agriculture, University of Ruhuna
kn-affil=

affil-num=4
en-affil=Clion Co. Ltd
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=22
cd-vols=
no-issue=3
article-no=
start-page=e220018
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Origin of the unique topology of the triangular water cluster in &lt;i&gt;Rubrobacter xylanophilus&lt;/i&gt; rhodopsin
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The crystal structure of Rubrobacter xylanophilus rhodopsin (RxR) reveals a triangular cluster of three water molecules (W413, W415, and W419) at the extracellular proton-release site, near Glu187 and Glu197. Using a quantum mechanical/molecular mechanical approach, we identified the structural nature of this unique water cluster. The triangular shape is best reproduced when all three water molecules are neutral H2O with protonated Glu187 and deprotonated Glu197. Attempts to place H3O+ at any of these water molecules result in spontaneous proton transfer to one of the acidic residues and significant distortion from the crystal structure. The plane defined by the triangular water cluster extends into the guanidinium plane of Arg71, with both aligned along the W413...W419 axis. This extended plane lies nearly perpendicular to a five-membered, ring-like H-bond network involving two carboxyl oxygen atoms from Glu187 and one from Glu197. The resulting bipartite planar architecture, defined by the water triangle, Arg71, and the Glu187/Glu197 network may reflect the exceptional thermal stability in RxR.
en-copyright=
kn-copyright=

en-aut-name=NojiTomoyasu
en-aut-sei=Noji
en-aut-mei=Tomoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TsujimuraMasaki
en-aut-sei=Tsujimura
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SaitoKeisuke
en-aut-sei=Saito
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KojimaKeiichi
en-aut-sei=Kojima
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SudoYuki
en-aut-sei=Sudo
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IshikitaHiroshi
en-aut-sei=Ishikita
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo
kn-affil=

affil-num=2
en-affil=Department of Advanced Interdisciplinary Studies, The University of Tokyo
kn-affil=

affil-num=3
en-affil=Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo
kn-affil=

affil-num=4
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo
kn-affil=
en-keyword=microbial rhodopsin
kn-keyword=microbial rhodopsin
en-keyword=proton transfer pathway
kn-keyword=proton transfer pathway
en-keyword=H3O+
kn-keyword=H3O+
en-keyword=pKa
kn-keyword=pKa
en-keyword=proton release group
kn-keyword=proton release group
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=1
article-no=
start-page=8786
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251002
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Efficient and stable n-type sulfide overall water splitting with separated hydrogen production
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=N-type sulfide semiconductors are promising photocatalysts due to their broad visible-light absorption, facile synthesis and chemical diversity. However, photocorrosion and limited electron transport in one-step excitation and solid-state Z-scheme systems hinder efficient overall water splitting. Liquid-phase Z-schemes offer a viable alternative, but sluggish mediator kinetics and interfacial side reactions impede their construction. Here we report a stable Z-scheme system integrating n-type CdS and BiVO₄ with a [Fe(CN)₆]³⁻/[Fe(CN)₆]⁴⁻ mediator, achieving 10.2% apparent quantum yield at 450 nm with stoichiometric H₂/O₂ evolution. High activity reflects synergies between Pt@CrOx and Co3O4 cocatalysts on CdS, and cobalt-directed facet asymmetry in BiVO₄, resulting in matched kinetics for hydrogen and oxygen evolution in a reversible mediator solution. Stability is dramatically improved through coating CdS and BiVO4 with different oxides to inhibit Fe4[Fe(CN)6]3 precipitation and deactivation by a hitherto unrecognized mechanism. Separate hydrogen and oxygen production is also demonstrated in a two-compartment reactor under visible light and ambient conditions. This work unlocks the long-sought potential of n-type sulfides for efficient, durable and safe solar-driven hydrogen production.
en-copyright=
kn-copyright=

en-aut-name=LuoHaolin
en-aut-sei=Luo
en-aut-mei=Haolin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=LiuZhixi
en-aut-sei=Liu
en-aut-mei=Zhixi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LvHaifeng
en-aut-sei=Lv
en-aut-mei=Haifeng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=VequizoJunie Jhon M.
en-aut-sei=Vequizo
en-aut-mei=Junie Jhon M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ZhengMengting
en-aut-sei=Zheng
en-aut-mei=Mengting
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HanFeng
en-aut-sei=Han
en-aut-mei=Feng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YeZhen
en-aut-sei=Ye
en-aut-mei=Zhen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamakataAkira
en-aut-sei=Yamakata
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShangguanWenfeng
en-aut-sei=Shangguan
en-aut-mei=Wenfeng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=LeeAdam F.
en-aut-sei=Lee
en-aut-mei=Adam F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=WuXiaojun
en-aut-sei=Wu
en-aut-mei=Xiaojun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KazunariDomen
en-aut-sei=Kazunari
en-aut-mei=Domen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=LuJun
en-aut-sei=Lu
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=JiangZhi
en-aut-sei=Jiang
en-aut-mei=Zhi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University
kn-affil=

affil-num=2
en-affil=Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University
kn-affil=

affil-num=3
en-affil=State Key Laboratory of Precision and Intelligent Chemistry, School of Chemistry and Material Sciences, and Collaborative Innovation Center of Chemistry for Energy Materials (iChEM), University of Science and Technology of China
kn-affil=

affil-num=4
en-affil=Institute of Aqua Regeneration, Shinshu University
kn-affil=

affil-num=5
en-affil=College of Chemical and Biological Engineering, Zhejiang University
kn-affil=

affil-num=6
en-affil=Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University
kn-affil=

affil-num=7
en-affil=Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University
kn-affil=

affil-num=8
en-affil=Faculty of Natural Science and Technology, Okayama University
kn-affil=

affil-num=9
en-affil=Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University
kn-affil=

affil-num=10
en-affil=Centre for Catalysis and Clean Energy, School of Environment and Science, Griffith University
kn-affil=

affil-num=11
en-affil=State Key Laboratory of Precision and Intelligent Chemistry, School of Chemistry and Material Sciences, and Collaborative Innovation Center of Chemistry for Energy Materials (iChEM), University of Science and Technology of China
kn-affil=

affil-num=12
en-affil=Institute of Aqua Regeneration, Shinshu University
kn-affil=

affil-num=13
en-affil=College of Chemical and Biological Engineering, Zhejiang University
kn-affil=

affil-num=14
en-affil=Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=6
article-no=
start-page=dsaf030
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251022
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=MedakaBase as a unified genomic resource platform for medaka fish biology
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Medaka, a group of small, mostly freshwater fishes in the teleost order Beloniformes, includes the rice fish Oryzias latipes, a useful model organism studied in diverse biological fields. Chromosome-scale genome sequences of the Hd-rR strain of this species were obtained in 2007, and its improved version has facilitated various genome-wide studies. However, despite its widespread utility, omics data for O. latipes are dispersed across various public databases and lack a unified platform. To address this, the medaka section of the National Bioresource Project (NBRP) of Japan established a genome informatics team in 2022 tasked with providing various in silico solutions for bench biologists. This initiative led to the launch of MedakaBase (https://medakabase.nbrp.jp), a web server that enables gene-oriented analysis including exhaustive sequence similarity searches. MedakaBase also provides on-demand browsing of diverse genome-wide datasets, including tissue-specific transcriptomes and intraspecific genomic variations, integrated with gene models from different sources. Additionally, the platform offers gene models optimized for single-cell transcriptome analysis, which often requires coverage of the 3′ untranslated region (UTR) of transcripts. Currently, MedakaBase provides genome-wide data for seven Oryzias species, including original data for O. mekongensis and O. luzonensis produced by the NBRP team. This article outlines technical details behind the data provided by MedakaBase.
en-copyright=
kn-copyright=

en-aut-name=MorikamiKenji
en-aut-sei=Morikami
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanizawaYasuhiro
en-aut-sei=Tanizawa
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YaguraMasaru
en-aut-sei=Yagura
en-aut-mei=Masaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakamotoMika
en-aut-sei=Sakamoto
en-aut-mei=Mika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KawamotoShoko
en-aut-sei=Kawamoto
en-aut-mei=Shoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakamuraYasukazu
en-aut-sei=Nakamura
en-aut-mei=Yasukazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamaguchiKatsushi
en-aut-sei=Yamaguchi
en-aut-mei=Katsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShigenobuShuji
en-aut-sei=Shigenobu
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NaruseKiyoshi
en-aut-sei=Naruse
en-aut-mei=Kiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=AnsaiSatoshi
en-aut-sei=Ansai
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KurakuShigehiro
en-aut-sei=Kuraku
en-aut-mei=Shigehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Molecular Life History Laboratory, Department of Genomics and Evolutionary Biology, National Institute of Genetics, Research Organization of Information and Systems
kn-affil=

affil-num=2
en-affil=Genome Informatics Laboratory, National Institute of Genetics, Research Organization of Information and Systems
kn-affil=

affil-num=3
en-affil=Molecular Life History Laboratory, Department of Genomics and Evolutionary Biology, National Institute of Genetics, Research Organization of Information and Systems
kn-affil=

affil-num=4
en-affil=Genome Informatics Laboratory, National Institute of Genetics, Research Organization of Information and Systems
kn-affil=

affil-num=5
en-affil=Department of Genetics, Sokendai (Graduate University for Advanced Studies)
kn-affil=

affil-num=6
en-affil=Genome Informatics Laboratory, National Institute of Genetics, Research Organization of Information and Systems
kn-affil=

affil-num=7
en-affil=Trans-Omics Facility, National Institute for Basic Biology
kn-affil=

affil-num=8
en-affil=Trans-Omics Facility, National Institute for Basic Biology
kn-affil=

affil-num=9
en-affil=Laboratory of Bioresources, National Institute for Basic Biology, National Institutes of Natural Sciences
kn-affil=

affil-num=10
en-affil=Ushimado Marine Institute, Okayama University
kn-affil=

affil-num=11
en-affil=Molecular Life History Laboratory, Department of Genomics and Evolutionary Biology, National Institute of Genetics, Research Organization of Information and Systems
kn-affil=
en-keyword=medaka
kn-keyword=medaka
en-keyword=comparative genomics
kn-keyword=comparative genomics
en-keyword=genome browser
kn-keyword=genome browser
en-keyword=MedakaBase
kn-keyword=MedakaBase
en-keyword=Beloniformes
kn-keyword=Beloniformes
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=8
article-no=
start-page=954
end-page=963
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250819
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Long-term functional and quality of life outcomes after cementless minimally invasive extendable endoprosthesis replacement in skeletally immature patients with bone sarcomas at the lower limb a Japanese Musculoskeletal Oncology Group (JMOG) study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aims<br>
Extendable endoprostheses are utilized to reconstruct segmental defects following resection of bone sarcomas in skeletally immature children. However, there remains a paucity of data regarding long-term functional and quality of life outcomes.<br>
Methods<br>
We conducted a retrospective, multicentre study and reviewed 45 children who underwent cementless minimally invasive extendable endoprosthetic replacement. Anatomical sites included the distal femur (n = 29), proximal femur (n = 4), proximal tibia (n = 11), and total femur (n = 1). The mean follow-up period was 12 years. The mean age at extendable endoprosthetic replacement was ten years (5 to 15). Most patients (96%, 43/45) had reached skeletal maturity at the final follow-up.<br>
Results<br>
The ten-year endoprosthetic failure-free survival rate was 60%. Of the 45 patients, 25 (56%) had 42 complications which were frequently related to structural failure (45%, 19/42), with extension mechanism jamming being the most common (n = 7, 17%). Excluding lengthening procedures, 20 patients (44%) underwent additional surgery with a mean of two surgeries per patient. The mean limb-length discrepancy at the final follow-up was 2.3 cm. Limb salvage was achieved in 44 (98%) patients. The mean Musculoskeletal Tumor Society (MSTS) scores, Toronto Extremity Salvage Score (TESS), and EuroQol five-dimension five-level questionnaire (EQ-5D-5L) were 78%, 92%, and 92% at the last follow-up, respectively. Multiple additional surgeries (≥ 2 times) for complications were associated with worse MSTS scores compared with those without multiple additional surgeries (p = 0.009). Moreover, limb-length discrepancy > 3 cm showed significantly worse MSTS scores compared with those ≤ 3 cm (p = 0.019).<br>
Conclusion<br>
Extendable endoprostheses were associated with a high complication rate and need for additional surgeries over time, especially for structural-related complications. Despite this, successful limb salvage with reasonable function/quality of life and small limb-length discrepancy were achievable in the long term. Patients’ function in the long term depended on the experience of postoperative complications and limb-length discrepancy.
en-copyright=
kn-copyright=

en-aut-name=TsudaYusuke
en-aut-sei=Tsuda
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishidaYoshihiro
en-aut-sei=Nishida
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SakamotoAkio
en-aut-sei=Sakamoto
en-aut-mei=Akio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OguraKoichi
en-aut-sei=Ogura
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujiwaraTomohiro
en-aut-sei=Fujiwara
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SekitaTetsuya
en-aut-sei=Sekita
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawanoHirotaka
en-aut-sei=Kawano
en-aut-mei=Hirotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KobayashiHiroshi
en-aut-sei=Kobayashi
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, The University of Tokyo Hospital
kn-affil=

affil-num=2
en-affil=Department of Rehabilitation, Nagoya University Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University
kn-affil=

affil-num=4
en-affil=Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Teikyo University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, The University of Tokyo Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=23
cd-vols=
no-issue=1
article-no=
start-page=1387
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251208
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Tumor marker–guided precision BNCT for CA19-9–positive cancers: a new paradigm in molecularly targeted chemoradiation therapy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Boron neutron capture therapy (BNCT) is a molecularly targeted chemoradiation modality that relies on boron delivery agents such as p-borophenylalanine (BPA), which require LAT1 (L-type amino acid transporter 1) for tumor uptake. However, the limited efficacy of BPA in LAT1-low tumors restricts its therapeutic scope. To address this limitation, we developed a tumor marker–guided BNCT strategy targeting cancers overexpressing the clinically validated glycan biomarker CA19-9.<br>
Methods: We conducted transcriptomic analyses using The Cancer Genome Atlas (TCGA) datasets to identify LAT1-low cancers with high CA19-9 expression. These analyses revealed elevated expression of fucosyltransferase 3 (FUT3), which underlies CA19-9 biosynthesis, in pancreatic, biliary, and ovarian malignancies. Based on this, we synthesized a novel boron compound, fucose-BSH, designed to selectively accumulate in CA19-9–positive tumors. We evaluated its physicochemical properties, pharmacokinetics, biodistribution, and antitumor efficacy in cell lines and xenograft models, comparing its performance to that of BPA.<br>
Results: Fucose-BSH demonstrated significantly greater boron uptake in CA19-9–positive cell lines (AsPC-1, Panc 04.03, HuCCT-1, HSKTC, OVISE) compared to CA19-9–negative PANC-1. In HuCCT-1 xenografts, boron accumulation reached 36.2 ppm with a tumor/normal tissue ratio of 2.1, outperforming BPA. Upon neutron irradiation, fucose-BSH–mediated BNCT achieved > 80% tumor growth inhibition. Notably, fucose-BSH retained therapeutic efficacy in LAT1-deficient models where BPA was ineffective, confirming LAT1-independent targeting.<br>
Conclusions: This study establishes a novel precision BNCT approach by leveraging CA19-9 as a tumor-selective glycan marker for boron delivery. Fucose-BSH offers a promising platform for expanding BNCT to previously inaccessible LAT1-low malignancies, including pancreatic, biliary, and ovarian cancers. These findings provide a clinically actionable strategy for tumor marker–driven chemoradiation and lay the foundation for translational application in BNCT. This strategy has the potential to support companion diagnostic development and precision stratification in ongoing and future BNCT clinical trials.<br>
Translational Relevance: Malignancies with elevated CA19-9 expression, such as pancreatic, biliary, and ovarian cancers, are associated with poor prognosis and limited response to current therapies. This study presents a tumor marker–guided strategy for boron neutron capture therapy (BNCT) by leveraging CA19-9 glycan biology to enable selective tumor targeting via fucose-BSH, a novel boron compound. Through transcriptomic data mining and preclinical validation, fucose-BSH demonstrated LAT1-independent boron delivery, potent BNCT-mediated cytotoxicity, and tumor-specific accumulation in CA19-9–positive models. These findings support a precision chemoradiation approach that addresses a critical gap in BNCT applicability, offering a clinically actionable pathway for patient stratification and therapeutic development in CA19-9–expressing cancers.
en-copyright=
kn-copyright=

en-aut-name=KanehiraNoriyuki
en-aut-sei=Kanehira
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TeraishiFuminori
en-aut-sei=Teraishi
en-aut-mei=Fuminori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TajimaTomoyuki
en-aut-sei=Tajima
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OsoneTatsunori
en-aut-sei=Osone
en-aut-mei=Tatsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=GotohKazuyoshi
en-aut-sei=Gotoh
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujimotoTakuya
en-aut-sei=Fujimoto
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SakuraiYoshinori
en-aut-sei=Sakurai
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KondoNatsuko
en-aut-sei=Kondo
en-aut-mei=Natsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NagahisaNarikazu
en-aut-sei=Nagahisa
en-aut-mei=Narikazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KameiKaoru
en-aut-sei=Kamei
en-aut-mei=Kaoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujitaTaiga
en-aut-sei=Fujita
en-aut-mei=Taiga
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MoriharaAkira
en-aut-sei=Morihara
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TakaguchiYutaka
en-aut-sei=Takaguchi
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KitamatsuMizuki
en-aut-sei=Kitamatsu
en-aut-mei=Mizuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakaradaTakeshi
en-aut-sei=Takarada
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShigeyasuKunitoshi
en-aut-sei=Shigeyasu
en-aut-mei=Kunitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SuzukiMinoru
en-aut-sei=Suzuki
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=MichiueHiroyuki
en-aut-sei=Michiue
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Institute for Integrated Radiation and Nuclear Science, Kyoto University
kn-affil=

affil-num=8
en-affil=Institute for Integrated Radiation and Nuclear Science, Kyoto University
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=11
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=12
en-affil=Graduate School of Environmental, Life Science, Okayama University
kn-affil=

affil-num=13
en-affil=Faculty of Sustainable Design, Department of Material Design and Engineering, University of Toyama
kn-affil=

affil-num=14
en-affil=Department of Applied Chemistry, Kindai University
kn-affil=

affil-num=15
en-affil=Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Institute for Integrated Radiation and Nuclear Science, Kyoto University
kn-affil=

affil-num=18
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Neutron Therapy Research Center, Okayama University
kn-affil=
en-keyword=Boron neutron capture therapy (BNCT)
kn-keyword=Boron neutron capture therapy (BNCT)
en-keyword=Precision BNCT
kn-keyword=Precision BNCT
en-keyword=Fucose-conjugated medicine
kn-keyword=Fucose-conjugated medicine
en-keyword=CA19-9
kn-keyword=CA19-9
en-keyword=Drug discovery
kn-keyword=Drug discovery
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=JCO-24-02835
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose For patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations (eg, S768I, L861Q, G719X), efficacy of current treatment options is limited.<br>
Patients and Methods CHRYSALIS-2 Cohort C enrolled participants with NSCLC harboring atypical EGFR mutations (G719X, S768I, L861Q, etc) and ≤2 previous lines of therapy. Participants were treatment-naïve or previously received first- or second-generation EGFR tyrosine kinase inhibitors. Coexisting exon 20 insertions, exon 19 deletions, or exon 21 L858R mutations were exclusionary. Participants received 1,050 mg (1,400 mg if ≥80 kg) intravenous amivantamab once weekly for the first 4 weeks and then once every 2 weeks plus 240 mg oral lazertinib once daily. The primary end point was investigator-assessed objective response rate (ORR).<br>
Results As of January 12, 2024, 105 participants received amivantamab-lazertinib. Most common atypical mutations were G719X (56%), L861X (26%), and S768I (23%), including single and compound mutations. In the overall population (median follow-up: 16.1 months), the ORR was 52% (95% CI, 42 to 62). The median duration of response (mDoR) was 14.1 months (95% CI, 9.5 to 26.2). The median progression-free survival (mPFS) was 11.1 months (95% CI, 7.8 to 17.8); median overall survival (mOS) was not estimable (NE; 95% CI, 22.8 to NE). Adverse events were consistent with previous studies and primarily grade 1 and 2. Among treatment-naïve participants, the ORR was 57% (95% CI, 42 to 71). The mPFS was 19.5 months (95% CI, 11.2 to NE), the mDoR was 20.7 months (95% CI, 9.9 to NE), and mOS was NE (95% CI, 26.3 to NE). Solitary or compound EGFR mutations had no major impact on ORR. The ORR in participants with P-loop and αC-helix compressing, classical-like, and T790M-like mutations was 45% (n = 38), 64% (n = 14), and 67% (n = 3), respectively.<br>
Conclusion In participants with atypical EGFR-mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.
en-copyright=
kn-copyright=

en-aut-name=TomasiniPascale
en-aut-sei=Tomasini
en-aut-mei=Pascale
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=WangYongsheng
en-aut-sei=Wang
en-aut-mei=Yongsheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LiYongsheng
en-aut-sei=Li
en-aut-mei=Yongsheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FelipEnriqueta
en-aut-sei=Felip
en-aut-mei=Enriqueta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WuLin
en-aut-sei=Wu
en-aut-mei=Lin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=CuiJiuwei
en-aut-sei=Cui
en-aut-mei=Jiuwei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=BesseBenjamin
en-aut-sei=Besse
en-aut-mei=Benjamin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SpiraAlexander I.
en-aut-sei=Spira
en-aut-mei=Alexander I.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NealJoel W.
en-aut-sei=Neal
en-aut-mei=Joel W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=GotoKoichi
en-aut-sei=Goto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=BaikChristina S.
en-aut-sei=Baik
en-aut-mei=Christina S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MarmarelisMelina E.
en-aut-sei=Marmarelis
en-aut-mei=Melina E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IchiharaEiki
en-aut-sei=Ichihara
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ZhangYiping
en-aut-sei=Zhang
en-aut-mei=Yiping
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=LeeJong-Seok
en-aut-sei=Lee
en-aut-mei=Jong-Seok
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=LeeSe-Hoon
en-aut-sei=Lee
en-aut-mei=Se-Hoon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=YangJames Chih-Hsin
en-aut-sei=Yang
en-aut-mei=James Chih-Hsin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MichelsSebastian
en-aut-sei=Michels
en-aut-mei=Sebastian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=AnastasiouZacharias
en-aut-sei=Anastasiou
en-aut-mei=Zacharias
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=CurtinJoshua C.
en-aut-sei=Curtin
en-aut-mei=Joshua C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=LyuXuesong
en-aut-sei=Lyu
en-aut-mei=Xuesong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MahoneyJanine
en-aut-sei=Mahoney
en-aut-mei=Janine
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=DemirdjianLevon
en-aut-sei=Demirdjian
en-aut-mei=Levon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=MeyerCraig S.
en-aut-sei=Meyer
en-aut-mei=Craig S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=ZhangYouyi
en-aut-sei=Zhang
en-aut-mei=Youyi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=LeconteIsabelle
en-aut-sei=Leconte
en-aut-mei=Isabelle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=LorenziniPatricia
en-aut-sei=Lorenzini
en-aut-mei=Patricia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=KnoblauchRoland E.
en-aut-sei=Knoblauch
en-aut-mei=Roland E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=TraniLeonardo
en-aut-sei=Trani
en-aut-mei=Leonardo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=BaigMahadi
en-aut-sei=Baig
en-aut-mei=Mahadi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=BaumlJoshua M.
en-aut-sei=Bauml
en-aut-mei=Joshua M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=ChoByoung Chul
en-aut-sei=Cho
en-aut-mei=Byoung Chul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

affil-num=1
en-affil=Aix Marseille University - CNRS, INSERM, CRCM; CEPCM - AP-HM Hôpital de La Timone
kn-affil=

affil-num=2
en-affil=Division of Thoracic Tumor Multimodality Treatment, Cancer Center and Clinical Trial Center, West China Hospital, Sichuan University
kn-affil=

affil-num=3
en-affil=Chongqing University Cancer Hospital
kn-affil=

affil-num=4
en-affil=Medical Oncology Service, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona
kn-affil=

affil-num=5
en-affil=Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
kn-affil=

affil-num=6
en-affil=The First Hospital of Jilin University
kn-affil=

affil-num=7
en-affil=Paris-Saclay University, Institut Gustave Roussy
kn-affil=

affil-num=8
en-affil=Virginia Cancer Specialists
kn-affil=

affil-num=9
en-affil=Stanford Cancer Institute, Stanford University
kn-affil=

affil-num=10
en-affil=National Cancer Center Hospital East
kn-affil=

affil-num=11
en-affil=University of Washington Fred Hutchinson Cancer Research Center
kn-affil=

affil-num=12
en-affil=Perelman School of Medicine, University of Pennsylvania
kn-affil=

affil-num=13
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=14
en-affil=Zhejiang Cancer Hospital
kn-affil=

affil-num=15
en-affil=Seoul National University College of Medicine and Seoul National University Hospital
kn-affil=

affil-num=16
en-affil=Samsung Medical Center, Sungkyunkwan University School of Medicine
kn-affil=

affil-num=17
en-affil=National Taiwan University Cancer Center
kn-affil=

affil-num=18
en-affil=Department I for Internal Medicine, Faculty of Medicine and University Hospital Cologne, Lung Cancer Group Cologne, Center for Integrated Oncology Aachen Köln Bonn Düsseldorf, University of Cologne
kn-affil=

affil-num=19
en-affil=Johnson & Johnson
kn-affil=

affil-num=20
en-affil=Johnson & Johnson
kn-affil=

affil-num=21
en-affil=Johnson & Johnson
kn-affil=

affil-num=22
en-affil=Johnson & Johnson
kn-affil=

affil-num=23
en-affil=Johnson & Johnson
kn-affil=

affil-num=24
en-affil=Johnson & Johnson
kn-affil=

affil-num=25
en-affil=Johnson & Johnson
kn-affil=

affil-num=26
en-affil=Johnson & Johnson
kn-affil=

affil-num=27
en-affil=Johnson & Johnson
kn-affil=

affil-num=28
en-affil=Johnson & Johnson
kn-affil=

affil-num=29
en-affil=Johnson & Johnson
kn-affil=

affil-num=30
en-affil=Johnson & Johnson
kn-affil=

affil-num=31
en-affil=Johnson & Johnson
kn-affil=

affil-num=32
en-affil=Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=5
article-no=
start-page=651
end-page=664
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202505
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Treatment options for patients with EGFR-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy are limited.<br>
Methods: CHRYSALIS-2 cohort A evaluated amivantamab plus lazertinib in patients with EGFR exon 19 deletion- or L858R-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy. Primary end point was investigator-assessed objective response rate (ORR). The patients received 1050 mg of intravenous amivantamab (1400 mg if ≥ 80 kg) plus 240 mg of oral lazertinib.<br>
Results: In cohort A (N = 162), the investigator-assessed ORR was 28% (95% confidence interval [CI]: 22–36). The blinded independent central review–assessed ORR was 35% (95% CI: 27–42), with a median duration of response of 8.3 months (95% CI: 6.7–10.9) and a clinical benefit rate of 58% (95% CI: 50–66). At a median follow-up of 12 months, 32 of 56 responders (57%) achieved a duration of response of more than or equal to 6 months. Median progression-free survival by blinded independent central review was 4.5 months (95% CI: 4.1–5.8); median overall survival was 14.8 months (95% CI: 12.2–18.0). Preliminary evidence of central nervous system antitumor activity was reported in seven patients with baseline brain lesions and no previous brain radiation or surgery. Exploratory biomarker analyses using next-generation sequencing of circulating tumor DNA revealed responses in patients with and without EGFR- or MET-dependent resistance. The most frequent adverse events were rash (grouped term; 81%), infusion-related reaction (68%), and paronychia (52%). The most common grade greater than or equal to 3 treatment-related adverse events were rash (grouped term; 10%), infusion-related reaction (9%), and hypoalbuminemia (6%).<br>
Conclusions: For patients with limited treatment options, amivantamab plus lazertinib demonstrated an antitumor activity with a safety profile characterized by EGFR- or MET-related adverse events, which were generally manageable.
en-copyright=
kn-copyright=

en-aut-name=BesseBenjamin
en-aut-sei=Besse
en-aut-mei=Benjamin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=GotoKoichi
en-aut-sei=Goto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WangYongsheng
en-aut-sei=Wang
en-aut-mei=Yongsheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=LeeSe-Hoon
en-aut-sei=Lee
en-aut-mei=Se-Hoon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MarmarelisMelina E.
en-aut-sei=Marmarelis
en-aut-mei=Melina E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OheYuichiro
en-aut-sei=Ohe
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=Bernabe CaroReyes
en-aut-sei=Bernabe Caro
en-aut-mei=Reyes
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KimDong-Wan
en-aut-sei=Kim
en-aut-mei=Dong-Wan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=LeeJong-Seok
en-aut-sei=Lee
en-aut-mei=Jong-Seok
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=CousinSophie
en-aut-sei=Cousin
en-aut-mei=Sophie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IchiharaEiki
en-aut-sei=Ichihara
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=LiYongsheng
en-aut-sei=Li
en-aut-mei=Yongsheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=Paz-AresLuis
en-aut-sei=Paz-Ares
en-aut-mei=Luis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OnoAkira
en-aut-sei=Ono
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=SanbornRachel E.
en-aut-sei=Sanborn
en-aut-mei=Rachel E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=WatanabeNaohiro
en-aut-sei=Watanabe
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=de MiguelMaria Jose
en-aut-sei=de Miguel
en-aut-mei=Maria Jose
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=HelisseyCarole
en-aut-sei=Helissey
en-aut-mei=Carole
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ShuCatherine A.
en-aut-sei=Shu
en-aut-mei=Catherine A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SpiraAlexander I.
en-aut-sei=Spira
en-aut-mei=Alexander I.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=TomasiniPascale
en-aut-sei=Tomasini
en-aut-mei=Pascale
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=YangJames Chih-Hsin
en-aut-sei=Yang
en-aut-mei=James Chih-Hsin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=ZhangYiping
en-aut-sei=Zhang
en-aut-mei=Yiping
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=FelipEnriqueta
en-aut-sei=Felip
en-aut-mei=Enriqueta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=GriesingerFrank
en-aut-sei=Griesinger
en-aut-mei=Frank
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=WaqarSaiama N.
en-aut-sei=Waqar
en-aut-mei=Saiama N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=CallesAntonio
en-aut-sei=Calles
en-aut-mei=Antonio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=NealJoel W.
en-aut-sei=Neal
en-aut-mei=Joel W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=BaikChristina S.
en-aut-sei=Baik
en-aut-mei=Christina S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=JännePasi A.
en-aut-sei=Jänne
en-aut-mei=Pasi A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=ShreeveS. Martin
en-aut-sei=Shreeve
en-aut-mei=S. Martin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=CurtinJoshua C.
en-aut-sei=Curtin
en-aut-mei=Joshua C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=PatelBharvin
en-aut-sei=Patel
en-aut-mei=Bharvin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=GormleyMichael
en-aut-sei=Gormley
en-aut-mei=Michael
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=LyuXuesong
en-aut-sei=Lyu
en-aut-mei=Xuesong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=ChenJun
en-aut-sei=Chen
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=ChuPei-Ling
en-aut-sei=Chu
en-aut-mei=Pei-Ling
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=MahoneyJanine
en-aut-sei=Mahoney
en-aut-mei=Janine
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=TraniLeonardo
en-aut-sei=Trani
en-aut-mei=Leonardo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=BaumlJoshua M.
en-aut-sei=Bauml
en-aut-mei=Joshua M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=ThayuMeena
en-aut-sei=Thayu
en-aut-mei=Meena
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=KnoblauchRoland E.
en-aut-sei=Knoblauch
en-aut-mei=Roland E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=ChoByoung Chul
en-aut-sei=Cho
en-aut-mei=Byoung Chul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

affil-num=1
en-affil=Paris-Saclay University, Institut Gustave Roussy
kn-affil=

affil-num=2
en-affil=National Cancer Center Hospital East
kn-affil=

affil-num=3
en-affil=Institute of Clinical Trial Center and Cancer Center, West China Hospital, Sichuan University
kn-affil=

affil-num=4
en-affil=Samsung Medical Center, Sungkyunkwan University School of Medicine
kn-affil=

affil-num=5
en-affil=University of Pennsylvania, Perelman School of Medicine
kn-affil=

affil-num=6
en-affil=National Cancer Center Hospital
kn-affil=

affil-num=7
en-affil=Hospital Universitario Virgen Del Rocio
kn-affil=

affil-num=8
en-affil=Seoul National University College of Medicine and Seoul National University Hospital
kn-affil=

affil-num=9
en-affil=Seoul National University College of Medicine and Seoul National University Hospital
kn-affil=

affil-num=10
en-affil=Institut Bergonié
kn-affil=

affil-num=11
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Chongqing University Cancer Hospital
kn-affil=

affil-num=13
en-affil=Hospital Universitario 12 de Octubre
kn-affil=

affil-num=14
en-affil=Shizuoka Cancer Center
kn-affil=

affil-num=15
en-affil=Earle A. Chiles Research Institute, Providence Cancer Institute
kn-affil=

affil-num=16
en-affil=Department of Thoracic Oncology, Aichi Cancer Center Hospital
kn-affil=

affil-num=17
en-affil=START Madrid-CIOCC, Hospital HM Sanchinarro
kn-affil=

affil-num=18
en-affil=Clinical Research unit, Military Hospital Begin
kn-affil=

affil-num=19
en-affil=Columbia University Medical Center
kn-affil=

affil-num=20
en-affil=Virginia Cancer Specialists
kn-affil=

affil-num=21
en-affil=Aix Marseille University - CNRS, INSERM, CRCM; CEPCM - AP-HM Hopital de La Timone
kn-affil=

affil-num=22
en-affil=National Taiwan University Cancer Center
kn-affil=

affil-num=23
en-affil=Zhejiang Cancer Hospital
kn-affil=

affil-num=24
en-affil=Medical Oncology Service, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Campus, Universitat Autonoma de Barcelona
kn-affil=

affil-num=25
en-affil=Pius-Hospital, University Medicine of Oldenburg
kn-affil=

affil-num=26
en-affil=Division of Oncology, Washington University School of Medicine
kn-affil=

affil-num=27
en-affil=Hospital General Universitario Gregorio Marañón
kn-affil=

affil-num=28
en-affil=Stanford University Medical Center
kn-affil=

affil-num=29
en-affil=University of Washington, Fred Hutchinson Cancer Center
kn-affil=

affil-num=30
en-affil=Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute
kn-affil=

affil-num=31
en-affil=Johnson & Johnson
kn-affil=

affil-num=32
en-affil=Johnson & Johnson
kn-affil=

affil-num=33
en-affil=Johnson & Johnson
kn-affil=

affil-num=34
en-affil=Johnson & Johnson
kn-affil=

affil-num=35
en-affil=Johnson & Johnson
kn-affil=

affil-num=36
en-affil=Johnson & Johnson
kn-affil=

affil-num=37
en-affil=Johnson & Johnson
kn-affil=

affil-num=38
en-affil=Johnson & Johnson
kn-affil=

affil-num=39
en-affil=Johnson & Johnson
kn-affil=

affil-num=40
en-affil=Johnson & Johnson
kn-affil=

affil-num=41
en-affil=Johnson & Johnson
kn-affil=

affil-num=42
en-affil=Johnson & Johnson
kn-affil=

affil-num=43
en-affil=Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
kn-affil=
en-keyword=Amivantamab
kn-keyword=Amivantamab
en-keyword=Biomarker analyses
kn-keyword=Biomarker analyses
en-keyword=Lazertinib
kn-keyword=Lazertinib
en-keyword=NSCLC
kn-keyword=NSCLC
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=10
article-no=
start-page=715
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241012
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Photocatalytic Ammonia Decomposition Using Dye-Encapsulated Single-Walled Carbon Nanotubes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The photocatalytic decomposition of ammonia to produce N2 and H2 was achieved using single-walled carbon nanotube (SWCNT) nanohybrids. The physical modification of ferrocene-dye-encapsulated CNTs by amphiphilic C60-dendron yielded nanohybrids with a dye/CNT/C60 coaxial heterojunction. Upon irradiation with visible light, an aqueous solution of NH3 and dye@CNT/C60-dendron nanohybrids produced both N2 and H2 in a stoichiometric ratio of 1/3. The action spectra of this reaction clearly demonstrated that the encapsulated dye acted as the photosensitizer, exhibiting an apparent quantum yield (AQY) of 0.22% at 510 nm (the λmax of the dye). This study reports the first example of dye-sensitized ammonia decomposition and provides a new avenue for developing efficient and sustainable photocatalytic hydrogen production systems.
en-copyright=
kn-copyright=

en-aut-name=TajimaTomoyuki
en-aut-sei=Tajima
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YanoKotone
en-aut-sei=Yano
en-aut-mei=Kotone
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MukaiKazushi
en-aut-sei=Mukai
en-aut-mei=Kazushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakaguchiYutaka
en-aut-sei=Takaguchi
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Materials Design and Engineering, University of Toyama
kn-affil=

affil-num=4
en-affil=Department of Materials Design and Engineering, University of Toyama
kn-affil=
en-keyword=photocatalyst
kn-keyword=photocatalyst
en-keyword=ammonia decomposition
kn-keyword=ammonia decomposition
en-keyword=dye sensitization
kn-keyword=dye sensitization
en-keyword=hydrogen evolution
kn-keyword=hydrogen evolution
en-keyword=carbon nanotube
kn-keyword=carbon nanotube
en-keyword=fullerene
kn-keyword=fullerene
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=e13537
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251203
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Atomic-Level Insights into Thermal Carbonization of Ethynyl-Containing Boron Compounds
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study reports the design, synthesis, and characterization of boron-doped carbon (BDC) derived from a triethynylborane-pyridine complex. Triethynylborane is stabilized by coordination with pyridine, facilitating its synthesis and handling in ambient conditions. The complex is subjected to thermal treatment at various temperatures to form BDC. Powder XRD and single-crystal XRD analyses reveal that BDC prepared at 200 °C retains an ordered structure, while higher temperatures induce alkyne structural changes without significant weight or surface area alterations. Coin cells are assembled using BDC as the anode, demonstrating unique Li-ion and Na-ion storage properties distinct from graphite. These results suggest that the BDC reflects the precursor's crystal structure, enabling novel electrochemical behavior. These findings offer insight into the development of advanced BDC materials for energy storage applications.
en-copyright=
kn-copyright=

en-aut-name=OhkuraKentaro
en-aut-sei=Ohkura
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HayakawaSatoshi
en-aut-sei=Hayakawa
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiNaoki
en-aut-sei=Takahashi
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamazakiKen
en-aut-sei=Yamazaki
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KanoJun
en-aut-sei=Kano
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NishinaYuta
en-aut-sei=Nishina
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=2
en-affil=Faculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Environment Life Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Environment Life Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environment Life Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=
en-keyword=boron-doped carbon
kn-keyword=boron-doped carbon
en-keyword=carbonization
kn-keyword=carbonization
en-keyword=ethynyl group
kn-keyword=ethynyl group
en-keyword=Li-ion
kn-keyword=Li-ion
en-keyword=Na-ion
kn-keyword=Na-ion
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=28
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Airway management during sedation for dental treatment in people with intellectual disabilities: a review
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The oral health of people with intellectual disabilities remains poor due to a complex combination of physical and social problems, and often requires invasive dental treatment. However, it can be difficult to obtain their cooperation for dental treatment because they may not fully understand the need for treatment or may experience high levels of anxiety due to lack of understanding and/or sensory aversions to stimuli present in the dental environment, and behavioral management is often necessary during such treatment. Sedation is a very useful patient management method for dental treatment for people with intellectual disabilities; however, the dental treatment-related sedation of people with intellectual disabilities has different characteristics to the dental treatment-related sedation of others or other procedure-related sedation. For example, deep sedation is required for behavioral management; drug interactions between the patient’s regular medications, such as antiepileptic and antipsychotic drugs, and anesthetics may make the depth of sedation deeper; and the prevalence rate of obesity is higher among people with intellectual disabilities. The fact that the patient is in the supine position with their mouth open also makes airway management during sedation for dental treatment more difficult. It is therefore imperative that airway management during dental treatment for people with intellectual disabilities be conducted with the utmost precision and vigilance. Various attempts have been made to improve airway management during such sedation, and new technologies, such as capnography, nasal high-flow systems, and acoustic respiration monitors, may help. The objective of this review is to enhance comprehension of the attributes of airway management in dental sedation for people with intellectual disabilities and to properly understand the usefulness of the techniques that have been attempted thus far to ensure safer and more secure airway management for this population. The ultimate goal is to provide them with safe and secure medical care and improve their health outcomes.
en-copyright=
kn-copyright=

en-aut-name=HiguchiHitoshi
en-aut-sei=Higuchi
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishiokaYukiko
en-aut-sei=Nishioka
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyakeSaki
en-aut-sei=Miyake
en-aut-mei=Saki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyawakiTakuya
en-aut-sei=Miyawaki
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Dental Anesthesiology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Dental Anesthesiology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Dentistry
kn-keyword=Dentistry
en-keyword=sedation
kn-keyword=sedation
en-keyword=airway management
kn-keyword=airway management
en-keyword=people with intellectual disabilities
kn-keyword=people with intellectual disabilities
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=10
article-no=
start-page=908
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251016
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Comparative Study of Authoring Performances Between In-Situ Mobile and Desktop Tools for Outdoor Location-Based Augmented Reality
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In recent years, Location-Based Augmented Reality (LAR) systems have been increasingly implemented in various applications for tourism, navigation, education, and entertainment. Unfortunately, the LAR content creation using conventional desktop-based authoring tools has become a bottleneck, as it requires time-consuming and skilled work. Previously, we proposed an in-situ mobile authoring tool as an efficient solution to this problem by offering direct authoring interactions in real-world environments using a smartphone. Currently, the evaluation through the comparison between the proposal and conventional ones is not sufficient to show superiority, particularly in terms of interaction, authoring performance, and cognitive workload, where our tool uses 6DoF device movement for spatial input, while desktop ones rely on mouse-pointing. In this paper, we present a comparative study of authoring performances between the tools across three authoring phases: (1) Point of Interest (POI) location acquisition, (2) AR object creation, and (3) AR object registration. For the conventional tool, we adopt Unity and ARCore SDK. As a real-world application, we target the LAR content creation for pedestrian landmark annotation across campus environments at Okayama University, Japan, and Brawijaya University, Indonesia, and identify task-level bottlenecks in both tools. In our experiments, we asked 20 participants aged 22 to 35 with different LAR development experiences to complete equivalent authoring tasks in an outdoor campus environment, creating various LAR contents. We measured task completion time, phase-wise contribution, and cognitive workload using NASA-TLX. The results show that our tool made faster creations with 60% lower cognitive loads, where the desktop tool required higher mental efforts with manual data input and object verifications.
en-copyright=
kn-copyright=

en-aut-name=BrataKomang Candra
en-aut-sei=Brata
en-aut-mei=Komang Candra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FunabikiNobuo
en-aut-sei=Funabiki
en-aut-mei=Nobuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=Sandi KyawHtoo Htoo
en-aut-sei=Sandi Kyaw
en-aut-mei=Htoo Htoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=RiyantokoPrismahardi Aji
en-aut-sei=Riyantoko
en-aut-mei=Prismahardi Aji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=Noprianto
en-aut-sei=Noprianto
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MentariMustika
en-aut-sei=Mentari
en-aut-mei=Mustika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Information and Communication Systems, Okayama University
kn-affil=
en-keyword=location-based augmented reality (LAR)
kn-keyword=location-based augmented reality (LAR)
en-keyword=in-situ authoring
kn-keyword=in-situ authoring
en-keyword=authoring workflow
kn-keyword=authoring workflow
en-keyword=cognitive workload
kn-keyword=cognitive workload
en-keyword=NASA-TLX
kn-keyword=NASA-TLX
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=8
article-no=
start-page=e0328792
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250814
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Risk stratification for the prediction of skeletal-related events in patients with castration-resistant prostate cancer with bone metastases
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Skeletal-related events (SREs) are common in patients with bone metastases from castration-resistant prostate cancer (CRPC). Despite advances in prostate cancer treatment, clinically validated predictive models for SREs in CRPC patients with bone metastases remain elusive. This gap in prognostic tools hinders optimal patient management and treatment planning for this high-risk population. This study aimed to develop a prediction model for SRE by investigating potential risk factors and classifying them into different groups. This model can be used to identify patients at high risk of SREs who need close follow-up. Between 2004 and 2013, 68 male patients with bone metastases from CRPC who were treated at our institute were evaluated for survival without SREs and survival without SREs of the spinal cord. The study analyzed clinical data at enrollment to identify risk factors for initial and spinal SREs. Multivariate analysis revealed that a high count of metastatic vertebrae, along with visceral or lymph node metastases, were significant risk factors. Patients were categorized into four subgroups based on the number of vertebral metastases and presence of visceral or lymph node metastases: 1) extensive vertebral and both types of metastases, 2) extensive vertebral without additional metastases, 3) some vertebral with other metastases, 4) some vertebral without additional metastases. The first SRE and spinal SRE occurred significantly sooner in the first subgroup compared to others. Incidence rates at 12 months for the first SRE were 56%, 40%, 27%, and 5%, and for the first spinal SRE were 47%, 40%, 27%, and 0% respectively. Patients with extensive vertebral and additional metastases require vigilant monitoring to mitigate SREs.
en-copyright=
kn-copyright=

en-aut-name=HamadaMasanori
en-aut-sei=Hamada
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakataEiji
en-aut-sei=Nakata
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakaharaRyuichi
en-aut-sei=Nakahara
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SugiharaShinsuke
en-aut-sei=Sugihara
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatayamaHaruyoshi
en-aut-sei=Katayama
en-aut-mei=Haruyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItanoTakuto
en-aut-sei=Itano
en-aut-mei=Takuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=InoueTomohiro
en-aut-sei=Inoue
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakihiraShota
en-aut-sei=Takihira
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AkezakiYoshiteru
en-aut-sei=Akezaki
en-aut-mei=Yoshiteru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=
kn-affil=

affil-num=2
en-affil=
kn-affil=

affil-num=3
en-affil=
kn-affil=

affil-num=4
en-affil=
kn-affil=

affil-num=5
en-affil=
kn-affil=

affil-num=6
en-affil=
kn-affil=

affil-num=7
en-affil=
kn-affil=

affil-num=8
en-affil=
kn-affil=

affil-num=9
en-affil=
kn-affil=

affil-num=10
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=26
cd-vols=
no-issue=19
article-no=
start-page=9630
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251002
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Critical Requirement of Senescence-Associated CCN3 Expression in CD44-Positive Stem Cells for Osteoarthritis Progression
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Osteoarthritis (OA) is a degenerative joint disease characterized by progressive cartilage breakdown, synovial inflammation, and subchondral bone remodeling. Previous studies have shown that cellular communication network factor 3 (CCN3) expression increases with age in cartilage, and its overexpression promotes OA-like changes by inducing senescence-associated secretory phenotypes. This study aimed to investigate the effect of Ccn3 knockout (KO) on OA development using a murine OA model. Destabilization of the medial meniscus (DMM) surgery was performed in wild-type (WT) and Ccn3-KO mice. Histological scoring and staining were used to assess cartilage degeneration and proteoglycan loss. Gene and protein expressions of catabolic enzyme (Mmp9), hypertrophic chondrocyte marker (Col10a1), senescence marker, and cyclin-dependent kinase inhibitor 1A (Cdkn1a) were evaluated. Single-cell RNA sequencing (scRNA-seq) data from WT and Sox9-deficient cartilage were reanalyzed to identify Ccn3+ progenitor populations. Immunofluorescence staining assessed CD44 and Ki67 expression in articular cartilage. The effects of Ccn3 knockdown on IL-1β-induced Mmp13 and Adamts5 expression in chondrocytes were examined in vitro. Ccn3 KO mice exhibited reduced cartilage degradation and catabolic gene expression compared with WT mice post-DMM. scRNA-seq revealed enriched Ccn3-Cd44 double-positive cells in osteoblast progenitor, synovial mesenchymal stem cell, and mesenchymal stem cell clusters. Immunofluorescence showed increased CCN3+/CD44+ cells in femoral and tibial cartilage and meniscus. Ki67+ cells were significantly increased in DMM-treated Ccn3 KO cartilage, mostly CD44+. In vitro Ccn3 knockdown attenuated IL-1β-induced Mmp13 and Adamts5 expressions in chondrocytes. Ccn3 contributes to OA pathogenesis by promoting matrix degradation, inducing hypertrophic changes, and restricting progenitor cell proliferation, highlighting Ccn3 as a potential therapeutic target for OA.
en-copyright=
kn-copyright=

en-aut-name=HabumugishaJanvier
en-aut-sei=Habumugisha
en-aut-mei=Janvier
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkudaRyuichiro
en-aut-sei=Okuda
en-aut-mei=Ryuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiroseKazuki
en-aut-sei=Hirose
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KuwaharaMiho
en-aut-sei=Kuwahara
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WangZiyi
en-aut-sei=Wang
en-aut-mei=Ziyi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OnoMitsuaki
en-aut-sei=Ono
en-aut-mei=Mitsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KamiokaHiroshi
en-aut-sei=Kamioka
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KubotaSatoshi
en-aut-sei=Kubota
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HattoriTakako
en-aut-sei=Hattori
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Orthodontics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=articular
kn-keyword=articular
en-keyword=cartilage
kn-keyword=cartilage
en-keyword=mesenchymal stem cells
kn-keyword=mesenchymal stem cells
en-keyword=nephroblastoma overexpressed protein
kn-keyword=nephroblastoma overexpressed protein
en-keyword=osteoarthritis
kn-keyword=osteoarthritis
END

start-ver=1.4
cd-journal=joma
no-vol=60
cd-vols=
no-issue=5
article-no=
start-page=573
end-page=582
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250214
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn’s disease activity in the small bowel
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Small bowel (SB) lesions in Crohn’s disease (CD) are often asymptomatic despite being highly active. Fecal calprotectin (FC) is the most widely used biomarker of CD activity, but its drawbacks include a large intra-individual sample variability and the burden of collecting stool samples. Meanwhile, serum leucine-rich alpha-2 glycoprotein (LRG) has recently attracted attention as a biomarker that can address the limitations of FC. This study determined the diagnostic accuracy of LRG and its cut-off values for diagnosing CD activity in SB.<br>
Methods This was a retrospective, multi-center study of CD patients undergoing retrograde balloon-assisted endoscopy. For ileal- and ileocolonic-type patients with a colon SES-CD score of 0, we estimated the receiver operating characteristic curve of LRG and determined the cut-off value to achieve a target sensitivity level of 80%.<br>
Results Among 285 patients with SB lesions, LRG had an area under the curve (AUC) of 0.72 (95% CI 0.67–0.78) with a sensitivity of 80.2% and specificity of 47.2% for a cut-off value of 10.5 when diagnosing endoscopic remission (modified SES-CD ≤ 3), while it had an AUC of 0.72 (95% CI 0.65–0.78) with a sensitivity of 81.2% and specificity of 46.2% for a cut-off value of 10.1 when diagnosing complete ulcer healing (modified SES-CD ≤ 1).<br>
Conclusion LRG was effective for diagnosing CD activity in SB, specifically with cut-off values of 10.5 and 10.1 for endoscopic remission and complete ulcer healing, respectively. A future prospective validation study will assess its clinical utility.
en-copyright=
kn-copyright=

en-aut-name=OkitaMuneyori
en-aut-sei=Okita
en-aut-mei=Muneyori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakenakaKento
en-aut-sei=Takenaka
en-aut-mei=Kento
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiraiFumihito
en-aut-sei=Hirai
en-aut-mei=Fumihito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AshizukaShinya
en-aut-sei=Ashizuka
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IijimaHideki
en-aut-sei=Iijima
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=BambaShigeki
en-aut-sei=Bamba
en-aut-mei=Shigeki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FujiiToshimitsu
en-aut-sei=Fujii
en-aut-mei=Toshimitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WatanabeKenji
en-aut-sei=Watanabe
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShimodairaYosuke
en-aut-sei=Shimodaira
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ShigaHisashi
en-aut-sei=Shiga
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HiraokaSakiko
en-aut-sei=Hiraoka
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=InokuchiToshihiro
en-aut-sei=Inokuchi
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YamamuraTakeshi
en-aut-sei=Yamamura
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=EmotoRyo
en-aut-sei=Emoto
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=MatsuiShigeyuki
en-aut-sei=Matsui
en-aut-mei=Shigeyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Biostatistics, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Institute of Science Tokyo
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Osaka International Medical & Science Center, Osaka Keisatsu Hospital
kn-affil=

affil-num=6
en-affil=Department of Fundamental Nursing, Shiga University of Medical Science
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Institute of Science Tokyo
kn-affil=

affil-num=8
en-affil=Department of Internal Medicine for Inflammatory Bowel Disease, Toyama University
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Neurology, Akita University Graduate School of Medicine
kn-affil=

affil-num=10
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology and Hepatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Research Center for Intestinal Health Science, Okayama University
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Biostatistics, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Biostatistics, Nagoya University Graduate School of Medicine
kn-affil=
en-keyword=LRG
kn-keyword=LRG
en-keyword=Biomarker
kn-keyword=Biomarker
en-keyword=Crohn’s disease
kn-keyword=Crohn’s disease
END

start-ver=1.4
cd-journal=joma
no-vol=1873
cd-vols=
no-issue=2
article-no=
start-page=120091
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=SPRED2 controls the severity of cisplatin-induced acute kidney injury by inhibiting ERK activation and TNFα production in mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Cisplatin is an effective chemotherapeutic agent used to treat solid tumors, but its clinical use is limited by acute kidney injury (AKI), in which ERK signaling plays a crucial role. Here, we investigated whether Sprouty-related EVH1 domain-containing protein 2 (SPRED2), an endogenous inhibitor of the Ras/Raf/ERK pathway, protects against cisplatin-induced AKI. Spred2−/− mice showed more severe renal injury and stronger ERK activation than wild-type (WT) mice, whereas pretreatment with the MEK inhibitor U0126 markedly attenuated the injury. In HK-2 cells (proximal tubular cells), SPRED2 knockdown enhanced cisplatin-induced apoptosis and caspase-3 activation, accompanied by decreased Bcl-2 expression. Spred2−/− kidneys displayed increased macrophage infiltration and elevated Tnfα, Il1b, and Ccl2 expression. Neutralization of TNFα with anti-TNFα antibody ameliorated renal injury and reduced the levels of Il1b and Ccl2 mRNA in Spred2−/− mice. In vitro, TNFα slightly decreased the viability of control and SPRED2 knockdown HK-2 cells without cisplatin treatment, but the decreased viability was augmented in SPRED2 knockdown cells by cisplatin. Immunohistochemistry revealed that macrophages were the predominant TNFα-positive cell population. Bone marrow–derived macrophages from Spred2−/− mice produced higher levels of TNFα in response to cisplatin compared with control cells, and this increase was markedly suppressed by U0126.<br>
These findings indicate that endogenous SPRED2 protects kidneys from cisplatin-induced AKI by limiting ERK activation, tubular apoptosis, and TNFα-mediated inflammation.
en-copyright=
kn-copyright=

en-aut-name=YangXu
en-aut-sei=Yang
en-aut-mei=Xu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HeJiali
en-aut-sei=He
en-aut-mei=Jiali
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GaoTong
en-aut-sei=Gao
en-aut-mei=Tong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujisawaMasayoshi
en-aut-sei=Fujisawa
en-aut-mei=Masayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OharaToshiaki
en-aut-sei=Ohara
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KunkelSteven L.
en-aut-sei=Kunkel
en-aut-mei=Steven L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshimuraTeizo
en-aut-sei=Yoshimura
en-aut-mei=Teizo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsukawaAkihiro
en-aut-sei=Matsukawa
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Pathology, University of Michigan Medical School
kn-affil=

affil-num=7
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Cisplatin
kn-keyword=Cisplatin
en-keyword=ERK
kn-keyword=ERK
en-keyword=Macrophage
kn-keyword=Macrophage
en-keyword=SPRED2
kn-keyword=SPRED2
en-keyword=TNFα
kn-keyword=TNFα
END

start-ver=1.4
cd-journal=joma
no-vol=65
cd-vols=
no-issue=9
article-no=
start-page=1662
end-page=1672
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250725
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Novel method for autologous peripheral blood stem cell harvest using highly concentrated sodium citrate solution replacing acid citrate dextrose solution A
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: As the processed blood volume increases, a larger amount of anticoagulant (AC) is required, which leads to a serious issue of fluid dilution in large-volume leukocytapheresis (defined as ≥3-fold total blood volume). We previously reported a novel method for allogeneic peripheral blood stem cell harvest (PBSCH) using highly concentrated sodium citrate (HSC; 5.32%), which shortened the procedure time and reduced the need for an AC solution without heparin. In this study, we extended this novel method to autologous PBSCH (auto-PBSCH) and compared it with patients who received auto-PBSCH using normal concentrated sodium citrate (NSC; 2.2%).<br>
Study Design and Methods: We retrospectively analyzed consecutive auto-PBSCH data obtained using the Spectra Optia continuous mononuclear cell collection mode between May 2017 and May 2025 at our institution.<br>
Results: Leukocytapheresis was performed using NSC in 36 patients and HSC in 22. In the HSC group, patients tended to be younger, had significantly lower body weight, and had significantly fewer hematopoietic tumors as primary diseases compared to the NSC group. After propensity score-matched cohort adjusted for patient background, the total amount of AC solution was significantly lower (694 [range, 77–1648] vs. 298 mL [range, 64–797], p = .02), and procedure time was significantly shorter (224 [range, 117–395] vs. 181 min [range, 103–309], p = .048) in the HSC group. Furthermore, the loss rates of magnesium and potassium were lower in the HSC group.<br>
Conclusion: This novel leukocytapheresis method demonstrated the efficacy and safety in auto-PBSCH, while minimizing the patient burden.
en-copyright=
kn-copyright=

en-aut-name=KitamuraWataru
en-aut-sei=Kitamura
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujiiKeiko
en-aut-sei=Fujii
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AbeMasaya
en-aut-sei=Abe
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IkeuchiKazuhiro
en-aut-sei=Ikeuchi
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShimonoJoji
en-aut-sei=Shimono
en-aut-mei=Joji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WashioKana
en-aut-sei=Washio
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OtsukaFumio
en-aut-sei=Otsuka
en-aut-mei=Fumio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Division of Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=
en-keyword=acid citrate dextrose solution A
kn-keyword=acid citrate dextrose solution A
en-keyword=anticoagulant
kn-keyword=anticoagulant
en-keyword=autologous
kn-keyword=autologous
en-keyword=highly concentrated sodium citrate
kn-keyword=highly concentrated sodium citrate
en-keyword=peripheral blood stem cell
kn-keyword=peripheral blood stem cell
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=3
article-no=
start-page=e80656
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250316
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Case of Charcot Spine Arthropathy at the Lumbosacral Level in a Patient With Ankylosis of the Spine
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Charcot spinal arthropathy, a rare refractory progressive disease, is characterized by symptoms such as pain, deformity, and neurological impairment, which can significantly reduce functional ability, quality of life, and life expectancy. We report a case of Charcot spine at the L5/S1 level with long segment ankylosis to the L5 vertebra. We first performed thorough debridement via a posterior approach. We used antibiotic-containing cement as a spacer to fill the dead space, facilitating the second surgery approach. In the second surgery, transdiscal screws, which have a low profile and strong force, were used as anchors, and bulk bone harvested from both iliac bones was grafted to the intervertebral space. The lumbosacral alignment was kyphotic, and the patient could sit and move independently. Disimpaction was impossible, and a stoma had to be created.
en-copyright=
kn-copyright=

en-aut-name=OdaYoshiaki
en-aut-sei=Oda
en-aut-mei=Yoshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UotaniKoji
en-aut-sei=Uotani
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TetsunagaTomoko
en-aut-sei=Tetsunaga
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShinoharaKensuke
en-aut-sei=Shinohara
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Musculoskeletal Traumatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=ankylosing spine
kn-keyword=ankylosing spine
en-keyword=charcot spine
kn-keyword=charcot spine
en-keyword=charcot spine arthropathy
kn-keyword=charcot spine arthropathy
en-keyword=lumbosacral segment
kn-keyword=lumbosacral segment
en-keyword=paraplegia
kn-keyword=paraplegia
en-keyword=transdiscal screw
kn-keyword=transdiscal screw
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=小胞型グルタミン酸輸送体3はポドサイトにおけるグルタミン酸を用いた細胞間シグナル伝達に関与する
kn-title=Vesicular Glutamate Transporter 3 Is Involved in Glutamatergic Signalling in Podocytes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NISHIINaoko
en-aut-sei=NISHII
en-aut-mei=Naoko
kn-aut-name=西井尚子
kn-aut-sei=西井
kn-aut-mei=尚子
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=西日本の大学病院に勤務する看護師の疼痛マネジメント実践に影響を与える要因：階層的重回帰分析を用いた横断的研究
kn-title=Factors influencing pain management practices among nurses in university hospitals in Western Japan: A cross-sectional study using hierarchical multiple regression analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=XIMengyao
en-aut-sei=XI
en-aut-mei=Mengyao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=岡山大学大学院保健学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=脳卒中右片麻痺者の非利き手による書字練習初期の習熟に対する主観的評価の様相
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=DAITOMaki
en-aut-sei=DAITO
en-aut-mei=Maki
kn-aut-name=大東真紀
kn-aut-sei=大東
kn-aut-mei=真紀
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=岡山大学大学院保健学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=３次元モデルの利用による港湾施工管理の効率化のための測深技術の開発
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NAKAHARAHiromi
en-aut-sei=NAKAHARA
en-aut-mei=Hiromi
kn-aut-name=中原浩実
kn-aut-sei=中原
kn-aut-mei=浩実
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=岡山大学大学院環境生命科学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=道路法面の3次元点群データに基づく変状抽出手法の確立と実用化に関する研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=HOSHINOYuji
en-aut-sei=HOSHINO
en-aut-mei=Yuji
kn-aut-name=星野裕二
kn-aut-sei=星野
kn-aut-mei=裕二
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=岡山大学大学院環境生命科学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=分泌REICタンパク質によるPD-L1制御を介した抗腫瘍機序の解明 
kn-title=Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=GOHARAYuma
en-aut-sei=GOHARA
en-aut-mei=Yuma
kn-aut-name=合原勇馬
kn-aut-sei=合原
kn-aut-mei=勇馬
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=HIF-PH阻害剤はT細胞に擬似低酸素状態を誘導し、抗腫瘍免疫応答を増強することでマイクロサテライト安定型大腸癌の増殖を抑制する
kn-title=HIF‐PH inhibitors induce pseudohypoxia in T cells and suppress the growth of microsatellite stable colorectal cancer by enhancing antitumor immune responses
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=CHENYUEHUA
en-aut-sei=CHEN
en-aut-mei=YUEHUA
kn-aut-name=陈悦华
kn-aut-sei=陈
kn-aut-mei=悦华
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=突発性難聴に対するサルベージ療法としてのステロイド鼓室内注入の応用
kn-title=Application of intratympanic steroid injection as salvage therapy for idiopathic sudden sensorineural hearing loss
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KOMATSUBARAYasutoshi
en-aut-sei=KOMATSUBARA
en-aut-mei=Yasutoshi
kn-aut-name=小松原靖聡
kn-aut-sei=小松原
kn-aut-mei=靖聡
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=3つの非侵襲的マーカーの組み合わせによるクローン病における内視鏡的寛解の効果的な診断
kn-title=Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of three non-invasive markers
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TAKEIKensuke
en-aut-sei=TAKEI
en-aut-mei=Kensuke
kn-aut-name=竹井健介
kn-aut-sei=竹井
kn-aut-mei=健介
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=12
article-no=
start-page=2351
end-page=2363
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251024
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Multicenter, Prospective, Observational, and Single-Arm Interventional Study of Mirogabalin in Diabetic Peripheral Neuropathic Pain: Rationale and Design of Dia-NeP
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: The exact prevalence of and recent changes in diabetic polyneuropathy (DPN) and diabetic peripheral neuropathic pain (DPNP) in Japan are unclear. The oral gabapentinoid, mirogabalin besylate (mirogabalin), is effective with a good safety profile for DPNP with moderate-to-severe pain (numerical rating scale [NRS] scores ≥ 4). However, clinical evidence for mild pain (NRS scores ≤ 3) is unclear. The Dia-NeP study aims to examine: (1) the prevalences of DPN and DPNP and background factors in patients with type 2 diabetes mellitus (T2DM); and (2) the efficacy and safety of mirogabalin in patients with DPNP, including those with mild pain.<br>
Methods: The Dia-NeP study is a multicenter, prospective study consisting of two parts, a baseline survey and an interventional study, to be conducted from March 2025 to August 2026 in patients with T2DM in Japan. The baseline survey is the observational study investigating the epidemiology of DPN and DPNP, and the interventional study is an exploratory, single-arm, open-label study of 12-week mirogabalin treatment. Of patients with T2DM enrolled in the baseline survey, those diagnosed with DPNP who have an NRS score for pain ≥ 1 will be included in the interventional study. The target sample size is 1000 to 3000 patients for the baseline survey and 100 for the interventional study.<br>
Planned Outcomes: The primary endpoint is the change from baseline in the NRS score at week 12 in the interventional study. The safety endpoint is adverse events. This study will not only show the latest prevalence of DPN and DPNP in Japan, but is also the first study to investigate the efficacy and safety of mirogabalin in patients with DPNP having mild pain, as well as moderate-to-severe pain, and is expected to provide useful evidence for future DPN and DPNP treatment.<br>
Trial Registration: Japan Registry of Clinical Trials (jRCTs031240623, registered 20/January/2025, https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031240623).
en-copyright=
kn-copyright=

en-aut-name=KamiyaHideki
en-aut-sei=Kamiya
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SuzukiRyo
en-aut-sei=Suzuki
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=DeguchiTakahisa
en-aut-sei=Deguchi
en-aut-mei=Takahisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HimenoTatsuhito
en-aut-sei=Himeno
en-aut-mei=Tatsuhito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamamotoShuhei
en-aut-sei=Yamamoto
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyamaTaiki
en-aut-sei=Toyama
en-aut-mei=Taiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakamuraJiro
en-aut-sei=Nakamura
en-aut-mei=Jiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Diabetes, Metabolism and Endocrinology, Tokyo Medical University
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Diabetes, Metabolism and Endocrinology, Kagoshima University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=5
en-affil=Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine
kn-affil=

affil-num=6
en-affil=Data Intelligence Department, Daiichi Sankyo Co., Ltd.
kn-affil=

affil-num=7
en-affil=Primary Medical Science Department, Daiichi Sankyo Co., Ltd.
kn-affil=

affil-num=8
en-affil=Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine
kn-affil=
en-keyword=Diabetic peripheral neuropathic pain
kn-keyword=Diabetic peripheral neuropathic pain
en-keyword=Diabetic polyneuropathy
kn-keyword=Diabetic polyneuropathy
en-keyword=Epidemiological survey
kn-keyword=Epidemiological survey
en-keyword=Exploratory study
kn-keyword=Exploratory study
en-keyword=Mirogabalin
kn-keyword=Mirogabalin
en-keyword=Quality of life
kn-keyword=Quality of life
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=1
article-no=
start-page=42195
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251126
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Elucidation of puberulic acid–induced nephrotoxicity using stem cell-based kidney organoids
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Recent cases of acute kidney injury (AKI) in Japan have been linked to Beni-koji CholesteHelp supplements, with puberulic acid identified as a potential nephrotoxic contaminant. To address the need for a reliable in vitro nephrotoxicity testing platform, we developed a screening model using kidney organoids derived from adult rat kidney stem (KS) cells. The organoids were exposed to known nephrotoxicants, including cisplatin and gentamicin, to validate the system. Puberulic acid toxicity was evaluated in both KS cell-derived organoids and wild-type mice. The organoids recapitulated tubular injury induced by known nephrotoxins and showed significant Kim-1 mRNA upregulation. Puberulic acid-treated organoids and mice exhibited morphological features of acute tubular necrosis (ATN), mitochondrial damage, and reduced cytochrome c oxidase subunit IV (COX-IV) expression. Markers of oxidative stress and apoptosis, such as 8-hydroxy-2’-deoxyguanosine (8-OHdG) and cleaved caspase-3, were also elevated. These findings suggest that puberulic acid induces mitochondrial dysfunction and oxidative stress, leading to tubular cell death. Puberulic acid-induced nephrotoxicity was demonstrated using our kidney organoid model. KS cell-derived kidney organoids may provide a simple, reproducible, and rapid platform for nephrotoxicity assessment, which may complement conventional animal experiments.
en-copyright=
kn-copyright=

en-aut-name=NakanohHiroyuki
en-aut-sei=Nakanoh
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TsujiKenji
en-aut-sei=Tsuji
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UchidaNaruhiko
en-aut-sei=Uchida
en-aut-mei=Naruhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FukushimaKazuhiko
en-aut-sei=Fukushima
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HaraguchiSoichiro
en-aut-sei=Haraguchi
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KitamuraShinji
en-aut-sei=Kitamura
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Kidney organoid
kn-keyword=Kidney organoid
en-keyword=Kidney stem cell
kn-keyword=Kidney stem cell
en-keyword=Puberulic acid
kn-keyword=Puberulic acid
en-keyword=Nephrotoxicity
kn-keyword=Nephrotoxicity
en-keyword=Mitochondrial dysfunction
kn-keyword=Mitochondrial dysfunction
END

start-ver=1.4
cd-journal=joma
no-vol=26
cd-vols=
no-issue=11
article-no=
start-page=e13960
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Missing the Target: A Scoping Review of the Use of Percent Weight Loss for Obesity Management
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: To co-create comprehensive targets for obesity management, we need to understand the genesis and current use of percent weight loss targets in research. The goals of our scoping review are to (1) synthesize the literature on percent weight loss targets for adults with obesity and (2) discuss the percent weight loss targets in context with their health benefits.<br>
Methods: We searched Cochrane, MEDLINE, and EMBASE for English language, pharmaceutical, and/or behavioral intervention studies in adults with obesity where the explicit aim of the study was weight reduction defined as a percent of body weight. Reviewers screened citations and extracted data including study characteristics.<br>
Results: From 16,164 abstracts, we included 30 citations which were mostly randomized controlled trials (RCTs) (n = 17) or quasi-experimental studies (n = 12) published between 1992 and 2024. Most of the studies had target weight loss goals between 3% and 10% of body weight (n = 28), while n = 2 had body weight loss goals of 15% or 30%. The proportion of participants who met the percent weight loss target ranged from 5.9% (nutrition only study) to 85% (pharmaceutical study). The studies reported different reasons for targeting a percentage of weight loss such as disease-specific outcomes, reduced risk of disease, or patient-reported outcomes.<br>
Conclusion: Percent weight loss targets were based on similar research and were often not feasible nor sustainable for most participants. The design of these interventions and evaluation of obesity management would benefit from more patient-focused parameters which could help to co-design comprehensive targets for research and practice.
en-copyright=
kn-copyright=

en-aut-name=SherifaliDiana
en-aut-sei=Sherifali
en-aut-mei=Diana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=RaceyMegan
en-aut-sei=Racey
en-aut-mei=Megan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=Fitzpatrick‐LewisDonna
en-aut-sei=Fitzpatrick‐Lewis
en-aut-mei=Donna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=GreenwayMichelle
en-aut-sei=Greenway
en-aut-mei=Michelle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SockalingamSanjeev
en-aut-sei=Sockalingam
en-aut-mei=Sanjeev
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TeohSoo Huat
en-aut-sei=Teoh
en-aut-mei=Soo Huat
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=PattonIan
en-aut-sei=Patton
en-aut-mei=Ian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MacklinDavid
en-aut-sei=Macklin
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=van RossumElizabeth F. C.
en-aut-sei=van Rossum
en-aut-mei=Elizabeth F. C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=BusettoLuca
en-aut-sei=Busetto
en-aut-mei=Luca
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HornDeborah Bade
en-aut-sei=Horn
en-aut-mei=Deborah Bade
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=Patricia NeceJ. D.
en-aut-sei=Patricia Nece
en-aut-mei=J. D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=LeguedeMorgan Emile Gabriel Salmon
en-aut-sei=Leguede
en-aut-mei=Morgan Emile Gabriel Salmon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=PearceNicole
en-aut-sei=Pearce
en-aut-mei=Nicole
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=Le RouxCarel
en-aut-sei=Le Roux
en-aut-mei=Carel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=ArdJamy
en-aut-sei=Ard
en-aut-mei=Jamy
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=AlbergaAngela S.
en-aut-sei=Alberga
en-aut-mei=Angela S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KaplanLee
en-aut-sei=Kaplan
en-aut-mei=Lee
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SharmaArya M.
en-aut-sei=Sharma
en-aut-mei=Arya M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=WhartonSean
en-aut-sei=Wharton
en-aut-mei=Sean
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University
kn-affil=

affil-num=2
en-affil=McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University
kn-affil=

affil-num=3
en-affil=McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University
kn-affil=

affil-num=4
en-affil=McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University
kn-affil=

affil-num=5
en-affil=Obesity Canada
kn-affil=

affil-num=6
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Clinical Medicine, Advanced Medical and Dental Institute, Universiti Sains Malaysia
kn-affil=

affil-num=8
en-affil=Obesity Canada
kn-affil=

affil-num=9
en-affil=Temerty Faculty of Medicine, University of Toronto
kn-affil=

affil-num=10
en-affil=Department of Internal Medicine, Division of Endocrinology, and Obesity Center CGG, Erasmus MC, University Medical Center Rotterdam
kn-affil=

affil-num=11
en-affil=Department of Medicine, University of Padova
kn-affil=

affil-num=12
en-affil=Center of Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School
kn-affil=

affil-num=13
en-affil=Obesity Action Coalition
kn-affil=

affil-num=14
en-affil=ABHispalis Spain, Alianza Hispana de Personas con Obesidad Latin America
kn-affil=

affil-num=15
en-affil=Obesity Canada
kn-affil=

affil-num=16
en-affil=School of Medicine, University College Dublin
kn-affil=

affil-num=17
en-affil=School of Medicine, Wake Forest University
kn-affil=

affil-num=18
en-affil=Department of Health, Kinesiology, and Applied Physiology, Concordia University
kn-affil=

affil-num=19
en-affil=Obesity, Metabolism and Nutrition Institute Massachusetts General Hospital and Harvard Medical School
kn-affil=

affil-num=20
en-affil=Department of Medicine, University of Alberta
kn-affil=

affil-num=21
en-affil=Temerty Faculty of Medicine, University of Toronto
kn-affil=
en-keyword=obesity management
kn-keyword=obesity management
en-keyword=percent body weight
kn-keyword=percent body weight
en-keyword=scoping review
kn-keyword=scoping review
en-keyword=target
kn-keyword=target
en-keyword=weight loss
kn-keyword=weight loss
END

start-ver=1.4
cd-journal=joma
no-vol=190
cd-vols=
no-issue=
article-no=
start-page=157
end-page=169
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251128
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Practical Application and Review of Home Economics Classes in the “Career Training” Program at Okayama Mitsu Senior High School in 2024
kn-title=令和６年度岡山御津高等学校「キャリア実習」における家庭科授業の実践と検討
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本実践研究は，「高等学校の教育課程」の「エ　学校特設科目及び学校設定教科」の中で，岡山県立岡山御津高等学校が独自に設定している教科「総合」の中の一科目「キャリア実習」に焦点を当て，令和６年度に実施した地域協働系列２年次の「キャリア実習」における家庭科授業を分析・評価し，令和７年度に地域協働系列３年次生が履修する「キャリア実習」の在り方を検討すると共に，本校の家庭科の学びについて考えるための示唆を得ることを目的とした。
en-copyright=
kn-copyright=

en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=佐藤園
kn-aut-sei=佐藤
kn-aut-mei=園
aut-affil-num=1
ORCID=

en-aut-name=HASEGAWAChika
en-aut-sei=HASEGAWA
en-aut-mei=Chika
kn-aut-name=長谷川千華
kn-aut-sei=長谷川
kn-aut-mei=千華
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学名誉教授

affil-num=2
en-affil=Okayama Mitsu Senior High School
kn-affil=岡山県立岡山御津高等学校
en-keyword=家庭科
kn-keyword=家庭科
en-keyword=キャリア教育
kn-keyword=キャリア教育
en-keyword=高等学校
kn-keyword=高等学校
en-keyword=普通科目
kn-keyword=普通科目
en-keyword=専門科目
kn-keyword=専門科目
END

start-ver=1.4
cd-journal=joma
no-vol=190
cd-vols=
no-issue=
article-no=
start-page=95
end-page=108
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251128
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Trends in Population Mobility in Rural and Mountainous Areas in Japan: A Case Study of Kagamino Town, Okayama Prefecture
kn-title=中山間地域における人口移動の動向 ― 岡山県苫田郡鏡野町の事例 ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本稿の目的は，2006 年以降の岡山県鏡野町の人口動態を明らかにすることである。分析によって，次の4 点を明らかにした。(1) 鏡野町の人口は2006 年以降一貫して減少しているが，近年はその減少幅が拡大している。2006 年以降は自然減が続き，2010 年代後半からは社会減も拡大した。両効果が働いたために，2010 年代後半から人口減少が加速した。(2) 2006 年以降，鏡野町の人口移動はおおむね安定した傾向が見られた。そして，その人口移動は，津山圏との間における集中的かつ均衡した人口移動，近畿地方・岡山圏・関東地方への転出超過，真庭圏・阿新圏からの小規模な転入超過と特徴づけることができる。(3) 2010 年代後半から，鏡野町は岡山圏への転出超過が顕著となり，近畿地方および関東地方への転出もそれに続いた。その結果，鏡野町は社会減が大きくなった。農林業・製造業・商業の停滞や都市部との賃金格差が若年層の流出を促進し，社会減の拡大に繋がった。(4) 人口移動の中心は一貫して20 歳代と30 歳代であった。
en-copyright=
kn-copyright=

en-aut-name=NOBEMasao
en-aut-sei=NOBE
en-aut-mei=Masao
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学名誉教授
en-keyword=中山間地域
kn-keyword=中山間地域
en-keyword=人口動態
kn-keyword=人口動態
en-keyword=自然減
kn-keyword=自然減
en-keyword=社会減
kn-keyword=社会減
en-keyword=人口移動
kn-keyword=人口移動
END

start-ver=1.4
cd-journal=joma
no-vol=190
cd-vols=
no-issue=
article-no=
start-page=33
end-page=45
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251128
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Characteristics of Assertive Self-expression Examined Through a Comparison of Three Forms of Selfexpression: Using Comparison with the Relationship of Four Variable Aimed at Educational Intervention
kn-title=３つの自己表現の比較を通してみたアサーティブな自己表現の特徴 ― 教育的介入を目指した４つの変数の比較を通して ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　グローバル化，多様性が拡大する社会では，適切に自己を表現する方法の獲得が重要になるのではなかろうか。本研究では，このアサーティブな自己表現の獲得を促す教育的介入を目指して，3 つのタイプの自己表現（攻撃的な自己表現，非主張的な自己表現，アサーティブな自己表現）を比較して，アサーティブな自己表現の特徴を明らかにすることを目指す。先行研究を参考に，これらの自己表現を区別する指標として，評価への敏感さ，被受容感，視点取得，自尊感情を取り上げた。180 人の大学生を対象に調査を行い，分析を行った結果，アサーティブな自己表現には視点取得と自尊感情が関係していることが示された。他方で被主張的な自己表現は，評価への敏感さと被受容感との関係が見られた。攻撃的な自己表現は，視点取得との負の関係が見られた。これらの結果から，教育現場で児童生徒が適切に自己表現できるように促すためには，子供の存在を認め，自尊感情を高めること，他者の視点を配慮する意識を育てること，そして，周囲の評価を気にし過ぎないように促すことが重要である可能性が示唆された。
en-copyright=
kn-copyright=

en-aut-name=AOKITazuko
en-aut-sei=AOKI
en-aut-mei=Tazuko
kn-aut-name=青木多寿子
kn-aut-sei=青木
kn-aut-mei=多寿子
aut-affil-num=1
ORCID=

en-aut-name=TSURUYoshino
en-aut-sei=TSURU
en-aut-mei=Yoshino
kn-aut-name=都留慶
kn-aut-sei=都留
kn-aut-mei=慶
aut-affil-num=2
ORCID=

en-aut-name=YASUNAGAKazuhiro
en-aut-sei=YASUNAGA
en-aut-mei=Kazuhiro
kn-aut-name=安永和央
kn-aut-sei=安永
kn-aut-mei=和央
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域

affil-num=2
en-affil=Okayama Municipal Fukuda Elementary School
kn-affil=岡山市立福田小学校

affil-num=3
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=アサーティブな自己表現
kn-keyword=アサーティブな自己表現
en-keyword=評価への敏感さ
kn-keyword=評価への敏感さ
en-keyword=視点取得
kn-keyword=視点取得
en-keyword=被受容感
kn-keyword=被受容感
en-keyword=自尊感情
kn-keyword=自尊感情
END

start-ver=1.4
cd-journal=joma
no-vol=190
cd-vols=
no-issue=
article-no=
start-page=13
end-page=31
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251128
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Study on the System of the Teacher Training at/by Universities in Imperial Russia: Enactment of the Imperial University Acts in 1804 and the Objective Training for Secondary School Teachers
kn-title=帝政ロシアの総合大学における教員養成の法制 ― 1804 年帝国大学令の制定と中等学校教員の目的養成 ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　1804 年に公布された帝国大学令は，各教育管区の諸学校を管理・指導する総合大学にギムナジア等の中等学校教員を目的養成する附属教育大学の設置を定めていた。モスクワ帝国大学，カザン帝国大学及びハリコフ帝国大学に設置された附属教育大学は，高等教育機関を卒業した学士を対象に3 年間の教員養成教育を提供する機関であり，修了後に3 年間以上のギムナジアの上級教員を勤めた者については，定数外の助教授として総合大学に任官できる場合があるとされた。これに対して，サンクトペテルブルク教育管区では，ギムナジア等を卒業した者を対象とする教育大学が帝国大学に先行して設けられ，その後，独立した高等教育レベルの教員養成機関である中央教育大学に改編された。
en-copyright=
kn-copyright=

en-aut-name=TAKASEAtsushi
en-aut-sei=TAKASE
en-aut-mei=Atsushi
kn-aut-name=髙瀬淳
kn-aut-sei=髙瀬
kn-aut-mei=淳
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=帝政ロシア
kn-keyword=帝政ロシア
en-keyword=教員養成
kn-keyword=教員養成
en-keyword=帝国大学令
kn-keyword=帝国大学令
en-keyword=附属教育大学
kn-keyword=附属教育大学
en-keyword=中央教育大学
kn-keyword=中央教育大学
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=
article-no=
start-page=1568338
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250807
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A pilot transcriptomic study of a novel multitargeted BRT regimen for anti–MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM) is associated with severe outcomes, primarily due to rapidly progressive interstitial lung disease (RP-ILD), which is often refractory to standard therapies such as calcineurin inhibitors (e.g., tacrolimus) combined with cyclophosphamide (TC-Tx). This study evaluated the efficacy of a novel multitargeted regimen combining baricitinib, rituximab, and tacrolimus (BRT-Tx) in improving survival outcomes for MDA5-DM patients with poor prognostic factors.<br>
Methods: Fourteen MDA5-DM patients with multiple adverse prognostic factors were studied. Seven received the BRT-Tx regimen, and the remaining seven, previously treated with TC-Tx, served as historical controls. Twelve-month survival was assessed. Transcriptome analysis was performed for six patients (BRT=3, TC=3), beginning with cluster analysis to evaluate whether changes in peripheral blood gene expression varied according to treatment or prognosis. Gene ontology analysis characterized expression profiles in survivors and distinguished treatment effects. Alterations in the type I, II, and III interferon signatures were also assessed.<br>
Results: In the TC-Tx group, four of seven patients succumbed to RP-ILD, whereas all seven BRT-Tx patients survived the 12-month observation period. Only one BRT-Tx patient required combined rescue therapies, including plasma exchange, and one case of unexplained limbic encephalitis (LE) occurred. Cytomegalovirus reactivation was observed in both groups (BRT: 5/7; TC: 6/7). Transcriptomic analysis revealed no treatment-specific clustering of differentially expressed genes (DEGs) before and after therapy. However, survivors and nonsurvivors formed distinct clusters, with survivors showing significant posttreatment suppression of B-cell-related gene expression. Moreover, interferon signature scores were significantly lower after treatment in survivors than in nonsurvivors. BRT-Tx effectively suppressed B-cell-mediated immune responses and maintained a low interferon signature, while TC-Tx resulted in nonspecific gene suppression, and in nonsurvivors, an elevated interferon signature was observed.<br>
Conclusion: BRT-Tx has the potential to improve survival in MDA5-DM patients by effectively targeting hyperactive immune pathways. The combination of rituximab and tacrolimus is expected to disrupt B-cell–T-cell interactions and reduce autoantibody production, whereas baricitinib may suppress both IFN and GM-CSF signaling, regulating excessive autoimmunity mediated by cells such as macrophages. Unlike TC-Tx, BRT-Tx avoids cyclophosphamide-associated risks such as infertility and secondary malignancies. Future randomized controlled trials are warranted to validate its efficacy and safety.
en-copyright=
kn-copyright=

en-aut-name=TokunagaMoe
en-aut-sei=Tokunaga
en-aut-mei=Moe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakaiYu
en-aut-sei=Nakai
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SatoYoshiharu
en-aut-sei=Sato
en-aut-mei=Yoshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HiratsukaMitori
en-aut-sei=Hiratsuka
en-aut-mei=Mitori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MatsumotoYoshinori
en-aut-sei=Matsumoto
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakatsueTakeshi
en-aut-sei=Nakatsue
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SaekiTakako
en-aut-sei=Saeki
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UmayaharaTakatsune
en-aut-sei=Umayahara
en-aut-mei=Takatsune
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KoyamaYoshinobu
en-aut-sei=Koyama
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Division of Rheumatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=3
en-affil=DNA Chip Research Inc., Medical Laboratory
kn-affil=

affil-num=4
en-affil=DNA Chip Research Inc., Medical Laboratory
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Division of Rheumatology and Nephrology, Department of Internal Medicine, Nagaoka Red Cross Hospital
kn-affil=

affil-num=7
en-affil=Division of Rheumatology and Nephrology, Department of Internal Medicine, Nagaoka Red Cross Hospital
kn-affil=

affil-num=8
en-affil=Division of Dermatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=9
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Division of Rheumatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital
kn-affil=
en-keyword=anti-MDA5 antibody-positive dermatomyositis (MDA5-DM)
kn-keyword=anti-MDA5 antibody-positive dermatomyositis (MDA5-DM)
en-keyword=JAK inhibitor
kn-keyword=JAK inhibitor
en-keyword=baricitinib
kn-keyword=baricitinib
en-keyword=rituximab
kn-keyword=rituximab
en-keyword=multitargeted treatment
kn-keyword=multitargeted treatment
en-keyword=IFN signature
kn-keyword=IFN signature
en-keyword=transcriptome analysis
kn-keyword=transcriptome analysis
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=27481
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241111
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Chronic kidney disease-mineral and bone disorder (CKD-MBD) are recognized as a systemic disease affecting the prognosis of patients with CKD. Proper management of CKD-MBD is important to improve the prognosis of patients with CKD. Although proteinuria is recognized as a poor prognostic factor in these patients, few reports have examined its association with CKD-MBD. We examined the association between proteinuria and CKD-MBD using data from the Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex). Among the patients registered in the J-CKD-DB-Ex, 30,977 with CKD stages G2–G5 who had serum creatinine, albumin, calcium, and phosphate concentrations measured at least once and urinalysis performed were included. The patients were divided into four groups (negative, 1+, 2+, and 3+) according to the degree of proteinuria. The association between proteinuria and CKD-MBD was examined by a logistic regression analysis. In a model adjusted for age, sex, diabetes, and the estimated glomerular filtration rate (eGFR), the odds ratio of the 3 + group compared with the negative group significantly increased to 2.67 (95% confidence interval, 2.29–3.13) for hyperphosphatemia, 2.68 (1.94–3.71) for hypocalcemia, and 1.56 (1.24–1.98) for hypomagnesemia. Proteinuria is associated with hyperphosphatemia, hypocalcemia, and hypomagnesemia in patients with CKD independently of eGFR.
en-copyright=
kn-copyright=

en-aut-name=ShimamotoSho
en-aut-sei=Shimamoto
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakaharaTakako
en-aut-sei=Nakahara
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamadaShunsuke
en-aut-sei=Yamada
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NagasuHajime
en-aut-sei=Nagasu
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KishiSeiji
en-aut-sei=Kishi
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakashimaNaoki
en-aut-sei=Nakashima
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TsuruyaKazuhiko
en-aut-sei=Tsuruya
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkadaHirokazu
en-aut-sei=Okada
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TamuraKouichi
en-aut-sei=Tamura
en-aut-mei=Kouichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NaritaIchiei
en-aut-sei=Narita
en-aut-mei=Ichiei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MaruyamaShoichi
en-aut-sei=Maruyama
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YanoYuichiro
en-aut-sei=Yano
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YokooTakashi
en-aut-sei=Yokoo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=WadaTakashi
en-aut-sei=Wada
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KandaEiichiro
en-aut-sei=Kanda
en-aut-mei=Eiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KataokaHiromi
en-aut-sei=Kataoka
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NangakuMasaomi
en-aut-sei=Nangaku
en-aut-mei=Masaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KashiharaNaoki
en-aut-sei=Kashihara
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=NakanoToshiaki
en-aut-sei=Nakano
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=2
en-affil=Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare
kn-affil=

affil-num=3
en-affil=Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=4
en-affil=Department of Nephrology and Hypertension, Kawasaki Medical School
kn-affil=

affil-num=5
en-affil=Department of Nephrology and Hypertension, Kawasaki Medical School
kn-affil=

affil-num=6
en-affil=Department of Medical Informatics, Graduate School of Medical Science, Kyushu University
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Nara Medical University
kn-affil=

affil-num=8
en-affil=Department of Nephrology, Faculty of Medicine, Saitama Medical University
kn-affil=

affil-num=9
en-affil=Department of Medical Science and Cardiorenal Medicine, Graduate School of Medicine, Yokohama City University
kn-affil=

affil-num=10
en-affil=Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=11
en-affil=Department of Nephrology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of General Medicine, Juntendo University Faculty of Medicine
kn-affil=

affil-num=13
en-affil=Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Nephrology and Rheumatology, Kanazawa University
kn-affil=

affil-num=15
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Health Data Science, Kawasaki Medical School
kn-affil=

affil-num=17
en-affil=Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare
kn-affil=

affil-num=18
en-affil=Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine
kn-affil=

affil-num=19
en-affil=Department of Nephrology and Hypertension, Kawasaki Medical School
kn-affil=

affil-num=20
en-affil=Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=
en-keyword=CKD-MBD
kn-keyword=CKD-MBD
en-keyword=Proteinuria
kn-keyword=Proteinuria
en-keyword=Hyperphosphatemia
kn-keyword=Hyperphosphatemia
en-keyword=Hypocalcemia
kn-keyword=Hypocalcemia
en-keyword=Hypomagnesemia
kn-keyword=Hypomagnesemia
en-keyword=J-CKD-DB-Ex
kn-keyword=J-CKD-DB-Ex
END